WO2010092180A1 - Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy - Google Patents

Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy Download PDF

Info

Publication number
WO2010092180A1
WO2010092180A1 PCT/EP2010/051903 EP2010051903W WO2010092180A1 WO 2010092180 A1 WO2010092180 A1 WO 2010092180A1 EP 2010051903 W EP2010051903 W EP 2010051903W WO 2010092180 A1 WO2010092180 A1 WO 2010092180A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
optionally substituted
alkylene
crc
Prior art date
Application number
PCT/EP2010/051903
Other languages
French (fr)
Inventor
Wilhelm Amberg
Michael Ochse
Udo Lange
Andreas Kling
Berthold Behl
Wilfried Hornberger
Mario Mezler
Charles Hutchins
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK10706575.7T priority Critical patent/DK2396296T3/en
Priority to EP10706575.7A priority patent/EP2396296B1/en
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Priority to CN201080017287.9A priority patent/CN102395558B/en
Priority to BRPI1008045A priority patent/BRPI1008045A2/en
Priority to ES10706575.7T priority patent/ES2584002T3/en
Priority to NZ594928A priority patent/NZ594928A/en
Priority to AU2010212762A priority patent/AU2010212762B2/en
Priority to JP2011549597A priority patent/JP5816557B2/en
Priority to SG2011052636A priority patent/SG173079A1/en
Priority to UAA201111056A priority patent/UA105036C2/en
Priority to MX2011008634A priority patent/MX2011008634A/en
Priority to RU2011138027/04A priority patent/RU2546649C2/en
Priority to CA2750793A priority patent/CA2750793A1/en
Publication of WO2010092180A1 publication Critical patent/WO2010092180A1/en
Priority to IL214175A priority patent/IL214175A/en
Priority to ZA2011/05486A priority patent/ZA201105486B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/19—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to aminotetraline derivatives, pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes.
  • the aminotetraline derivatives are GIyTI inhibitors.
  • NMDA receptor function can be modulated by altering the availability of the co-agonist glycine.
  • This approach has the critical advantage of maintaining activity-dependent activation of the NMDA receptor because an increase in the synaptic concentration of glycine will not produce an activation of NMDA receptors in the absence of glutamate. Since syn- aptic glutamate levels are tightly maintained by high affinity transport mechanisms, an increased activation of the glycine site will only enhance the NMDA component of activated synapses.
  • GIyTI and GlyT2 Two specific glycine transporters, GIyTI and GlyT2 have been identified and shown to belong to the Na/CI-dependent family of neurotransmitter transporters which includes taurine, gamma-aminobutyric acid (GABA), proline, monoamines and orphan transporters.
  • GABA gamma-aminobutyric acid
  • GABA gamma-aminobutyric acid
  • GABA gamma-aminobutyric acid
  • GABA gamma-aminobutyric acid
  • GABA gamma-aminobutyric acid
  • GlyT2 has been reported to be expressed by glycinergic nerve endings in rat spinal cord whereas GIyTI appears to be preferentially expressed by glial cells.
  • GIyT-I a three variants of GIyTI , termed GIyT-I b and GIyT-I c, each of which displays a unique distribution in the brain and peripheral tissues.
  • the variants arise by differential splicing and exon usage, and differ in their N-terminal regions.
  • Glycine transporter inhibitors are already known in the art, for example:
  • the present invention relates to aminotetraline derivatives of the formula (I)
  • A is a 5- or 6-membered ring
  • R is R 1 -W-A 1 -Q-Y-A 2 -X 1 -;
  • R 1 is hydrogen, alkyl, cycloalkylalkyl, halogenated alkyl, trialkylsilylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkylcarbonylaminoalkyl, alkyloxycarbonylaminoalkyl, alkylaminocarbonylaminoalkyl, dialkylaminocarbonyl- aminoalkyl, alkylsulfonylaminoalkyl, (optionally substituted arylalkyl), aminoalkyl, op- tionally substituted arylalkyl, optionally substituted heterocyclylalkyl, cycloalkyl, al- kylcarbonyl, alkoxycarbonyl, halogenated alkoxycarbonyl, aryloxycarbonyl, amino- carbonyl, alkylaminocarbonyl, (halogenated alkyl)amino
  • W is -NR 8 - or a bond
  • a 1 is optionally substituted alkylene or a bond
  • Q is -S(O) 2 - or -C(O)-;
  • Y is -NR 9 - or a bond
  • a 2 is optionally substituted alkylene, alkylene-CO-, -CO-alkylene, alkylene-O-alkylene, alkylene-NR 10 -alkylene, optionally substituted alkenylen, optionally substituted al- kynylene, optionally substituted arylene, optionally substituted heteroarylene or a bond;
  • X 1 is -O-, -NR 11 -, -S-, optionally substituted alkylene, optionally substituted alkenylen, optionally substituted alkynylene;
  • R 2 is hydrogen, halogen, alkyl, halogenated alkyl, hydroxyalkyl, -CN, alkenyl, alkynyl, optionally substituted aryl, hydroxy, alkoxy, halogenated alkoxy, alkoxycarbonyl, al- kenyloxy, arylalkoxy, alkylcarbonyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino- sulfonyl, amino, alkylamino, alkenylamino, nitro or optionally substituted heterocy- clyl, or two radicals R 2 together with the ring atoms of A to which they are bound form a 5- or 6-membered ring;
  • R 3 is hydrogen, halogen, alkyl or alkoxy, or two radicals R 3 together with the carbon atom to which they are attached form a carbonyl group;
  • R 4a , R 4b together are optionally substituted alkylene, wherein one -CH 2 - of alkylene may be replaced by an oxygen atom or -NR 16 ;
  • X 2 is -O-, -NR 6 -, -S-, >CR 12a R 12b or a bond;
  • X 3 is -O-, -NR 7 -, -S-, >CR 13a R 13b or a bond;
  • R 5 is optionally substituted aryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl;
  • n 0, 1 or 2;
  • R 6 is hydrogen or alkyl
  • R 7 is hydrogen or alkyl
  • R 8 is hydrogen or alkyl
  • R 9 is hydrogen, alkyl, cycloalkyl, aminoalkyl, optionally substituted arylalkyl or heterocyclyl; or
  • R 9 , R 1 together are alkylene
  • R 9 is alkylene that is bound to a carbon atom in A 2 and A 2 is alkylene or to a carbon atom in X 1 and X 1 is alkylene;
  • R 10 is hydrogen, alkyl or alkylsulfonyl
  • R 11 is hydrogen or alkyl, or
  • R 9 , R 11 together are alkylene
  • R 12a is hydrogen, optionally substituted alkyl, alkylaminoalkyl, dialkylaminoalkyl, hetero- cyclylalkyl, optionally substituted aryl or hydroxy;
  • R 12b is hydrogen or alkyl, or together are carbonyl or optionally substituted alkylene, wherein one -CH 2 - of al- kylene may be replaced by an oxygen atom or -NR 14 -;
  • R 13a is hydrogen, optionally substituted alkyl, alkylaminoalkyl, dialkylaminoalkyl, hetero- cyclylalkyl, optionally substituted aryl or hydroxy;
  • R 13b is hydrogen or alkyl, or
  • R 13a , R 13b together are carbonyl or optionally substituted alkylene, wherein one -CH 2 - of alkylene may be replaced by an oxygen atom or -NR 15 -;
  • R 14 is hydrogen or alkyl
  • R 15 is hydrogen or alkyl
  • R 16 is hydrogen or alkyl
  • A, R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 , n are as defined herein.
  • the present invention relates to aminotetraline derivatives of formula (I) wherein R is -CN, i.e. aminotetraline derivatives having the formula (Ib) wherein A, R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 , n are as defined herein.
  • Said compounds of formual (I), i.e., the aminotetraline derivatives of formual (I) and their physiologically tolerated acid addition salts, are glycine transporter inhibitors and thus useful as pharmaceuticals.
  • the present invention thus further relates to the compounds of formula (I) for use in therapy.
  • the present invention also relates to pharmaceutical compositions which comprise a carrier and a compound of formula (I).
  • said compounds i.e., the aminotetraline derivatives and their physiologically tolerated acid addition salts, are inhibitors of the glycine transporter GIyTI .
  • the present invention thus further relates to the compounds of formula (I) for use in inhibiting the glycine transporter.
  • the present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for inhibiting the glycine transporter GIyTI and corresponding methods of inhibiting the glycine transporter GIyTL
  • Glycine transport inhibitors and in particular inhibitors of the glycine transporter GIyTI are known to be useful in treating a variety of neurologic and psychiatric disorders.
  • the present invention thus further relates to the compounds of formula (I) for use in treating a neurologic or psychiatric disorder.
  • the present invention further relates to the compounds of formula (I) for use in treating pain.
  • the present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating a neurologic or psychiatric disorder and corresponding methods of treating said disorders.
  • the present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating pain and corresponding methods of treating pain.
  • the present invention further relates to aminotetraline derivatives of formula (II)
  • L is an amino-protecting group
  • Y is NR 9
  • a 2 , X 1 , R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 , n and R 9 are defined as above.
  • aminotetraline derivatives of formula (II) are useful as intermediates in the preparation of GIyTI inhibitors, in particular those of formula (I).
  • aminotetraline derivatives of the formula (I) or (II) of a given constitution may exist in different spatial arrangements, for example if they possess one or more centers of asymmetry, polysubstituted rings or double bonds, or as different tautomers, it is also possible to use enantiomeric mixtures, in particular racemates, diastereomeric mix- tures and tautomeric mixtures, preferably, however, the respective essentially pure enan- tiomers, diastereomers and tautomers of the compounds of formula (I) or (II) and/or of their salts.
  • an enantiomer of the aminotetraline derivatives of the pre- sent invention has the following formula:
  • an enantiomer of the aminotetraline derivatives of the present invention has the following formula:
  • an enantiomer of the aminotetraline derivatives of the present invention has the following formula:
  • an enantiomer of the aminotetraline derivatives of the present invention has the following formula:
  • physiologically tolerated salts of the aminotetraline derivatives of the formula (I) or (II) are especially acid addition salts with physiologically tolerated acids.
  • suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, d-C 4 -alkylsulfonic acids, such as methanesulfonic acid, cycloaliphatic sulfonic acids, such as S-(+)-10-campher sulfonic acid, aromatic sulfo- nic acids, such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having 2 to 10 carbon atoms, such as oxalic acid, malonic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, glycolic acid, adipic acid and benzoic acid.
  • Other utilizable acids are described, e
  • the present invention moreover relates to compounds of formula (I) or (II) as defined herein, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope (e.g., hydrogen by deuterium, 12 C by 13 C, 14 N by 15 N, 16 O by 18 O) and preferably wherein at least one hydrogen atom has been replaced by a deuterium atom.
  • stable, non-radioactive isotope e.g., hydrogen by deuterium, 12 C by 13 C, 14 N by 15 N, 16 O by 18 O
  • Stable isotopes are nonradioactive isotopes which contain one or more additional neutron than the normally abundant isotope of the respective atom.
  • Deuterated compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the non deuterated parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)).
  • Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp.
  • Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These changes may influence the fate of the drug at different steps along its passage through the body. Absorption, distribution, metabolism or excretion can be changed. Absorption and distribution are processes that depend primarily on the molecular size and the lipophilicity of the substance. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction.
  • Drug metabolism can give rise to large isotopic effect if the breaking of a chemical bond to a deuterium atom is the rate limiting step in the process. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: be- cause of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. In any reaction in which the breaking of this bond is the rate limiting step, the reaction will proceed slower for the molecule with the heavy isotope due to "kinetic isotope effect".
  • a reaction involving breaking a C-D bond can be up to 700 percent slower than a similar reaction involving breaking a C-H bond. If the C-D bond is not involved in any of the steps leading to the metabolite, there may not be any effect to alter the behavior of the drug. If a deuterium is placed at a site involved in the metabolism of a drug, an isotope effect will be observed only if breaking of the C-D bond is the rate limiting step. There is evidence to suggest that whenever cleavage of an aliphatic C-H bond occurs, usually by oxidation catalyzed by a mixed-function oxidase, replacement of the hydrogen by deuterium will lead to observable isotope effect. It is also important to understand that the incorporation of deuterium at the site of metabolism slows its rate to the point where another metabolite produced by attack at a carbon atom not substituted by deuterium becomes the major pathway a process called "metabolic switching".
  • Deuterium tracers such as deuterium-labeled drugs and doses, in some cases repeatedly, of thousands of milligrams of deuterated water, are also used in healthy humans of all ages, including neonates and pregnant women, without reported incident (e.g. Pons G and Rey E, Pediatrics 1999 104: 633; Coward W A et al., Lancet 1979 7: 13; Schwarcz H P, Control. Clin. Trials 1984 5(4 Suppl): 573; Rodewald L E et al., J. Pediatr. 1989 1 14: 885; Butte N F et al. Br. J. Nutr. 1991 65: 3; MacLennan A H et al. Am. J. Obstet Gynecol. 1981 139: 948).
  • any deuterium released, for instance, during the metabolism of compounds of this invention poses no health risk.
  • the weight percentage of hydrogen in a mammal indicates that a 70 kg human normally contains nearly a gram of deuterium. Furthermore, replacement of up to about 15% of normal hydrogen with deuterium has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201 : 357).
  • enrichment Increasing the amount of deuterium present in a compound above its natural abundance is called enrichment or deuterium-enrichment.
  • the amount of enrichment include from about 0.5, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21 , 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71 , 75, 79, 84, 88, 92, 96, to about 100 mol %.
  • the hydrogens present on a particular organic compound have different capacities for exchange with deuterium.
  • Certain hydrogen atoms are easily exchangeable under physiological conditions and, if replaced by deuterium atoms, it is expected that they will readily exchange for protons after administration to a patient.
  • Certain hydrogen atoms may be exchanged for deuterium atoms by the action of a deuteric acid such as D 2 S(VD 2 O.
  • deuterium atoms may be incorporated in various combinations during the syn- thesis of compounds of the invention.
  • Certain hydrogen atoms are not easily exchangeable for deuterium atoms. However, deuterium atoms at the remaining positions may be incorporated by the use of deuterated starting materials or intermediates during the construction of compounds of the invention.
  • Deuterated and deuterium-enriched compounds of the invention can be prepared by using known methods described in the literature. Such methods can be carried out utilizing corresponding deuterated and optionally, other isotope-containing reagents and/or intermediates to synthesize the compounds delineated herein, or invoking standard synthetic protocols known in the art for introducing isotopic atoms to a chemical structure.
  • the organic moieties mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members.
  • the prefix C n -C m indicates in each case the possible number of carbon atoms in the group.
  • substituted means that a radical is substituted with 1 , 2 or 3, especially 1 , substituent which are in particular selected from the group consisting of halogen, d-C 4 -alkyl, hydroxy-CrC 4 -alkyl, Cs-C ⁇ -heterocyclyl-alkyl, Ci-C 4 -alkoxy- Ci-C 4 -alkyl, amino-C r C 4 -alkyl, C r C 4 -alkenyl, OH, SH, CN, CF 3 , 0-CF 3 , COOH, 0-CH 2 - COOH, d-Ce-alkoxy, C r C 6 -alkylthio, C 3 -C 7 -cycloalkyl, COO-C r C 6 -alkyl, CONH 2 , CONH- Ci-C 6 -alkyl, SO 2 NH-C r C 6 -alkyl, CON-(
  • halogen denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine or chlorine.
  • CrC 4 -Alkyl is a straight-chain or branched alkyl group having from 1 to 4 carbon atoms.
  • alkyl group examples include methyl, C 2 -C 4 -alkyl such as ethyl, n-propyl, iso-propyl, n- butyl, 2-butyl, iso-butyl or tert-butyl.
  • Ci-C 2 -Alkyl is methyl or ethyl
  • Ci-C 3 -alkyl is additionally n-propyl or isopropyl.
  • CrC 6 -Alkyl is a straight-chain or branched alkyl group having from 1 to 6 carbon atoms. Examples include methyl, C 2 -C 4 -alkyl as mentioned herein and also pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1- dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1 ,1 ,2-trimethylpropyl, 1 ,2,2-trimethyl
  • Halogenated CrC 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein at least one, e.g.
  • 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms, such as in halogenomethyl, diha- logenomethyl, trihalogenomethyl, (R)-i-halogenoethyl, (S)-i-halogenoethyl, 2- halogenoethyl, 1 ,1-dihalogenoethyl, 2,2-dihalogenoethyl, 2,2,2-trihalogenoethyl, (R)-1- halogenopropyl, (S)-i-halogenopropyl, 2-halogenopropyl, 3-halogenopropyl, 1 ,1- dihalogenopropyl, 2,2-dihalogenopropyl, 3,3-dihalogenopropyl, 3,3,3-trihalogenopropyl, (R)-2-halogeno-1 -methylethyl, (S)-2-halogen
  • C 6 -Ci 2 -Aryl-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by C6-Ci 2 -aryl, such as in benzyl.
  • Hydroxy-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein one or two hydrogen atoms are replaced by one or two hydroxyl groups, such as in hydroxy- methyl, (R)-i-hydroxyethyl, (S)-i-hydroxyethyl, 2-hydroxyethyl, (R)-i-hydroxypropyl, (S)- 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, (R)-2-hydroxy-1 -methylethyl, (S)-2- hydroxy-1 -methylethyl, 2-hydroxy-1-(hydroxymethyl)ethyl, (R)-i-hydroxybutyl, (S)-1- hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl.
  • Ci-C 6 -Alkoxy-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein one or two hydrogen atoms are replaced by one or two alkoxy groups having 1 to 6, preferably 1 to 4, in particular 1 or 2 carbon atoms, such as in methoxymethyl, (R)-i-methoxyethyl, (S)-i-methoxyethyl, 2-methoxyethyl, (R)-i-methoxypropyl, (S)-i-methoxypropyl, 2- methoxypropyl, 3-methoxypropyl, (R)-2-methoxy-1-methylethyl, (S)-2-methoxy-1- methylethyl, 2-methoxy-1-(methoxymethyl)ethyl, (R)-i-methoxybutyl, (
  • Amino-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by an amino group, such as in aminomethyl, 2-aminoethyl.
  • Ci-C 6 -Alkylamino-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 car- bon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a CrC ⁇ - alkylamino group, in particular by a Ci-C 4 -alkylamino group, such as in methylami- nomethyl, ethylaminomethyl, n-propylaminomethyl, iso-propylaminomethyl, n- butylaminomethyl, 2-butylaminomethyl, iso-butylaminomethyl or tert-butylaminomethyl.
  • Di-Ci-C 6 -Alkylamino-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a di-CrC ⁇ - Alkylamino group, in particular by a di-Ci-C 4 -alkylamino group, such as in dimethylami- nomethyl.
  • Ci-C 6 -Alkylcarbonylamino-C"i-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a d-C 6 - alkylcarbonylamino group, in particular by a Ci-C 4 -alkylcarbonylamino group, such as in methylcarbonylaminomethyl, ethylcarbonylaminomethyl, n-propylcarbonylaminomethyl, iso-propylcarbonylaminomethyl, n-butylcarbonylaminomethyl, 2- butylcarbonylaminomethyl, iso-butylcarbonylaminomethyl or tert- butylcarbonylaminomethyl.
  • Ci-C 6 -Alkylaminocarbonylamino-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a Ci-C ⁇ -alkylaminocarbonylamino group, in particular by a d-CU-alkylaminocarbonylamino group, such as in methylaminocarbonylaminomethyl, ethylaminocarbonylaminomethyl, n- propylaminocarbonylaminomethyl, iso-propylaminocarbonylaminomethyl, n- butylaminocarbonylaminomethyl, 2-butylaminocarbonylaminomethyl, iso- butylaminocarbonylaminomethyl or tert-butylaminocarbonylaminomethyl.
  • Di-Ci-C 6 -alkylaminocarbonylamino-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a di-Ci-C 6 -alkylaminocarbonylamino group, in particular by a di-Ci-C 4 -alkylaminocarbo- nylamino group, such as in dimethylaminocarbonylaminomethyl, dimethylaminocarbonyl- aminoethyl, dimethylaminocarbonylaminon-propyl.
  • Ci-C 6 -Alkylsulfonylamino-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a CrC ⁇ - alkylsulfonylamino group, in particular by a Ci-C 4 -alkylsulfonylamino group, such as in methylsulfonylaminomethyl, ethylsulfonylaminomethyl, n-propylsulfonylaminomethyl, iso- propylsulfonylaminomethyl, n-butylsulfonylaminomethyl, 2-butylsulfonylaminomethyl, iso- butylsulfonylaminomethyl or tert-butylsulfon
  • (C 6 -Ci 2 -Aryl-Ci-C6-alkyl)amino-Ci-C 4 alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a (C 6 -Ci 2 -aryl-Ci-C6-alkyl)amino group, in particular a (C 6 -Ci 2 -aryl-Ci-C 2 -alkyl)amino group, such as in benzylaminomethyl.
  • C 3 -Ci 2 -Heterocyclyl-Ci-C 4 -alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by C 3 -Ci 2 - heterocyclyl, such as in N-pyrrolidinylmethyl, N-piperidinylmethyl, N-morpholinylmethyl.
  • C 3 -Ci 2 -Cycloalkyl is a cycloaliphatic radical having from 3 to 12 carbon atoms.
  • 3 to 6 carbon atoms form the cyclic structure, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • the cyclic structure may be unsubstituted or may carry 1 , 2, 3 or 4 CrC 4 alkyl radicals, preferably one or more methyl radicals.
  • CrC ⁇ -Alkylcarbonyl is a radical of the formula R-C(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include acetyl, propionyl, n-butyryl, 2-methylpropionyl, pivaloyl.
  • Halogenated C-i-C ⁇ -alkylcarbonyl is C-i-C ⁇ -alkylcarbonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
  • Examples include fluoromethylcar- bonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl. Further examples are 1 ,1 ,1- trifluoroeth-2-ylcarbonyl, 1 ,1 ,1-trifluoroprop-3-ylcarbonyl.
  • C6-Ci 2 -Arylcarbonyl is a radical of the formula R-C(O)-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include benzoyl.
  • Ci-C 6 -Alkoxycarbonyl is a radical of the formula R-O-C(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include methoxycarbonyl and tert-butyloxycarbonyl.
  • Halogenated Ci-C 6 -alkoxycarbonyl is a Ci-C 6 -alkoxycarbonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a cor- responding number of identical or different halogen atoms.
  • C 6 -Ci 2 -Aryloxycarbonyl is a radical of the formula R-O-C(O)-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenoxycarbonyl.
  • Cyano is -C ⁇ N.
  • Aminocarbonyl is NH 2 C(O)-.
  • Ci-C 6 -Alkylaminocarbonyl is a radical of the formula R-NH-C(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include methylaminocarbonyl.
  • (Halogenated Ci-C 4 -alkyl)aminocarbonyl is a Ci-C 4 -alkylaminocarbonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different hydrogen atoms.
  • Ce-C ⁇ -Arylaminocarbonyl is a radical of the formula R-NH-C(O)-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylami- nocarbonyl.
  • C 2 -C 6 -Alkenyl is a singly unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms, e.g. vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl(2- methylprop-2-en-1-yl) and the like.
  • C 3 -C 5 -Alkenyl is, in particular, allyl, 1-methylprop-2-en- 1-yl, 2-buten-1-yl, 3-buten-1-yl, methallyl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1- methylbut-2-en-1 -yl or 2-ethylprop-2-en-1 -yl.
  • C 2 -C 6 -Alkynyl is a singly unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms, e.g. ethynyl, 2-propyn-1-yl, 1-propyn-1-yl, 2-propyn-2-yl and the like.
  • C 3 -C 5 -Alkynyl is, in particular, 2-propyn-1-yl, 2-butyn-1-yl, 3-butyn-1-yl, 2-pentyn-1-yl, 3-pentyn-1-yl, 4- pentyn-1-yl.
  • Ci-C 4 -Alkylene is straight-chain or branched alkylene group having from 1 to 4 carbon atoms. Examples include methylene and ethylene. A further example is propylene.
  • C 2 -C 4 -Alkenylene is straight-chain or branched alkenylene group having from 2 to 4 carbon atoms.
  • C 2 -C 4 -Alkynylene is straight-chain or branched alkynylene group having from 2 to 4 car- bon atoms. Examples include propynylene.
  • C 6 -Ci 2 -Aryl is a 6- to 12-membered, in particular 6- to 10-membered, aromatic cyclic radical. Examples include phenyl and naphthyl.
  • C 3 -Ci 2 -Arylene is an aryl diradical. Examples include phen-1 ,4-ylene and phen-1 ,3-ylene.
  • Ci-C 6 -Alkoxy is a radical of the formula R-O-, wherein R is a straight-chain or branched alkyl group having from 1 to 6, in particular 1 to 4 carbon atoms.
  • R is a straight-chain or branched alkyl group having from 1 to 6, in particular 1 to 4 carbon atoms.
  • Examples include meth- oxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, iso-butoxy (2-methylpropoxy), tert.-butoxy pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2- dimethylpropoxy, 1-ethylpropoxy, hexyloxy, 1 ,1-dimethylpropoxy, 1 ,2-dimethylpropoxy, 1- methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 4-methylpentyloxy, 1 ,1- dimethylbutyloxy, 1 ,2-d
  • Halogenated C-i-C ⁇ -alkoxy is a straight-chain or branched alkoxy group having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms, such as in halogenomethoxy, dihalogenomethoxy, trihalogenomethoxy, (R)-i-halogenoethoxy, (S)-i-halogenoethoxy, 2-halogenoethoxy, 1 ,1- dihalogenoethoxy, 2,2-dihalogenoethoxy, 2,2,2-trihalogenoethoxy, (R)-1- halogenopropoxy, (S)-i-halogenopropoxy, 2-halogenopropoxy, 3-halogenopropoxy, 1 ,1- dihalogenopropoxy, 2,2-dihalogenopropoxy, 3,3
  • Ci-C ⁇ -Hydroxyalkoxy is an alkoxy radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein, wherein one or two hydrogen atoms are replaced by hydroxy. Examples include 2-hydroxyethoxy, 3-hydroxypropoxy, 2-hydroxypropoxy, 1-methyl-2- hydroxyethoxy and the like.
  • Ci-C6-Alkoxy-CrC 4 -alkoxy is an alkoxy radical having from 1 to 4 carbon atoms, prefera- bly 1 or 2 carbon atoms as defined herein, wherein one or two hydrogen atoms are replaced by one or two alkoxy radicals having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include methoxymethoxy, 2-methoxyethoxy, 1- methoxyethoxy, 3-methoxypropoxy, 2-methoxypropoxy, 1-methyl-1-methoxyethoxy, eth- oxymethoxy, 2-ethoxyethoxy, 1 -ethoxyethoxy, 3-ethoxypropoxy, 2-ethoxypropoxy, 1- methyl-1 -ethoxyethoxy and the like.
  • Amino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an amino group. Examples include 2-aminoethoxy.
  • Ci-C6-Alkylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include methylaminomethoxy, ethylaminomethoxy, n-propylaminomethoxy, iso- propylaminomethoxy, n-butylaminomethoxy, 2-butylaminomethoxy, iso- butylaminomethoxy, tert-butylaminomethoxy, 2-(methylamino)ethoxy, 2- (ethylamino)ethoxy, 2-(n-propylamino)ethoxy, 2-(iso-propylamino)ethoxy, 2-(n- butylamino)ethoxy, 2-(2-butylamino)ethoxy, 2-(iso-butylamino)ethoxy, 2-(tert- butylamino)ethoxy.
  • Di-Ci-C6-alkylamino-CrC 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a di- alkylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include dimethylaminomethoxy, diethylaminomethoxy, N-methyl-N- ethylamino)ethoxy, 2-(dimethylamino)ethoxy, 2-(diethylamino)ethoxy, 2-(N-methyl-N- ethylamino)ethoxy.
  • Ci-C 6 -Alkylcarbonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an al- kylcarbonylamino group wherein the alkyl group has from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include methylcarbonylaminomethoxy, ethyl- carbonylaminomethoxy, n-propylcarbonylaminomethoxy, iso- propylcarbonylaminomethoxy, n-butylcarbonylaminomethoxy, 2- butylcarbonylaminomethoxy, iso-butylcarbonylaminomethoxy, tert-butylcarbonyl- aminomethoxy, 2-(methylcarbonylamino)ethoxy, 2-(ethylcarbonylamino)ethoxy, 2-(n- propylcarbonylamino)ethoxy, 2-(iso-propylcarbonylamino)ethoxy, 2-(n- butylcarbonylamino)ethoxy, 2-(2-butylcarbonylamino)ethoxy, 2-(iso-butylcarbonyl- amino)ethoxy, 2-(tert-butylcarbonylamino)ethoxy.
  • C 6 -Ci 2 -Arylcarbonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a Ce- Ci 2 -arylcarbonylamino group as defined herein.
  • Examples include 2- (benzoylamino)ethoxy.
  • Ci-C6-Alkoxycarbonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkoxycarbonylamino group wherein the alkoxy group has from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include methoxycarbonylaminomethoxy, ethoxycarbonylaminomethoxy, n-propoxycarbonylaminomethoxy, iso- propoxycarbonylaminomethoxy, n-butoxycarbonylaminomethoxy, 2- butoxycarbonylaminomethoxy, iso-butoxycarbonylaminomethoxy, tert- butoxycarbonylaminomethoxy, 2-(methoxycarbonylamino)ethoxy, 2-(ethoxycarbonyl- amino)ethoxy, 2-(n-propoxycarbonylamino)ethoxy, 2-(iso-propoxycarbonylamino)ethoxy, 2-(n-butoxycarbonylamino)ethoxy, 2-(2-butoxycarbonylamino)ethoxy, 2-(iso- butoxycarbonylamino)ethoxy, 2-(tert-butoxycarbonylamino)ethoxy.
  • C 2 -C6-Alkenyloxy is a radical of the formula R-O-, wherein R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms.
  • R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms. Examples include vinyloxy, allyloxy (2-propen-1-yloxy), 1-propen-1-yloxy, 2-propen-2-yloxy, methal- lyloxy (2-methylprop-2-en-1-yloxy) and the like.
  • C3-C 5 -Alkenyloxy is, in particular, allyloxy, 1-methylprop-2-en-1-yloxy, 2-buten-1-yloxy, 3-buten-1-yloxy, methallyloxy, 2-penten-1- yloxy, 3-penten-1-yloxy, 4-penten-1-yloxy, 1-methylbut-2-en-1-yloxy or 2-ethylprop-2-en-1- yloxy.
  • C6-Ci 2 -Aryl-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C 6 -Ci 2 -aryl group as defined herein. Examples include benzyloxy.
  • Ci-C6-Alkylsulfonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkyl- sulfonylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include 2-(methylsulfonylamino)ethoxy, 2-(ethylsulfonylamino)ethoxy, 2- [(2-methylpropyl)sulfonylamino]ethoxy.
  • (Halogenated Ci-C 6 -alkyl)sulfonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylsulfonylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein, wherein the alkyl group is halogenated. Examples include 2- (trifluoromethylsulfonylamino)ethoxy.
  • C6-Ci 2 -Arylsulfonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C 6 -Ci 2 - arylsulfonylamino group as defined herein.
  • Examples include 2- (phenylsulfonylamino)ethoxy, 2-(naphthylsulfonylamino)ethoxy.
  • (C6-Ci 2 -Aryl-Ci-C6-alkyl)sulfonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is re- placed by a (C 6 -Ci 2 -aryl-Ci-C6-alkyl)sulfonylamino group, preferably by a (C 6 -Ci 2 -aryl-Ci- C 2 -alkyl)sulfonylamino group.
  • Examples include 2-(benzylsulfonylamino)ethoxy.
  • C 3 -Ci 2 -Heterocyclylsulfonylamino-Ci-C 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C3-Ci 2 -heterocyclylsulfonylamino group as defined herein. Examples include 2- (pyridin-3-yl-sulfonylamino)ethoxy.
  • C3-Ci 2 -Heterocyclyl-CrC 4 -alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C3-C 12 - heterocyclyl group as defined herein.
  • Examples include 2-(N-pyrrolidinyl)ethoxy, 2-(N- morpholinyl)ethoxy and 2-(N-imidazolyl)ethoxy.
  • Ci-C 2 -Alkylenedioxo is a radical of the formula -O-R-O-, wherein R is a straight-chain or branched alkylene group having from 1 or 2 carbon atoms as defined herein. Examples include methylenedioxo.
  • C 6 -Ci 2 -Aryloxy is a radical of the formula R-O-, wherein R is an aryl group having from 6 to 12, in particular 6 carbon atoms as defined herein. Examples include phenoxy.
  • C 3 -Ci 2 -Heterocyclyloxy is a radical of the formula R-O-, wherein R is a C 3 -Ci 2 -heterocyclyl group having from 3 to 12, in particular from 3 to 7 carbon atoms as defined herein. Examples include pyridin-2-yloxy.
  • d-C ⁇ -Alkylthio is a radical of the formula R-S-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include methylthio, ethylthio, propylthio, butylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3- methylbutylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1 ,1- dimethylpropylthio, 1 ,2-dimethylpropylthio, 1-methylpentylthio, 2-methylpentylthio, 3- methylpentylthio, 4-methylpentylthio, 1 ,1-dimethylbutylthio, 1 ,2-
  • Halogenated d-C 6 -alkylthio is a radical of the formula R-S-, wherein R is a halogenated alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • R is a halogenated alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include halogenomethylthio, dihalogenomethylthio, trihalogenomethylthio, (R)- 1-halogenoethylthio, (S)-i-halogenoethylthio, 2-halogenoethylthio, 1 ,1- dihalogenoethylthio, 2,2-dihalogenoethylthio, 2,2,2-trihalogenoethylthio, (R)-1- halogenopropylthio, (S)-i-halogenopropylthio, 2-halogenopropylthio, 3- halogenopropy
  • Ci-C 6 -Alkylsulfinyl is a radical of the formula R-S(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include me- thylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, pentylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 3-methylbutylsulfinyl, 2,2-dimethylpropylsulfinyl, 1- ethylpropylsulfinyl, hexylsulfinyl, 1 ,1-dimethylpropylsulfinyl, 1 ,2-dimethylprop
  • Ci-C ⁇ -Alkylsulfonyl is a radical of the formula R-S(O )r, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • Examples include methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, 1- methylbutylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, 2,2- dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, hexylsulfonyl, 1 ,1-dimethylpropylsulfonyl, 1 ,2-dimethylpropylsulf
  • Halogenated CrC 6 -alkyl)sulfonyl is a C-i-C ⁇ -alkylsulfonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
  • C6-Ci 2 -Arylsulfonyl is a radical of the formula R-S(O )r, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein.
  • R is an aryl radical having from 6 to 12 carbon atoms as defined herein.
  • Examples include phenylsulfonyl.
  • (C 6 -Ci 2 -Aryl-Ci-C 4 -alkyl)sulfonyl is a radical of the formula R-S(O) 2 -, wherein R is a C 6 - Ci 2 -aryl-Ci-C 4 -alkyl radical, in particular a C 6 -Ci 2 -aryl-Ci-C 2 -alkyl radical as defined herein.
  • Examples include benzylsulfonyl.
  • C 3 -Ci 2 -Heterocyclylsulfonyl is a radical of the formula R-S(O) 2 -, wherein R is C 3 -Ci 2 - heterocyclyl as defined herein.
  • Aminosulfonyl is NH 2 -S(O) 2 -.
  • Ci-C 6 -Alkylaminosulfonyl is a radical of the formula R-NH-S(O) 2 - wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein.
  • R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, iso- propylaminosulfonyl, n-butylaminosulfonyl, 2-butylaminosulfonyl, iso-butylaminosulfonyl, tert-butylaminosulfonyl.
  • Di-Ci-C ⁇ -alkylaminosulfonyl is a radical of the formula RR 1 N-S(O) 2 - wherein R and R' are independently of each other an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include dimethylaminosulfonyl, diethylaminosul- fonyl, N-methyl-N-ethylaminosulfonyl.
  • C 6 -Ci 2 -Arylaminosulfonyl is a radical of the formula R-NH-S(O) 2 - wherein R is an aryl radical having from 6 to 12, preferably 6 carbon atoms as defined herein.
  • Amino is NH 2 .
  • Ci-C 6 -Alkylamino is a radical of the formula R-NH- wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include methylamino, ethylamino, n-propylamino, iso-propylamino, n-butylamino, 2-butylamino, iso-butylamino, tert-butylamino.
  • (Halogenated Ci-C6-alkyl)amino is a Ci-C ⁇ -alkylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
  • Di-d-C ⁇ -alkylamino is a radical of the formula RR'N- wherein R and R' are independently of each other an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include dimethylamino, diethylamino, N-methyl-N-ethylamino.
  • Di-(halogenated Ci-C6-alkyl)amino is a di-CrC6-alkylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
  • d-C ⁇ -Alkylcarbonylamino is a radical of the formula R-C(O)-NH-, wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein.
  • R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein.
  • examples include acetamido (methylcarbonylamino), propionamido, n-butyramido, 2- methylpropionamido (isopropylcarbonylamino), 2,2-dimethylpropionamido and the like.
  • (Halogenated Ci-C 6 -alkyl)carbonylamino is a Ci-C 6 -alkylcarbonylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
  • C 6 -Ci 2 -Arylcarbonylamino is a radical of the formula R-C(O)-NH-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylcar- bonylamino.
  • C 2 -C 6 -Alkenylamino is a radical of the formula R-NH-, wherein R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms.
  • R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms.
  • Examples include vinylamino, allylamino (2-propen-1-ylamino), 1-propen-1-ylamino, 2-propen-2- ylamino, methallylamino (2-methylprop-2-en-1-ylamino) and the like.
  • C 3 -C 5 -Alkenylamino is, in particular, allylamino, 1-methylprop-2-en-1-ylamino, 2-buten-1-ylamino, 3-buten-1- ylamino, methallylamino, 2-penten-1-ylamino, 3-penten-1-ylamino, 4-penten-1-ylamino, 1- methylbut-2-en-1 -ylamino or 2-ethylprop-2-en-1 -ylamino.
  • Ci-C 6 -Alkylsulfonylamino is a radical of the formula R-S(O) 2 -NH-, wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein.
  • R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include methylsulfonylamino, ethylsulfonylamino, n-propylsulfonylamino, iso- propylsulfonylamino, n-butylsulfonylamino, 2-butylsulfonylamino, iso-butylsulfonylamino, tert-butylsulfonylamino.
  • Halogenated C-i-C ⁇ alkyl is a Ci-C6-alkylsulfonylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
  • C6-Ci 2 -Arylsulfonylamino is a radical of the formula R-S(O) 2 -NH-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylsul- fonylamino. Nitro is -NO 2 .
  • C 3 -Ci 2 -Heterocyclyl is a 3- to 12-membered heterocyclic radical including a saturated heterocyclic radical, which generally has 3, 4, 5, 6, or 7 ring forming atoms (ring members), an unsaturated non-aromatic heterocyclic radical, which generally has 5, 6 or 7 ring forming atoms, and a heteroaromatic radical (hetaryl), which generally has 5, 6 or 7 ring forming atoms.
  • the heterocyclic radicals may be bound via a carbon atom (C-bound) or a nitrogen atom (N-bound).
  • Preferred heterocyclic radicals comprise 1 nitrogen atom as ring member atom and optionally 1 , 2 or 3 further heteroatoms as ring members, which are selected, independently of each other from O, S and N.
  • preferred heterocyclic radicals comprise 1 heteroatom as ring member, which is selected from O, S and N, and optionally 1 , 2 or 3 further nitrogen atoms as ring members.
  • C 3 -Ci 2 -heterocyclyl examples include:
  • N-bound, 5-membered, saturated rings such as tetrahydropyrrol-1-yl (pyrrolidin-1-yl), tetrahydropyrazol-1-yl, tetrahydroisoxazol-2-yl, tetra- hydroisothiazol-2-yl, tetrahydroimidazol-1-yl, tetrahydrooxazol-3-yl, tetrahydrothiazol-3-yl;
  • N-bound, 6-membered, saturated rings such as piperidin-1-yl, hexahydropyrimidin-1-yl, hexahydropyrazin-1-yl (piperazin-1-yl), hexahydro- pyridazin-1-yl, tetrahydro-1 ,3-oxazin-3-yl, tetrahydro-1 ,3-thiazin-3-yl, tetrahydro-1 ,4- thiazin-4-yl, tetrahydro-1 ,4-oxazin-4-yl (morpholin-1-yl), tetrahydro-1 ,2-oxazin-2-yl;
  • N-bound, 5-membered, partially unsaturated rings such as 2,3-dihydro-1 H-pyrrol-1-yl, 2,5-dihydro-1 H-pyrrol-1-yl, 4,5-dihydro-1 H-pyrazol-1-yl, 2,5- dihydro-1 H-pyrazol-1-yl, 2,3-dihydro-1 H-pyrazol-1-yl, 2,5-dihydroisoxazol-2-yl, 2,3- dihydroisoxazol-2-yl, 2,5-dihydroisothiazol-2-yl, 2,3-dihydroisoxazol-2-yl, 4,5-dihydro-1 H- imidazol-1-yl, 2,5-dihydro-1 H-imidazol-1-yl, 2,3-dihydro-1 H-imidazol-1-yl, 2,3- dihydrooxazol-3-yl, 2,3-dihydrothiazol-3-
  • N-bound, 6-membered, partially unsaturated rings such as
  • C-bound, 6-membered, heteroaromatic rings such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl (4-pyridyl), pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2- yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, 1 ,3,5-triazin-2-yl, 1 ,2,4-triazin-3-yl, 1 ,2,4- triazin-5-yl, 1 ,2,4-triazin-6-yl, 1 ,2,4,5-tetrazin-3-yl;
  • N-bound, 5-membered, heteroaromatic rings such as pyrrol-1-yl, pyrazol-1-yl, imidazol-1-yl, 1 ,2,3-triazol-1-yl, 1 ,2,4-triazol-1-yl, tetrazol-1-yl.
  • Heterocyclyl also includes bicyclic heterocycles, which comprise one of the described 5- or 6-membered heterocyclic rings and a further anellated, saturated or unsaturated or aromatic carbocycle, such as a benzene, cyclohexane, cyclohexene or cyclohexadiene ring, or a futher anellated 5- or 6-membered heterocyclic ring, this heterocyclic ring being saturated or unsaturated or aromatic.
  • bicyclic heterocycles which comprise one of the described 5- or 6-membered heterocyclic rings and a further anellated, saturated or unsaturated or aromatic carbocycle, such as a benzene, cyclohexane, cyclohexene or cyclohexadiene ring, or a futher anellated 5- or 6-membered heterocyclic ring, this heterocyclic ring being saturated or unsaturated or aromatic.
  • Examples of 5- or 6-membered heteroaromatic compounds comprising an anellated cycloalkenyl ring include dihydroindolyl, dihydroindoliz- inyl, dihydroisoindolyl, dihydrochinolinyl, dihydroisoquinolinyl, chromenyl and chromanyl.
  • C 3 -Ci 2 -Heteroarylene is a heteroaryl diradical.
  • Examples include pyrid-2,5-ylene and pyrid-2,4-ylene.
  • variables A, R, R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4 , X 2 , X 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , n preferably have the following meanings which, when taken alone or in combination, represent particular embodiments of the aminotetraline derivatives of the formula (I), (II) or any other formula disclosed herein.
  • a is 1 , 2 or 3
  • b is 1 , 2, 3, 4, 5 or 6 and c is 1.
  • R 2 these may be the same or different radicals.
  • R 3 these may be the same or different radicals.
  • A is a 5- or 6-membered ring which includes two carbon atoms from the cyclopentane, cyclohexane or cycloheptane moiety to which A is fused.
  • A may be a homocyclic or heterocyclic ring.
  • the ring may be saturated, unsaturated non-aromatic or aromatic.
  • A is a benzene ring.
  • A may include 1 , 2 or 3 heteroatoms as ring member atoms, which are selected, independently of each other from N, S and O.
  • Preferred heterocyclic rings comprise 1 nitrogen atom as ring member atom and optionally 1 or 2 further heteroatoms as ring members, which are selected, independently of each other from O, S and N.
  • preferred heterocyclic radicals comprise 1 heteroatom as ring member atom, which is selected from O, S and N, and optionally 1 or 2 further nitrogen atoms as ring member atoms.
  • A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
  • hydrogen atoms are not depicted. This is meant to illustrate that the free valency of a carbon or nitrogen atom may be either bound to a hydrogen atom, to R or to R 2 . Accordingly, R and R 2 may be C- or N-bound at any position of ring A.
  • A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
  • A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
  • A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
  • ring A is a 5-membered heterocyclic ring it is preferred that R is bound to G 1 or G 2 , in particular G 2 :
  • ring A is 6-membered heterocyclic ring it is preferred that R is bound to G 1 or G 2 , in particular G 2 :
  • Heterocyclic compounds having the following partial structures are preferred:
  • Heterocyclic compounds having the following partial structures are particularly preferred:
  • R and R 2 are as defined herein. If there is more than one radical R 2 , these may be the same or different radicals.
  • the partial structures depicted above are fused with a cyclohexane moiety (i.e., n is 1 ).
  • n is 1
  • n is 1
  • R is cyano
  • R is R 1 -W-A 1 -Q-Y-A 2 -X 1 - and A, R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 are as defined herein.
  • R 1 is hydrogen, d-C 6 -alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl, a further example being n-butyl or n-pentyl), C 3 -Ci 2 -cycloalkyl-Ci-C 4 -alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl, a further example being cyclopropylmethyl), halogenated CrC ⁇ -alkyl (e.g.
  • phenyl a further example being 2-methylphenyl
  • hydroxy Ci-C 6 -alkoxy (e.g. tert-butyloxy), halogenated CrC 6 - alkoxy, CrC 6 -hydroxyalkoxy, Ci-C 6 -alkoxy-CrC 4 -alkoxy, amino-CrC 4 -alkoxy, CrC 6 - alkylamino-CrC 4 -alkoxy, di-Ci-C 6 -alkylamino-CrC 4 -alkoxy, Ci-C 6 -alkylcarbonylamino-Cr C 4 -alkoxy, C 6 -Ci 2 -arylcarbonylamino-Ci-C 4 -alkoxy, Ci-C 6 -alkoxycarbonylamino-CrC 4 - alkoxy, C 6 -Ci 2 -aryl-Ci-C 4 -alkoxy, Ci-C 6 -alkoxycarbony
  • dimethylamino di-(halogenated CrC 6 -alkyl)amino, CrC 6 - alkylcarbonylamino, (halogenated CrCe-alky ⁇ carbonylamino, CerC ⁇ -arylcarbonylamino, CrC 6 -alkylsulfonylamino, (halogenated CrC 6 -alkyl)sulfonylamino, C 6 -Ci 2 - arylsulfonylamino or optionally substituted C 3 -Ci 2 -heterocyclyl (e.g.
  • R 1 is Ci-C 6 -alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl, a further example being n-butyl or n-pentyl), C 3 -Ci 2 -cycloalkyl-Ci-C 4 -alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl, a further example being cyclopropylmethyl), halogenated Ci-C 6 -alkyl (e.g.
  • Ci-C 6 -alkoxy-Ci-C 4 - alkyl e.g. ethoxyethyl
  • amino-CrC 4 -alkyl Ci-Ce-alkylamino-Ci-Cralkyl, di-Ci-C 6 - alkylamino-Ci-C 4 -alkyl
  • Ci-C 6 -alkyloxycarbonylamino-CrC 4 -alkyl CrC 6 - alkylaminocarbonylamino-Ci-C 4 -alkyl, C 6 -Ci 2 -aryl-Ci-C 4 -alkyl, C 3 -Ci 2 -cycloalkyl (e.g.
  • C 2 -C 6 -alkenyl e.g. prop-1 ,2-en-1-yl
  • optionally substituted C 6 - Ci 2 -aryl e.g. phenyl
  • hydroxy, CrC 6 -alkylamino e.g. phenyl
  • halogenated Ci-C 6 -alkyl e.g.
  • R 1 is tri-(Ci -C 4 -a I ky I )-si Iy I -Ci -C 4 -a I ky I (e.g. trimethylsilyle
  • R 1 is Ci-C 6 -alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl, a further example being n-butyl or n-pentyl), C 3 -Ci 2 -cycloalkyl-Ci-C 4 -alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl, a further example being cyclopropylmethyl), halogenated Ci-C 6 -alkyl (e.g.
  • R 1 may also be tri-(d-C 4 -alkyl)- silyl-CrC 4 -alkyl (e.g. trimethylsilylethyl).
  • substituted C6-Ci 2 -aryl in particular includes C6-Ci 2 -aryl, such as phenyl or naphthyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, cyano, Ci-C 4 -alkoxy, Ci-C 4 -haloalkoxy, amino, Ci-C 4 -alkylamino, Ci-C 4 -dialkylamino, morpholino and piperidinyl.
  • substituted C 6 -Ci 2 -aryl in substituted C 6 -Ci 2 -aryl-Ci-C 4 -alkyl.
  • substituted C 3 -Ci 2 -heterocyclyl in particular includes C 3 -Ci 2 - heterocyclyl, such as pyridyl, thienyl, diazolyl, quinolinyl, piperidinyl, piperazinyl or mor- pholinyl (pyrrolyl, isoxazolyl and triazolyl being further examples of such C 3 -Ci 2 - heterocyclyl), substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkoxycarbonyl, cyano, Ci-C 4 -alkoxy, CrC 4 - haloalkoxy, Ci-C 4 -alkylsulfonyl, amino, Ci-C 4 -alkylamino, Ci-C 4 -dialkylamino, C 6 -Ci
  • W is -NR 8 - and Y is a bond.
  • W is a bond and Y is -NR 9 -.
  • W is a bond and Y is a bond, especially if R 1 is a nitrogen-bound radical, e.g. nitrogen- bound heterocyclyl such as piperazinyl or morpholinyl.
  • Q is -S(O ) 2 -.
  • Q is -C(O)-.
  • -W-A 1 -Q-Y- is -W-A 1 -S (O) 2 - N R 9 -, -NR 8 -S(O) 2 -, -A 1 - S(O) 2 - or -S(O) 2 -.
  • -W-A 1 -Q-Y- is -W-A 1 -C0- NR 9 - or -NR 8 -CO-.
  • a 1 is optionally substituted CrC 4 -alkylene or a bond.
  • substituted d- C 4 -alkylene in particular includes Ci-C 4 -alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, d-C 4 -alkyl and cyano.
  • a 1 is a bond. If A 1 is C r C 4 -alkylene, W is preferably -NR 8 -.
  • a 2 is optionally substituted Ci-C 4 -alkylene (e.g. 1 ,2-ethylene or 1 ,3-propylene), d-C 4 - alkylene-CO-, -CO-C r C 4 -alkylene, Ci-C 4 -alkylene-O-Ci-C 4 -alkylene, d-C 4 -alkylene-NR 10 - Ci-C 4 -alkylene, optionally substituted C 6 -Ci 2 -arylene, optionally substituted C 6 -Ci 2 - heteroarylene or a bond. Additionally, A 2 may be optionally substituted C 2 -C 4 -alkenylen or optionally substituted C 2 -C 4 -alkynylene.
  • Ci-C 4 -alkylene e.g. 1 ,2-ethylene or 1 ,3-propylene
  • Ci-C 4 -alkylene-O-Ci-C 4 -alkylene Ci-C 4 -alky
  • a 2 is optionally substituted d-C 4 - alkylene (e.g. 1 ,2-ethylene or 1 ,3-propylene). More preferably, A 2 is Ci-C 4 -alkylene (e.g. 1 ,2-ethylene or 1 ,3-propylene).
  • a 2 is optionally substituted C 6 -Ci 2 -arylene, in particular C 6 -Ci 2 -arylene selected from the group consisting of phen- 1 ,4-ylene and phen-1 ,3-ylene, or optionally substituted C 6 -Ci 2 -heteroarylene, in particular C 6 -Ci 2 -heteroarylene selected from the group consisting of pyrid-2,5-ylene and pyrid-2,4- ylene.
  • X 1 is preferably optionally substituted CrC 4 -alkylene.
  • X 1 is in particular optionally substituted C 2 -C 4 -alkenylene or optionally substi- tuted C 2 -C 4 -alkynylene.
  • substituted CrC 4 -alkylene in particular includes CrC 4 -alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, d- d-alkyl, d-C 4 -haloalkyl and cyano.
  • substituted C 2 -C 4 -alkenylene or substituted C 2 -C 4 -alkynylene in particular includes C 2 -C 4 -alkenylene or C 2 -C 4 -alkynylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, d-C 4 -alkyl, d-C 4 -haloalkyl and cyano.
  • substituted C6-Ci 2 -arylene in particular includes C6-Ci 2 -arylene substituted with 1 , 2 or 3 substituents selected from the group consisting of d-C 4 -alkyl, d-C 4 - haloalkyl, d-C 4 -alkoxycarbonyl, cyano, d-C 4 -alkoxy, d-C 4 -haloalkoxy, d-C 4 - alkylsulfonyl, amino, Ci-C 4 -alkylamino, Ci-C 4 -dialkylamino, C 6 -Ci 2 -arylamino and C 3 -Ci 2 - heterocyclyl (e.g., morpholino or piperidinyl).
  • substituents selected from the group consisting of d-C 4 -alkyl, d-C 4 - haloalkyl, d-C 4 -alkoxycarbonyl, cyano,
  • substituted C6-Ci 2 -heteroarylene in particular includes C6-C 12 - heteroarylene substituted with 1 , 2 or 3 substituents selected from the group consisting of Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkoxycarbonyl, cyano, Ci-C 4 -alkoxy, Ci-C 4 -haloalkoxy, CrC 4 -alkylsulfonyl, amino, Ci-C 4 -alkylamino, Ci-C 4 -dialkylamino, C6-Ci 2 -arylamino and C 3 -Ci 2 -heterocyclyl (e.g, morpholino or piperidinyl).
  • substituents selected from the group consisting of Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkoxycarbonyl, cyano, Ci-C 4 -alkoxy,
  • X 1 is -O-, -NR 11 -, -S- or optionally substituted Ci-C 4 -alkylene (e.g. -CH 2 -, a further example being 1 ,2-ethylene and 1 ,3-popylene).
  • substituted CrC 4 -alkylene in particular includes CrC 4 -alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl and cyano.
  • X 1 may be optionally substituted C 2 -C 4 -alkenylen or optionally substituted C 2 -C 4 -alkynylene (e.g.
  • substituted C 2 -C 4 -alkenylene or substituted C 2 -C 4 - alkynylene in particular includes C 2 -C 4 -alkenylene or C 2 -C 4 -alkynylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C 4 -alkyl, d-C 4 - haloalkyl and cyano.
  • X 1 is -O-, -NR 11 , -S-. More preferably, X 1 is -O-.
  • a 2 is a bond and X 1 is optionally substituted d-C 4 - alkylene, optionally substituted C 2 -C 4 -alkenylene or optionally substituted C 2 -C 4 - alkynylene.
  • R 1 -W-A 1 -Q-Y-A 2 -X 1 - is R 1 -S(O) 2 -NH-A 2 -X 1 -, R 1 -NH- S(O) 2 -A 2 -X 1 -, R 1 -C(O)-NH-A 2 -X 1 - or R 1 -N H-C(O )-A 2 -X 1 -.
  • the structural element -Y-A 2 -X 1 - comprises at least 2, 3 or 4 atoms in the main chain. According to further particular embodiments the structural element -Y-A 2 -X 1 - has up to 4, 5 or 6 atoms in the main chain, such as 2 to 6, 2 to 5 or 2 to 4 atoms in the main chain, especially 2, 3 or 4 atoms in the main chain.
  • -Y-A 2 -X 1 - is -Ci-C 4 -alkylene-O- or -NR 9 -Ci- C 4 -alkylene-O-, with -Y-A 2 -X 1 - preferably having 2 to 6, 3 to 5 and especially 4 atoms in the main chain.
  • -Y-A 2 -X 1 - include -(CH 2 ) 3 -O- and -NR 9 -(CH 2 ) 2 -O-.
  • R 9 is as defined herein and preferably R 9 is hydrogen, d-C 6 - alkyl (e.g.
  • R 9 is Ci-C 4 -alkylene that is bound to a carbon atom in A 2 which is CrC 4 -alkylene.
  • -Y-A 2 -X 1 - is -NR 9 -Ci-C 4 -alkylene- (e.g.
  • R 9 is as defined herein and preferably R 9 is hydrogen, Ci-C ⁇ -alkyl (e.g. methyl or ethyl) or C 3 -Ci 2 -cycloalkyl (e.g. cyclopropyl); or R 9 is Ci-C 4 -alkylene that is bound to a carbon atom in X 1 which is CrC 4 -alkylene. If A is a heterocyclic ring, this embodiment of -Y-A 2 -X 1 - is particularly suitable.
  • -Y-A 2 -X 1 - is -NR 9 -C 2 -C 4 -alkenylene- or -NR 9 - C 2 -C 4 -alkynylene- (e.g. -NH-CH 2 -C ⁇ C-), with -Y-A 2 -X 1 - preferably having 2 to 6, 3 to 5 and especially 4 atoms in the main chain.
  • R 9 is as defined herein and preferably is R 9 is hydrogen, d-C 6 -alkyl (e.g. methyl or ethyl) or C 3 -Ci 2 -cycloalkyl (e.g. cyclopropyl or cyclobutyl). If A is a heterocyclic ring, this embodiment of -Y-A 2 -X 1 - is particularly suitable.
  • -Y-A 2 -X 1 - is -Ci-C 4 -alkylene- (e.g. -(CH 2 ) 2 -), with -Y-A 2 -X 1 - preferably having 2 to 6, 2 to 5, 2 to 4 and especially 2 atoms in the main chain. If A is a heterocyclic ring, this embodiment of -Y-A 2 -X 1 - is particularly suitable.
  • the structural motif -Y-A 2 -X 1 as disclosed herein is bound to Q being -S(O) 2 - or -C(O)-.
  • Particular examples for this embimdnet include heterocyclic compounds of the invention wherein R is R 1 -S(O) 2 -Y-A 2 -X 1 or R 1 -C(0)- Y-A 2 -X 1 .
  • radical R and in particular the radical R 1 -W-A 1 -Q-Y-A 2 -X 1 - may, in principle, be bound to the 5-, 6-, 7- or 8-position of the aminotetraline skeleton:
  • R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 , n are as defined herein.
  • heterocyclic compounds of the above formulae wherein the radical R 1 -W-A 1 -Q-Y-A 2 -X 1 - is replaced by the radical -CN.
  • Aminotetraline derivatives having the radical R 1 -W-A 1 -Q-Y-A 2 -X 1 - (or the radical -CN) in the 5-, 6-, 7-position are preferred. Particularly preferred are aminotetraline derivatives having the radical R 1 -W-A 1 -Q-Y-A 2 -X 1 - (or the radical -CN) in the 7-position.
  • the aminotetraline derivatives of the invention may have one or more than one further substituent bound to the ring A. In these positions, the skeleton of the aminotetraline derivatives may thus be substituted with one or more than one radical R 2 . If there is more than one radical R 2 , these may be the same or different radicals. In particular, in 5-, 6-, 7- and/or 8-position, the aminotetraline skeleton may be substituted with one or more than one radical R 2 .
  • the aminotetraline derivatives of the invention may therefore be represented by one of the following formulae:
  • R 1 -W-A 1 -Q-Y-A 2 -X 1 - is replaced by the radical -CN, wherein R 2a , R 2b , R 2c , R 2d independently have one of the meanings given for R 2 , and R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 , n are as defined herein.
  • R 2 is hydrogen, halogen, d-C 6 -alkyl, halogenated Ci-C 4 -alkyl, hydroxy-CrC 4 -alkyl, -CN, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, optionally substituted C 6 -Ci 2 -aryl, hydroxy, Ci-C 6 -alkoxy, halogenated Ci-C 6 -alkoxy, Ci-C 6 -alkoxycarbonyl, C 2 -C 6 -alkenyloxy, C 6 -Ci 2 -aryl-Ci-C 4 - alkoxy, Ci-Ce-alkylcarbonyloxy, Ci-C 6 -alkylthio, CrC 6 -alkylsulfinyl, CrC 6 -alkylsulfonyl, aminosulfonyl, amino, CrC ⁇ -alkylamino, C 2 -C6-al
  • An optionally substituted 5- or 6-membered ring that is formed by two radicals R 2 together with the ring atoms of A to which they are bound is, for instance, a benzene ring.
  • substituted C 6 -Ci 2 -aryl in particular includes C 6 -Ci 2 -aryl, such as phenyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halo- gen and Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, cyano, Ci-C 4 -alkoxy and Ci-C 4 -haloalkoxy.
  • substituted C3-Ci 2 -heterocyclyl in particular includes C3-C 12 - heterocyclyl, such as morpholinyl, pyrrolidinyl and piperidinyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, cyano, Ci-C 4 -alkoxy and Ci-C 4 -haloalkoxy.
  • R 2 is hydrogen, halogen or d-C 6 -alkoxy.
  • R 2 is hydrogen.
  • the aminotetraline derivatives of the invention have one of the following formulae: or by corresponding formulae wherein the radical R 1 -W-A 1 -Q-Y-A 2 -X 1 - is replaced by the radical -CN, wherein R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 , n are as defined herein.
  • the aminotetraline derivatives of the invention may be substituted with one or more than one radical R 3 . If there is more than one radical R 3 , these may be the same or different radicals.
  • the aminotetraline derivatives of the invention may therefore be represented by the following formula:
  • R , R , R , R , R independently have one of the meanings given for R , and A, R, R ⁇ , R J , R 4a , R 4D , X ⁇ , X J , R b , n are as defined herein.
  • the aminotetraline derivatives of the invention have one of the following formulae:
  • R , R JD , R Jt independently have the meaning of R J and A, R, R z , R , R 4a , R 4D , X z , X 3 , R 5 , n are as defined herein.
  • R 3 is hydrogen, halogen, Ci-C ⁇ -alkyl, Ci-C 6 -alkoxy, or two radicals R 3 together with the carbon atom to which they are attached form a carbonyl group.
  • R 3 is hydrogen or d-C 6 -alkyl.
  • R 3 is hydrogen.
  • R is hydrogen, d-C 6 -alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C 3 -Ci 2 -cycloalkyl- Ci-C 4 -alkyl (e.g. cyclopropylmethyl), halogenated Ci-C 4 -alkyl (e.g. 2-fluoroethyl or 2,2,2- trifluoroethyl), hydroxy-C r C 4 -alkyl, Ci-C 6 -alkoxy-CrC 4 -alkyl, amino-C r C 4 -alkyl, CH 2 CN, ⁇ CHO, Ci-C 4 -alkylcarbonyl (e.g.
  • methylcarbonyl or isopropylcarbonyl a further example being ethylcarbonyl
  • (halogenated C- ⁇ -C 4 -alkyl)carbonyl e.g. fluoromethylcarbonyl, di- fluoromethylcarbonyl or trifluoromethylcarbonyl, a further example being 1 ,1 ,1-trifluoroeth- 2-ylcarbonyl or 1 ,1 ,1-trifluoroprop-3-ylcarbonyl
  • C 6 -Ci 2 -arylcarbonyl e.g. phenylcarbonyl
  • Ci-C 4 -alkoxycarbonyl e.g.
  • C 6 -Ci 2 - aryloxycarbonyl e.g. phenoxycarbonyl
  • R 4a is hydrogen, d-C 6 -alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C 3 -Ci 2 - cycloalkyl-CrC 4 -alkyl (e.g. cyclopropylmethyl), halogenated Ci-C 4 -alkyl (e.g. 2-fluoroethyl or 2,2,2-trifluoroethyl), amino-Ci-C 4 -alkyl, CH 2 CN, d-C 4 -alkylcarbonyl (e.g.
  • Ci-C 4 -alkylcarbonyl e.g. fluoromethylcarbonyl, difluoromethylcarbonyl or trifluoromethylcarbonyl
  • C 6 -Ci 2 -arylcarbonyl e.g. phenylcarbonyl
  • Ci-C 4 -alkoxycarbonyl e.g. ethoxycarbonyl or tert-butyloxycarbonyl
  • C 6 -Ci 2 - aryloxycarbonyl e.g.
  • R 1 is -CHO.
  • R 4a is hydrogen, Ci-C 6 -alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C 3 -Ci 2 - cycloalkyl-CrC 4 -alkyl (e.g. cyclopropylmethyl), halogenated Ci-C 4 -alkyl (e.g. 2-fluoroethyl or 2,2,2-trifluoroethyl), d-C 4 -alkylcarbonyl (e.g. methylcarbonyl or isopropylcarbonyl), (halogenated Ci-C 4 -alkyl)carbonyl (e.g.
  • R 4a may also be -CHO.
  • R 4b is hydrogen, Ci-C 6 -alkyl (e.g. methyl, a further example being ethyl).
  • R 4a , R 4b together are optionally substituted Ci-C 6 -alkylene (e.g. 1 ,4-butylene, a further example being 1 ,3-propylene, 2-fluoro-but-1 ,4-ylene or 1 -oxo-but-1 ,4-ylene), wherein one -CH 2 - of d-C 4 -alkylene may be replaced by an oxygen atom (e.g. -CH 2 -CH 2 - 0-CH 2 -CH 2 -) or -NR 16 .
  • X 2 is -O-, -NR 6 -, -S-, >CR 12a R 12b or a bond.
  • X 2 is >CR 12a R 12b .
  • X 3 is -O-, -NR 7 -, -S-, >CR 13a R 13b or a bond.
  • X 3 is a bond.
  • X 2 is >CR 12a R 12b and X 3 is a bond.
  • R 12a is hydrogen, optionally substituted Ci-C 6 -alkyl, Ci-C 6 -alkylamino-Ci-C 4 -alkyl, di-d- C 6 -alkylamino-Ci-C 4 -alkyl, C 3 -Ci 2 -heterocyclyl-Ci-C 6 -alkyl, optionally substituted C 6 -Ci 2 - aryl or hydroxy.
  • R 12a is hydrogen or d-C 6 -alkyl.
  • R 13a is hydrogen, optionally substituted Ci-C 6 -alkyl, Ci-C 6 -alkylamino-Ci-C 4 -alkyl, di-C r C 6 -alkylamino-Ci-C 4 -alkyl, C 3 -Ci 2 -heterocyclyl-Ci-C 6 -alkyl, optionally substituted C 6 -Ci 2 - aryl or hydroxy.
  • R 13a is hydrogen or Ci-C 6 -alkyl.
  • substituted CrC 6 -alkyl in particular includes CrC 6 -alkyl substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, hydroxy, Ci-C 4 -alkoxy and amino.
  • substituted C 6 -Ci 2 -aryl in particular includes C 6 -Ci 2 -aryl, such as phenyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, cyano, Ci-C 4 -alkoxy and Ci-C 4 -haloalkoxy.
  • R 12b is hydrogen or Ci-C 6 -alkyl. According to a particular embodiment, R 12b is hydrogen.
  • R 13b is hydrogen or Ci-C 6 -alkyl. According to a particular embodiment, R 13b is hydrogen.
  • R 12a and R 12b , or R 13a and R 13b together are together are carbonyl or, preferably, optionally substituted Ci-C 4 -alkylene (e.g. 1 ,3-propylene), wherein one -CH 2 - of Cr C 4 -alkylene may be replaced by an oxygen atom or -NR 14 -.
  • Ci-C 4 -alkylene e.g. 1 ,3-propylene
  • substituted C r C 4 -alkylene in particular includes CrC 4 -alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, cyano, Ci-C 4 -alkoxy and CrC 4 - haloalkoxy.
  • R 12a is CrC 6 -alkyl and R 12b is hydrogen or CrC 6 - alkyl, or R 13a is C r C 6 -alkyl and R 13b is hydrogen or C r C 6 -alkyl. According to a further particular embodiement, R 12a is hydrogen and R 12b is hydrogen, or R 13a is hydrogen and R 13b is hydrogen.
  • R 12a and R 12b together are optionally substi- tuted 1 ,3-propylene, or R 13a and R 13b together are optionally substituted 1 ,3-propylene.
  • R 5 is optionally substituted C 6 -Ci 2 -aryl (e.g. phenyl, 3-chlorophenyl, 3,4-dichlorophenyl or 2,4-dichlorophenyl, a further example being 2-fluorophenyl, 2-chlorophenyl, 3- fluorophenyl, 3-chlorophenyl; 3-cyanophenyl, 3-methylphenyl, 3-trifluoromethylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 3,4-difluorophenyl, 3,5- difluorophenyl, 3-fluoro-5-chlorophenyl, 3-chloro-4-fluorophenyl), optionally substituted C 3 - Ci 2 -cycloalkyl (e.g. cyclohexyl) or optionally substituted C 3 -Ci 2 -heterocyclyl.
  • substituted C 3 -Ci 2 -cycloalkyl in particular includes C 3 -Ci 2 -cycloalkyl, such as cyclopropyl or cyclohexyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, optionally substituted Ci-C 6 -alkyl, halogenated Ci-C 6 -alkyl, CN, hydroxy, Ci-C 6 -alkoxy, halogenated Ci-C 6 -alkoxy, amino, Ci-C 6 -alkylamino, di-Ci-C 6 - alkylamino and C 3 -Ci 2 -heterocyclyl.
  • substituents selected from the group consisting of halogen, optionally substituted Ci-C 6 -alkyl, halogenated Ci-C 6 -alkyl, CN, hydroxy, Ci-C 6 -alkoxy, halogenated Ci-C 6 -alkoxy, amino, Ci
  • substituted C6-Ci 2 -aryl in particular includes C6-Ci 2 -aryl, such as phenyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen (e.g. F, Cl, Br), optionally substituted Ci-C 6 -alkyl (e.g. methyl), halogenated d-C 6 - alkyl (e.g. trifluoromethyl), CN, hydroxy, Ci-C 6 -alkoxy (e.g.
  • halogen e.g. F, Cl, Br
  • Ci-C 6 -alkyl e.g. methyl
  • halogenated d-C 6 - alkyl e.g. trifluoromethyl
  • CN hydroxy
  • Ci-C 6 -alkoxy e.g.
  • substituted C 3 -Ci 2 -heterocyclyl in particular includes C 3 -Ci 2 - heterocyclyl substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, optionally substituted Ci-C 6 -alkyl, halogenated Ci-C 6 -alkyl, CN, hydroxy, d-C 6 - alkoxy, halogenated Ci-C 6 -alkoxy, amino, Ci-C 6 -alkylamino, di-Ci-C 6 -alkylamino and C 3 - C ⁇ -heterocyclyl.
  • substituents selected from the group consisting of halogen, optionally substituted Ci-C 6 -alkyl, halogenated Ci-C 6 -alkyl, CN, hydroxy, d-C 6 - alkoxy, halogenated Ci-C 6 -alkoxy, amino, Ci-C 6 -alkylamino, di-Ci-C 6
  • C 3 -Ci 2 -heterocyclyl in particular is C 3 -Ci 2 -heteroaryl.
  • R 5 is optionally substituted C 6 -Ci 2 -aryl, in particular as in the aminotetraline derivatives of the formula: wherein A, R, R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , n are as defined herein, and R 15a , R 15b , R 15c , R 15d , R 15e independently are hydrogen, halogen (e.g. F, Cl or Br), optionally substituted Ci-C 6 -alkyl (e.g. methyl), halogenated Ci-C 6 -alkyl (e.g. trifluoromethyl), CN, hydroxy, Ci-C 6 -alkoxy (e.g. methoxy), amino, Ci-C 6 -alkylamino, di-Ci-C 6 -alkylamino or Cs-C ⁇ -heterocyclyl.
  • halogen e.g. F, Cl or Br
  • the invention relates to aminotetralin derivatives of the formula:
  • R 5 preferably being optionally substituted aryl and in particular optionally substituted phenyl as disclosed herein.
  • substituted C r C 6 -alkyl in particular includes Ci-C 6 -alkyl, especially Ci-C 4 -alkyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of hydroxy, Ci-C 6 -alkoxy, amino, Ci-C 6 -alkylamino, di-Ci-C 6 - alkylamino and C3-Ci 2 -heterocyclyl (e.g. morpholinyl or piperidinyl).
  • Ci-C 6 -alkyl especially Ci-C 4 -alkyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of hydroxy, Ci-C 6 -alkoxy, amino, Ci-C 6 -alkylamino, di-Ci-C 6 - alkylamino and C3-Ci 2 -heterocyclyl (e.g. morpholinyl or piperidinyl).
  • R 15a , R 15b , R 15d , R 15e are hydrogen and R 15c is different from hydrogen (para-mono-substitution).
  • R 15a , R 15c , R 15d , R 15e are hydrogen and R 15b is different from hydrogen (meta-mono-substitution).
  • R 15a , R 15b , R 15c , R 15d , R 15e , C 3 -Ci 2 -heterocyclyl in particular includes morpholinyl, imidazolyl and pyrazolyl.
  • n 0, 1 or 2. According to a particular embodiment, n is 1.
  • R 6 is hydrogen or d-C 6 -alkyl. Preferably, R 6 is hydrogen.
  • R 7 is hydrogen or d-C ⁇ -alkyl. Preferably, R 7 is hydrogen.
  • R 8 is hydrogen or d-C 6 -alkyl. Preferably, R 8 is hydrogen.
  • R 9 is hydrogen, d-C 6 -alkyl (e.g. methyl or ethyl), C 3 -Ci 2 -cycloalkyl (e.g. cyclopropyl), amino-Ci-C 6 -alkyl, optionally substituted C 6 -Ci 2 -aryl-Ci-C 4 -alkyl or C 3 -Ci 2 -heterocyclyl (e.g. 3-azetidinyl).
  • R 9 is hydrogen or d-C 6 -alkyl (e.g. methyl or ethyl).
  • R 9 and R 1 together are d-d-alkylene (e.g. 1 ,3- propylene, a further example being 1 ,2-ethylene) so as that R 9 and R 1 together with the atom in Q to which R 1 is bound and the nitrogen atom to which R 9 is bound form an heterocyclic ring having, in particular, 4, 5 or 6 ring member atoms (including the nitrogen atom and Q).
  • W and A 1 both being a bond such a ring may be represented by the following partial structure:
  • Q is as defined herein (e.g. S(O) 2 ) and n is 0, 1 , 2, 3 or 4.
  • R 9 is d-d-alkylene (e.g. methylene or 1 ,3- propylene) that is bound to a carbon atom in A 2 and A 2 is d-d-alkylene so that R 9 and at least part of A 2 together with the nitrogen atom to which R 9 is bound form an N-containing heterocyclic ring having, in particular, 4, 5 , 6 or 7 ring member atoms (including the nitrogen atom).
  • a ring may be represented by the following partial structure: wherein R 1 , W, A 1 , Q and X 1 are as defined herein, p is 1 or 2, r is 0, 1 or 2 and q is 0, 1 or 2.
  • X 1 preferably is -O-.
  • p is 0, r is 3 and q is 1 , with X 1 preferably being -O-.
  • R 9 is Ci-C 4 -alkylene (e.g. methylene or 1 ,3- propylene) that is bound to a carbon atom in X 1 and X 1 is Ci-C 4 -alkylene (e.g. 1 ,2- ethylene) so that R 9 and at least part of X 1 together with the nitrogen atom to which R 9 is bound form an N-containing heterocyclic ring having, in particular, 4, 5 , 6 or 7 ring member atoms (including the nitrogen atom).
  • a 2 being a bond
  • such a ring may be represented by the following partial structure:
  • R 10 is hydrogen, d-C 6 -alkyl or CrC 6 -alkylsulfonyl. Preferably, R 10 is hydrogen.
  • R 11 is hydrogen or d-C 6 -alkyl. Preferably, R 11 is hydrogen.
  • R 9 , R 11 together are Ci-C 4 -alkylene (e.g. ethylene).
  • R 14 is hydrogen or d-C 6 -alkyl. Preferably, R 14 is hydrogen.
  • R 15 is hydrogen or C r C 6 -alkyl. Preferably, R 15 is hydrogen.
  • R 16 is hydrogen or d-C 6 -alkyl. Preferably, R 16 is hydrogen.
  • A is a 5- or 6-membered ring
  • R is R 1 -W-A 1 -Q-Y-A 2 -X 1 - or -CN
  • R 1 is hydrogen, CrC 6 -alkyl, C 3 -Ci 2 -cycloalkyl-Ci-C 4 -alkyl, halogenated CrC 6 -alkyl, hy- droxy-Ci-C 4 -alkyl, Ci-C 6 -alkoxy-Ci-C 4 -alkyl, amino-CrC 4 -alkyl, Ci-C 6 -alkylamino- Ci-C 4 -alkyl, di-Ci-C 6 -alkylamino-Ci-C 4 -alkyl, Ci-C 6 -alkylcarbonylamino-Ci-C 4 -alkyl, Ci-C 6 -alkyloxycarbonylamino-Ci-C 4 -alkyl, Ci-C
  • C 4 -alkyl (optionally substituted C 6 -Ci 2 -aryl-Ci-C6-alkyl)amino-Ci-C 4 -alkyl, optionally substituted C 6 -Ci 2 -aryl-Ci-C 4 -alkyl, optionally substituted C 3 -Ci 2 -heterocyclyl-Ci-C 4 - alkyl, C 3 -Ci 2 -cycloalkyl, CrC 6 -alkylcarbonyl, CrC 6 -alkoxycarbonyl, halogenated d- C 6 -alkoxycarbonyl, C 6 -Ci 2 -aryloxycarbonyl, aminocarbonyl, CrC 6 - alkylaminocarbonyl, (halogenated Ci-C 4 -alkyl)aminocarbonyl, C 6 -Ci 2 - arylaminocarbonyl, C 2 -C 6 -alkenyl, C 2
  • W is -NR 8 - or a bond
  • a 1 is optionally substituted Ci-C 4 -alkylene or a bond
  • Q is -S(O) 2 - or -C(O)-;
  • Y is -NR 9 - or a bond
  • a 2 is optionally substituted C r C 4 -alkylene, C r C 4 -alkylene-CO-, -CO-d-C ⁇ alkylene, d-d-alkylene-O-d-d-alkylene, Ci-C 4 -alkylene-NR 10 -Ci-C 4 -alkylene, optionally substituted C 6 -Ci 2 -arylene, optionally substituted C 6 -Ci 2 -heteroarylene or a bond;
  • X 1 is -O-, -NR 11 -, -S-, optionally substituted d-C 4 -alkylene;
  • R 2 is hydrogen, halogen, d-C 6 -alkyl, halogenated Ci-C 4 -alkyl, hydroxy-CrC 4 -alkyl, - CN, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, optionally substituted C 6 -Ci 2 -aryl, hydroxy, CrC 6 - alkoxy, halogenated Ci-C 6 -alkoxy, Ci-C 6 -alkoxycarbonyl, C 2 -C 6 -alkenyloxy, C 6 -Ci 2 - aryl-Ci-C 4 -alkoxy, Ci-Ce-alkylcarbonyloxy, Ci-C 6 -alkylthio, CrC 6 -alkylsulfinyl, CrC 6
  • R 3 is hydrogen, halogen, Ci-C 6 -alkyl or Ci-C 6 -alkoxy, or two radicals R 3 together with the carbon atom to which they are attached form a carbonyl group;
  • R 4a is hydrogen, Ci-C 6 -alkyl, C 3 -Ci 2 -cycloalkyl-CrC 4 -alkyl, halogenated Ci-C 4 -alkyl, hy- droxy-Ci-C 4 -alkyl, CrCe-alkoxy-CrOralkyl, amino-C r C 4 -alkyl, CH 2 CN, -CHO, C r C 4 -alkylcarbonyl, (halogenated Ci-C 4 -alkyl)carbonyl, C 6 -Ci 2 -arylcarbonyl, CrC 4 - alkoxycarbonyl, C 6 -Ci 2 -aryloxycarbonyl, Ci-Ce-alkylaminocarbon
  • R 4a , R 4b together are optionally substituted Ci-C 6 -alkylene, wherein one -CH 2 - of CrC 4 - alkylene may be replaced by an oxygen atom or -NR 16 ;
  • X 2 is -O-, -NR 6 -, -S-, >CR 12a R 12b or a bond;
  • X 3 is -O-, -NR 7 -, -S-, >CR 13a R 13b or a bond;
  • R 5 is optionally substituted C 6 -Ci 2 -aryl, optionally substituted C 3 -Ci 2 -cycloalkyl or optionally substituted C 3 -Ci 2 -heterocyclyl; n is O, 1 or 2; R 6 is hydrogen or C r C 6 -alkyl;
  • R 7 is hydrogen or Ci-C 6 -alkyl
  • R 8 is hydrogen or Ci-C 6 -alkyl
  • R 9 is hydrogen, Ci-C 6 -alkyl, C 3 -Ci 2 -cycloalkyl, amino-CrC 6 -alkyl, optionally substituted C 6 -Ci 2 -aryl-Ci-C 4 -alkyl; or R 9 , R 1 together are CrC 4 -alkylene; or R 9 is Ci-C 4 -alkylene that is bound to a carbon atom in A 2 and A 2 is CrC 4 -alkylene or to a carbon atom in X 1 and X 1 is Ci-C 4 -alkylene; R 10 is hydrogen, d-C 6 -alkyl or CrC 6 -alkylsulfonyl; R 11 is hydrogen or CrC 6 -alkyl, or R 9 , R 11 together are CrC 4 -alkylene,
  • R 12a is hydrogen, optionally substituted Ci-C 6 -alkyl, Ci-C 6 -alkylamino-Ci-C 4 -alkyl, di-d- C 6 -alkylamino-Ci-C 4 -alkyl, C 3 -Ci 2 -heterocyclyl-Ci-C 6 -alkyl, optionally substituted C 6 -
  • R 12b is hydrogen or d-C 6 -alkyl, or p12a p12b together are carbonyl or optionally substituted Ci-C 4 -alkylene, wherein one -CH 2 - of Ci-C 4 -alkylene may be replaced by an oxygen atom or -NR 14 -;
  • R 13a is hydrogen, optionally substituted Ci-C 6 -alkyl, Ci-C 6 -alkylamino-Ci-C 4 -alkyl, di-C r
  • R 13b is hydrogen or C r C 6 -alkyl, or R 13a , R 13b together are carbonyl or optionally substituted Ci-C 4 -alkylene, wherein one -CH 2 - of
  • Ci-C 4 -alkylene may be replaced by an oxygen atom or -NR 15 -;
  • R 14 is hydrogen or Ci-C 6 -alkyl;
  • R 15 is hydrogen or Ci-C 6 -alkyl;
  • R 16 is hydrogen or C r C 6 -alkyl, or if one or more of said variables A, R, R 1 , W, A 1 , Q, Y, A 2 , X 1 , R 2 , R 3 , R 4 , X 2 , X 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , n are defined more precidely as disclosed herein.
  • A is a benzene ring
  • R is R 1 -W-A 1 -Q-Y-A 2 -X 1 -;
  • R 1 is Ci-C 6 -alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, n-pentyl), C 3 -
  • Ci 2 -cycloalkyl-CrC 4 -alkyl e.g. cyclopropylmethyl, cyclopentylmethyl, cyclohexyl- methyl
  • halogenated Ci-C 6 -alkyl e.g. 3-fluoroprop-1-yl, 3-chloroprop-1-yl, 3,3,3- trifluoroprop-1-yl
  • tri-(Ci-C 4 -alkyl)-silyl-Ci-C 4 -alkyl e.g. trimethylsilylethyl
  • CrC 6 - alkoxy-Ci-C 4 -alkyl e.g.
  • C 3 -Ci 2 -cycloalkyl e.g. cyclopropyl, cyclobutyl, cyclohexyl
  • C 2 -C 6 -alkenyl e.g. prop-1 ,2-en-1-yl
  • optionally substituted C 6 -Ci 2 -aryl e.g. phenyl, 2-methylphenyl
  • optionally substituted C 3 -Ci 2 -heterocyclyl e.g.
  • W is a bond
  • a 1 is a bond
  • Q is -S(O) 2 - or -C(O)-;
  • Y is -NR 9 - or a bond;
  • a 2 is Ci-C 4 -alkylene (e.g. 1 ,2-ethylene, 1 ,3-propylene) or a bond;
  • X 1 is -O- or optionally substituted Ci-C 4 -alkylene (e.g. methylene, 1 ,2-ethylene, 1 ,3- propylene) or C 2 -C 4 -alkynylene (e.g. prop-1 ,2-yn-1 ,3-ylene);
  • Ci-C 4 -alkylene e.g. methylene, 1 ,2-ethylene, 1 ,3- propylene
  • C 2 -C 4 -alkynylene e.g. prop-1 ,2-yn-1 ,3-ylene
  • R 4a is hydrogen, d-C 6 -alkyl (e.g. methyl, ethyl, n-propyl, isopropyl), C 3 -Ci 2 -cycloalkyl- Ci-C 4 -alkyl (e.g. cyclopropylmethyl), halogenated Ci-C 4 -alkyl (e.g. 2-fluoroethyl, 2,2,2-trifluoroethyl), -CHO, Ci-C 4 -alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, isopropylcarbonyl), (halogenated Ci-C 4 -alkyl)carbonyl (e.g. fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, 1 ,1 ,1-trifluoroeth-2-ylcarbonyl,
  • C 6 -Ci 2 -arylcarbonyl e.g. phenylcarbonyl
  • d-C 4 - alkoxycarbonyl e.g. ethoxycarbonyl, tert-butyloxycarbonyl
  • C 6 -Ci 2 -aryloxycarbonyl e.g. phenoxycarbonyl
  • R 4b is hydrogen or d-C 6 -alkyl (e.g. methyl, ethyl); or R 4a , R 4b together are optionally substituted Ci-C 6 -alkylene (e.g. 1 ,3-propylene, 1 ,4-butylene, 2-fluoro-but-1 ,4-ylene, 1-oxo-but-1 ,4-ylene), wherein one -CH 2 - of CrC 4 -alkylene may be replaced by an oxygen atom (e.g. -CH 2 -CH 2 -O-CH 2 -CH 2 -);
  • Ci-C 6 -alkylene e.g. 1 ,3-propylene, 1 ,4-butylene, 2-fluoro-but-1 ,4-ylene, 1-oxo-but-1 ,4-ylene
  • one -CH 2 - of CrC 4 -alkylene may be replaced by an oxygen atom (e.g. -CH 2
  • X 2 is CR 12a R 12b ; X 3 is a bond;
  • R 5 is optionally substituted phenyl (e.g. phenyl, 2-fluorophenyl, 2-chlorophenyl, 3- fluorophenyl, 3-chlorophenyl, 3-cyanophenyl, 3-methylphenyl, 3- trifluoromethylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- methoxyphenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-chlorophenyl, 3- chloro-4-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl) or optionally substituted C 3 -Ci 2 -cycloalkyl (e.g. cyclohexyl); n is 1 ;
  • R 9 is hydrogen, d-C 6 -alkyl (e.g. methyl, ethyl) or C 3 -Ci 2 -cycloalkyl [cyclopropyl), or R 9 , R 1 together are Ci-C 4 -alkylene (e.g. 1 ,3-propylene); or
  • R 9 is Ci-C 4 -alkylene (e.g. methylene, 1 ,3-propylene) that is bound to a carbon atom in A 2 and A 2 is Ci-C 4 -alkylene (e.g. 1 ,2-ethylene, 1 ,3-propylene) or to a carbon atom in X 1 and X 1 is C r C 4 -alkylene (e.g. 1 ,2-ethylene); R 12a is hydrogen; and
  • R 12b is hydrogen
  • A is a benzene ring
  • R is R 1 -W-A 1 -Q-Y-A 2 -X 1 -;
  • R 1 is Ci-C 6 -alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl), C 3 -Ci 2 -cycloalkyl- Ci-C 4 -alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl), halogenated Ci-C 6 -alkyl (e.g. 3-fluoroprop-1-yl, 3-chloroprop-1-yl or 3,3,3-trifluoroprop-1-yl), C 3 -Ci 2 - cycloalkyl (e.g.
  • cyclopropyl or cyclobutyl C 2 -C 6 -alkenyl (e.g. prop-1 ,2-en-1-yl), op- tionally substituted C 6 -Ci 2 -aryl (e.g. phenyl), or optionally substituted C 3 -Ci 2 - heterocyclyl (e.g.
  • W is a bond
  • a 1 is a bond
  • Q is -S(O) 2 - or -C(O)-;
  • Y is -NR 9 - or a bond
  • a 2 is Ci-C 4 -alkylene (e.g. methylene or 1 ,3-propylene) or a bond
  • X 1 is -O- or optionally substituted Ci-C 4 -alkylene (e.g. methylene);
  • R 2 is hydrogen
  • R 3 is hydrogen;
  • R 4a is hydrogen, d-C 6 -alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C 3 -Ci 2 -cycloalkyl- Ci-C 4 -alkyl (e.g. cyclopropylmethyl), halogenated Ci-C 4 -alkyl (e.g. 2-fluoroethyl or 2,2,2-trifluoroethyl), Ci-C 4 -alkylcarbonyl (e.g. methylcarbonyl or, isopropylcarbonyl), (halogenated Ci-C 4 -alkyl)carbonyl (e.g.
  • fluoromethylcarbonyl difluoromethylcarbo- nyl or trifluoromethylcarbonyl
  • C 6 -Ci 2 -arylcarbonyl e.g. phenylcarbonyl
  • d-C 4 - alkoxycarbonyl e.g. ethoxycarbonyl or tert-butyloxycarbonyl
  • C 6 -Ci 2 - aryloxycarbonyl e.g. phenoxycarbonyl
  • R 4b is hydrogen or C r C 6 -alkyl (e.g. methyl);
  • X 2 is CR 12a R 12b ;
  • X 3 is a bond
  • R 5 is optionally substituted phenyl (e.g. phenyl, 3-chlorophenyl, 3,4-dichlorophenyl or 2,4-dichlorophenyl); n is 1 ;
  • R 6 is hydrogen
  • R 9 is hydrogen or alkyl (e.g. methyl or ethyl); or
  • R 9 , R 1 together are Ci-C 4 -alkylene (e.g. 1 ,3-propylene); or
  • R 9 is Ci-C 4 -alkylene (e.g. methylene or 1 ,3-propylene) that is bound to a carbon atom in A 2 and A 2 is C r C 4 -alkylene;
  • R 10 is hydrogen
  • R 11 is hydrogen
  • R 12a is hydrogen
  • R 12b is hydrogen
  • Particular compounds of the present invention are the aminotetraline derivatives disclosed in preparation examples and physiologically tolerated acid addition salts thereof. These include for each preparation example the exemplified compound as well as the corresponding free base and any other physiologically tolerated acid addition salts of the free base (if the exemplified compound is a salt), or any physiologically tolerated acid addition salt of the free base (if the exemplified compound is a free base). These further include enantiomers, diastereomers, tautomers and any other isomeric forms of said compounds, be they explicitly or implicitly disclosed.
  • the compounds of the formula (I) can be prepared by analogy to methods which are well known in the art. Suitable methods for the preparation of compounds of formula (I) is outlined in the following schemes.
  • L a suitable protecting group
  • the process depicted in scheme 1 is also useful for obtaining ami- notetralines, wherein X is optionally substituted alkylene.
  • L is a group that represents, or can be converted into, the desired side chain R 1 -W-A 1 -Q-Y-A 2 -.
  • the compound of general formula 4 readily undergoes alkylation to give the compound of general formula 5.
  • Conversion to the acid chloride and subsequent ring closure with ethylene in the presence of a Lewis acid affords compound 3 (e.g. J. Het. Chem., 23 (2), 343, 1986 and Bioorg. Med. Chem. Let, 17 (22), 6160, 2007)
  • Compounds 3 can be further converted to compounds of the general formula (I).
  • the intermediate of general formula 35 reacts with various nucleophiles of general formula H 2 N-NH-R in an alcoholic solvent preferably methanol or ethanol at a temperature of about 20° to 80 0 C to obtain the compounds of general formulae 36 and 37.
  • an alcoholic solvent preferably methanol or ethanol at a temperature of about 20° to 80 0 C.
  • monosubstituted hydrazines regioisomeric products are formed.
  • Compounds 36 and 37 can be transformed to compounds of the general formula (I) as depicted in Scheme 9.
  • variable R is as defined herein.
  • R 2 -CO 2 Me, -CO 2 Et, -CN, NO 2 etc
  • the intermediate of general formula 53 readily can undergo condensation with dimethylformamide dimethyl acetal to give the compound of general formula 54, which reacts with various nucleophiles of general formula H 2 N-NH-R in an alcoholic solvent, preferably methanol or ethanol, at a temperature of about 20° to 80 0 C to afford the compound of general formula 55 and 56.
  • Compounds 55 and 56 can be trans- formed to compounds of the general formula (I) as depicted in the previous schemes.
  • the acid addition salts of the aminotetraline derivatives of formula (I) are prepared in a customary manner by mixing the free base with a corresponding acid, optionally in solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or pro- panol, an ether, such as methyl tert-butyl ether or diisopropyl ether, a ketone, such as acetone or methyl ethyl ketone, or an ester, such as ethyl acetate.
  • a lower alcohol such as methanol, ethanol or pro- panol
  • an ether such as methyl tert-butyl ether or diisopropyl ether
  • a ketone such as acetone or methyl ethyl ketone
  • an ester such as ethyl acetate.
  • L is an amino-protecting group
  • Y is NR 9
  • a 2 , X 1 , R 2 , R 3 , R 4a , R 4b , X 2 , X 3 , R 5 , n are defined as above are useful as intermediates in the preparation of GIyTI inhibitors, in particular those of formula (I).
  • Suitable amino-protecting groups are well known in the art such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
  • L is optionally substituted alkylcarbonyl (e.g., tert- butylcarbonyl), optionally substituted arylcarbonyl, optionally substituted arylalkycarbonyl (e.g., benzylcarbonyl), optionally substituted alkoxycarbonyl (e.g., methoxycarbonyl or tert-butyloxycarbonyl), optionally substituted aryloxycarbonyl (e.g. phenoxycarbonyl) or optionally substituted arylalkoxycarbonyl.
  • alkylcarbonyl e.g., tert- butylcarbonyl
  • arylalkycarbonyl e.g., benzylcarbonyl
  • alkoxycarbonyl e.g., methoxycarbonyl or tert-butyloxycarbonyl
  • aryloxycarbonyl e.g. phenoxycarbonyl
  • the compounds of the formula (I) are capable of inhibiting the activity of glycine transporter, in particular glycine transporter 1 (GIyTI ).
  • GIyTI activity may be demonstrated by method- ology known in the art.
  • human GIyTI c expressing recombinant hGlyT1 c_5_CHO cells can be used for measuring glycine uptake and its inhibition (IC 5 o) by a compound of formula (I).
  • IC 5 o glycine uptake and its inhibition
  • compounds of the formula (I) those are preferred which achieve effective inhibition at low concentrations.
  • compounds of the formula (I) are preferred which inhibit glycine transporter 1 (GIyTI ) at a level of IC 50 ⁇ 1 ⁇ Mol, more preferably at a level of IC 5 O ⁇ 0.5 ⁇ Mol, particularly preferably at a level of IC 5 O ⁇ 0.2 ⁇ Mol and most pref- erably at a level of IC 5 O ⁇ 0.1 ⁇ Mol.
  • GIyTI glycine transporter 1
  • the present invention therefore also relates to pharmaceutical compositions which comprise an inert carrier and a compound of the formula (I).
  • the present invention also relates to the use of the compounds of the formula (I) in the manufacture of a medicament for inhibiting the glycine transporter GIyTI , and to corre- sponding methods of inhibiting the glycine transporter GIyTI .
  • the NMDA receptor is central to a wide range of CNS processes, and its role in a variety of diseases in humans or other species has been described.
  • GIyTI inhibitors slow the removal of glycine from the synapse, causing the level of synaptic glycine to rise. This in turn increases the occupancy of the glycine binding site on the NMDA receptor, which increases activation of the NMDA receptor following glutamate release from the presynaptic terminal.
  • Glycine transport inhibitors and in particular inhibitors of the glycine transporter GIyTI are thus known to be useful in treating a variety of neurologic and psychiatric disorders.
  • glycine A receptors play a role in a variety of diseases in humans or other species.
  • Glycine transport inhibitors and in particular inhibitors of the glycine transporter GIyTI are thus useful in treating a variety of neurologic and psychiatric disorders.
  • the present invention thus further relates to the use of the compounds of the formula (I) for the manufacture of a medicament for treating a neurologic or psychiatric disorder, and to corresponding methods of treating said disorders.
  • the disorder is associated with glycinergic or glu- tamatergic neurotransmission dysfunction.
  • the disorder is one or more of the following conditions or diseases: schizophrenia or a psychotic disorder including schizophrenia (paranoid, disorganized, catatonic or undifferentiated), schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition and substance- induced psychotic disorder, including both the positive and the negative symptoms of schizophrenia and other psychoses; cognitive disorders including dementia (associated with AIz- heimer's disease, ischemia, multi-infarct dementia, trauma, vascular problems or stroke, HIV disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jacob disease, perinatal hypoxia, other general medical conditions or substance abuse); delirium, amnestic disorders or cognitive impairment including age related cognitive decline; anxiety disorders including acute stress disorder, agoraphobia, generalized anxiety disor- der, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder,
  • the disorder is pain, in particular chronic pain and especially neuropathic pain.
  • Acute pain which occurs following tissue injury, is self-limiting, serves as an alert to ongoing tissue damage and following tissue repair it will usually subside. There are minimal psychological symptoms associated with acute pain apart from mild anxiety. Acute pain is nociceptive in nature and occurs following chemical, mechanical and thermal stimulation of A-delta and C-polymodal pain receptors.
  • Chronic pain serves no protective biological function. Rather than being the symptom of tissue damage it is a disease in its own right. Chronic pain is unrelenting and not self-limiting and can persist for years, perhaps decades after the initial injury. Chronic pain can be refractory to multiple treatment regimes. Psychological symptoms associated with chronic pain include chronic anxiety, fear, depression, sleeplessness and impairment of social interaction. Chronic non-malignant pain is predominantly neuropathic in nature and involves damage to either the peripheral or central nervous systems.
  • Acute pain and chronic pain are caused by different neuro-physiological processes and therefore tend to respond to different types of treatments.
  • Acute pain can be somatic or visceral in nature. Somatic pain tends to be a well localised, constant pain and is described as sharp, aching, throbbing or gnawing. Visceral pain, on the other hand, tends to be vague in distribution, paroxysmal in nature and is usually described as deep, aching, squeezing or colicky in nature. Examples of acute pain include post-operative pain, pain associated with trauma and the pain of arthritis. Acute pain usually responds to treatment with opioids or non-steroidal anti-inflammatory drugs.
  • Chronic pain in contrast to acute pain, is described as burning, electric, tingling and shooting in nature. It can be continuous or paroxysmal in presentation.
  • the hallmarks of chronic pain are chronic allodynia and hyperalgesia. Allodynia is pain resulting from a stimulus that normally does not ellicit a painful response, such as a light touch.
  • Hyperalgesia is an increased sensitivity to normally painful stimuli. Primary hyperalgesia occurs immediately within the area of the injury. Secondary hyperalgesia occurs in the undam- aged area surrounding the injury.
  • chronic pain examples include complex regional pain syndrome, pain arising from peripheral neuropathies, post-operative pain, chronic fatigue syndrome pain, tension-type headache, pain arising from mechanical nerve injury and severe pain associated with diseases such as cancer, metabolic disease, neurotropic viral disease, neurotoxicity, inflammation, multiple sclerosis or any pain arising as a consequence of or associated with stress or depressive illness.
  • opioids are cheap and effective, serious and potentially life-threatening side effects occur with their use, most notably respiratory depression and muscle rigidity.
  • the doses of opioids which can be administered are limited by nausea, emesis, constipation, pruritis and urinary retention, often resulting in patients electing to receive sub- optimal pain control rather than suffer these distressing side-effects. Furthermore, these side-effects often result in patients requiring extended hospitalisation.
  • Opioids are highly addictive and are scheduled drugs in many territories.
  • the compounds of formula (I) are particularly useful in the treatment of schizophrenia, bipolar disorder, depression including unipolar depression, seasonal depression and postpartum depression, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PDD), learning disorders, pervasive developmental disorder including autistic disorder, attention deficit disorders including Attention-Deficit/Hyperactivity Disorder, tic disorders including Tourette's disorder, anxiety disorders including phobia and post traumatic stress disorder, cognitive disorders associated with dementia, AIDS dementia, Alzheimer's, Parkinson's, Huntington's disease, spasticity, myoclonus, muscle spasm, tinnitus and hearing impairment and loss are of particular importance.
  • Particular cognitive disorders are dementia, delirium, amnestic disorders and cognitive impartment including age-related cognitive decline.
  • Particular anxiety disorders are generalized anxiety disorder, obsessive-compulsive disor- der and panic attack.
  • Particular schizophrenia or psychosis pathologies are paranoid, disorganized, catatonic or undifferentiated schizophrenia and substance-induced psychotic disorder.
  • Particular neurologic disorders that can be treated with the compounds of of the formula (I) include in particular a cognitive disorder such as dementia, cognitive impairment, attention deficit hyperactivity disorder.
  • Particular psychiatric disorders that can be treated with the compounds of of the formula (I) include in particular an anxiety disorder, a mood disorder such as depression or a bipolar disorder, schizophrenia, a psychotic disorder.
  • the use according to the invention of the compounds of the formula (I) involves a method.
  • an effective quantity of one or more compounds or the formula (I), as a rule formulated in accordance with pharmaceutical and veterinary practice, is administered to the individual to be treated, preferably a mammal, in particular a human being.
  • a mammal in particular a human being.
  • Whether such a treatment is indicated, and in which form it is to take place, depends on the individual case and is subject to medical assessment (diagnosis) which takes into consideration signs, symptoms and/or malfunctions which are present, the risks of developing particular signs, symptoms and/or malfunctions, and other factors.
  • the treatment is effected by means of single or repeated daily administration, where appropriate together, or alternating, with other drugs or drug-containing preparations.
  • the invention also relates to the manufacture of pharmaceutical compositions for treating an individual, preferably a mammal, in particular a human being.
  • the compounds of the formula (I) are customarily administered in the form of pharmaceutical compositions which comprise an inert carrier (e.g. a pharmaceutically acceptable excipient) together with at least one compound according to the invention and, where appropriate, other drugs.
  • an inert carrier e.g. a pharmaceutically acceptable excipient
  • These compositions can, for example, be administered orally, rectally, transder- mally, subcutaneously, intravenously, intramuscularly or intranasally.
  • suitable pharmaceutical formulations are solid medicinal forms, such as powders, granules, tablets, in particular film tablets, lozenges, sachets, cachets, sugar- coated tablets, capsules, such as hard gelatin capsules and soft gelatin capsules, sup- positories or vaginal medicinal forms, semisolid medicinal forms, such as ointments, creams, hydrogels, pastes or plasters, and also liquid medicinal forms, such as solutions, emulsions, in particular oil-in-water emulsions, suspensions, for example lotions, injection preparations and infusion preparations, and eyedrops and eardrops.
  • Implanted release devices can also be used for administering inhibitors according to the invention. In addi- tion, it is also possible to use liposomes or microspheres.
  • the compounds according to the invention are optionally mixed or diluted with one or more carriers (excipients).
  • Carriers can be solid, semisolid or liquid materials which serve as vehicles, carriers or medium for the active compound.
  • Suitable carriers are listed in the specialist medicinal monographs.
  • the formulations can comprise pharmaceutically acceptable auxiliary substances, such as wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirri- tants; chelating agents; coating auxiliaries; emulsion stabilizers; film formers; gel formers; odor masking agents; taste corrigents; resin; hydrocolloids; solvents; solubilizers; neutralizing agents; diffusion accelerators; pigments; quaternary ammonium compounds; refat- ting and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; spreading auxiliaries; stabilizers; sterilants; suppository bases; tablet auxiliaries, such as binders, fillers, glidants, disintegrants or coatings; propellants; drying agents; opacifiers; thickeners; waxes; plasticizers and white mineral oils.
  • auxiliary substances such as wetting agents; emulsifying and suspending
  • a formulation in this regard is based on specialist knowledge as described, for example, in Fiedler, H. P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende füre [Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields], 4 th edition, Aulendorf: ECV- Editio-Cantor-Verlag, 1996.
  • the compounds of formula (I) may also be suitable for combination with other therapeutic agents.
  • the present invention also provides: i) a combination comprising a compound of formula (I) with one or more further therapeutic agents; ii) a pharmaceutical composition comprising a combination product as defined in i) above and at least one carrier, diluent or excipient; iii) the use of a combination as defined in i) above in the manufacture of a medicament for treating or preventing a disorder, disease or condition as defined herein; iv) a combination as defined in i) above for use in treating or preventing a disorder, dis- ease or condition as defined herein; v) a kit-of-parts for use in the treatment of a disorder, disease or condition as defined herein, comprising a first dosage form comprising a compound of formula (I) and one or more further dosage forms each comprising one or more further therapeutic agents for simultaneous therapeutic administration, vi) a combination as defined in i) above for use in therapy; vii) a method of treatment or prevention of a disorder, disease or condition as defined herein comprising administer
  • the combination therapies of the invention may be administered adjunctively.
  • adjunc- tive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices.
  • This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration.
  • Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) and at least one further therapeutic agent are within the scope of the current invention.
  • a patient is typically stabilised on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component.
  • the combination therapies of the invention may also be administered simultaneously.
  • simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or de- vices, each comprising one of the components, administered simultaneously.
  • Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one antipsychotic agent to a patient receiving therapeutic administration of compounds of formula (I).
  • the invention provides the use of at least one antipsychotic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I).
  • the inven- tion further provides at least one antipsychotic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I).
  • the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) in combination with at least one antipsychotic agent.
  • the invention further provides the use of a combination of compounds of formula (I) and at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psy- chotic disorder.
  • the invention further provides a combination of compounds of formula (I) and at least one antipsychotic agent for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • the invention further provides the use of compounds of formula (I) in the manufacture of a medicament for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder.
  • the invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder.
  • the invention further provides the use of at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a psychotic disorder.
  • the invention further pro- vides at least one antipsychotic agent for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a psychotic disorder.
  • the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent, a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent, the use of a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent in the manufacture of a medicament for the treatment of a psychotic disorder, and a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent for use in the treatment of a psychotic disorder.
  • Antipsychotic agents include both typical and atypical antipsychotic drugs.
  • antipsychotic drugs that are useful in the present invention include, but are not limited to: butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene; thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines; imidazolidinones; benziso- thiazolyl-piperazines; triazine such as lamotrigine; dibenzoxazepines, such as loxapine; dihydroindo
  • tradenames and suppliers of selected antipsychotic drugs are as follows: clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis); olanzapine (available under the tradename ZYPREX®, from Lilly); ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); haloperidol (available under the tradename HALDOL®, from Ortho-McNeil); chlorpromazine (available under the tradename
  • THORAZINE® from SmithKline Beecham (GSK)
  • fluphenazine available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena
  • thiothixene available under the tradename NAVANE®, from Pfizer
  • trifluoperazine (10-[3-(4-methyl-1-piperazinyl)propyl]-2- (trifluoro- methyl)phenothiazine dihydrochloride, available under the tradename STELAZINE®, from Smith Klein Beckman
  • perphenazine available under the tradename TRILAFON®; from Schering
  • thioridazine available under the tradename MELLARIL®; from Novartis, Rox- ane, HiTech, Teva, and Alpharma
  • molindone available under the tradename MOBAN®, from Endo
  • loxapine available under the tradename LOXITANE(D; from Watson).
  • benperidol (Glianimon®), perazine (Taxilan®) or melperone (Eunerpan®) may be used.
  • Other antipsychotic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRI N®), chlor- prothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®), pro- chlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename Pl- POTRIL®), ziprasidone, and hoperidone.
  • promazine available under the tradename SPARINE®
  • triflurpromazine available under the tradename VESPRI N®
  • chlor- prothixene available under the tradename TARACTAN®
  • the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by adjunctive therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease to a patient receiving therapeutic administration of compounds of formula (I).
  • the invention provides the use of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of compounds of formula (I).
  • the invention further provides at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of compounds of formula (I).
  • the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by simultaneous therapeutic administration of com- pounds of formula (I) in combination with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention further provides the use of a combination of compounds of formula (I) and at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention further provides a combination of compounds of formula (I) and at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for simultaneous therapeutic administration in the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention further provides the use of compounds of formula (I) in the manufac- ture of a medicament for simultaneous therapeutic administration with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention further provides the use of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • the invention further provides at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a neurodegenerative disorder such as Alzheimer Disease.
  • agents suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease include, but are not limited to: cholinesterase inhibitors, agents targeting nicotinic or muscarinic acetylcholine receptors, NMDA receptors, amyloid formation, mitochondrial dysfunctions, disease associated cal- pain activity, neuroinflamation, tumor necrosis factor receptors, NF-kappaB, peroxisome proliferator activator receptor gamma, Apolipoprotein E variant 4 (ApoE4), disease- associated increase of the HPA axis, epileptic discharges, vascular dysfunction, vascular risk factors, and oxidative stress.
  • cholinesterase inhibitors agents targeting nicotinic or muscarinic acetylcholine receptors, NMDA receptors, amyloid formation, mitochondrial dysfunctions, disease associated cal- pain activity, neuroinflamation, tumor necrosis factor receptors, NF-kappaB, peroxisome proliferator activator receptor gam
  • Suitable cholinesterase inhibitors which may be used in combination with the compounds of the inventions include for example tacrine, donepezil, galantamine and rivastigmine.
  • Suitable NMDA receptors targeting agents which may be used in combination with the compounds of the inventions include for example memantine.
  • Suitable agents affecting increased HPA axis activity which may be used in combination with the compounds of the inventions include for example CRF1 antagonists or V1 b antagonists.
  • the invention provides a method of treatment of pain by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain.
  • the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain.
  • the invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain.
  • the invention provides a method of treatment of pain by adjunctive therapeutic administration of at least one agent suitable for the treatment of pain to a patient receiving therapeutic administration of compounds of formula (I).
  • the invention provides the use of at least one agent suitable for the treatment of pain in the manufacture of a medicament for adjunctive therapeutic administration for the treat- ment of pain in a patient receiving therapeutic administration of compounds of formula (I).
  • the invention further provides at least one agent suitable for the treatment of pain for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of compounds of formula (I).
  • the invention provides a method of treatment of pain by simultaneous therapeutic administration of compounds of formula (I) in combination with at least one agent suitable for the treatment of pain.
  • the invention further provides the use of a combination of compounds of formula (I) and at least one agent suitable for the treatment of pain in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of pain.
  • the invention further provides a combination of compounds of formula (I) and at least one agent suitable for the treatment of pain for simultaneous therapeutic administration in the treatment of pain.
  • the invention further provides the use of compounds of formula (I) in the manufacture of a medicament for simultaneous therapeu- tic administration with at least one agent suitable for the treatment of pain in the treatment of pain.
  • the invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one agent suitable for the treatment of pain in the treatment of pain.
  • the invention further provides the use of at least one agent suitable for the treatment of pain in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of pain.
  • the invention further provides at least one agent suitable for the treatment of pain for simultaneous therapeutic administration with compounds of formula (I) in the treatment of pain.
  • agents suitable for the treatment of pain include, but are not limited to: NSAIDs (Nonsteroidal Antiinflammatory Drugs), anticonvulsant drugs such as carbamazepine and gabapentin, sodium channel blockers, antidepressant drugs, cannabinoids and local anaesthetics.
  • NSAIDs Nonsteroidal Antiinflammatory Drugs
  • anticonvulsant drugs such as carbamazepine and gabapentin
  • sodium channel blockers such as sodium channel blockers
  • antidepressant drugs such as cannabinoids and local anaesthetics.
  • Suitable agents used in combination with the compounds of the inventions include for ex- ample celecoxib, etoricoxib, lumiracoxib, paracetamol, tramadol, methadone, venlafaxine, imipramine, duloxetine, bupropion, gabapentin, pregabalin, lamotrigine, fentanyl, pare- coxib, nefopam, remifentanil, pethidine, diclofenac, rofecoxib, nalbuphine, sufentanil, pethidine, diamorphine and butorphanol.
  • antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1 B antagonists, 5HT1 D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents, as well as cognitive enhancers.
  • antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1 B antagonists, 5HT1 D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents,
  • Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
  • Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
  • Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • Suitable anticonvulsant agents which may be used in combination of the compounds of the invention include for example divalproex, carbamazepine and diazepam.
  • the compounds were characterized by mass spectrometry, generally recorded via HPLC- MS in a fast gradient on C18-material (electrospray-ionisation (ESI) mode).
  • Example 7 1 -(3,4-Dichloro-benzyl)-7-[2-(propane-1 -sulfonylamino)-ethoxy]-1 ,2,3, 4-tetrahydro-naphthalen-2-yl ⁇ -carbamic acid ethyl ester
  • N-(2-(7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)propane- 1 -sulfonamide (example 3, 150 mg, 0.318 mmol) and triethylamine (32.2 mg, 0.318 mmol) were dissolved in THF (10 ml) and trifluoro acetic anhydride (66.8 mg, 0.318 mmol) was added. The mixture was stirred at RT for 48 h. Ethyl acetate was added and the mixture was extracted with water and then washed with a NaHCO 3 solution and a saturated NaCI solution.
  • N- ⁇ 1 -(3,4-Dichloro-benzyl)-7-[2-(1 -methyl-1 H-imidazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl ⁇ -2,2,2-trifluoro-acetamide was prepared analogously to example 1 1 using the product of example 3 in place of example 8.
  • Ethyl 1-(3,4-dichlorobenzyl)-7-(2-(1-methyl-1 H-imidazole-4-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (example3, 60.0 mg, 0.103 mmol) was dissolved in THF (5 ml) and LiAIH 4 (7.83 mg, 0.206 mmol) was added at RT. The residue was added to 2N NaOH and extracted with dichloromethane. The organic layer was washed with saturated NaHCC>3 solution and then with saturated NaCI solution, dried and evaporated.
  • Example 22 ⁇ 1 -(3,4-Dichloro-benzyl)-7-[2-(3-fluoro-propane-1 -sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl ⁇ -carbamic acid ethyl ester
  • Ethyl 1-(3,4-dichlorobenzyl)-7-(2-(1-methyl-1 H-imidazole-4-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (example 3, 60.0 mg, 0.103 mmol) was dissolved in dichloromethane (5 ml) and acetaldehyde (5.45 mg, 0.124 mmol ⁇ l) and molsieve 3 ⁇ were added and the mixture was stirred for 3h. Acetic acid (7.07 mg, 0.1 18 mmol) was added and the mixture was stirred for another 3h.
  • N- dimethylsulfuric diamide hydrochloride was prepared analogously to example 3 using di- methylsulfamoyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride.
  • Example 26
  • 1-Methyl-1 H-imidazole-4-sulfonic acid ⁇ 2-[7-amino-8-(4-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl ⁇ -amide hydrochloride was prepared analogously to example 3 using 1-methyl-1 H-imidazole-4-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4- sulfonyl chloride and 4-(bromomethyl)-1-dichlorobenzene instead of 4-(bromomethyl)-1 ,2- dichlorobenzene.
  • Example 28 1 -Methyl-1 H-pyrazole-4-sulfonic acid ⁇ 2-[7-amino-8-(4-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl ⁇ -amide hydrochloride
  • Ethyl 1-(3,4-dichlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (700 mg, 1.775 mmol, cf. example 3d) and 1 ,1 ,1-trifluoro-N-phenyl-N- (trifluoromethylsulfonyl)methanesulfonamide (761 mg, 2.13 mmol) were dissolved in di- chloromethane (30 ml_). The reaction mixture was cooled to 0 0 C and a solution of triethyl- amine (0.495 ml_, 3.55 mmol) in dichloromethane (5 ml.) was added dropwise.
  • DPPF (8.1 mg, 0.015 mmol) and Pd 2 dba 3 (3.35 mg, 0.00365 mmol) were suspended in dimethylformamide ( 0.4 ml.) and after stirring at room temperature under an inert atmosphere of nitrogen for 20 min 7-[(tert-butoxycarbonyl)amino]-8-(4-chlorobenzyl)-5,6,7,8- tetrahydronaphthalen-2-yl trifluoromethanesulfonate (38 mg, 0.073 mmol) and zinc cyanide (12.87 mg, 0.110 mmol) were added. The reaction mixture was stirred at 90 0 C for 1 h. The solvent was evaporated in vacuo.
  • Example 33 1-(3-chlorobenzyl)-7-[2-(1 ,1-dioxidoisothiazolidin-2-yl)ethoxy]-1 ,2,3,4- tetrahydronaphthalen-2-amine hydrochloride
  • Diphenylphosphinoferrocene 100 mg, 0.18 mmol
  • dipalladium trisdibenzylideneacetone 41 mg, 0.045 mmol
  • 7- [(tert-butoxycarbonyl)amino]-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate 0.5 g, 0.902 mmol
  • zinc cyanide 159 mg, 1.353 mmol
  • the compound was prepared analogously to example 40 using cyclobutylsulfonyl chloride in place of n-propane-1-sulfonyl chloride.
  • Example 54 ⁇ 1 -(3-Chloro-benzyl)-7-[2-(4-methyl-thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl ⁇ -carbamic acid ethyl ester
  • Example 59 ⁇ -Chloro-thiophene ⁇ -sulfonic acid ⁇ 2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl ⁇ -amide
  • Example 63 ⁇ 1 -(2,4-Dichloro-benzyl)-7-[2-(thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl ⁇ -carbamic acid ethyl ester
  • Example 85 Cyclohexanesulfonic acid ⁇ 2-[7-amino-8-(3,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl ⁇ -amide hydrochloride
  • Example 89 1 -Methyl-1 H-pyrazole-4-sulfonic acid ⁇ 2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1-yl-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl ⁇ -methyl-amide hydrochloride
  • Butane-1 -sulfonic acid ⁇ 2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-
  • Butane-1 -sulfonic acid ⁇ 2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl ⁇ -amide hydrochloride was prepared in analogy to example 3.
  • Example 91

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GIyT1 inhibitors.

Description

Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
Background Of The Invention
The present invention relates to aminotetraline derivatives, pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GIyTI inhibitors.
Dysfunction of glutamatergic pathways has been implicated in a number of disease states in the human central nervous system (CNS) including but not limited to schizophrenia, cognitive deficits, dementia, Parkinson disease, Alzheimer disease and bipolar disorder. A large number of studies in animal models lend support to the NMDA hypofunction hypothesis of schizophrenia.
NMDA receptor function can be modulated by altering the availability of the co-agonist glycine. This approach has the critical advantage of maintaining activity-dependent activation of the NMDA receptor because an increase in the synaptic concentration of glycine will not produce an activation of NMDA receptors in the absence of glutamate. Since syn- aptic glutamate levels are tightly maintained by high affinity transport mechanisms, an increased activation of the glycine site will only enhance the NMDA component of activated synapses.
Two specific glycine transporters, GIyTI and GlyT2 have been identified and shown to belong to the Na/CI-dependent family of neurotransmitter transporters which includes taurine, gamma-aminobutyric acid (GABA), proline, monoamines and orphan transporters. GIyTI and GlyT2 have been isolated from different species and shown to have only 50% identity at the amino acid level. They also have a different pattern of expression in mammalian central nervous system, with GlyT2 being expressed in spinal cord, brainstem and cerebellum and GIyTI present in these regions as well as forebrain areas such as cortex, hippocampus, septum and thalamus. At the cellular level, GlyT2 has been reported to be expressed by glycinergic nerve endings in rat spinal cord whereas GIyTI appears to be preferentially expressed by glial cells. These expression studies have led to the suggestion that GlyT2 is predominantly responsible for glycine uptake at glycinergic synapses whereas GIyTI is involved in monitoring glycine concentration in the vicinity of NMDA receptor expressing synapses. Recent functional studies in rat have shown that blockade of GIyTI with the potent inhibitor (N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])- sarcosine (NFPS) potentiates NMDA receptor activity and NMDA receptor-dependent long-term potentiation in rat.
M/49235-PCT Molecular cloning has further revealed the existence of three variants of GIyTI , termed GIyT-I a, GIyT-I b and GIyT-I c, each of which displays a unique distribution in the brain and peripheral tissues. The variants arise by differential splicing and exon usage, and differ in their N-terminal regions.
The physiological effects of GIyTI in forebrain regions together with clinical reports showing the beneficial effects of GIyTI inhibitor sarcosine in improving symptoms in schizophrenia patients suggest that selective GIyTI inhibitors represent a new class of antipsychotic drugs.
Glycine transporter inhibitors are already known in the art, for example:
Figure imgf000004_0001
EP 1 284 257
Figure imgf000004_0002
Figure imgf000005_0001
Figure imgf000005_0002
Figure imgf000005_0003
Figure imgf000006_0001
Figure imgf000007_0001
WO 2005037783
Figure imgf000007_0002
Figure imgf000008_0001
WO 2005037785
Figure imgf000008_0002
Figure imgf000009_0001
WO 2005023260
Figure imgf000009_0002
Figure imgf000010_0001
Figure imgf000010_0002
Figure imgf000011_0001
O
IUo
I
Figure imgf000011_0002
WO 2003087086
Figure imgf000011_0003
Figure imgf000012_0001
(see also Hashimoto K., Recent Patents on CNS Drug Discovery, 2006, 1 , 43-53; Harsing L. G. et al., Current Medicinal Chemistry, 2006, 13, 1017-1044; Javitt D. C, Molecular Psychiatry (2004) 9, 984-997; Lindsley, CW. et al., Current Topics in Medicinal Chemis- try, 2006, 6, 771-785; Lindsley CW. et al., Current Topics in Medicinal Chemistry, 2006, 6, 1883-1896).
It was one object of the present invention to provide further glycine transporter inhibitors.
Summary Of The Invention
The present invention relates to aminotetraline derivatives of the formula (I)
Figure imgf000012_0002
wherein A is a 5- or 6-membered ring;
R is R1-W-A1-Q-Y-A2-X1-;
R1 is hydrogen, alkyl, cycloalkylalkyl, halogenated alkyl, trialkylsilylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkylcarbonylaminoalkyl, alkyloxycarbonylaminoalkyl, alkylaminocarbonylaminoalkyl, dialkylaminocarbonyl- aminoalkyl, alkylsulfonylaminoalkyl, (optionally substituted arylalkyl), aminoalkyl, op- tionally substituted arylalkyl, optionally substituted heterocyclylalkyl, cycloalkyl, al- kylcarbonyl, alkoxycarbonyl, halogenated alkoxycarbonyl, aryloxycarbonyl, amino- carbonyl, alkylaminocarbonyl, (halogenated alkyl)aminocarbonyl, arylaminocar- bonyl, alkenyl , alkynyl, optionally substituted aryl, hydroxy, alkoxy, halogenated alkoxy, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, alkylaminoalkoxy, dialkylami- noalkoxy, alkylcarbonylaminoalkoxy, arylcarbonylaminoalkoxy, alkoxycarbonylami- noalkoxy, arylalkoxy, alkylsulfonylaminoalkoxy, (halogenated akyl)sulfonylaminoalkoxy, arylsulfonylaminoalkoxy, (arylalkyl)sulfonylaminoalkoxy, heterocyclylsulfonylaminoalkoxy, heterocyclylalkoxy, aryloxy, heterocyclyloxy, alkyl- thio, halogenated alkylthio, alkylamino, (halogenated alkyl)amino, dialkylamino, di- (halogenated alkyl)amino, alkylcarbonylamino, (halogenated alkyl)carbonylamino, arylcarbonylamino, alkylsulfonylamino, (halogenated alkyl)sulfonylamino, arylsul- fonylamino or optionally substituted heterocyclyl;
W is -NR8- or a bond;
A1 is optionally substituted alkylene or a bond;
Q is -S(O)2- or -C(O)-;
Y is -NR9- or a bond;
A2 is optionally substituted alkylene, alkylene-CO-, -CO-alkylene, alkylene-O-alkylene, alkylene-NR10-alkylene, optionally substituted alkenylen, optionally substituted al- kynylene, optionally substituted arylene, optionally substituted heteroarylene or a bond;
X1 is -O-, -NR11-, -S-, optionally substituted alkylene, optionally substituted alkenylen, optionally substituted alkynylene;
R2 is hydrogen, halogen, alkyl, halogenated alkyl, hydroxyalkyl, -CN, alkenyl, alkynyl, optionally substituted aryl, hydroxy, alkoxy, halogenated alkoxy, alkoxycarbonyl, al- kenyloxy, arylalkoxy, alkylcarbonyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino- sulfonyl, amino, alkylamino, alkenylamino, nitro or optionally substituted heterocy- clyl, or two radicals R2 together with the ring atoms of A to which they are bound form a 5- or 6-membered ring;
R3 is hydrogen, halogen, alkyl or alkoxy, or two radicals R3 together with the carbon atom to which they are attached form a carbonyl group;
R4a is hydrogen, alkyl, cycloalkylalkyl, halogenated alkyl, hydroxyalkyl, alkoxyalkyl, ami- noalkyl, CH2CN, -CHO, alkylcarbonyl, (halogenated alkyl)carbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, alkenyl, -C(=NH)NH2, - C(=NH)NHCN, alkylsulfonyl, arylsulfonyl, amino, -NO or heterocyclyl;
R4b is hydrogen, alkyl, halogenated alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, CH2CN, -CHO, alkylcarbonyl, (halogenated alkyl)carbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, alkenyl, -C(=NH)NH2, -C(=NH)NHCN, alkylsul- fonyl, arylsulfonyl, amino, -NO or heterocyclyl; or
R4a, R4b together are optionally substituted alkylene, wherein one -CH2- of alkylene may be replaced by an oxygen atom or -NR16;
X2 is -O-, -NR6-, -S-, >CR12aR12b or a bond;
X3 is -O-, -NR7-, -S-, >CR13aR13b or a bond; R5 is optionally substituted aryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl;
n is 0, 1 or 2;
R6 is hydrogen or alkyl;
R7 is hydrogen or alkyl;
R8 is hydrogen or alkyl;
R9 is hydrogen, alkyl, cycloalkyl, aminoalkyl, optionally substituted arylalkyl or heterocyclyl; or
R9, R1 together are alkylene; or
R9 is alkylene that is bound to a carbon atom in A2 and A2 is alkylene or to a carbon atom in X1 and X1 is alkylene;
R10 is hydrogen, alkyl or alkylsulfonyl;
R11 is hydrogen or alkyl, or
R9, R11 together are alkylene,
R12a is hydrogen, optionally substituted alkyl, alkylaminoalkyl, dialkylaminoalkyl, hetero- cyclylalkyl, optionally substituted aryl or hydroxy;
R12b is hydrogen or alkyl, or together are carbonyl or optionally substituted alkylene, wherein one -CH2- of al- kylene may be replaced by an oxygen atom or -NR14-;
R13a is hydrogen, optionally substituted alkyl, alkylaminoalkyl, dialkylaminoalkyl, hetero- cyclylalkyl, optionally substituted aryl or hydroxy;
R13b is hydrogen or alkyl, or
R13a, R13b together are carbonyl or optionally substituted alkylene, wherein one -CH2- of alkylene may be replaced by an oxygen atom or -NR15-;
R14 is hydrogen or alkyl;
R15 is hydrogen or alkyl; and
R16 is hydrogen or alkyl,
or a physiologically tolerated salt thereof.
Thus, the present invention relates to aminotetraline derivatives having the formula (Ia)
Figure imgf000016_0001
wherein A, R1, W, A1, Q, Y, A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
Fruther, the present invention relates to aminotetraline derivatives of formula (I) wherein R is -CN, i.e. aminotetraline derivatives having the formula (Ib)
Figure imgf000017_0001
wherein A, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
Thus, the term aminotetraline derivative is used herein to denote in particular ami- notetralines (n=1 ) and fused cyclohexanes (n=1 ) wherein the benzene ring is replaced by a 5- or 6-membered heterocyclic ring as well as homologous bicyclic compounds wherein n is 0 or 2.
Said compounds of formual (I), i.e., the aminotetraline derivatives of formual (I) and their physiologically tolerated acid addition salts, are glycine transporter inhibitors and thus useful as pharmaceuticals.
The present invention thus further relates to the compounds of formula (I) for use in therapy.
The present invention also relates to pharmaceutical compositions which comprise a carrier and a compound of formula (I).
In particular, said compounds, i.e., the aminotetraline derivatives and their physiologically tolerated acid addition salts, are inhibitors of the glycine transporter GIyTI .
The present invention thus further relates to the compounds of formula (I) for use in inhibiting the glycine transporter.
The present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for inhibiting the glycine transporter GIyTI and corresponding methods of inhibiting the glycine transporter GIyTL
Glycine transport inhibitors and in particular inhibitors of the glycine transporter GIyTI are known to be useful in treating a variety of neurologic and psychiatric disorders.
The present invention thus further relates to the compounds of formula (I) for use in treating a neurologic or psychiatric disorder. The present invention further relates to the compounds of formula (I) for use in treating pain.
The present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating a neurologic or psychiatric disorder and corresponding methods of treating said disorders. The present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating pain and corresponding methods of treating pain.
The present invention further relates to aminotetraline derivatives of formula (II)
Figure imgf000018_0001
wherein L is an amino-protecting group, Y is NR9, and A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n and R9 are defined as above.
The aminotetraline derivatives of formula (II) are useful as intermediates in the preparation of GIyTI inhibitors, in particular those of formula (I).
Detailed Description Of The Invention
Provided that the aminotetraline derivatives of the formula (I) or (II) of a given constitution may exist in different spatial arrangements, for example if they possess one or more centers of asymmetry, polysubstituted rings or double bonds, or as different tautomers, it is also possible to use enantiomeric mixtures, in particular racemates, diastereomeric mix- tures and tautomeric mixtures, preferably, however, the respective essentially pure enan- tiomers, diastereomers and tautomers of the compounds of formula (I) or (II) and/or of their salts.
According to one embodiment, an enantiomer of the aminotetraline derivatives of the pre- sent invention has the following formula:
Figure imgf000019_0001
wherein A, R, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
According to another embodiment, an enantiomer of the aminotetraline derivatives of the present invention has the following formula:
Figure imgf000019_0002
wherein A, R, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
According to one embodiment, an enantiomer of the aminotetraline derivatives of the present invention has the following formula:
Figure imgf000019_0003
wherein A, R, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
According to another embodiment, an enantiomer of the aminotetraline derivatives of the present invention has the following formula:
Figure imgf000020_0001
wherein A, R, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
The physiologically tolerated salts of the aminotetraline derivatives of the formula (I) or (II) are especially acid addition salts with physiologically tolerated acids. Examples of suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, d-C4-alkylsulfonic acids, such as methanesulfonic acid, cycloaliphatic sulfonic acids, such as S-(+)-10-campher sulfonic acid, aromatic sulfo- nic acids, such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having 2 to 10 carbon atoms, such as oxalic acid, malonic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, glycolic acid, adipic acid and benzoic acid. Other utilizable acids are described, e.g., in Fortschritte der Arzneimittelforschung [Advances in drug research], Volume 10, pages 224 ff., Birkhauser Verlag, Basel and Stuttgart, 1966.
The present invention moreover relates to compounds of formula (I) or (II) as defined herein, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope (e.g., hydrogen by deuterium, 12C by 13C, 14N by 15N, 16O by 18O) and preferably wherein at least one hydrogen atom has been replaced by a deuterium atom.
Of course, such compounds contain more of the respective isotope than this naturally occurs and thus is anyway present in the compounds (I) or (II).
Stable isotopes (e.g., deuterium, 13C, 15N, 18O) are nonradioactive isotopes which contain one or more additional neutron than the normally abundant isotope of the respective atom. Deuterated compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the non deuterated parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut, 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999).
Incorporation of a heavy atom particularly substitution of deuterium for hydrogen, can give rise to an isotope effect that could alter the pharmacokinetics of the drug. This effect is usually insignificant if the label is placed at a metabolically inert position of the molecule.
Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These changes may influence the fate of the drug at different steps along its passage through the body. Absorption, distribution, metabolism or excretion can be changed. Absorption and distribution are processes that depend primarily on the molecular size and the lipophilicity of the substance. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction.
Drug metabolism can give rise to large isotopic effect if the breaking of a chemical bond to a deuterium atom is the rate limiting step in the process. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: be- cause of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. In any reaction in which the breaking of this bond is the rate limiting step, the reaction will proceed slower for the molecule with the heavy isotope due to "kinetic isotope effect". A reaction involving breaking a C-D bond can be up to 700 percent slower than a similar reaction involving breaking a C-H bond. If the C-D bond is not involved in any of the steps leading to the metabolite, there may not be any effect to alter the behavior of the drug. If a deuterium is placed at a site involved in the metabolism of a drug, an isotope effect will be observed only if breaking of the C-D bond is the rate limiting step. There is evidence to suggest that whenever cleavage of an aliphatic C-H bond occurs, usually by oxidation catalyzed by a mixed-function oxidase, replacement of the hydrogen by deuterium will lead to observable isotope effect. It is also important to understand that the incorporation of deuterium at the site of metabolism slows its rate to the point where another metabolite produced by attack at a carbon atom not substituted by deuterium becomes the major pathway a process called "metabolic switching".
Deuterium tracers, such as deuterium-labeled drugs and doses, in some cases repeatedly, of thousands of milligrams of deuterated water, are also used in healthy humans of all ages, including neonates and pregnant women, without reported incident (e.g. Pons G and Rey E, Pediatrics 1999 104: 633; Coward W A et al., Lancet 1979 7: 13; Schwarcz H P, Control. Clin. Trials 1984 5(4 Suppl): 573; Rodewald L E et al., J. Pediatr. 1989 1 14: 885; Butte N F et al. Br. J. Nutr. 1991 65: 3; MacLennan A H et al. Am. J. Obstet Gynecol. 1981 139: 948). Thus, it is clear that any deuterium released, for instance, during the metabolism of compounds of this invention poses no health risk.
The weight percentage of hydrogen in a mammal (approximately 9%) and natural abundance of deuterium (approximately 0.015%) indicates that a 70 kg human normally contains nearly a gram of deuterium. Furthermore, replacement of up to about 15% of normal hydrogen with deuterium has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201 : 357). Higher deuterium concentrations, usually in excess of 20%, can be toxic in animals. However, acute replacement of as high as 15%-23% of the hydrogen in humans' fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in "Dosimetry & Treatment Planning for Neutron Capture Therapy", Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp.125-134; Diabetes Metab. 23: 251 (1997)).
Increasing the amount of deuterium present in a compound above its natural abundance is called enrichment or deuterium-enrichment. Examples of the amount of enrichment include from about 0.5, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21 , 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71 , 75, 79, 84, 88, 92, 96, to about 100 mol %.
The hydrogens present on a particular organic compound have different capacities for exchange with deuterium. Certain hydrogen atoms are easily exchangeable under physiological conditions and, if replaced by deuterium atoms, it is expected that they will readily exchange for protons after administration to a patient. Certain hydrogen atoms may be exchanged for deuterium atoms by the action of a deuteric acid such as D2S(VD2O. Alternatively, deuterium atoms may be incorporated in various combinations during the syn- thesis of compounds of the invention. Certain hydrogen atoms are not easily exchangeable for deuterium atoms. However, deuterium atoms at the remaining positions may be incorporated by the use of deuterated starting materials or intermediates during the construction of compounds of the invention.
Deuterated and deuterium-enriched compounds of the invention can be prepared by using known methods described in the literature. Such methods can be carried out utilizing corresponding deuterated and optionally, other isotope-containing reagents and/or intermediates to synthesize the compounds delineated herein, or invoking standard synthetic protocols known in the art for introducing isotopic atoms to a chemical structure. Relevant pro- cedures and intermediates are disclosed, for instance in Lizondo, J et al., Drugs Fut, 21 (11 ), 1 116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al., Org Lett, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271 , WO2006008754; US Patent Nos. 7538189; 7534814; 7531685; 7528131 ; 7521421 ; 7514068; 7511013; and US Patent Application Publication Nos.
20090137457; 20090131485; 20090131363; 200901 18238; 2009011 1840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; 20090082471 , the methods are hereby incorporated by reference.
The organic moieties mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The prefix Cn-Cm indicates in each case the possible number of carbon atoms in the group.
Unless indicated otherwise, the term "substituted" means that a radical is substituted with 1 , 2 or 3, especially 1 , substituent which are in particular selected from the group consisting of halogen, d-C4-alkyl, hydroxy-CrC4-alkyl, Cs-C^-heterocyclyl-alkyl, Ci-C4-alkoxy- Ci-C4-alkyl, amino-CrC4-alkyl, CrC4-alkenyl, OH, SH, CN, CF3, 0-CF3, COOH, 0-CH2- COOH, d-Ce-alkoxy, CrC6-alkylthio, C3-C7-cycloalkyl, COO-CrC6-alkyl, CONH2, CONH- Ci-C6-alkyl, SO2NH-CrC6-alkyl, CON-(CrC6-alkyl)2, SO2N-(Ci-C6-alkyl)2, NH2, NH-CrC6- alkyl, N-(CrC6-alkyl)2, NH-(CrC4-alkyl- C6-Ci2-aryl), NH-CO-CrC6-alkyl, NH-SO2-CrC6- alkyl, SO2-CrC6-alkyl, C6-Ci2-aryl, O-C6-Ci2-aryl, O-CH2-C6-Ci2-aryl, CONH-C6-Ci2-aryl, SO2NH-C6-Ci2-aryl, CONH-C3-Ci2-heterocyclyl, SO2NH-C3-Ci2-heterocyclyl, SO2-C6-Ci2- aryl, NH-SO2-C6-Ci2-aryl, NH-CO-C6-Ci2-aryl, NH-SO2-C3-Ci2-heterocyclyl, NH-CO-C3- Ci2-heterocyclyl and C3-Ci2-heterocyclyl, wherein aryl and heterocyclyl in turn may be unsubstituted or substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy and Ci-C4-haloalkoxy.
The term halogen denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine or chlorine.
CrC4-Alkyl is a straight-chain or branched alkyl group having from 1 to 4 carbon atoms. Examples of an alkyl group are methyl, C2-C4-alkyl such as ethyl, n-propyl, iso-propyl, n- butyl, 2-butyl, iso-butyl or tert-butyl. Ci-C2-Alkyl is methyl or ethyl, Ci-C3-alkyl is additionally n-propyl or isopropyl.
CrC6-Alkyl is a straight-chain or branched alkyl group having from 1 to 6 carbon atoms. Examples include methyl, C2-C4-alkyl as mentioned herein and also pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1- dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1 ,1 ,2-trimethylpropyl, 1 ,2,2-trimethylpropyl, 1- ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.
Halogenated CrC4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms, such as in halogenomethyl, diha- logenomethyl, trihalogenomethyl, (R)-i-halogenoethyl, (S)-i-halogenoethyl, 2- halogenoethyl, 1 ,1-dihalogenoethyl, 2,2-dihalogenoethyl, 2,2,2-trihalogenoethyl, (R)-1- halogenopropyl, (S)-i-halogenopropyl, 2-halogenopropyl, 3-halogenopropyl, 1 ,1- dihalogenopropyl, 2,2-dihalogenopropyl, 3,3-dihalogenopropyl, 3,3,3-trihalogenopropyl, (R)-2-halogeno-1 -methylethyl, (S)-2-halogeno-1 -methylethyl, (R)-2,2-dihalogeno-1 - methylethyl, (S )-2,2-dihalogeno-1 -methylethyl, (R)-1 ,2-dihalogeno-1 -methylethyl, (S)-1 ,2- dihalogeno-1 -methylethyl, (R)-2,2,2-trihalogeno-1 -methylethyl, (S)-2,2,2-trihalogeno-1- methylethyl, 2-halogeno-1 -(halogenomethyl)ethyl, 1 -(dihalogenomethyl)-2,2- dihalogenoethyl, (R)-i-halogenobutyl, (S)-i-halogenobutyl, 2-halogenobutyl, 3- halogenobutyl, 4-halogenobutyl, 1 ,1-dihalogenobutyl, 2,2-dihalogenobutyl, 3,3- dihalogenobutyl, 4,4-dihalogenobutyl, 4,4,4-trihalogenobutyl, etc. Particular examples in- elude the fluorinated C1-C4 alkyl groups as defined, such as trifluoromethyl.
C6-Ci2-Aryl-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by C6-Ci2-aryl, such as in benzyl.
Hydroxy-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein one or two hydrogen atoms are replaced by one or two hydroxyl groups, such as in hydroxy- methyl, (R)-i-hydroxyethyl, (S)-i-hydroxyethyl, 2-hydroxyethyl, (R)-i-hydroxypropyl, (S)- 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, (R)-2-hydroxy-1 -methylethyl, (S)-2- hydroxy-1 -methylethyl, 2-hydroxy-1-(hydroxymethyl)ethyl, (R)-i-hydroxybutyl, (S)-1- hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl.
Ci-C6-Alkoxy-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein one or two hydrogen atoms are replaced by one or two alkoxy groups having 1 to 6, preferably 1 to 4, in particular 1 or 2 carbon atoms, such as in methoxymethyl, (R)-i-methoxyethyl, (S)-i-methoxyethyl, 2-methoxyethyl, (R)-i-methoxypropyl, (S)-i-methoxypropyl, 2- methoxypropyl, 3-methoxypropyl, (R)-2-methoxy-1-methylethyl, (S)-2-methoxy-1- methylethyl, 2-methoxy-1-(methoxymethyl)ethyl, (R)-i-methoxybutyl, (S)-i-methoxybutyl, 2-methoxybutyl, 3-methoxybutyl, 4-methoxybutyl, ethoxymethyl, (R)-i-ethoxyethyl, (S)-1- ethoxyethyl, 2-ethoxyethyl, (R)-i-ethoxypropyl, (S)-i-ethoxypropyl, 2-ethoxypropyl, 3- ethoxypropyl, (R)-2-ethoxy-1-methylethyl, (S)-2-ethoxy-1-methylethyl, 2-ethoxy-1-
(ethoxymethyl)ethyl, (R)-i-ethoxybutyl, (S)-i-ethoxybutyl, 2-ethoxybutyl, 3-ethoxybutyl, 4- ethoxybutyl.
Amino-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by an amino group, such as in aminomethyl, 2-aminoethyl.
Ci-C6-Alkylamino-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 car- bon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a CrCβ- alkylamino group, in particular by a Ci-C4-alkylamino group, such as in methylami- nomethyl, ethylaminomethyl, n-propylaminomethyl, iso-propylaminomethyl, n- butylaminomethyl, 2-butylaminomethyl, iso-butylaminomethyl or tert-butylaminomethyl.
Di-Ci-C6-Alkylamino-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a di-CrCβ- Alkylamino group, in particular by a di-Ci-C4-alkylamino group, such as in dimethylami- nomethyl.
Ci-C6-Alkylcarbonylamino-C"i-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a d-C6- alkylcarbonylamino group, in particular by a Ci-C4-alkylcarbonylamino group, such as in methylcarbonylaminomethyl, ethylcarbonylaminomethyl, n-propylcarbonylaminomethyl, iso-propylcarbonylaminomethyl, n-butylcarbonylaminomethyl, 2- butylcarbonylaminomethyl, iso-butylcarbonylaminomethyl or tert- butylcarbonylaminomethyl.
Ci-C6-Alkylaminocarbonylamino-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a Ci-Cβ-alkylaminocarbonylamino group, in particular by a d-CU-alkylaminocarbonylamino group, such as in methylaminocarbonylaminomethyl, ethylaminocarbonylaminomethyl, n- propylaminocarbonylaminomethyl, iso-propylaminocarbonylaminomethyl, n- butylaminocarbonylaminomethyl, 2-butylaminocarbonylaminomethyl, iso- butylaminocarbonylaminomethyl or tert-butylaminocarbonylaminomethyl.
Di-Ci-C6-alkylaminocarbonylamino-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a di-Ci-C6-alkylaminocarbonylamino group, in particular by a di-Ci-C4-alkylaminocarbo- nylamino group, such as in dimethylaminocarbonylaminomethyl, dimethylaminocarbonyl- aminoethyl, dimethylaminocarbonylaminon-propyl.
Ci-C6-Alkylsulfonylamino-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a CrCβ- alkylsulfonylamino group, in particular by a Ci-C4-alkylsulfonylamino group, such as in methylsulfonylaminomethyl, ethylsulfonylaminomethyl, n-propylsulfonylaminomethyl, iso- propylsulfonylaminomethyl, n-butylsulfonylaminomethyl, 2-butylsulfonylaminomethyl, iso- butylsulfonylaminomethyl or tert-butylsulfonylaminomethyl.
(C6-Ci2-Aryl-Ci-C6-alkyl)amino-Ci-C4 alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a (C6-Ci2-aryl-Ci-C6-alkyl)amino group, in particular a (C6-Ci2-aryl-Ci-C2-alkyl)amino group, such as in benzylaminomethyl.
C3-Ci2-Heterocyclyl-Ci-C4-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by C3-Ci2- heterocyclyl, such as in N-pyrrolidinylmethyl, N-piperidinylmethyl, N-morpholinylmethyl.
C3-Ci2-Cycloalkyl is a cycloaliphatic radical having from 3 to 12 carbon atoms. In particular, 3 to 6 carbon atoms form the cyclic structure, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cyclic structure may be unsubstituted or may carry 1 , 2, 3 or 4 CrC4 alkyl radicals, preferably one or more methyl radicals.
Carbonyl is >C=O. CrCβ-Alkylcarbonyl is a radical of the formula R-C(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include acetyl, propionyl, n-butyryl, 2-methylpropionyl, pivaloyl.
Halogenated C-i-Cβ-alkylcarbonyl is C-i-Cβ-alkylcarbonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms. Examples include fluoromethylcar- bonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl. Further examples are 1 ,1 ,1- trifluoroeth-2-ylcarbonyl, 1 ,1 ,1-trifluoroprop-3-ylcarbonyl.
C6-Ci2-Arylcarbonyl is a radical of the formula R-C(O)-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include benzoyl.
Ci-C6-Alkoxycarbonyl is a radical of the formula R-O-C(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include methoxycarbonyl and tert-butyloxycarbonyl.
Halogenated Ci-C6-alkoxycarbonyl is a Ci-C6-alkoxycarbonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a cor- responding number of identical or different halogen atoms.
C6-Ci2-Aryloxycarbonyl is a radical of the formula R-O-C(O)-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenoxycarbonyl.
Cyano is -C≡N.
Aminocarbonyl is NH2C(O)-.
Ci-C6-Alkylaminocarbonyl is a radical of the formula R-NH-C(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include methylaminocarbonyl.
(Halogenated Ci-C4-alkyl)aminocarbonyl is a Ci-C4-alkylaminocarbonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different hydrogen atoms.
Ce-C^-Arylaminocarbonyl is a radical of the formula R-NH-C(O)-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylami- nocarbonyl. C2-C6-Alkenyl is a singly unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms, e.g. vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl(2- methylprop-2-en-1-yl) and the like. C3-C5-Alkenyl is, in particular, allyl, 1-methylprop-2-en- 1-yl, 2-buten-1-yl, 3-buten-1-yl, methallyl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1- methylbut-2-en-1 -yl or 2-ethylprop-2-en-1 -yl.
C2-C6-Alkynyl is a singly unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms, e.g. ethynyl, 2-propyn-1-yl, 1-propyn-1-yl, 2-propyn-2-yl and the like. C3-C5-Alkynyl is, in particular, 2-propyn-1-yl, 2-butyn-1-yl, 3-butyn-1-yl, 2-pentyn-1-yl, 3-pentyn-1-yl, 4- pentyn-1-yl.
Ci-C4-Alkylene is straight-chain or branched alkylene group having from 1 to 4 carbon atoms. Examples include methylene and ethylene. A further example is propylene.
C2-C4-Alkenylene is straight-chain or branched alkenylene group having from 2 to 4 carbon atoms.
C2-C4-Alkynylene is straight-chain or branched alkynylene group having from 2 to 4 car- bon atoms. Examples include propynylene.
C6-Ci2-Aryl is a 6- to 12-membered, in particular 6- to 10-membered, aromatic cyclic radical. Examples include phenyl and naphthyl.
C3-Ci2-Arylene is an aryl diradical. Examples include phen-1 ,4-ylene and phen-1 ,3-ylene.
Hydroxy is -OH.
Ci-C6-Alkoxy is a radical of the formula R-O-, wherein R is a straight-chain or branched alkyl group having from 1 to 6, in particular 1 to 4 carbon atoms. Examples include meth- oxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, iso-butoxy (2-methylpropoxy), tert.-butoxy pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2- dimethylpropoxy, 1-ethylpropoxy, hexyloxy, 1 ,1-dimethylpropoxy, 1 ,2-dimethylpropoxy, 1- methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 4-methylpentyloxy, 1 ,1- dimethylbutyloxy, 1 ,2-dimethylbutyloxy, 1 ,3-dimethylbutyloxy, 2,2-dimethylbutyloxy, 2,3- dimethylbutyloxy, 3,3-dimethylbutyloxy, 1-ethylbutyloxy, 2-ethylbutyloxy, 1 ,1 ,2- trimethylpropoxy, 1 ,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and 1-ethyl-2- methylpropoxy. Halogenated C-i-Cβ-alkoxy is a straight-chain or branched alkoxy group having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms, such as in halogenomethoxy, dihalogenomethoxy, trihalogenomethoxy, (R)-i-halogenoethoxy, (S)-i-halogenoethoxy, 2-halogenoethoxy, 1 ,1- dihalogenoethoxy, 2,2-dihalogenoethoxy, 2,2,2-trihalogenoethoxy, (R)-1- halogenopropoxy, (S)-i-halogenopropoxy, 2-halogenopropoxy, 3-halogenopropoxy, 1 ,1- dihalogenopropoxy, 2,2-dihalogenopropoxy, 3,3-dihalogenopropoxy, 3,3,3- trihalogenopropoxy, (R)-2-halogeno-1-methylethoxy, (S)-2-halogeno-1-methylethoxy, (R)- 2,2-dihalogeno-1-methylethoxy, (S)-2,2-dihalogeno-1-methylethoxy, (R)-1 ,2-dihalogeno-1- methylethoxy, (S)-1 ,2-dihalogeno-1-methylethoxy, (R)-2,2,2-trihalogeno-1-methylethoxy, (S)-2,2,2-trihalogeno-1 -methylethoxy, 2-halogeno-1 -(halogenomethyl)ethoxy, 1 -(dihaloge- nomethyl)-2,2-dihalogenoethoxy, (R)-i-halogenobutoxy, (S)-i-halogenobutoxy, 2- halogenobutoxy, 3-halogenobutoxy, 4-halogenobutoxy, 1 ,1-dihalogenobutoxy, 2,2- dihalogenobutoxy, 3,3-dihalogenobutoxy, 4,4-dihalogenobutoxy, 4,4,4-trihalogenobutoxy, etc. Particular examples include the fluorinated CrC4 alkoxy groups as defined, such as trifluoromethoxy.
Ci-Cβ-Hydroxyalkoxy is an alkoxy radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein, wherein one or two hydrogen atoms are replaced by hydroxy. Examples include 2-hydroxyethoxy, 3-hydroxypropoxy, 2-hydroxypropoxy, 1-methyl-2- hydroxyethoxy and the like.
Ci-C6-Alkoxy-CrC4-alkoxy is an alkoxy radical having from 1 to 4 carbon atoms, prefera- bly 1 or 2 carbon atoms as defined herein, wherein one or two hydrogen atoms are replaced by one or two alkoxy radicals having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methoxymethoxy, 2-methoxyethoxy, 1- methoxyethoxy, 3-methoxypropoxy, 2-methoxypropoxy, 1-methyl-1-methoxyethoxy, eth- oxymethoxy, 2-ethoxyethoxy, 1 -ethoxyethoxy, 3-ethoxypropoxy, 2-ethoxypropoxy, 1- methyl-1 -ethoxyethoxy and the like.
Amino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an amino group. Examples include 2-aminoethoxy.
Ci-C6-Alkylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylaminomethoxy, ethylaminomethoxy, n-propylaminomethoxy, iso- propylaminomethoxy, n-butylaminomethoxy, 2-butylaminomethoxy, iso- butylaminomethoxy, tert-butylaminomethoxy, 2-(methylamino)ethoxy, 2- (ethylamino)ethoxy, 2-(n-propylamino)ethoxy, 2-(iso-propylamino)ethoxy, 2-(n- butylamino)ethoxy, 2-(2-butylamino)ethoxy, 2-(iso-butylamino)ethoxy, 2-(tert- butylamino)ethoxy.
Di-Ci-C6-alkylamino-CrC4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a di- alkylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include dimethylaminomethoxy, diethylaminomethoxy, N-methyl-N- ethylamino)ethoxy, 2-(dimethylamino)ethoxy, 2-(diethylamino)ethoxy, 2-(N-methyl-N- ethylamino)ethoxy.
Ci-C6-Alkylcarbonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an al- kylcarbonylamino group wherein the alkyl group has from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylcarbonylaminomethoxy, ethyl- carbonylaminomethoxy, n-propylcarbonylaminomethoxy, iso- propylcarbonylaminomethoxy, n-butylcarbonylaminomethoxy, 2- butylcarbonylaminomethoxy, iso-butylcarbonylaminomethoxy, tert-butylcarbonyl- aminomethoxy, 2-(methylcarbonylamino)ethoxy, 2-(ethylcarbonylamino)ethoxy, 2-(n- propylcarbonylamino)ethoxy, 2-(iso-propylcarbonylamino)ethoxy, 2-(n- butylcarbonylamino)ethoxy, 2-(2-butylcarbonylamino)ethoxy, 2-(iso-butylcarbonyl- amino)ethoxy, 2-(tert-butylcarbonylamino)ethoxy.
C6-Ci2-Arylcarbonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a Ce- Ci2-arylcarbonylamino group as defined herein. Examples include 2- (benzoylamino)ethoxy.
Ci-C6-Alkoxycarbonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkoxycarbonylamino group wherein the alkoxy group has from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methoxycarbonylaminomethoxy, ethoxycarbonylaminomethoxy, n-propoxycarbonylaminomethoxy, iso- propoxycarbonylaminomethoxy, n-butoxycarbonylaminomethoxy, 2- butoxycarbonylaminomethoxy, iso-butoxycarbonylaminomethoxy, tert- butoxycarbonylaminomethoxy, 2-(methoxycarbonylamino)ethoxy, 2-(ethoxycarbonyl- amino)ethoxy, 2-(n-propoxycarbonylamino)ethoxy, 2-(iso-propoxycarbonylamino)ethoxy, 2-(n-butoxycarbonylamino)ethoxy, 2-(2-butoxycarbonylamino)ethoxy, 2-(iso- butoxycarbonylamino)ethoxy, 2-(tert-butoxycarbonylamino)ethoxy.
C2-C6-Alkenyloxy is a radical of the formula R-O-, wherein R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms. Examples include vinyloxy, allyloxy (2-propen-1-yloxy), 1-propen-1-yloxy, 2-propen-2-yloxy, methal- lyloxy (2-methylprop-2-en-1-yloxy) and the like. C3-C5-Alkenyloxy is, in particular, allyloxy, 1-methylprop-2-en-1-yloxy, 2-buten-1-yloxy, 3-buten-1-yloxy, methallyloxy, 2-penten-1- yloxy, 3-penten-1-yloxy, 4-penten-1-yloxy, 1-methylbut-2-en-1-yloxy or 2-ethylprop-2-en-1- yloxy.
C6-Ci2-Aryl-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C6-Ci2-aryl group as defined herein. Examples include benzyloxy.
Ci-C6-Alkylsulfonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkyl- sulfonylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include 2-(methylsulfonylamino)ethoxy, 2-(ethylsulfonylamino)ethoxy, 2- [(2-methylpropyl)sulfonylamino]ethoxy.
(Halogenated Ci-C6-alkyl)sulfonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylsulfonylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein, wherein the alkyl group is halogenated. Examples include 2- (trifluoromethylsulfonylamino)ethoxy.
C6-Ci2-Arylsulfonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C6-Ci2- arylsulfonylamino group as defined herein. Examples include 2- (phenylsulfonylamino)ethoxy, 2-(naphthylsulfonylamino)ethoxy.
(C6-Ci2-Aryl-Ci-C6-alkyl)sulfonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is re- placed by a (C6-Ci2-aryl-Ci-C6-alkyl)sulfonylamino group, preferably by a (C6-Ci2-aryl-Ci- C2-alkyl)sulfonylamino group. Examples include 2-(benzylsulfonylamino)ethoxy.
C3-Ci2-Heterocyclylsulfonylamino-Ci-C4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C3-Ci2-heterocyclylsulfonylamino group as defined herein. Examples include 2- (pyridin-3-yl-sulfonylamino)ethoxy.
C3-Ci2-Heterocyclyl-CrC4-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C3-C12- heterocyclyl group as defined herein. Examples include 2-(N-pyrrolidinyl)ethoxy, 2-(N- morpholinyl)ethoxy and 2-(N-imidazolyl)ethoxy.
Ci-C2-Alkylenedioxo is a radical of the formula -O-R-O-, wherein R is a straight-chain or branched alkylene group having from 1 or 2 carbon atoms as defined herein. Examples include methylenedioxo.
C6-Ci2-Aryloxy is a radical of the formula R-O-, wherein R is an aryl group having from 6 to 12, in particular 6 carbon atoms as defined herein. Examples include phenoxy.
C3-Ci2-Heterocyclyloxy is a radical of the formula R-O-, wherein R is a C3-Ci2-heterocyclyl group having from 3 to 12, in particular from 3 to 7 carbon atoms as defined herein. Examples include pyridin-2-yloxy.
d-Cβ-Alkylthio is a radical of the formula R-S-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylthio, ethylthio, propylthio, butylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3- methylbutylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1 ,1- dimethylpropylthio, 1 ,2-dimethylpropylthio, 1-methylpentylthio, 2-methylpentylthio, 3- methylpentylthio, 4-methylpentylthio, 1 ,1-dimethylbutylthio, 1 ,2-dimethylbutylthio, 1 ,3- dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1- ethylbutylthio, 2-ethylbutylthio, 1 ,1 ,2-trimethylpropylthio, 1 ,2,2-trimethylpropylthio, 1-ethyl- 1-methylpropyl and 1-ethyl-2-methylpropyl.
Halogenated d-C6-alkylthio is a radical of the formula R-S-, wherein R is a halogenated alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include halogenomethylthio, dihalogenomethylthio, trihalogenomethylthio, (R)- 1-halogenoethylthio, (S)-i-halogenoethylthio, 2-halogenoethylthio, 1 ,1- dihalogenoethylthio, 2,2-dihalogenoethylthio, 2,2,2-trihalogenoethylthio, (R)-1- halogenopropylthio, (S)-i-halogenopropylthio, 2-halogenopropylthio, 3- halogenopropylthio, 1 ,1-dihalogenopropylthio, 2,2-dihalogenopropylthio, 3,3-dihalo- genopropylthio, 3,3,3-trihalogenopropylthio, (R)-2-halogeno-1-methylethylthio, (S)-2- halogeno-1 -methylethylthio, (R)-2,2-dihalogeno-1 -methylethylthio, (S)-2,2-dihalogeno-1 - methylethylthio, (R)-1 ,2-dihalogeno-1 -methylethylthio, (S)-1 ,2-dihalogeno-1- methylethylthio, (R)-2,2,2-trihalogeno-1 -methylethylthio, (S)-2,2,2-trihalogeno-1 - methylethylthio, 2-halogeno-1 -(halogenomethyl)ethylthio, 1 -(dihalogenomethyl)-2,2- dihalogenoethylthio, (R)-i-halogenobutylthio, (S)-i-halogenobutylthio, 2- halogenobutylthio, 3-halogenobutylthio, 4-halogenobutylthio, 1 ,1-dihalogenobutylthio, 2,2- dihalogenobutylthio, 3,3-dihalogenobutylthio, 4,4-dihalogenobutylthio, 4,4,4- trihalogenobutylthio, etc. Particular examples include the fluorinated d-C4 alkylthio groups as defined, such as trifluoromethylthio.
Ci-C6-Alkylsulfinyl is a radical of the formula R-S(O)-, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include me- thylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, pentylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 3-methylbutylsulfinyl, 2,2-dimethylpropylsulfinyl, 1- ethylpropylsulfinyl, hexylsulfinyl, 1 ,1-dimethylpropylsulfinyl, 1 ,2-dimethylpropylsulfinyl, 1- methylpentylsulfinyl, 2-methylpentylsulfinyl, 3-methylpentylsulfinyl, 4-methylpentylsulfinyl, 1 ,1-dimethylbutylsulfinyl, 1 ,2-dimethylbutylsulfinyl, 1 ,3-dimethylbutylsulfinyl, 2,2- dimethylbutylsulfinyl, 2,3-dimethylbutylsulfinyl, 3,3-dimethylbutylsulfinyl, 1- ethylbutylsulfinyl, 2-ethylbutylsulfinyl, 1 ,1 ,2-trimethylpropylsulfinyl, 1 ,2,2- trimethylpropylsulfinyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.
Ci-Cβ-Alkylsulfonyl is a radical of the formula R-S(O )r, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, 1- methylbutylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, 2,2- dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, hexylsulfonyl, 1 ,1-dimethylpropylsulfonyl, 1 ,2-dimethylpropylsulfonyl, 1-methylpentylsulfonyl, 2-methylpentylsulfonyl, 3- methylpentylsulfonyl, 4-methylpentylsulfonyl, 1 ,1-dimethylbutylsulfonyl, 1 ,2- dimethylbutylsulfonyl, 1 ,3-dimethylbutylsulfonyl, 2,2-dimethylbutylsulfonyl, 2,3- dimethylbutylsulfonyl, 3,3-dimethylbutylsulfonyl, 1-ethylbutylsulfonyl, 2-ethylbutylsulfonyl, 1 ,1 ,2-trimethylpropylsulfonyl, 1 ,2,2-trimethylpropylsulfonyl, 1-ethyl-1-methylpropyl and 1- ethyl-2-methylpropyl.
(Halogenated CrC6-alkyl)sulfonyl is a C-i-Cβ-alkylsulfonyl as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
C6-Ci2-Arylsulfonyl is a radical of the formula R-S(O )r, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylsulfonyl. (C6-Ci2-Aryl-Ci-C4-alkyl)sulfonyl is a radical of the formula R-S(O)2-, wherein R is a C6- Ci2-aryl-Ci-C4-alkyl radical, in particular a C6-Ci2-aryl-Ci-C2-alkyl radical as defined herein. Examples include benzylsulfonyl.
C3-Ci2-Heterocyclylsulfonyl is a radical of the formula R-S(O)2-, wherein R is C3-Ci2- heterocyclyl as defined herein.
Aminosulfonyl is NH2-S(O)2-.
Ci-C6-Alkylaminosulfonyl is a radical of the formula R-NH-S(O)2- wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, iso- propylaminosulfonyl, n-butylaminosulfonyl, 2-butylaminosulfonyl, iso-butylaminosulfonyl, tert-butylaminosulfonyl.
Di-Ci-Cβ-alkylaminosulfonyl is a radical of the formula RR1N-S(O)2- wherein R and R' are independently of each other an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include dimethylaminosulfonyl, diethylaminosul- fonyl, N-methyl-N-ethylaminosulfonyl.
C6-Ci2-Arylaminosulfonyl is a radical of the formula R-NH-S(O)2- wherein R is an aryl radical having from 6 to 12, preferably 6 carbon atoms as defined herein.
Amino is NH2.
Ci-C6-Alkylamino is a radical of the formula R-NH- wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include methylamino, ethylamino, n-propylamino, iso-propylamino, n-butylamino, 2-butylamino, iso-butylamino, tert-butylamino.
(Halogenated Ci-C6-alkyl)amino is a Ci-Cβ-alkylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
Di-d-Cβ-alkylamino is a radical of the formula RR'N- wherein R and R' are independently of each other an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include dimethylamino, diethylamino, N-methyl-N-ethylamino. Di-(halogenated Ci-C6-alkyl)amino is a di-CrC6-alkylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
d-Cβ-Alkylcarbonylamino is a radical of the formula R-C(O)-NH-, wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include acetamido (methylcarbonylamino), propionamido, n-butyramido, 2- methylpropionamido (isopropylcarbonylamino), 2,2-dimethylpropionamido and the like.
(Halogenated Ci-C6-alkyl)carbonylamino is a Ci-C6-alkylcarbonylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
C6-Ci2-Arylcarbonylamino is a radical of the formula R-C(O)-NH-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylcar- bonylamino.
C2-C6-Alkenylamino is a radical of the formula R-NH-, wherein R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms. Examples include vinylamino, allylamino (2-propen-1-ylamino), 1-propen-1-ylamino, 2-propen-2- ylamino, methallylamino (2-methylprop-2-en-1-ylamino) and the like. C3-C5-Alkenylamino is, in particular, allylamino, 1-methylprop-2-en-1-ylamino, 2-buten-1-ylamino, 3-buten-1- ylamino, methallylamino, 2-penten-1-ylamino, 3-penten-1-ylamino, 4-penten-1-ylamino, 1- methylbut-2-en-1 -ylamino or 2-ethylprop-2-en-1 -ylamino.
Ci-C6-Alkylsulfonylamino is a radical of the formula R-S(O)2-NH-, wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include methylsulfonylamino, ethylsulfonylamino, n-propylsulfonylamino, iso- propylsulfonylamino, n-butylsulfonylamino, 2-butylsulfonylamino, iso-butylsulfonylamino, tert-butylsulfonylamino.
(Halogenated C-i-Cβ alkyl)sulfonylamino is a Ci-C6-alkylsulfonylamino as defined herein, wherein at least one, e.g. 1 , 2, 3, 4 or all of the hydrogen atoms are replaced by 1 , 2, 3, 4 or a corresponding number of identical or different halogen atoms.
C6-Ci2-Arylsulfonylamino is a radical of the formula R-S(O)2-NH-, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylsul- fonylamino. Nitro is -NO2.
C3-Ci2-Heterocyclyl is a 3- to 12-membered heterocyclic radical including a saturated heterocyclic radical, which generally has 3, 4, 5, 6, or 7 ring forming atoms (ring members), an unsaturated non-aromatic heterocyclic radical, which generally has 5, 6 or 7 ring forming atoms, and a heteroaromatic radical (hetaryl), which generally has 5, 6 or 7 ring forming atoms. The heterocyclic radicals may be bound via a carbon atom (C-bound) or a nitrogen atom (N-bound). Preferred heterocyclic radicals comprise 1 nitrogen atom as ring member atom and optionally 1 , 2 or 3 further heteroatoms as ring members, which are selected, independently of each other from O, S and N. Likewise preferred heterocyclic radicals comprise 1 heteroatom as ring member, which is selected from O, S and N, and optionally 1 , 2 or 3 further nitrogen atoms as ring members.
Examples of C3-Ci2-heterocyclyl include:
C- or N-bound 3-4-membered, saturated rings, such as
2-oxiranyl, 2-oxetanyl, 3-oxetanyl, 2-aziridinyl, 3-thiethanyl, 1-azetidinyl, 2-azetidinyl, 3- azetidinyl;
C-bound, 5-membered, saturated rings, such as tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetra- hydropyrrol-2-yl, tetrahydropyrrol-3-yl, tetrahydropyrazol-3-yl, tetrahydro-pyrazol-4-yl, tet- rahydroisoxazol-3-yl, tetrahydroisoxazol-4-yl, tetrahydroisoxazol-5-yl, 1 ,2-oxathiolan-3-yl, 1 ,2-oxathiolan-4-yl, 1 ,2-oxathiolan-5-yl, tetrahydroisothiazol-3-yl, tetrahydroisothiazol-4-yl, tetrahydroisothiazol-5-yl, 1 ,2-dithiolan-3-yl, 1 ,2-dithiolan-4-yl, tetrahydroimidazol-2-yl, tet- rahydroimidazol-4-yl, tetrahydrooxazol-2-yl, tetrahydrooxazol-4-yl, tetrahydrooxazol-5-yl, tetrahydrothiazol-2-yl, tetrahydrothiazol-4-yl, tetrahydrothiazol-5-yl, 1 ,3-dioxolan-2-yl, 1 ,3- dioxolan-4-yl, 1 ,3-oxathiolan-2-yl, 1 ,3-oxathiolan-4-yl, 1 ,3-oxathiolan-5-yl, 1 ,3-dithiolan-2- yl, 1 ,3-dithiolan-4-yl, 1 ,3,2-dioxathiolan-4-yl;
C-bound, 6-membered, saturated rings, such as tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, piperidin-2-yl, piperidin-3- yl, piperidin-4-yl, tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4- yl, 1 ,3-dioxan-2-yl, 1 ,3-dioxan-4-yl, 1 ,3-dioxan-5-yl, 1 ,4-dioxan-2-yl, 1 ,3-dithian-2-yl, 1 ,3- dithian-4-yl, 1 ,3-dithian-5-yl, 1 ,4-dithian-2-yl, 1 ,3-oxathian-2-yl, 1 ,3-oxathian-4-yl, 1 ,3- oxathian-5-yl, 1 ,3-oxathian-6-yl, 1 ,4-oxathian-2-yl, 1 ,4-oxathian-3-yl, 1 ,2-dithian-3-yl, 1 ,2- dithian-4-yl, hexahydropyrimidin-2-yl, hexahydropyrimidin-4-yl, hexahydropyrimidin-5-yl, hexahydropyrazin-2-yl, hexahydropyridazin-3-yl, hexahydropyridazin-4-yl, tetra hydro- 1 ,3- oxazin-2-yl, tetrahydro-1 ,3-oxazin-4-yl, tetrahydro-1 ,3-oxazin-5-yl, tetrahydro-1 ,3-oxazin- 6-yl, tetrahydro-1 ,3-thiazin-2-yl, tetrahydro-1 ,3-thiazin-4-yl, tetrahydro-1 ,3-thiazin-5-yl, tetrahydro-1 ,3-thiazin-6-yl, tetrahydro-1 ,4-thiazin-2-yl, tetrahydro-1 ,4-thiazin-3-yl, tetrahy- dro-1 ,4-oxazin-2-yl, tetrahydro-1 ,4-oxazin-3-yl, tetrahydro-1 ,2-oxazin-3-yl, tetrahydro-1 ,2- oxazin-4-yl, tetrahydro-1 ,2-oxazin-5-yl, tetrahydro-1 ,2-oxazin-6-yl;
N-bound, 5-membered, saturated rings, such as tetrahydropyrrol-1-yl (pyrrolidin-1-yl), tetrahydropyrazol-1-yl, tetrahydroisoxazol-2-yl, tetra- hydroisothiazol-2-yl, tetrahydroimidazol-1-yl, tetrahydrooxazol-3-yl, tetrahydrothiazol-3-yl;
N-bound, 6-membered, saturated rings, such as piperidin-1-yl, hexahydropyrimidin-1-yl, hexahydropyrazin-1-yl (piperazin-1-yl), hexahydro- pyridazin-1-yl, tetrahydro-1 ,3-oxazin-3-yl, tetrahydro-1 ,3-thiazin-3-yl, tetrahydro-1 ,4- thiazin-4-yl, tetrahydro-1 ,4-oxazin-4-yl (morpholin-1-yl), tetrahydro-1 ,2-oxazin-2-yl;
C-bound, 5-membered, partially unsaturated rings, such as
2,3-dihydrofuran-2-yl, 2,3-dihydrofuran-3-yl, 2,5-dihydrofuran-2-yl, 2,5-di-hydrofuran-3-yl, 4,5-dihydrofuran-2-yl, 4,5-dihydrofuran-3-yl, 2,3-dihydro-thien-2-yl, 2,3-dihydrothien-3-yl, 2,5-dihydrothien-2-yl, 2,5-dihydrothien-3-yl, 4,5-dihydrothien-2-yl, 4,5-dihydrothien-3-yl, 2,3-dihydro-1 H-pyrrol-2-yl, 2,3-dihydro-1 H-pyrrol-3-yl, 2,5-dihydro-1 H-pyrrol-2-yl, 2,5- dihydro-1 H-pyrrol-3-yl, 4,5-dihydro-1 H-pyrrol-2-yl, 4,5-dihydro-1 H-pyrrol-3-yl, 3,4-dihydro- 2H-pyrrol-2-yl, 3,4-dihydro-2H-pyrrol-3-yl, 3,4-dihydro-5H-pyrrol-2-yl, 3,4-dihydro-5H- pyrrol-3-yl, 4,5-dihydro-1 H-pyrazol-3-yl, 4,5-dihydro-1 H-pyrazol-4-yl, 4,5-dihydro-1 H- pyrazol-5-yl, 2,5-dihydro-1 H-pyrazol-3-yl, 2,5-dihydro-1 H-pyrazol-4-yl, 2,5-dihydro-1 H- pyrazol-5-yl, 4,5-dihydroisoxazol-3-yl, 4,5-dihydroisoxazol-4-yl, 4,5-dihydroisoxazol-5-yl, 2,5-dihydroisoxazol-3-yl, 2,5-dihydroisoxazol-4-yl, 2,5-dihydroisoxazol-5-yl, 2,3- dihydroisoxazol-3-yl, 2,3-dihydroisoxazol-4-yl, 2,3-dihydroisoxazol-5-yl, 4,5- dihydroisothiazol-3-yl, 4,5-dihydroisothiazol-4-yl, 4,5-dihydroisothiazol-5-yl, 2,5- dihydroisothiazol-3-yl, 2,5-dihydroisothiazol-4-yl, 2,5-dihydroisothiazol-5-yl, 2,3- dihydroisothiazol-3-yl, 2,3-dihydroisothiazol-4-yl, 2,3-dihydroisothiazol-5-yl, 4,5-dihydro- 1 H-imidazol-2-yl, 4,5-dihydro-1 H-imidazol-4-yl, 4,5-dihydro-1 H-imidazol-5-yl, 2,5-dihydro- 1 H-imidazol-2-yl, 2, 5-dihydro-1 H-imidazol-4-yl, 2, 5-dihydro-1 H-imidazol-5-yl, 2,3-dihydro- 1 H-imidazol-2-yl, 2, 3-dihydro-1 H-imidazol-4-yl, 4,5-dihydro-oxazol-2-yl, 4,5-dihydrooxazol- 4-yl, 4,5-dihydrooxazol-5-yl, 2,5-dihydrooxazol-2-yl, 2,5-dihydrooxazol-4-yl, 2,5- dihydrooxazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 4,5-dihydrothiazol-2-yl, 4,5-dihydrothiazol-4-yl, 4,5-dihydrothiazol-5-yl, 2,5-dihydrothiazol- 2-yl, 2,5-dihydrothiazol-4-yl, 2,5-dihydrothiazol-5-yl, 2,3-dihydrothiazol-2-yl, 2,3-dihydro- thiazol-4-yl, 2,3-dihydrothiazol-5-yl, 1 ,3-dioxol-2-yl, 1 ,3-dioxol-4-yl, 1 ,3-dithiol-2-yl, 1 ,3- dithiol-4-yl, 1 ,3-oxathiol-2-yl, 1 ,3-oxathiol-4-yl, 1 ,3-oxathiol-5-yl; C-bound, 6-membered, partially unsaturated rings, such as
2H-3,4-dihydropyran-6-yl, 2H-3,4-dihydropyran-5-yl, 2H-3,4-dihydropyran-4-yl, 2H-3.4- dihydropyran-3-yl, 2H-3,4-dihydropyran-2-yl, 2H-3,4-dihydrothiopyran-6-yl, 2H-3.4- dihydrothiopyran-5-yl, 2H-3,4-dihydrothiopyran-4-yl, 2H-3,4-dihydrothiopyran-3-yl, 2H-3,4- dihydrothiopyran-2-yl, 1 ,2,3,4-tetrahydropyridin-6-yl, 1 ,2,3,4-tetrahydropyridin-5-yl,
1 ,2,3,4-tetrahydropyridin-4-yl, 1 ,2,3,4-tetra-hydropyridin-3-yl, 1 ,2,3,4-tetrahydropyridin-2- yl, 2H-5,6-dihydropyran-2-yl, 2H-5,6-dihydropyran-3-yl, 2H-5,6-dihydropyran-4-yl, 2H-5.6- dihydropyran-5-yl, 2H-5,6-dihydropyran-6-yl, 2H-5,6-dihydrothiopyran-2-yl, 2H-5,6- dihydrothiopyran-3-yl, 2H-5,6-dihydrothiopyran-4-yl, 2H-5,6-dihydrothiopyran-5-yl, 2H-5,6- dihydrothiopyran-6-yl, 1 ,2,5,6-tetrahydropyridin-2-yl, 1 ,2,5,6-tetrahydropyridin-3-yl,
1 ,2,5,6-tetrahydropyridin-4-yl, 1 ,2,5,6-tetrahydropyridin-5-yl, 1 ,2,5,6-tetrahydropyridin-6-yl, 2,3,4,5-tetrahydropyridin-2-yl, 2,3,4,5-tetrahydropyridin-3-yl, 2,3,4,5-tetrahydropyridin-4-yl, 2,3,4,5-tetrahydropyridin-5-yl, 2,3,4,5-tetrahydropyridin-6-yl, 4H-pyran-2-yl, 4H-pyran-3-yl- , 4H-pyran-4-yl, 4H-thiopyran-2-yl, 4H-thiopyran-3-yl, 4H-thiopyran-4-yl, 1 ,4- dihydropyridin-2-yl, 1 ,4-dihydropyridin-3-yl, 1 ,4-dihydropyridin-4-yl, 2H-pyran-2-yl, 2H- pyran-3-yl, 2H-pyran-4-yl, 2H-pyran-5-yl, 2H-pyran-6-yl, 2H-thiopyran-2-yl, 2H-thiopyran- 3-yl, 2H-thiopyran-4-yl, 2H-thiopyran-5-yl, 2H-thiopyran-6-yl, 1 ,2-dihydropyridin-2-yl, 1 ,2- dihydro-pyridin-3-yl, 1 ,2-dihydropyridin-4-yl, 1 ,2-dihydropyridin-5-yl, 1 ,2-dihydro-pyridin-6- yl, 3,4-dihydropyridin-2-yl, 3,4-dihydropyridin-3-yl, 3,4-dihydro-pyridin-4-yl, 3,4- dihydropyridin-5-yl, 3,4-dihydropyridin-6-yl, 2,5-dihydropyridin-2-yl, 2,5-dihydropyridin-3-yl, 2,5-dihydropyridin-4-yl, 2,5-dihydropyridin-5-yl, 2,5-dihydropyridin-6-yl, 2,3-dihydropyridin- 2-yl, 2,3-dihydropyridin-3-yl, 2,3-dihydropyridin-4-yl, 2,3-dihydropyridin-5-yl, 2,3- dihydropyridin-6-yl, 2H-5,6-dihydro-1 ,2-oxazin-3-yl, 2H-5,6-dihydro-1 ,2-oxazin-4-yl, 2H- 5,6-dihydro-1 ,2-oxazin-5-yl, 2H-5,6-dihydro-1 ,2-oxazin-6-yl, 2H-5,6-dihydro-1 ,2-thiazin-3- yl, 2H-5,6-dihydro-1 ,2-thiazin-4-yl, 2H-5,6-dihydro-1 ,2-thiazin-5-yl, 2H-5,6-dihydro-1 ,2- thiazin-6-yl, 4H-5,6-dihydro-1 ,2-oxazin-3-yl, 4H-5,6-dihydro-1 ,2-oxazin-4-yl, 4H-5,6-di- hydro-1 ,2-oxazin-5-yl, 4H-5,6-dihydro-1 ,2-oxazin-6-yl, 4H-5,6-dihydro-1 ,2-thiazin-3-yl, 4H- 5,6-dihydro-1 ,2-thiazin-4-yl, 4H-5,6-dihydro-1 ,2-thiazin-5-yl, 4H-5,6-dihydro-1 ,2-thiazin-6- yl, 2H-3,6-dihydro-1 ,2-oxazin-3-yl, 2H-3,6-dihydro-1 ,2-oxazin-4-yl, 2H-3,6-dihydro-1 ,2- oxazin-5-yl, 2H-3,6-dihydro-1 ,2-oxazin-6-yl, 2H-3,6-dihydro-1 ,2-thiazin-3-yl, 2H-3,6- dihydro-1 ,2-thiazin-4-yl, 2H-3,6-dihydro-1 ,2-thiazin-5-yl, 2H-3,6-dihydro-1 ,2-thiazin-6-yl, 2H-3,4-dihydro-1 ,2-oxazin-3-yl, 2H-3,4-dihydro-1 ,2-oxazin-4-yl, 2H-3,4-dihydro-1 ,2- oxazin-5-yl, 2H-3,4-dihydro-1 ,2-oxazin-6-yl, 2H-3,4-dihydro-1 ,2-thiazin-3-yl, 2H-3,4- dihydro-1 ,2-thiazin-4-yl, 2H-3,4-dihydro-1 ,2-thiazin-5-yl, 2H-3,4-dihydro-1 ,2-thiazin-6-yl, 2,3,4,5-tetrahydropyridazin-3-yl, 2,3,4,5-tetrahydropyridazin-4-yl, 2,3,4,5- tetrahydropyridazin-5-yl, 2,3,4,5-tetrahydropyridazin-6-yl, 3,4,5,6-tetrahydropyridazin-3-yl, 3,4,5,6-tetrahydropyridazin-4-yl, 1 ,2,5,6-tetrahydropyridazin-3-yl, 1 ,2,5,6- tetrahydropyridazin-4-yl, 1 ,2,5,6-tetra-hydropyridazin-5-yl, 1 ,2,5,6-tetrahydropyridazin-6-yl, 1 ,2,3,6-tetrahydro-pyridazin-3-yl, 1 ,2,3,6-tetrahydropyridazin-4-yl, 4H-5,6-dihydro-1 ,3- oxazin-2-yl, 4H-5,6-dihydro-1 ,3-oxazin-4-yl, 4H-5,6-dihydro-1 ,3-oxazin-5-yl, 4H-5,6- dihydro-1 ,3-oxazin-6-yl, 4H-5,6-dihydro-1 ,3-thiazin-2-yl, 4H-5,6-dihydro-1 ,3-thiazin-4-yl, 4H-5,6-dihydro-1 ,3-thiazin-5-yl, 4H-5,6-dihydro-1 ,3-thiazin-6-yl, 3,4,5-6- tetrahydropyrimidin-2-yl, 3,4,5,6-tetrahydropyrimidin-4-yl, 3,4,5,6-tetrahydropyrimidin-5-yl, 3,4,5,6-tetrahydropyrimidin-6-yl, 1 ,2,3,4-tetrahydropyrazin-2-yl, 1 ,2,3,4-tetrahydropyrazin- 5-yl, 1 ,2,3,4-tetrahydro-pyrimidin-2-yl, 1 ,2,3,4-tetrahydropyrimidin-4-yl, 1 ,2,3,4- tetrahydropyrimidin-5-yl, 1 ,2,3,4-tetrahydropyrimidin-6-yl, 2,3-dihydro-1 ,4-thiazin-2-yl, 2,3- dihydro-1 ,4-thiazin-3-yl, 2,3-dihydro-1 ,4-thiazin-5-yl, 2,3-dihydro-1 ,4-thiazin-6-yl, 2H-1 ,3- oxazin-2-yl, 2H-1 ,3-oxazin-4-yl, 2H-1 ,3-oxazin-5-yl, 2H-1 ,3-oxazin-6-yl, 2H-1 ,3-thiazin-2- yl, 2H-1 ,3-thiazin-4-yl, 2H-1 ,3-thiazin-5-yl, 2H-1 ,3-thiazin-6-yl, 4H-1 ,3-oxazin-2-yl, 4H-1 ,3- oxazin-4-yl, 4H-1 ,3-oxazin-5-yl, 4H-1 ,3-oxazin-6-yl, 4H-1 ,3-thiazin-2-yl, 4H-1 ,3-thiazin-4- yl, 4H-1 ,3-thiazin-5-yl, 4H-1 ,3-thiazin-6-yl, 6H-1 ,3-oxazin-2-yl, 6H-1 ,3-oxazin-4-yl, 6H-1 ,3- oxazin-5-yl, 6H-1 ,3-oxazin-6-yl, 6H-1 ,3-thiazin-2-yl, 6H-1 ,3-oxazin-4-yl, 6H-1 ,3-oxazin-5- yl, 6H-1 ,3-thiazin-6-yl, 2H-1 ,4-oxazin-2-yl, 2H-1 ,4-oxazin-3-yl, 2H-1 ,4-oxazin-5-yl, 2H-1 ,4- oxazin-6-yl, 2H-1 ,4-thiazin-2-yl, 2H-1 ,4-thiazin-3-yl, 2H-1 ,4-thiazin-5-yl, 2H-1 ,4-thiazin-6- yl, 4H-1 ,4-oxazin-2-yl, 4H-1 ,4-oxazin-3-yl, 4H-1 ,4-thiazin-2-yl, 4H-1 ,4-thiazin-3-yl, 1 ,4- dihydropyridazin-3-yl, 1 ,4-dihydropyridazin-4-yl, 1 ,4-dihydropyridazin-5-yl, 1 ,4- dihydropyridazin-6-yl, 1 ,4-dihydropyrazin-2-yl, 1 ,2-dihydropyrazin-2-yl, 1 ,2-dihydropyrazin- 3-yl, 1 ,2-dihydropyrazin-5-yl, 1 ,2-dihydropyrazin-6-yl, 1 ,4-dihydropyrimidin-2-yl, 1 ,4- dihydropyrimidin-4-yl, 1 ,4-dihydropyrimidin-5-yl, 1 ,4-dihydropyrimidin-6-yl, 3,4- dihydropyrimidin-2-yl, 3,4-dihydropyrimidin-4-yl, 3,4-dihydropyrimidin-5-yl or 3,4- dihydropyrimidin-6-yl;
N-bound, 5-membered, partially unsaturated rings, such as 2,3-dihydro-1 H-pyrrol-1-yl, 2,5-dihydro-1 H-pyrrol-1-yl, 4,5-dihydro-1 H-pyrazol-1-yl, 2,5- dihydro-1 H-pyrazol-1-yl, 2,3-dihydro-1 H-pyrazol-1-yl, 2,5-dihydroisoxazol-2-yl, 2,3- dihydroisoxazol-2-yl, 2,5-dihydroisothiazol-2-yl, 2,3-dihydroisoxazol-2-yl, 4,5-dihydro-1 H- imidazol-1-yl, 2,5-dihydro-1 H-imidazol-1-yl, 2,3-dihydro-1 H-imidazol-1-yl, 2,3- dihydrooxazol-3-yl, 2,3-dihydrothiazol-3-yl;
N-bound, 6-membered, partially unsaturated rings, such as
1 ,2,3,4-tetrahydropyridin-1-yl, 1 ,2,5,6-tetrahydropyridin-1-yl, 1 ,4-dihydro-pyridin-1-yl, 1 ,2- dihydropyridin-1-yl, 2H-5,6-dihydro-1 ,2-oxazin-2-yl, 2H-5,6-dihydro-1 ,2-thiazin-2-yl, 2H- 3,6-dihydro-1 ,2-oxazin-2-yl, 2H-3,6-dihydro-1 ,2-thiazin-2-yl, 2H-3,4-dihydro-1 ,2-oxazin-2- yl, 2H-3,4-dihydro-1 ,2-thiazin-2-yl, 2,3,4,5-tetrahydropyridazin-2-yl, 1 ,2,5,6- tetrahydropyridazin-1 -yl, 1 ,2,5,6-tetrahydropyridazin-2-yl, 1 ,2,3,6-tetrahydropyridazin-1 -yl, 3,4,5,6-tetrahydropyrimidin-3-yl, 1 ,2,3,4-tetrahydropyrazin-1-yl, 1 ,2,3,4- tetrahydropyrimidin-1-yl, 1 ,2,3,4-tetrahydropyrimidin-3-yl, 2,3-dihdro-1 ,4-thiazin-4-yl, 2H- 1 ,2-oxazin-2-yl, 2H-1 ,2-thiazin-2-yl, 4H-1 ,4-oxazin-4-yl, 4H-1 ,4-thiazin-4-yl, 1 ,4- dihydropyridazin-1-yl, 1 ,4-dihydropyrazin-i-yl, 1 ,2-dihydropyrazin-i-yl, 1 ,4- dihydropyrimidin-1-yl or 3,4-dihydropyrimidin-3-yl;
C-bound, 5-membered, heteroaromatic rings, such as 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, pyrrol-2-yl, pyrrol-3-yl, pyrazol-3-yl, pyrazol-4-yl, isoxa- zol-3-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, imida- zol-2-yl, imidazol-4-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thia- zol-5-yl, 1 ,2,3-oxadiazol-4-yl, 1 ,2,3-oxadiazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4,-oxadiazol-5- yl, 1 ,3,4-oxadiazol-2-yl, 1 ,2,3-thiadiazol-4-yl, 1 ,2,3-thiadiazol-5-yl, 1 ,2,4-thiadiazol-3-yl, 1 ,2,4-thiadiazol-5-yl, 1 ,3,4-thiadiazolyl-2-yl, 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl, tetrazol-5- yi;
C-bound, 6-membered, heteroaromatic rings, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl (4-pyridyl), pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2- yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, 1 ,3,5-triazin-2-yl, 1 ,2,4-triazin-3-yl, 1 ,2,4- triazin-5-yl, 1 ,2,4-triazin-6-yl, 1 ,2,4,5-tetrazin-3-yl;
N-bound, 5-membered, heteroaromatic rings, such as pyrrol-1-yl, pyrazol-1-yl, imidazol-1-yl, 1 ,2,3-triazol-1-yl, 1 ,2,4-triazol-1-yl, tetrazol-1-yl.
Heterocyclyl also includes bicyclic heterocycles, which comprise one of the described 5- or 6-membered heterocyclic rings and a further anellated, saturated or unsaturated or aromatic carbocycle, such as a benzene, cyclohexane, cyclohexene or cyclohexadiene ring, or a futher anellated 5- or 6-membered heterocyclic ring, this heterocyclic ring being saturated or unsaturated or aromatic. These include quinolinyl, isoquinolinyl, indolyl, indol- izinyl, isoindolyl, indazolyl, benzofuryl, benzthienyl, benzo[b]thiazolyl, benzoxazolyl, benzthiazolyl and benzimidazolyl. Examples of 5- or 6-membered heteroaromatic compounds comprising an anellated cycloalkenyl ring include dihydroindolyl, dihydroindoliz- inyl, dihydroisoindolyl, dihydrochinolinyl, dihydroisoquinolinyl, chromenyl and chromanyl.
C3-Ci2-Heteroarylene is a heteroaryl diradical. Examples include pyrid-2,5-ylene and pyrid-2,4-ylene.
With respect to the compounds' capability of inhibiting glycine transporter 1 , the variables A, R, R1, W, A1, Q, Y, A2, X1, R2, R3, R4, X2, X3, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, n preferably have the following meanings which, when taken alone or in combination, represent particular embodiments of the aminotetraline derivatives of the formula (I), (II) or any other formula disclosed herein. In said formula (I) or (II), there may be one or more than one substituent R, R2 and/or R3. More particularly, there may be up to 3 substituents R2, and up to 6 substituents R3. Preferably there is one substituent R and 1 , 2 or 3 substituents R2. Formula (I) may thus be depicted as follows:
Figure imgf000041_0001
wherein a is 1 , 2 or 3, b is 1 , 2, 3, 4, 5 or 6 and c is 1. If there is more than one radical R2, these may be the same or different radicals. If there is more than one radical R3, these may be the same or different radicals.
A is a 5- or 6-membered ring which includes two carbon atoms from the cyclopentane, cyclohexane or cycloheptane moiety to which A is fused. A may be a homocyclic or heterocyclic ring. The ring may be saturated, unsaturated non-aromatic or aromatic. According to a particular embodiment, A is a benzene ring. As a heterocyclic ring, A may include 1 , 2 or 3 heteroatoms as ring member atoms, which are selected, independently of each other from N, S and O. Preferred heterocyclic rings comprise 1 nitrogen atom as ring member atom and optionally 1 or 2 further heteroatoms as ring members, which are selected, independently of each other from O, S and N. Likewise preferred heterocyclic radicals comprise 1 heteroatom as ring member atom, which is selected from O, S and N, and optionally 1 or 2 further nitrogen atoms as ring member atoms. According to a particular embodiment, A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
Figure imgf000042_0001
Figure imgf000042_0002
In said formulae, hydrogen atoms are not depicted. This is meant to illustrate that the free valency of a carbon or nitrogen atom may be either bound to a hydrogen atom, to R or to R2. Accordingly, R and R2 may be C- or N-bound at any position of ring A.
The skilled person will appreciate that some of the rings depicted above may be represented with a different structure, e.g. with hydrogen atoms having other positions than those shown above, for instance as given in the following structures:
Figure imgf000043_0001
Preferably, A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
Figure imgf000043_0002
According to a further particular embodiment, A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
Figure imgf000044_0001
According to a perferred embodiment, A is a heterocyclic ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
Figure imgf000044_0002
and
Figure imgf000044_0003
If ring A is a 5-membered heterocyclic ring it is preferred that R is bound to G1 or G2, in particular G2:
Figure imgf000044_0004
In said formula, G1, G2 and G3 independently are -CH=, -CH2-, -N=, -NH-, S or O, the dotted line represents a single or a double bond and R3, R4, X2, X3, R5 are as defined herein.
If ring A is 6-membered heterocyclic ring it is preferred that R is bound to G1 or G2, in particular G2:
Figure imgf000045_0001
In said formula, G1, G2, G3 and G4 independently are -CH=, -CH2-, -N=, -NH-, S or O, the dotted line represents a single or a double bond and R3, R4, X2, X3, R5 are as defined herein.
Heterocyclic compounds having the following partial structures are preferred:
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000047_0002
Figure imgf000047_0003
Heterocyclic compounds having the following partial structures are particularly preferred:
Figure imgf000048_0001
Figure imgf000048_0002
Figure imgf000048_0004
Figure imgf000048_0003
In said formulae, R and R2 are as defined herein. If there is more than one radical R2, these may be the same or different radicals.
According to a particular embodiment, the partial structures depicted above are fused with a cyclohexane moiety (i.e., n is 1 ). The same applies to the preferred and particular embodiments disclosed for ring A.
According to one embodiment, R is cyano.
Preferably, R is R1-W-A1-Q-Y-A2-X1- and A, R1, W, A1, Q, Y, A2, X1, R2, R3, R4a, R4b, X2, X3, R5 are as defined herein.
R1 is hydrogen, d-C6-alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl, a further example being n-butyl or n-pentyl), C3-Ci2-cycloalkyl-Ci-C4-alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl, a further example being cyclopropylmethyl), halogenated CrCβ-alkyl (e.g. 3-fluoroprop-1-yl, 3-chloroprop-1-yl or 3,3,3-trifluoroprop-1-yl), hydroxy-Ci-C4-alkyl, Ci-C6-alkoxy-Ci-C4-alkyl (e.g. ethoxyethyl), amino-Ci-C4-alkyl, Ci-C6-alkylamino-CrC4- alkyl, di-Ci-C6-alkylamino-Ci-C4-alkyl, Ci-C6-alkylcarbonylamino-Ci-C4-alkyl, CrC6- alkyloxycarbonylamino-Ci-C4-alkyl, Ci-C6-alkylaminocarbonylamino-Ci-C4-alkyl, di-Ci-C6- alkylaminocarbonylamino-Ci-C4-alkyl, Ci-C6-alkylsulfonylamino-CrC4-alkyl, (optionally substituted C6-Ci2-aryl-Ci-C6-alkyl)amino-Ci-C4-alkyl, optionally substituted C6-Ci2-aryl- Ci-C4-alkyl, optionally substituted C3-Ci2-heterocyclyl-Ci-C4-alkyl, C3-Ci2-cycloalkyl (e.g. cyclopropyl or cyclobutyl), CrC6-alkylcarbonyl, CrC6-alkoxycarbonyl, halogenated CrC6- alkoxycarbonyl, C6-Ci2-aryloxycarbonyl, aminocarbonyl, Ci-Ce-alkylaminocarbonyl, (halogenated CrC4-alkyl)aminocarbonyl, CerC^-arylaminocarbonyl, C2-C6-alkenyl (e.g. prop- 1 ,2-en-1 -yl), C2-C6-alkynyl, optionally substituted C6-Ci2-aryl (e.g. phenyl, a further example being 2-methylphenyl), hydroxy, Ci-C6-alkoxy (e.g. tert-butyloxy), halogenated CrC6- alkoxy, CrC6-hydroxyalkoxy, Ci-C6-alkoxy-CrC4-alkoxy, amino-CrC4-alkoxy, CrC6- alkylamino-CrC4-alkoxy, di-Ci-C6-alkylamino-CrC4-alkoxy, Ci-C6-alkylcarbonylamino-Cr C4-alkoxy, C6-Ci2-arylcarbonylamino-Ci-C4-alkoxy, Ci-C6-alkoxycarbonylamino-CrC4- alkoxy, C6-Ci2-aryl-Ci-C4-alkoxy, Ci-C6-alkylsulfonylamino-CrC4-alkoxy, (halogenated d- C6-alkyl)sulfonylamino-CrC4-alkoxy, C6-Ci2-arylsulfonylamino-Ci-C4-alkoxy, (C6-Ci2-aryl- Ci-C6-alkyl)sulfonylamino-CrC4-alkoxy, C3-Ci2-heterocyclylsulfonylamino-CrC4-alkoxy, C3-Ci2-heterocyclyl-CrC4-alkoxy, C6-Ci2-aryloxy, C3-Ci2-heterocyclyloxy, Ci-C6-alkylthio, halogenated Ci-C6-alkylthio, CrC6-alkylamino, (halogenated CrC6-alkyl)amino, di-Ci-C6- alkylamino (e.g. dimethylamino), di-(halogenated CrC6-alkyl)amino, CrC6- alkylcarbonylamino, (halogenated CrCe-alky^carbonylamino, CerC^-arylcarbonylamino, CrC6-alkylsulfonylamino, (halogenated CrC6-alkyl)sulfonylamino, C6-Ci2- arylsulfonylamino or optionally substituted C3-Ci2-heterocyclyl (e.g. 3-pyridyl, 2-thienyl, 4- methyl-2-thienyl, 5-methyl-2-thienyl, 5-chloro-2-thienyl, 2,5-dimethyl-3-thienyl, 1 ,2-diazol- 4-yl, 1 -methyl-1 ,2-diazol-4-yl, 1 -ethyl-1 ,2-diazol-4-yl, 1 -difluormethyl-1 ,2-diazol-4-yl, 2- methyl-1 ,3-diazol-4-yl, 1 -methyl-1 ,3-diazol-4-yl, 2-methyl-1 ,3-thiazol-5-yl, 2,4-dimethyl-1 ,3- thiazol-5-yl or 3-pyrrolidinyl, a further example being 1-methyl-pyrrol-3-yl, 2-pyridyl, 1- methyl-1 ,2-diazol-3-yl, 1-methyl-3-trifluoromethyl-1 ,2-diazol-4-yl, 1 , 2-dimethyl-1 ,3-diazol- 4-yl, 5-methylisoxazol-3-yl or 1 -methyl-1 , 2, 4-triazol-3-yl). Additionally, R1 may also be tri- (Ci-C4-alkyl)-silyl-CrC4-alkyl (e.g. trimethylsilylethyl).
Preferably, R1 is Ci-C6-alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl, a further example being n-butyl or n-pentyl), C3-Ci2-cycloalkyl-Ci-C4-alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl, a further example being cyclopropylmethyl), halogenated Ci-C6-alkyl (e.g. 3-fluoroprop-1-yl, 3-chloroprop-1-yl or 3,3,3-trifluoroprop-1-yl), Ci-C6-alkoxy-Ci-C4- alkyl (e.g. ethoxyethyl), amino-CrC4-alkyl, Ci-Ce-alkylamino-Ci-Cralkyl, di-Ci-C6- alkylamino-Ci-C4-alkyl, Ci-C6-alkyloxycarbonylamino-CrC4-alkyl, CrC6- alkylaminocarbonylamino-Ci-C4-alkyl, C6-Ci2-aryl-Ci-C4-alkyl, C3-Ci2-cycloalkyl (e.g. cyclopropyl or cyclobutyl), C2-C6-alkenyl (e.g. prop-1 ,2-en-1-yl), optionally substituted C6- Ci2-aryl (e.g. phenyl), hydroxy, CrC6-alkylamino, (halogenated Ci-C6-alkyl)amino, di-Cr C6-alkylamino or optionally substituted C3-Ci2-heterocyclyl (e.g. 3-pyridyl, 2-thienyl, 4- methyl-2-thienyl, 5-methyl-2-thienyl, 5-chloro-2-thienyl, 2,5-dimethyl-3-thienyl, 1 ,2-diazol- 4-yl, 1-methyl-1 ,2-diazol-4-yl, 1-ethyl-1 ,2-diazol-4-yl, 1-difluormethyl-1 ,2-diazol-4-yl, 2- methyl-1 ,3-diazol-4-yl, 1-methyl-1 ,3-diazol-4-yl, 2-methyl-1 ,3-thiazol-5-yl, 2,4-dimethyl-1 ,3- thiazol-5-yl or 3-pyrrolidinyl). It is further preferred if R1 is tri-(Ci -C4-a I ky I )-si Iy I -Ci -C4-a I ky I (e.g. trimethylsilylethyl).
In particular, R1 is Ci-C6-alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl, a further example being n-butyl or n-pentyl), C3-Ci2-cycloalkyl-Ci-C4-alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl, a further example being cyclopropylmethyl), halogenated Ci-C6-alkyl (e.g. 3-fluoroprop-1-yl, 3-chloroprop-1-yl or 3,3,3-trifluoroprop-1-yl), C3-Ci2-cycloalkyl (e.g. cyclopropyl or cyclobutyl), C2-C6-alkenyl (e.g. prop-1 ,2-en-1-yl), optionally substituted C6- Ci2-aryl (e.g. phenyl), or optionally substituted C3-Ci2-heterocyclyl (e.g. 3-pyridyl, 2- thienyl, 4-methyl-2-thienyl, 5-methyl-2-thienyl, 5-chloro-2-thienyl, 2,5-dimethyl-3-thienyl, 1 ,2-diazol-4-yl, 1 -methyl-1 ,2-diazol-4-yl, 1 -ethyl-1 ,2-diazol-4-yl, 1 -difluormethyl-1 ,2-diazol- 4-yl, 2-methyl-1 ,3-diazol-4-yl, 1 -methyl-1 ,3-diazol-4-yl, 2-methyl-1 ,3-thiazol-5-yl, 2,4- dimethyl-1 ,3-thiazol-5-yl or 3-pyrrolidinyl). In particular, R1 may also be tri-(d-C4-alkyl)- silyl-CrC4-alkyl (e.g. trimethylsilylethyl).
In connection with R1, substituted C6-Ci2-aryl in particular includes C6-Ci2-aryl, such as phenyl or naphthyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C4-alkyl, Ci-C4-haloalkyl, cyano, Ci-C4-alkoxy, Ci-C4-haloalkoxy, amino, Ci-C4-alkylamino, Ci-C4-dialkylamino, morpholino and piperidinyl. The same applies to substituted C6-Ci2-aryl in substituted C6-Ci2-aryl-Ci-C4-alkyl.
In connection with R1, substituted C3-Ci2-heterocyclyl in particular includes C3-Ci2- heterocyclyl, such as pyridyl, thienyl, diazolyl, quinolinyl, piperidinyl, piperazinyl or mor- pholinyl (pyrrolyl, isoxazolyl and triazolyl being further examples of such C3-Ci2- heterocyclyl), substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxycarbonyl, cyano, Ci-C4-alkoxy, CrC4- haloalkoxy, Ci-C4-alkylsulfonyl, amino, Ci-C4-alkylamino, Ci-C4-dialkylamino, C6-Ci2- arylamino and C3-Ci2-heterocyclyl (e.g., morpholino or piperidinyl). The same applies to substituted C3-Ci2-heteroaryl in substituted C3-Ci2-heteroaryl-Ci-C4-alkyl.
According to one embodiment, W is -NR8- and Y is a bond. According to an alternative embodiment, W is a bond and Y is -NR9-. According to a further alternative embodiment, W is a bond and Y is a bond, especially if R1 is a nitrogen-bound radical, e.g. nitrogen- bound heterocyclyl such as piperazinyl or morpholinyl. According to one embodiment, Q is -S(O )2-. According to an alternative embodiment, Q is -C(O)-.
According to a particular embodiment, -W-A1 -Q-Y- is -W-A1 -S (O)2- N R9-, -NR8-S(O)2-, -A1- S(O)2- or -S(O)2-. According to a further particular embodiment, -W-A1 -Q-Y- is -W-A1-C0- NR9- or -NR8-CO-.
A1 is optionally substituted CrC4-alkylene or a bond. In connection with A1, substituted d- C4-alkylene in particular includes Ci-C4-alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, d-C4-alkyl and cyano. Preferably, A1 is a bond. If A1 is CrC4-alkylene, W is preferably -NR8-.
A2 is optionally substituted Ci-C4-alkylene (e.g. 1 ,2-ethylene or 1 ,3-propylene), d-C4- alkylene-CO-, -CO-CrC4-alkylene, Ci-C4-alkylene-O-Ci-C4-alkylene, d-C4-alkylene-NR10- Ci-C4-alkylene, optionally substituted C6-Ci2-arylene, optionally substituted C6-Ci2- heteroarylene or a bond. Additionally, A2 may be optionally substituted C2-C4-alkenylen or optionally substituted C2-C4-alkynylene. Preferably, A2 is optionally substituted d-C4- alkylene (e.g. 1 ,2-ethylene or 1 ,3-propylene). More preferably, A2 is Ci-C4-alkylene (e.g. 1 ,2-ethylene or 1 ,3-propylene). Alternatively, it is preferred that A2 is optionally substituted C6-Ci2-arylene, in particular C6-Ci2-arylene selected from the group consisting of phen- 1 ,4-ylene and phen-1 ,3-ylene, or optionally substituted C6-Ci2-heteroarylene, in particular C6-Ci2-heteroarylene selected from the group consisting of pyrid-2,5-ylene and pyrid-2,4- ylene. If A2 is a bond, X1 is preferably optionally substituted CrC4-alkylene. Alternatively, if A2 is a bond, X1 is in particular optionally substituted C2-C4-alkenylene or optionally substi- tuted C2-C4-alkynylene.
In connection with A2, substituted CrC4-alkylene in particular includes CrC4-alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, d- d-alkyl, d-C4-haloalkyl and cyano.
In connection with A2, substituted C2-C4-alkenylene or substituted C2-C4-alkynylene in particular includes C2-C4-alkenylene or C2-C4-alkynylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, d-C4-alkyl, d-C4-haloalkyl and cyano.
In connection with A2, substituted C6-Ci2-arylene in particular includes C6-Ci2-arylene substituted with 1 , 2 or 3 substituents selected from the group consisting of d-C4-alkyl, d-C4- haloalkyl, d-C4-alkoxycarbonyl, cyano, d-C4-alkoxy, d-C4-haloalkoxy, d-C4- alkylsulfonyl, amino, Ci-C4-alkylamino, Ci-C4-dialkylamino, C6-Ci2-arylamino and C3-Ci2- heterocyclyl (e.g., morpholino or piperidinyl).
In connection with A2, substituted C6-Ci2-heteroarylene in particular includes C6-C12- heteroarylene substituted with 1 , 2 or 3 substituents selected from the group consisting of Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxycarbonyl, cyano, Ci-C4-alkoxy, Ci-C4-haloalkoxy, CrC4-alkylsulfonyl, amino, Ci-C4-alkylamino, Ci-C4-dialkylamino, C6-Ci2-arylamino and C3-Ci2-heterocyclyl (e.g, morpholino or piperidinyl).
X1 is -O-, -NR11-, -S- or optionally substituted Ci-C4-alkylene (e.g. -CH2-, a further example being 1 ,2-ethylene and 1 ,3-popylene). In connection with X1, substituted CrC4-alkylene in particular includes CrC4-alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C4-alkyl, Ci-C4-haloalkyl and cyano. Additionally, X1 may be optionally substituted C2-C4-alkenylen or optionally substituted C2-C4-alkynylene (e.g. propynylene). In connection with X1, substituted C2-C4-alkenylene or substituted C2-C4- alkynylene in particular includes C2-C4-alkenylene or C2-C4-alkynylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C4-alkyl, d-C4- haloalkyl and cyano. Preferably, X1 is -O-, -NR11, -S-. More preferably, X1 is -O-. Alternatively, it is preferred if X1 is optionally substituted CrC4-alkylene (e.g. -CH2-, 1 ,2-ethylene and 1 ,3-popylene).
According to a particular embodiment, A2 is a bond and X1 is optionally substituted d-C4- alkylene, optionally substituted C2-C4-alkenylene or optionally substituted C2-C4- alkynylene.
According to a particular embodiment, R1-W-A1-Q-Y-A2-X1- is R1-S(O)2-NH-A2-X1-, R1-NH- S(O)2-A2-X1-, R1-C(O)-NH-A2-X1- or R1-N H-C(O )-A2-X1-.
According to a particular embodiment, the structural element -Y-A2-X1- comprises at least 2, 3 or 4 atoms in the main chain. According to further particular embodiments the structural element -Y-A2-X1- has up to 4, 5 or 6 atoms in the main chain, such as 2 to 6, 2 to 5 or 2 to 4 atoms in the main chain, especially 2, 3 or 4 atoms in the main chain.
According to a further particular embodiment, -Y-A2-X1- is -Ci-C4-alkylene-O- or -NR9-Ci- C4-alkylene-O-, with -Y-A2-X1- preferably having 2 to 6, 3 to 5 and especially 4 atoms in the main chain. Particular examples of -Y-A2-X1- include -(CH2)3-O- and -NR9-(CH2)2-O-. In this particular embodment, R9 is as defined herein and preferably R9 is hydrogen, d-C6- alkyl (e.g. methyl or ethyl) or C3-Ci2-cycloalkyl (e.g. cyclopropyl), or R9 is Ci-C4-alkylene that is bound to a carbon atom in A2 which is CrC4-alkylene. According to a further particular embodiment, -Y-A2-X1- is -NR9-Ci-C4-alkylene- (e.g. -NH- CH2-, a further example being -NH-(CH2)2- or -NH-(CH2)3-), with -Y-A2-X1- preferably having 2 to 6, 2 to 5, 2 to 4 and especially 2, 3 or 4 atoms in the main chain. In this particular embodment, R9 is as defined herein and preferably R9 is hydrogen, Ci-Cβ-alkyl (e.g. methyl or ethyl) or C3-Ci2-cycloalkyl (e.g. cyclopropyl); or R9 is Ci-C4-alkylene that is bound to a carbon atom in X1 which is CrC4-alkylene. If A is a heterocyclic ring, this embodiment of -Y-A2-X1- is particularly suitable.
According to a further particular embodiment, -Y-A2-X1- is -NR9-C2-C4-alkenylene- or -NR9- C2-C4-alkynylene- (e.g. -NH-CH2-C≡C-), with -Y-A2-X1- preferably having 2 to 6, 3 to 5 and especially 4 atoms in the main chain. In this particular embodment, R9 is as defined herein and preferably is R9 is hydrogen, d-C6-alkyl (e.g. methyl or ethyl) or C3-Ci2-cycloalkyl (e.g. cyclopropyl or cyclobutyl). If A is a heterocyclic ring, this embodiment of -Y-A2-X1- is particularly suitable.
According to a further particular embodiment, -Y-A2-X1- is -Ci-C4-alkylene- (e.g. -(CH2)2-), with -Y-A2-X1- preferably having 2 to 6, 2 to 5, 2 to 4 and especially 2 atoms in the main chain. If A is a heterocyclic ring, this embodiment of -Y-A2-X1- is particularly suitable.
According to a further particular embodiment, the structural motif -Y-A2-X1 as disclosed herein is bound to Q being -S(O)2- or -C(O)-. Particular examples for this embimdnet include heterocyclic compounds of the invention wherein R is R1-S(O)2-Y-A2-X1 or R1-C(0)- Y-A2-X1.
The radical R and in particular the radical R1-W-A1-Q-Y-A2-X1- may, in principle, be bound to the 5-, 6-, 7- or 8-position of the aminotetraline skeleton:
Figure imgf000054_0001
In said formulae, R1, W, A1, Q, Y, A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
Further particular examples include heterocyclic compounds of the above formulae wherein the radical R1-W-A1-Q-Y-A2-X1- is replaced by the radical -CN.
Aminotetraline derivatives having the radical R1-W-A1-Q-Y-A2-X1- (or the radical -CN) in the 5-, 6-, 7-position are preferred. Particularly preferred are aminotetraline derivatives having the radical R1-W-A1-Q-Y-A2-X1- (or the radical -CN) in the 7-position.
In addition to the radical R1-W-A1-Q-Y-A2-X1- (or the radical -CN), the aminotetraline derivatives of the invention may have one or more than one further substituent bound to the ring A. In these positions, the skeleton of the aminotetraline derivatives may thus be substituted with one or more than one radical R2. If there is more than one radical R2, these may be the same or different radicals. In particular, in 5-, 6-, 7- and/or 8-position, the aminotetraline skeleton may be substituted with one or more than one radical R2. The aminotetraline derivatives of the invention may therefore be represented by one of the following formulae:
Figure imgf000055_0001
Figure imgf000056_0001
or by corresponding formulae wherein the radical R1-W-A1-Q-Y-A2-X1- is replaced by the radical -CN, wherein R2a, R2b, R2c, R2d independently have one of the meanings given for R2, and R1, W, A1, Q, Y, A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
R2 is hydrogen, halogen, d-C6-alkyl, halogenated Ci-C4-alkyl, hydroxy-CrC4-alkyl, -CN, C2-C6-alkenyl, C2-C6-alkynyl, optionally substituted C6-Ci2-aryl, hydroxy, Ci-C6-alkoxy, halogenated Ci-C6-alkoxy, Ci-C6-alkoxycarbonyl, C2-C6-alkenyloxy, C6-Ci2-aryl-Ci-C4- alkoxy, Ci-Ce-alkylcarbonyloxy, Ci-C6-alkylthio, CrC6-alkylsulfinyl, CrC6-alkylsulfonyl, aminosulfonyl, amino, CrCβ-alkylamino, C2-C6-alkenylamino, nitro or optionally substituted C3-Ci2-heterocyclyl, or two radicals R2 together with the ring atoms of A to which they are bound form a 5- or 6 membered ring.
An optionally substituted 5- or 6-membered ring that is formed by two radicals R2 together with the ring atoms of A to which they are bound is, for instance, a benzene ring.
In connection with R2, substituted C6-Ci2-aryl in particular includes C6-Ci2-aryl, such as phenyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halo- gen and Ci-C4-alkyl, Ci-C4-haloalkyl, cyano, Ci-C4-alkoxy and Ci-C4-haloalkoxy.
In connection with R2, substituted C3-Ci2-heterocyclyl in particular includes C3-C12- heterocyclyl, such as morpholinyl, pyrrolidinyl and piperidinyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C4-alkyl, Ci-C4-haloalkyl, cyano, Ci-C4-alkoxy and Ci-C4-haloalkoxy.
Preferably, R2 is hydrogen, halogen or d-C6-alkoxy. In particular, R2 is hydrogen.
According to a particular embodiment, the aminotetraline derivatives of the invention have one of the following formulae:
Figure imgf000057_0001
or by corresponding formulae wherein the radical R1-W-A1-Q-Y-A2-X1- is replaced by the radical -CN, wherein R1, W, A1, Q, Y, A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n are as defined herein.
In 1-, 2,- 3-, 4- and/or 5-position, the aminotetraline derivatives of the invention may be substituted with one or more than one radical R3. If there is more than one radical R3, these may be the same or different radicals. The aminotetraline derivatives of the invention may therefore be represented by the following formula:
Figure imgf000057_0002
wherein R , R , R , R , R , R independently have one of the meanings given for R , and A, R, R^, RJ, R4a, R4D, X^, XJ, Rb, n are as defined herein. According to a particular embodiment, the aminotetraline derivatives of the invention have one of the following formulae:
Figure imgf000058_0001
wherein R , RJD, RJt independently have the meaning of RJ and A, R, Rz, R , R4a, R4D, Xz, X3, R5, n are as defined herein.
R3 is hydrogen, halogen, Ci-Cβ-alkyl, Ci-C6-alkoxy, or two radicals R3 together with the carbon atom to which they are attached form a carbonyl group.
Preferably, R3 is hydrogen or d-C6-alkyl. In particular, R3 is hydrogen.
R is hydrogen, d-C6-alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C3-Ci2-cycloalkyl- Ci-C4-alkyl (e.g. cyclopropylmethyl), halogenated Ci-C4-alkyl (e.g. 2-fluoroethyl or 2,2,2- trifluoroethyl), hydroxy-CrC4-alkyl, Ci-C6-alkoxy-CrC4-alkyl, amino-CrC4-alkyl, CH2CN, ■ CHO, Ci-C4-alkylcarbonyl (e.g. methylcarbonyl or isopropylcarbonyl, a further example being ethylcarbonyl), (halogenated C-ι-C4-alkyl)carbonyl (e.g. fluoromethylcarbonyl, di- fluoromethylcarbonyl or trifluoromethylcarbonyl, a further example being 1 ,1 ,1-trifluoroeth- 2-ylcarbonyl or 1 ,1 ,1-trifluoroprop-3-ylcarbonyl), C6-Ci2-arylcarbonyl (e.g. phenylcarbonyl), Ci-C4-alkoxycarbonyl (e.g. ethoxycarbonyl or tert-butyloxycarbonyl), C6-Ci2- aryloxycarbonyl (e.g. phenoxycarbonyl), Ci-C6-alkylaminocarbonyl, C2-C6-alkenyl, - C(=NH)NH2, -C(=NH)NHCN, Ci-C6-alkylsulfonyl, C6-Ci2-arylsulfonyl, amino, -NO or C3- Ci2-heterocyclyl.
Preferably, R4a is hydrogen, d-C6-alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C3-Ci2- cycloalkyl-CrC4-alkyl (e.g. cyclopropylmethyl), halogenated Ci-C4-alkyl (e.g. 2-fluoroethyl or 2,2,2-trifluoroethyl), amino-Ci-C4-alkyl, CH2CN, d-C4-alkylcarbonyl (e.g. methylcar- bonyl or isopropylcarbonyl), (halogenated Ci-C4-alkyl)carbonyl (e.g. fluoromethylcarbonyl, difluoromethylcarbonyl or trifluoromethylcarbonyl), C6-Ci2-arylcarbonyl (e.g. phenylcarbonyl), Ci-C4-alkoxycarbonyl (e.g. ethoxycarbonyl or tert-butyloxycarbonyl), C6-Ci2- aryloxycarbonyl (e.g. phenoxycarbonyl), -C(=NH)NH2, -C(=NH)NHCN, CrC6-alkylsulfonyl, amino, -NO or C3-Ci2-heterocyclyl. It is further preferred if R1 is -CHO.
In particular, R4a is hydrogen, Ci-C6-alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C3-Ci2- cycloalkyl-CrC4-alkyl (e.g. cyclopropylmethyl), halogenated Ci-C4-alkyl (e.g. 2-fluoroethyl or 2,2,2-trifluoroethyl), d-C4-alkylcarbonyl (e.g. methylcarbonyl or isopropylcarbonyl), (halogenated Ci-C4-alkyl)carbonyl (e.g. fluoromethylcarbonyl, difluoromethylcarbonyl or trifluoromethylcarbonyl), C6-Ci2-arylcarbonyl (e.g. phenylcarbonyl), d-C4-alkoxycarbonyl (e.g. ethoxycarbonyl or tert-butyloxycarbonyl), C6-Ci2-aryloxycarbonyl (e.g. phenoxycarbonyl). In particular, R4a may also be -CHO.
R4b is hydrogen, Ci-C6-alkyl (e.g. methyl, a further example being ethyl), halogenated d- d-alkyl, hydroxy-d-C4-alkyl, d-C6-alkoxy-d-C4-alkyl, amino-d-d-alkyl, CH2CN, -CHO, Ci-C4-alkylcarbonyl, (halogenated d-C4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, d-C4- alkoxycarbonyl, C6-Ci2-aryloxycarbonyl, Ci-Ceralkylaminocarbonyl, C2-C6-alkenyl, - C(=NH)NH2, -C(=NH)NHCN, CrC6-alkylsulfonyl, C6-Ci2-arylsulfonyl, amino, -NO or C3- Ci2-heterocyclyl.
Preferably, R4b is hydrogen, Ci-C6-alkyl (e.g. methyl, a further example being ethyl).
Alternatively, R4a, R4b together are optionally substituted Ci-C6-alkylene (e.g. 1 ,4-butylene, a further example being 1 ,3-propylene, 2-fluoro-but-1 ,4-ylene or 1 -oxo-but-1 ,4-ylene), wherein one -CH2- of d-C4-alkylene may be replaced by an oxygen atom (e.g. -CH2-CH2- 0-CH2-CH2-) or -NR16. X2 is -O-, -NR6-, -S-, >CR12aR12b or a bond. Preferably, X2 is >CR12aR12b.
X3 is -O-, -NR7-, -S-, >CR13aR13b or a bond. Preferably, X3 is a bond.
Thus, it is preferred if X2 is >CR12aR12b and X3 is a bond.
R12a is hydrogen, optionally substituted Ci-C6-alkyl, Ci-C6-alkylamino-Ci-C4-alkyl, di-d- C6-alkylamino-Ci-C4-alkyl, C3-Ci2-heterocyclyl-Ci-C6-alkyl, optionally substituted C6-Ci2- aryl or hydroxy. Preferably, R12a is hydrogen or d-C6-alkyl.
R13a is hydrogen, optionally substituted Ci-C6-alkyl, Ci-C6-alkylamino-Ci-C4-alkyl, di-Cr C6-alkylamino-Ci-C4-alkyl, C3-Ci2-heterocyclyl-Ci-C6-alkyl, optionally substituted C6-Ci2- aryl or hydroxy. Preferably, R13a is hydrogen or Ci-C6-alkyl.
In connection with R12a and R13a, substituted CrC6-alkyl in particular includes CrC6-alkyl substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, hydroxy, Ci-C4-alkoxy and amino.
In connection with R12a and R13a, substituted C6-Ci2-aryl in particular includes C6-Ci2-aryl, such as phenyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of Ci-C4-alkyl, Ci-C4-haloalkyl, cyano, Ci-C4-alkoxy and Ci-C4-haloalkoxy.
R12b is hydrogen or Ci-C6-alkyl. According to a particular embodiment, R12b is hydrogen.
R13b is hydrogen or Ci-C6-alkyl. According to a particular embodiment, R13b is hydrogen.
Alternatively, R12a and R12b, or R13a and R13b, together are together are carbonyl or, preferably, optionally substituted Ci-C4-alkylene (e.g. 1 ,3-propylene), wherein one -CH2- of Cr C4-alkylene may be replaced by an oxygen atom or -NR14-.
In connection with R12a and R12b, or R13a and R13b, substituted CrC4-alkylene in particular includes CrC4-alkylene substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, Ci-C4-alkyl, Ci-C4-haloalkyl, cyano, Ci-C4-alkoxy and CrC4- haloalkoxy.
According to a particular embodiement, R12a is CrC6-alkyl and R12b is hydrogen or CrC6- alkyl, or R13a is CrC6-alkyl and R13b is hydrogen or CrC6-alkyl. According to a further particular embodiement, R12a is hydrogen and R12b is hydrogen, or R13a is hydrogen and R13b is hydrogen.
According to a further particular embodiment, R12a and R12b together are optionally substi- tuted 1 ,3-propylene, or R13a and R13b together are optionally substituted 1 ,3-propylene.
R5 is optionally substituted C6-Ci2-aryl (e.g. phenyl, 3-chlorophenyl, 3,4-dichlorophenyl or 2,4-dichlorophenyl, a further example being 2-fluorophenyl, 2-chlorophenyl, 3- fluorophenyl, 3-chlorophenyl; 3-cyanophenyl, 3-methylphenyl, 3-trifluoromethylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 3,4-difluorophenyl, 3,5- difluorophenyl, 3-fluoro-5-chlorophenyl, 3-chloro-4-fluorophenyl), optionally substituted C3- Ci2-cycloalkyl (e.g. cyclohexyl) or optionally substituted C3-Ci2-heterocyclyl.
In connection with R5, substituted C3-Ci2-cycloalkyl in particular includes C3-Ci2-cycloalkyl, such as cyclopropyl or cyclohexyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, optionally substituted Ci-C6-alkyl, halogenated Ci-C6-alkyl, CN, hydroxy, Ci-C6-alkoxy, halogenated Ci-C6-alkoxy, amino, Ci-C6-alkylamino, di-Ci-C6- alkylamino and C3-Ci2-heterocyclyl.
In connection with R5, substituted C6-Ci2-aryl in particular includes C6-Ci2-aryl, such as phenyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen (e.g. F, Cl, Br), optionally substituted Ci-C6-alkyl (e.g. methyl), halogenated d-C6- alkyl (e.g. trifluoromethyl), CN, hydroxy, Ci-C6-alkoxy (e.g. methoxy), halogenated d-C6- alkoxy, amino, Ci-C6-alkylamino, di-Ci-C6-alkylamino and C3-Ci2-heterocyclyl.
In connection with R5, substituted C3-Ci2-heterocyclyl in particular includes C3-Ci2- heterocyclyl substituted with 1 , 2 or 3 substituents selected from the group consisting of halogen, optionally substituted Ci-C6-alkyl, halogenated Ci-C6-alkyl, CN, hydroxy, d-C6- alkoxy, halogenated Ci-C6-alkoxy, amino, Ci-C6-alkylamino, di-Ci-C6-alkylamino and C3- C^-heterocyclyl.
In connection with R5, C3-Ci2-heterocyclyl in particular is C3-Ci2-heteroaryl.
Preferably, R5 is optionally substituted C6-Ci2-aryl, in particular as in the aminotetraline derivatives of the formula:
Figure imgf000062_0001
wherein A, R, R2, R3, R4a, R4b, X2, X3, n are as defined herein, and R15a, R15b, R15c, R15d, R15e independently are hydrogen, halogen (e.g. F, Cl or Br), optionally substituted Ci-C6-alkyl (e.g. methyl), halogenated Ci-C6-alkyl (e.g. trifluoromethyl), CN, hydroxy, Ci-C6-alkoxy (e.g. methoxy), amino, Ci-C6-alkylamino, di-Ci-C6-alkylamino or Cs-C^-heterocyclyl.
According to a particular embodiment, the invention relates to aminotetralin derivatives of the formula:
Figure imgf000062_0002
wherein A, R, R2, R3, R4a, R4b,R5, n are as defined herein, R5 preferably being optionally substituted aryl and in particular optionally substituted phenyl as disclosed herein.
In connection with R5 or R15a, R15b, R15c, R15d, R15e, substituted CrC6-alkyl in particular includes Ci-C6-alkyl, especially Ci-C4-alkyl, substituted with 1 , 2 or 3 substituents selected from the group consisting of hydroxy, Ci-C6-alkoxy, amino, Ci-C6-alkylamino, di-Ci-C6- alkylamino and C3-Ci2-heterocyclyl (e.g. morpholinyl or piperidinyl).
According to a particular embodiment, R15a, R15b, R15d, R15e are hydrogen and R15c is different from hydrogen (para-mono-substitution). According to a further particular embodiment, R15a, R15c, R15d, R15e are hydrogen and R15b is different from hydrogen (meta-mono-substitution).
In connection with R15a, R15b, R15c, R15d, R15e, C3-Ci2-heterocyclyl in particular includes morpholinyl, imidazolyl and pyrazolyl.
The index n is 0, 1 or 2. According to a particular embodiment, n is 1.
R6 is hydrogen or d-C6-alkyl. Preferably, R6 is hydrogen.
R7 is hydrogen or d-Cβ-alkyl. Preferably, R7 is hydrogen.
R8 is hydrogen or d-C6-alkyl. Preferably, R8 is hydrogen.
R9 is hydrogen, d-C6-alkyl (e.g. methyl or ethyl), C3-Ci2-cycloalkyl (e.g. cyclopropyl), amino-Ci-C6-alkyl, optionally substituted C6-Ci2-aryl-Ci-C4-alkyl or C3-Ci2-heterocyclyl (e.g. 3-azetidinyl). Preferably, R9 is hydrogen or d-C6-alkyl (e.g. methyl or ethyl).
According to a particular embodiment, R9 and R1 together are d-d-alkylene (e.g. 1 ,3- propylene, a further example being 1 ,2-ethylene) so as that R9 and R1 together with the atom in Q to which R1 is bound and the nitrogen atom to which R9 is bound form an heterocyclic ring having, in particular, 4, 5 or 6 ring member atoms (including the nitrogen atom and Q). With W and A1 both being a bond, such a ring may be represented by the following partial structure:
Figure imgf000063_0001
wherein Q is as defined herein (e.g. S(O)2) and n is 0, 1 , 2, 3 or 4.
According to a further particular embodiment, R9 is d-d-alkylene (e.g. methylene or 1 ,3- propylene) that is bound to a carbon atom in A2 and A2 is d-d-alkylene so that R9 and at least part of A2 together with the nitrogen atom to which R9 is bound form an N-containing heterocyclic ring having, in particular, 4, 5 , 6 or 7 ring member atoms (including the nitrogen atom). Such a ring may be represented by the following partial structure:
Figure imgf000064_0001
wherein R1, W, A1, Q and X1 are as defined herein, p is 1 or 2, r is 0, 1 or 2 and q is 0, 1 or 2. In this particular embodiment, X1 preferably is -O-. Particular combinations of p, r and q include p=1 , r=0, q=1 ; and p=1 , r=0, q=0. Alternatively, p is 0, r is 3 and q is 1 , with X1 preferably being -O-.
According to a further particular embodiment, R9 is Ci-C4-alkylene (e.g. methylene or 1 ,3- propylene) that is bound to a carbon atom in X1 and X1 is Ci-C4-alkylene (e.g. 1 ,2- ethylene) so that R9 and at least part of X1 together with the nitrogen atom to which R9 is bound form an N-containing heterocyclic ring having, in particular, 4, 5 , 6 or 7 ring member atoms (including the nitrogen atom). With A2 being a bond, such a ring may be represented by the following partial structure:
Figure imgf000064_0002
wherein R1, W, A1, Q and X1 are as defined herein, p is 1 or 2, r is 0, 1 or 2 and q is 0, 1 or 2. Particular combinations of p, r and q include p=1 , r=0, q=0.
R10 is hydrogen, d-C6-alkyl or CrC6-alkylsulfonyl. Preferably, R10 is hydrogen.
R11 is hydrogen or d-C6-alkyl. Preferably, R11 is hydrogen.
Alternatively, R9, R11 together are Ci-C4-alkylene (e.g. ethylene).
R14 is hydrogen or d-C6-alkyl. Preferably, R14 is hydrogen.
R15 is hydrogen or CrC6-alkyl. Preferably, R15 is hydrogen.
R16 is hydrogen or d-C6-alkyl. Preferably, R16 is hydrogen.
Particular embodiments of aminotetraline derivatives of the invention result if A is a 5- or 6-membered ring; R is R1-W-A1-Q-Y-A2-X1- or -CN; R1 is hydrogen, CrC6-alkyl, C3-Ci2-cycloalkyl-Ci-C4-alkyl, halogenated CrC6-alkyl, hy- droxy-Ci-C4-alkyl, Ci-C6-alkoxy-Ci-C4-alkyl, amino-CrC4-alkyl, Ci-C6-alkylamino- Ci-C4-alkyl, di-Ci-C6-alkylamino-Ci-C4-alkyl, Ci-C6-alkylcarbonylamino-Ci-C4-alkyl, Ci-C6-alkyloxycarbonylamino-Ci-C4-alkyl, Ci-C6-alkylaminocarbonylamino-Ci-C4- alkyl, di-Ci-C6-alkylaminocarbonylamino-Ci-C4-alkyl, d-C6-alkylsulfonylamino-d-
C4-alkyl, (optionally substituted C6-Ci2-aryl-Ci-C6-alkyl)amino-Ci-C4-alkyl, optionally substituted C6-Ci2-aryl-Ci-C4-alkyl, optionally substituted C3-Ci2-heterocyclyl-Ci-C4- alkyl, C3-Ci2-cycloalkyl, CrC6-alkylcarbonyl, CrC6-alkoxycarbonyl, halogenated d- C6-alkoxycarbonyl, C6-Ci2-aryloxycarbonyl, aminocarbonyl, CrC6- alkylaminocarbonyl, (halogenated Ci-C4-alkyl)aminocarbonyl, C6-Ci2- arylaminocarbonyl, C2-C6-alkenyl, C2-C6-alkynyl, optionally substituted C6-Ci2-aryl, hydroxy, Ci-C6-alkoxy, halogenated Ci-C6-alkoxy, Ci-C6-hydroxyalkoxy, d-C6- alkoxy-Ci-C4-alkoxy, amino-Ci-C4-alkoxy, Ci-C6-alkylamino-CrC4-alkoxy, di-Ci-C6- alkylamino-Ci-C4-alkoxy, Ci-C6-alkylcarbonylamino-CrC4-alkoxy, C6-Ci2- arylcarbonylamino-Ci-C4-alkoxy, Ci-C6-alkoxycarbonylamino-CrC4-alkoxy, C6-Ci2- aryl-Ci-C4-alkoxy, Ci-C6-alkylsulfonylamino-CrC4-alkoxy, (halogenated CrC6- alkyl)sulfonylamino-CrC4-alkoxy, C6-Ci2-arylsulfonylamino-Ci-C4-alkoxy, (C6-Ci2- aryl-Ci-C6-alkyl)sulfonylamino-Ci-C4-alkoxy, C3-Ci2-heterocyclylsulfonylamino-d- C4-alkoxy, C3-Ci2-heterocyclyl-Ci-C4-alkoxy, C6-Ci2-aryloxy, C3-Ci2-heterocyclyloxy, Ci-C6-alkylthio, halogenated Ci-C6-alkylthio, CrC6-alkylamino, (halogenated CrC6- alkyl)amino, di-CrC6-alkylamino, di-(halogenated CrC6-alkyl)amino, CrC6- alkylcarbonylamino, (halogenated CrCeralky^carbonylamino, C6-Ci2- arylcarbonylamino, CrC6-alkylsulfonylamino, (halogenated CrC6- alkyl)sulfonylamino, C6-Ci2-arylsulfonylamino or optionally substituted C3-Ci2- heterocyclyl;
W is -NR8- or a bond;
A1 is optionally substituted Ci-C4-alkylene or a bond;
Q is -S(O)2- or -C(O)-;
Y is -NR9- or a bond; A2 is optionally substituted CrC4-alkylene, CrC4-alkylene-CO-, -CO-d-C^alkylene, d-d-alkylene-O-d-d-alkylene, Ci-C4-alkylene-NR10-Ci-C4-alkylene, optionally substituted C6-Ci2-arylene, optionally substituted C6-Ci2-heteroarylene or a bond;
X1 is -O-, -NR11-, -S-, optionally substituted d-C4-alkylene; R2 is hydrogen, halogen, d-C6-alkyl, halogenated Ci-C4-alkyl, hydroxy-CrC4-alkyl, - CN, C2-C6-alkenyl, C2-C6-alkynyl, optionally substituted C6-Ci2-aryl, hydroxy, CrC6- alkoxy, halogenated Ci-C6-alkoxy, Ci-C6-alkoxycarbonyl, C2-C6-alkenyloxy, C6-Ci2- aryl-Ci-C4-alkoxy, Ci-Ce-alkylcarbonyloxy, Ci-C6-alkylthio, CrC6-alkylsulfinyl, CrC6- alkylsulfonyl, aminosulfonyl, amino, CrC6-alkylamino, C2-C6-alkenylamino, nitro or optionally substituted C3-Ci2-heterocyclyl, or two radicals R2 together with the ring atoms of A to which they are bound form a 5- or 6 membered ring;
R3 is hydrogen, halogen, Ci-C6-alkyl or Ci-C6-alkoxy, or two radicals R3 together with the carbon atom to which they are attached form a carbonyl group; R4a is hydrogen, Ci-C6-alkyl, C3-Ci2-cycloalkyl-CrC4-alkyl, halogenated Ci-C4-alkyl, hy- droxy-Ci-C4-alkyl, CrCe-alkoxy-CrOralkyl, amino-CrC4-alkyl, CH2CN, -CHO, Cr C4-alkylcarbonyl, (halogenated Ci-C4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, CrC4- alkoxycarbonyl, C6-Ci2-aryloxycarbonyl, Ci-Ce-alkylaminocarbonyl, C2-C6-alkenyl, - C(=NH)NH2, -C(=NH)NHCN, CrC6-alkylsulfonyl, C6-Ci2-arylsulfonyl, amino, -NO or C3-Ci2-heterocyclyl;
R4b is hydrogen, CrC6-alkyl, halogenated Ci-C4-alkyl, hydroxy-Ci-C4-alkyl, CrC6- alkoxy-Ci-C4-alkyl, amino-CrC4-alkyl, CH2CN, -CHO, CrC4-alkylcarbonyl, (halogenated Ci-C4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, Ci-C4-alkoxycarbonyl, C6-Ci2- aryloxycarbonyl, CrCeralkylaminocarbonyl, C2-C6-alkenyl, -C(=NH)NH2, - C(=NH)NHCN, CrC6-alkylsulfonyl, C6-Ci2-arylsulfonyl, amino, -NO or C3-Ci2- heterocyclyl; or
R4a, R4b together are optionally substituted Ci-C6-alkylene, wherein one -CH2- of CrC4- alkylene may be replaced by an oxygen atom or -NR16; X2 is -O-, -NR6-, -S-, >CR12aR12b or a bond;
X3 is -O-, -NR7-, -S-, >CR13aR13b or a bond;
R5 is optionally substituted C6-Ci2-aryl, optionally substituted C3-Ci2-cycloalkyl or optionally substituted C3-Ci2-heterocyclyl; n is O, 1 or 2; R6 is hydrogen or CrC6-alkyl;
R7 is hydrogen or Ci-C6-alkyl;
R8 is hydrogen or Ci-C6-alkyl;
R9 is hydrogen, Ci-C6-alkyl, C3-Ci2-cycloalkyl, amino-CrC6-alkyl, optionally substituted C6-Ci2-aryl-Ci-C4-alkyl; or R9, R1 together are CrC4-alkylene; or R9 is Ci-C4-alkylene that is bound to a carbon atom in A2 and A2 is CrC4-alkylene or to a carbon atom in X1 and X1 is Ci-C4-alkylene; R10 is hydrogen, d-C6-alkyl or CrC6-alkylsulfonyl; R11 is hydrogen or CrC6-alkyl, or R9, R11 together are CrC4-alkylene,
R12a is hydrogen, optionally substituted Ci-C6-alkyl, Ci-C6-alkylamino-Ci-C4-alkyl, di-d- C6-alkylamino-Ci-C4-alkyl, C3-Ci2-heterocyclyl-Ci-C6-alkyl, optionally substituted C6-
Ci2-aryl or hydroxy; R12b is hydrogen or d-C6-alkyl, or p12a p12b together are carbonyl or optionally substituted Ci-C4-alkylene, wherein one -CH2- of Ci-C4-alkylene may be replaced by an oxygen atom or -NR14-;
R13a is hydrogen, optionally substituted Ci-C6-alkyl, Ci-C6-alkylamino-Ci-C4-alkyl, di-Cr
C6-alkylamino-Ci-C4-alkyl, C3-Ci2-heterocyclyl-Ci-C6-alkyl, optionally substituted C6-
Ci2-aryl or hydroxy; R13b is hydrogen or CrC6-alkyl, or R13a, R13b together are carbonyl or optionally substituted Ci-C4-alkylene, wherein one -CH2- of
Ci-C4-alkylene may be replaced by an oxygen atom or -NR15-; R14 is hydrogen or Ci-C6-alkyl; R15 is hydrogen or Ci-C6-alkyl; and R16 is hydrogen or CrC6-alkyl, or if one or more of said variables A, R, R1, W, A1, Q, Y, A2, X1, R2, R3, R4, X2, X3, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, n are defined more precidely as disclosed herein.
Further particular embodiments of aminotetraline derivatives of the invention result if
A is a benzene ring;
R is R1-W-A1-Q-Y-A2-X1-;
R1 is Ci-C6-alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, n-pentyl), C3-
Ci2-cycloalkyl-CrC4-alkyl (e.g. cyclopropylmethyl, cyclopentylmethyl, cyclohexyl- methyl), halogenated Ci-C6-alkyl (e.g. 3-fluoroprop-1-yl, 3-chloroprop-1-yl, 3,3,3- trifluoroprop-1-yl), tri-(Ci-C4-alkyl)-silyl-Ci-C4-alkyl (e.g. trimethylsilylethyl), CrC6- alkoxy-Ci-C4-alkyl (e.g. ethoxyethyl), C3-Ci2-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclohexyl), C2-C6-alkenyl (e.g. prop-1 ,2-en-1-yl), optionally substituted C6-Ci2-aryl (e.g. phenyl, 2-methylphenyl), or optionally substituted C3-Ci2-heterocyclyl (e.g. 1- methyl-pyrrol-3-yl, 2-pyridyl, 3-pyridyl, 2-thienyl, 4-methyl-2-thienyl, 5-methyl-2- thienyl, 5-chloro-2-thienyl, 2,5-dimethyl-3-thienyl, 1 ,2-diazol-4-yl, i-methyl-1 ,2- diazol-3-yl, 1-methyl-1 ,2-diazol-4-yl, 1-ethyl-1 ,2-diazol-4-yl, 1-difluormethyl-1 ,2- diazol-4-yl, 1-methyl-3-trifluoromethyl-1 ,2-diazol-4-yl, 2-methyl-1 ,3-diazol-4-yl, 1- methyl-1 ,3-diazol-4-yl, 1 , 2-dimethyl-1 ,3-diazol-4-yl, 5-methylisoxazol-3-yl, 2-methyl- 1 ,3-thiazol-5-yl, 2,4-dimethyl-i ,3-thiazol-5-yl, 1 -methyl-1 ,2,4-triazol-3-yl, 3- pyrrolidinyl);
W is a bond;
A1 is a bond;
Q is -S(O)2- or -C(O)-; Y is -NR9- or a bond;
A2 is Ci-C4-alkylene (e.g. 1 ,2-ethylene, 1 ,3-propylene) or a bond;
X1 is -O- or optionally substituted Ci-C4-alkylene (e.g. methylene, 1 ,2-ethylene, 1 ,3- propylene) or C2-C4-alkynylene (e.g. prop-1 ,2-yn-1 ,3-ylene);
R2 is hydrogen; R3 is hydrogen;
R4a is hydrogen, d-C6-alkyl (e.g. methyl, ethyl, n-propyl, isopropyl), C3-Ci2-cycloalkyl- Ci-C4-alkyl (e.g. cyclopropylmethyl), halogenated Ci-C4-alkyl (e.g. 2-fluoroethyl, 2,2,2-trifluoroethyl), -CHO, Ci-C4-alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, isopropylcarbonyl), (halogenated Ci-C4-alkyl)carbonyl (e.g. fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, 1 ,1 ,1-trifluoroeth-2-ylcarbonyl,
1 ,1 ,1-trifluoroprop-3-ylcarbonyl), C6-Ci2-arylcarbonyl (e.g. phenylcarbonyl), d-C4- alkoxycarbonyl (e.g. ethoxycarbonyl, tert-butyloxycarbonyl), C6-Ci2-aryloxycarbonyl (e.g. phenoxycarbonyl);
R4b is hydrogen or d-C6-alkyl (e.g. methyl, ethyl); or R4a, R4b together are optionally substituted Ci-C6-alkylene (e.g. 1 ,3-propylene, 1 ,4-butylene, 2-fluoro-but-1 ,4-ylene, 1-oxo-but-1 ,4-ylene), wherein one -CH2- of CrC4-alkylene may be replaced by an oxygen atom (e.g. -CH2-CH2-O-CH2-CH2-);
X2 is CR12aR12b; X3 is a bond;
R5 is optionally substituted phenyl (e.g. phenyl, 2-fluorophenyl, 2-chlorophenyl, 3- fluorophenyl, 3-chlorophenyl, 3-cyanophenyl, 3-methylphenyl, 3- trifluoromethylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- methoxyphenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-chlorophenyl, 3- chloro-4-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl) or optionally substituted C3-Ci2-cycloalkyl (e.g. cyclohexyl); n is 1 ;
R9 is hydrogen, d-C6-alkyl (e.g. methyl, ethyl) or C3-Ci2-cycloalkyl [cyclopropyl), or R9, R1 together are Ci-C4-alkylene (e.g. 1 ,3-propylene); or
R9 is Ci-C4-alkylene (e.g. methylene, 1 ,3-propylene) that is bound to a carbon atom in A2 and A2 is Ci-C4-alkylene (e.g. 1 ,2-ethylene, 1 ,3-propylene) or to a carbon atom in X1 and X1 is CrC4-alkylene (e.g. 1 ,2-ethylene); R12a is hydrogen; and
R12b is hydrogen.
Further particular embodiments of aminotetraline derivatives of the invention result if
A is a benzene ring; R is R1-W-A1-Q-Y-A2-X1-;
R1 is Ci-C6-alkyl (e.g. methyl, ethyl, n-propyl, isopropyl or sec-butyl), C3-Ci2-cycloalkyl- Ci-C4-alkyl (e.g. cyclopentylmethyl or cyclohexylmethyl), halogenated Ci-C6-alkyl (e.g. 3-fluoroprop-1-yl, 3-chloroprop-1-yl or 3,3,3-trifluoroprop-1-yl), C3-Ci2- cycloalkyl (e.g. cyclopropyl or cyclobutyl), C2-C6-alkenyl (e.g. prop-1 ,2-en-1-yl), op- tionally substituted C6-Ci2-aryl (e.g. phenyl), or optionally substituted C3-Ci2- heterocyclyl (e.g. 3-pyridyl, 2-thienyl, 4-methyl-2-thienyl, 5-methyl-2-thienyl, 5- chloro-2-thienyl, 2,5-dimethyl-3-thienyl, 1 ,2-diazol-4-yl, 1-methyl-1 ,2-diazol-4-yl, 1- ethyl-1 ,2-diazol-4-yl, 1-difluormethyl-1 ,2-diazol-4-yl, 2-methyl-1 ,3-diazol-4-yl, 1- methyl-1 ,3-diazol-4-yl, 2-methyl-1 ,3-thiazol-5-yl, 2,4-dimethyl-1 ,3-thiazol-5-yl or 3- pyrrolidinyl);
W is a bond;
A1 is a bond;
Q is -S(O)2- or -C(O)-;
Y is -NR9- or a bond; A2 is Ci-C4-alkylene (e.g. methylene or 1 ,3-propylene) or a bond;
X1 is -O- or optionally substituted Ci-C4-alkylene (e.g. methylene);
R2 is hydrogen;
R3 is hydrogen; R4a is hydrogen, d-C6-alkyl (e.g. methyl, ethyl, n-propyl or isopropyl), C3-Ci2-cycloalkyl- Ci-C4-alkyl (e.g. cyclopropylmethyl), halogenated Ci-C4-alkyl (e.g. 2-fluoroethyl or 2,2,2-trifluoroethyl), Ci-C4-alkylcarbonyl (e.g. methylcarbonyl or, isopropylcarbonyl), (halogenated Ci-C4-alkyl)carbonyl (e.g. fluoromethylcarbonyl, difluoromethylcarbo- nyl or trifluoromethylcarbonyl), C6-Ci2-arylcarbonyl (e.g. phenylcarbonyl), d-C4- alkoxycarbonyl (e.g. ethoxycarbonyl or tert-butyloxycarbonyl), C6-Ci2- aryloxycarbonyl (e.g. phenoxycarbonyl);
R4b is hydrogen or CrC6-alkyl (e.g. methyl);
X2 is CR12aR12b;
X3 is a bond; R5 is optionally substituted phenyl (e.g. phenyl, 3-chlorophenyl, 3,4-dichlorophenyl or 2,4-dichlorophenyl); n is 1 ;
R6 is hydrogen;
R7 is hydrogen; R8 is hydrogen;
R9 is hydrogen or alkyl (e.g. methyl or ethyl); or
R9, R1 together are Ci-C4-alkylene (e.g. 1 ,3-propylene); or
R9 is Ci-C4-alkylene (e.g. methylene or 1 ,3-propylene) that is bound to a carbon atom in A2 and A2 is CrC4-alkylene;
R10 is hydrogen;
R11 is hydrogen;
R12a is hydrogen; and
R12b is hydrogen.
Particular compounds of the present invention are the aminotetraline derivatives disclosed in preparation examples and physiologically tolerated acid addition salts thereof. These include for each preparation example the exemplified compound as well as the corresponding free base and any other physiologically tolerated acid addition salts of the free base (if the exemplified compound is a salt), or any physiologically tolerated acid addition salt of the free base (if the exemplified compound is a free base). These further include enantiomers, diastereomers, tautomers and any other isomeric forms of said compounds, be they explicitly or implicitly disclosed.
The compounds of the formula (I) can be prepared by analogy to methods which are well known in the art. Suitable methods for the preparation of compounds of formula (I) is outlined in the following schemes.
The process depicted in scheme 1 is useful for obtaining aminotetralines, wherein X1 is - O- or -S-.
Scheme 1 :
Figure imgf000071_0001
As shown in scheme 1 , the compound of general formula 1 readily undergoes enamine alkylation to give the compound of general formula 3.
In scheme 1 , the variables X2, X3, R5 are as defined herein and L a suitable protecting group (e.g. L = Me). The process depicted in scheme 1 is also useful for obtaining ami- notetralines, wherein X is optionally substituted alkylene. In this case, L is a group that represents, or can be converted into, the desired side chain R1-W-A1 -Q-Y-A2-.
Alternatively, compounds of formula 3 can be prepared as described in scheme 2.
Scheme 2:
Figure imgf000071_0002
As shown in scheme 2, the compound of general formula 4 readily undergoes alkylation to give the compound of general formula 5. Conversion to the acid chloride and subsequent ring closure with ethylene in the presence of a Lewis acid (e.g. AICI3) affords compound 3 (e.g. J. Het. Chem., 23 (2), 343, 1986 and Bioorg. Med. Chem. Let, 17 (22), 6160, 2007) The variables X2, X3, R5 are as defined herein and L, L1 are a suitable protecting group (e.g. L, L1 = Me). Compounds 3 can be further converted to compounds of the general formula (I).
The process depicted in scheme 3 is useful for obtaining aminotetralines, wherein X1 is O- or -S-, A2 is optionally substituted alkylene, Y is -NR9-, and Q is -S(O)2.
Scheme 3:
Figure imgf000072_0001
In scheme 3, the variables R1, W, A1, R2, R3, R4a, R4b, R5, R9, X2, X3 are as defined herein and L2 is a suitable protecting group (e.g. L2 = COOEt).
The process depicted in scheme 4 is useful for obtaining aminotetralines, wherein X1 is methylene, A2 is a bond, Y is -NR9-, and Q is -S(O)2.
Scheme 4:
Figure imgf000073_0001
Alternatively to triflate 19, the corresponding bromide or iodide can be used to prepare compound 20.
In scheme 4, the variables R1, W, A1, R2, R3, R4a, R4b, R5, R9, X2, X3 are as defined herein, and L3 is a suitable protecting group (e.g. L3 = COO1Bu).
The process depicted in scheme 5 is useful for obtaining aminotetralines, wherein X1 is optionally substituted alkylene, A2 is optionally substituted alkylene or a bond, Y is -NR9-, and Q is -S(O)2.
Scheme 5:
Figure imgf000074_0001
I R-W-A-S(O2 )CI
Figure imgf000074_0002
Instead of the trifluoroborate 66, the corresponding 9-borabicyclo[3.3.1]non-9-yl derivative can be used to prepare compound 26.
In scheme 5, the variables R1, W, A1, R2, R3, R4a, R4b, R5, R9, X2, X3, A2 are as defined herein, and L3 is a suitable protecting group (e.g. L3 = COO1Bu).
The process depicted in scheme 6 is useful for obtaining aminotetralines, wherein X is - NR11-, A2 is optionally substituted alkylene, Y is -NR9-, and Q is -S(O)2.
Scheme 6:
Figure imgf000074_0003
In scheme 5, the variables R1, W, A1, R2, R3, R4a, R4b, R5, R9, X2, X3, A2 are as defined herein, and L4 is a suitable protecting group.
The process depicted in the following schemes is useful for obtaining compounds of the general formula (I) in which A is a heterocycle.
Scheme 7:
Figure imgf000075_0001
34 35
As shown in scheme 7, the compound of general formula 34 readily undergoes condensation with dimethylformamide dimethyl acetal to give the compound of general formula 35.
Scheme 8:
Figure imgf000075_0002
35 36 37
As shown in the above scheme 8, the intermediate of general formula 35 reacts with various nucleophiles of general formula H2N-NH-R in an alcoholic solvent preferably methanol or ethanol at a temperature of about 20° to 80 0C to obtain the compounds of general formulae 36 and 37. In case of monosubstituted hydrazines regioisomeric products are formed. Compounds 36 and 37 can be transformed to compounds of the general formula (I) as depicted in Scheme 9.
In scheme 8, the variable R is as defined herein.
Scheme 9:
Figure imgf000075_0003
Alkylation of 38 can proceed via an enamine as described in scheme 1 , or via an enolate. Reductive amination of 39 leads to 40. Alkylation or acylation of 40 affords 41. In scheme 9, the variables R, R4a, R4b, R5, X2, X3 are as defined herein. Scheme 10:
Figure imgf000076_0001
34 42 43 G = S, O, N
Figure imgf000076_0002
As shown in scheme 10, the reaction of compound of general formula 34 with hy- droxyl(tosyloxy)iodobenzene gives the compound of formula 42. Reaction of compound of general formula 42 with 1 ,3-nucleophiles under appropriate conditions yield the compound of general formula 43. Further transformation to compounds of general formula 46 occurs as described in Scheme 9.
In scheme 10, the variables R, R4a, R4b, R5, X2, X3 are as defined herein.
Scheme 1 1 :
Figure imgf000076_0003
R2 = -CO 2Me, -CO2Et, -CN, NO2 etc
As shown in scheme 1 1 , the condensation of compound of general formula 35 with reagent of general formula 49 and ammonia acetate in refluxing acetic acid give compound of general formula 47, which can be further transformed to compounds of general formula 48.
In scheme 11 , the variables R, R4a, R4b, R5, X2, X3 are as defined herein.
Scheme 12:
Figure imgf000077_0001
As shown in scheme 12, the cyclocondensation of intermediate of general formula 35 with the 1 ,3-nucleophiles of general formula 50 in the presence of suitable organic or inorganic bases such as KOH, NaOH, NaHCO3, sodium ethoxide, sodium methoxide, triethyl amine and diisopropyl ethyl amine in an alcoholic solvent, preferably ethanol or methanol, at a temperature of about 20° to 800C yield the compound of general formula 51 , which can be transformed further to give compounds of general formula 52.
In scheme 12, the variables R, R , R , R , X , X are as defined herein.
Scheme 13:
Figure imgf000077_0002
As shown in scheme 13, the intermediate of general formula 53 readily can undergo condensation with dimethylformamide dimethyl acetal to give the compound of general formula 54, which reacts with various nucleophiles of general formula H2N-NH-R in an alcoholic solvent, preferably methanol or ethanol, at a temperature of about 20° to 80 0C to afford the compound of general formula 55 and 56. Compounds 55 and 56 can be trans- formed to compounds of the general formula (I) as depicted in the previous schemes.
In scheme 13, the variables R, R4a, R4b, R5, X2, X3 are as defined herein.
Scheme 14:
Figure imgf000078_0001
As shown in scheme 14, the reaction of compound of general formula 53 with hy- droxyl(tosyloxy)iodobenzene gives the compound of formula 59, which reacts with 1 ,3- nucleophiles under appropriate conditions to yield the compound of general formula 60. Further transformation to compounds of general formula 62 occurs as described in the previous schemes.
In scheme 14, the variables R, R , R , R , X , X are as defined herein.
Scheme 15:
Figure imgf000078_0002
As shown in scheme 15, the cyclocondensation of intermediate of general formula 54 with the 1 ,3-nucleophiles of general formula 50 in the presence of suitable organic or inorganic bases such as KOH, NaOH, NaHCO3, sodium ethoxide, sodium methoxide, triethyl amine and diisopropyl ethyl amine in an alcoholic solvent, preferably ethanol or methanol, at a temperature of about 20° to 800C yields the compound of general formula 63, which can be transformed further to give compounds of general formula 65 as described in the previous schemes.
In scheme 15, the variables R, R , R , R , X , X are as defined herein. The acid addition salts of the aminotetraline derivatives of formula (I) are prepared in a customary manner by mixing the free base with a corresponding acid, optionally in solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or pro- panol, an ether, such as methyl tert-butyl ether or diisopropyl ether, a ketone, such as acetone or methyl ethyl ketone, or an ester, such as ethyl acetate.
The aminotetraline derivatives of formula (II)
Figure imgf000079_0001
wherein L is an amino-protecting group, Y is NR9, and A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n are defined as above are useful as intermediates in the preparation of GIyTI inhibitors, in particular those of formula (I).
Suitable amino-protecting groups are well known in the art such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
According to a particular embodiment, L is optionally substituted alkylcarbonyl (e.g., tert- butylcarbonyl), optionally substituted arylcarbonyl, optionally substituted arylalkycarbonyl (e.g., benzylcarbonyl), optionally substituted alkoxycarbonyl (e.g., methoxycarbonyl or tert-butyloxycarbonyl), optionally substituted aryloxycarbonyl (e.g. phenoxycarbonyl) or optionally substituted arylalkoxycarbonyl.
The compounds of the formula (I) are capable of inhibiting the activity of glycine transporter, in particular glycine transporter 1 (GIyTI ).
The utility of the compounds in accordance with the present invention as inhibiting the glycine transporter activity, in particular GIyTI activity, may be demonstrated by method- ology known in the art. For instance, human GIyTI c expressing recombinant hGlyT1 c_5_CHO cells can be used for measuring glycine uptake and its inhibition (IC5o) by a compound of formula (I). Amongst the compounds of the formula (I) those are preferred which achieve effective inhibition at low concentrations. In particular, compounds of the formula (I) are preferred which inhibit glycine transporter 1 (GIyTI ) at a level of IC50 < 1 μMol, more preferably at a level of IC5O < 0.5 μMol, particularly preferably at a level of IC5O < 0.2 μMol and most pref- erably at a level of IC5O < 0.1 μMol.
The compounds of the formula (I) according to the present invention are thus uselful as pharmaceuticals.
The present invention therefore also relates to pharmaceutical compositions which comprise an inert carrier and a compound of the formula (I).
The present invention also relates to the use of the compounds of the formula (I) in the manufacture of a medicament for inhibiting the glycine transporter GIyTI , and to corre- sponding methods of inhibiting the glycine transporter GIyTI .
The NMDA receptor is central to a wide range of CNS processes, and its role in a variety of diseases in humans or other species has been described. GIyTI inhibitors slow the removal of glycine from the synapse, causing the level of synaptic glycine to rise. This in turn increases the occupancy of the glycine binding site on the NMDA receptor, which increases activation of the NMDA receptor following glutamate release from the presynaptic terminal. Glycine transport inhibitors and in particular inhibitors of the glycine transporter GIyTI are thus known to be useful in treating a variety of neurologic and psychiatric disorders. Further, glycine A receptors play a role in a variety of diseases in humans or other species. Increasing extracellular glycine concentrations by inhibiting glycine transport may enhance the activity of glycine A receptors. Glycine transport inhibitors and in particular inhibitors of the glycine transporter GIyTI are thus useful in treating a variety of neurologic and psychiatric disorders.
The present invention thus further relates to the use of the compounds of the formula (I) for the manufacture of a medicament for treating a neurologic or psychiatric disorder, and to corresponding methods of treating said disorders.
According to a particular embodiment, the disorder is associated with glycinergic or glu- tamatergic neurotransmission dysfunction.
According to a further particular embodiment, the disorder is one or more of the following conditions or diseases: schizophrenia or a psychotic disorder including schizophrenia (paranoid, disorganized, catatonic or undifferentiated), schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition and substance- induced psychotic disorder, including both the positive and the negative symptoms of schizophrenia and other psychoses; cognitive disorders including dementia (associated with AIz- heimer's disease, ischemia, multi-infarct dementia, trauma, vascular problems or stroke, HIV disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jacob disease, perinatal hypoxia, other general medical conditions or substance abuse); delirium, amnestic disorders or cognitive impairment including age related cognitive decline; anxiety disorders including acute stress disorder, agoraphobia, generalized anxiety disor- der, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobia, substance-induced anxiety disorder and anxiety due to a general medical condition; substance-related disorders and addictive behaviors (including substance-induced delirium, persisting dementia, persisting amnestic disorder, psychotic disorder or anxiety disorder; tolerance, depend- ence or withdrawal from substances including alcohol, amphetamines, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine, sedatives, hypnotics or anxiolytics); obesity, bulimia nervosa and compulsive eating disorders; bipolar disorders, mood disorders including depressive disorders; depression including unipolar depression, seasonal depression and post-partum depression, premenstrual syndrome (PMS) and pre- menstrual dysphoric disorder (PDD), mood disorders due to a general medical condition, and substance-induced mood disorders; learning disorders, pervasive developmental disorder including autistic disorder, attention deficit disorders including attention-deficit hyperactivity disorder (ADHD) and conduct disorder; movement disorders, including akinesias and akinetic-rigid syndromes (including Parkinson's disease, drug-induced parkinson- ism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonism-ALS dementia complex and basal ganglia calcification), medication-induced parkinsonism (such as neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic- induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremor), Gilles de Ia Tourette's syndrome, epilepsy, muscular spasms and disorders associated with muscular spasticity or weakness including tremors; dyskinesias [including tremor (such as rest tremor, postural tremor and intention tremor), chorea (such as Sydenham's chorea, Huntington's disease, benign hereditary chorea, neuroacanthocy- tosis, symptomatic chorea, drug-induced chorea and hemiballism), myoclonus (including generalised myoclonus and focal myoclonus), tics (including simple tics, complex tics and symptomatic tics), and dystonia (including generalised dystonia such as iodiopathic dystonia, drug-induced dystonia, symptomatic dystonia and paroxymal dystonia, and focal dystonia such as blepharospasm, oromandibular dystonia, spasmodic dysphonia, spasmodic torticollis, axial dystonia, dystonic writer's cramp and hemiplegic dystonia)]; urinary incontinence; neuronal damage including ocular damage, retinopathy or macular degeneration of the eye, tinnitus, hearing impairment and loss, and brain edema; emesis; and sleep disorders including insomnia and narcolepsy.
According to a further particular embodiment, the disorder is pain, in particular chronic pain and especially neuropathic pain.
Pain can be classified as acute and chronic pain. Acute pain and chronic pain differ in their etiology, pathophysiology, diagnosis and treatment.
Acute pain, which occurs following tissue injury, is self-limiting, serves as an alert to ongoing tissue damage and following tissue repair it will usually subside. There are minimal psychological symptoms associated with acute pain apart from mild anxiety. Acute pain is nociceptive in nature and occurs following chemical, mechanical and thermal stimulation of A-delta and C-polymodal pain receptors.
Chronic pain, on the other hand, serves no protective biological function. Rather than being the symptom of tissue damage it is a disease in its own right. Chronic pain is unrelenting and not self-limiting and can persist for years, perhaps decades after the initial injury. Chronic pain can be refractory to multiple treatment regimes. Psychological symptoms associated with chronic pain include chronic anxiety, fear, depression, sleeplessness and impairment of social interaction. Chronic non-malignant pain is predominantly neuropathic in nature and involves damage to either the peripheral or central nervous systems.
Acute pain and chronic pain are caused by different neuro-physiological processes and therefore tend to respond to different types of treatments. Acute pain can be somatic or visceral in nature. Somatic pain tends to be a well localised, constant pain and is described as sharp, aching, throbbing or gnawing. Visceral pain, on the other hand, tends to be vague in distribution, paroxysmal in nature and is usually described as deep, aching, squeezing or colicky in nature. Examples of acute pain include post-operative pain, pain associated with trauma and the pain of arthritis. Acute pain usually responds to treatment with opioids or non-steroidal anti-inflammatory drugs.
Chronic pain, in contrast to acute pain, is described as burning, electric, tingling and shooting in nature. It can be continuous or paroxysmal in presentation. The hallmarks of chronic pain are chronic allodynia and hyperalgesia. Allodynia is pain resulting from a stimulus that normally does not ellicit a painful response, such as a light touch. Hyperalgesia is an increased sensitivity to normally painful stimuli. Primary hyperalgesia occurs immediately within the area of the injury. Secondary hyperalgesia occurs in the undam- aged area surrounding the injury. Examples of chronic pain include complex regional pain syndrome, pain arising from peripheral neuropathies, post-operative pain, chronic fatigue syndrome pain, tension-type headache, pain arising from mechanical nerve injury and severe pain associated with diseases such as cancer, metabolic disease, neurotropic viral disease, neurotoxicity, inflammation, multiple sclerosis or any pain arising as a consequence of or associated with stress or depressive illness.
Although opioids are cheap and effective, serious and potentially life-threatening side effects occur with their use, most notably respiratory depression and muscle rigidity. In addi- tion the doses of opioids which can be administered are limited by nausea, emesis, constipation, pruritis and urinary retention, often resulting in patients electing to receive sub- optimal pain control rather than suffer these distressing side-effects. Furthermore, these side-effects often result in patients requiring extended hospitalisation. Opioids are highly addictive and are scheduled drugs in many territories.
The compounds of formula (I) are particularly useful in the treatment of schizophrenia, bipolar disorder, depression including unipolar depression, seasonal depression and postpartum depression, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PDD), learning disorders, pervasive developmental disorder including autistic disorder, attention deficit disorders including Attention-Deficit/Hyperactivity Disorder, tic disorders including Tourette's disorder, anxiety disorders including phobia and post traumatic stress disorder, cognitive disorders associated with dementia, AIDS dementia, Alzheimer's, Parkinson's, Huntington's disease, spasticity, myoclonus, muscle spasm, tinnitus and hearing impairment and loss are of particular importance.
Particular cognitive disorders are dementia, delirium, amnestic disorders and cognitive impartment including age-related cognitive decline.
Particular anxiety disorders are generalized anxiety disorder, obsessive-compulsive disor- der and panic attack.
Particular schizophrenia or psychosis pathologies are paranoid, disorganized, catatonic or undifferentiated schizophrenia and substance-induced psychotic disorder.
Particular neurologic disorders that can be treated with the compounds of of the formula (I) include in particular a cognitive disorder such as dementia, cognitive impairment, attention deficit hyperactivity disorder. Particular psychiatric disorders that can be treated with the compounds of of the formula (I) include in particular an anxiety disorder, a mood disorder such as depression or a bipolar disorder, schizophrenia, a psychotic disorder.
Within the context of the treatment, the use according to the invention of the compounds of the formula (I) involves a method. In this method, an effective quantity of one or more compounds or the formula (I), as a rule formulated in accordance with pharmaceutical and veterinary practice, is administered to the individual to be treated, preferably a mammal, in particular a human being. Whether such a treatment is indicated, and in which form it is to take place, depends on the individual case and is subject to medical assessment (diagnosis) which takes into consideration signs, symptoms and/or malfunctions which are present, the risks of developing particular signs, symptoms and/or malfunctions, and other factors.
As a rule, the treatment is effected by means of single or repeated daily administration, where appropriate together, or alternating, with other drugs or drug-containing preparations.
The invention also relates to the manufacture of pharmaceutical compositions for treating an individual, preferably a mammal, in particular a human being. Thus, the compounds of the formula (I) are customarily administered in the form of pharmaceutical compositions which comprise an inert carrier (e.g. a pharmaceutically acceptable excipient) together with at least one compound according to the invention and, where appropriate, other drugs. These compositions can, for example, be administered orally, rectally, transder- mally, subcutaneously, intravenously, intramuscularly or intranasally.
Examples of suitable pharmaceutical formulations are solid medicinal forms, such as powders, granules, tablets, in particular film tablets, lozenges, sachets, cachets, sugar- coated tablets, capsules, such as hard gelatin capsules and soft gelatin capsules, sup- positories or vaginal medicinal forms, semisolid medicinal forms, such as ointments, creams, hydrogels, pastes or plasters, and also liquid medicinal forms, such as solutions, emulsions, in particular oil-in-water emulsions, suspensions, for example lotions, injection preparations and infusion preparations, and eyedrops and eardrops. Implanted release devices can also be used for administering inhibitors according to the invention. In addi- tion, it is also possible to use liposomes or microspheres.
When producing the compositions, the compounds according to the invention are optionally mixed or diluted with one or more carriers (excipients). Carriers (excipients) can be solid, semisolid or liquid materials which serve as vehicles, carriers or medium for the active compound.
Suitable carriers (excipients) are listed in the specialist medicinal monographs. In addition, the formulations can comprise pharmaceutically acceptable auxiliary substances, such as wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirri- tants; chelating agents; coating auxiliaries; emulsion stabilizers; film formers; gel formers; odor masking agents; taste corrigents; resin; hydrocolloids; solvents; solubilizers; neutralizing agents; diffusion accelerators; pigments; quaternary ammonium compounds; refat- ting and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; spreading auxiliaries; stabilizers; sterilants; suppository bases; tablet auxiliaries, such as binders, fillers, glidants, disintegrants or coatings; propellants; drying agents; opacifiers; thickeners; waxes; plasticizers and white mineral oils. A formulation in this regard is based on specialist knowledge as described, for example, in Fiedler, H. P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete [Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields], 4th edition, Aulendorf: ECV- Editio-Cantor-Verlag, 1996.
The compounds of formula (I) may also be suitable for combination with other therapeutic agents.
Thus, the present invention also provides: i) a combination comprising a compound of formula (I) with one or more further therapeutic agents; ii) a pharmaceutical composition comprising a combination product as defined in i) above and at least one carrier, diluent or excipient; iii) the use of a combination as defined in i) above in the manufacture of a medicament for treating or preventing a disorder, disease or condition as defined herein; iv) a combination as defined in i) above for use in treating or preventing a disorder, dis- ease or condition as defined herein; v) a kit-of-parts for use in the treatment of a disorder, disease or condition as defined herein, comprising a first dosage form comprising a compound of formula (I) and one or more further dosage forms each comprising one or more further therapeutic agents for simultaneous therapeutic administration, vi) a combination as defined in i) above for use in therapy; vii) a method of treatment or prevention of a disorder, disease or condition as defined herein comprising administering an effective amount of a combination as defined in i) above; viii) a combination as defined in i) above for treating or preventing a disorder, disease or condition as defined herein.
The combination therapies of the invention may be administered adjunctively. By adjunc- tive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices. This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration. Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) and at least one further therapeutic agent are within the scope of the current invention. In one embodiment of adjunctive therapeutic administration as described herein, a patient is typically stabilised on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component.
The combination therapies of the invention may also be administered simultaneously. By simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or de- vices, each comprising one of the components, administered simultaneously. Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one antipsychotic agent. In a further aspect, the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent. The invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one antipsychotic agent to a patient receiving therapeutic administration of compounds of formula (I). In a further aspect, the invention provides the use of at least one antipsychotic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I). The inven- tion further provides at least one antipsychotic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I).
In a further aspect, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) in combination with at least one antipsychotic agent. The invention further provides the use of a combination of compounds of formula (I) and at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psy- chotic disorder. The invention further provides a combination of compounds of formula (I) and at least one antipsychotic agent for simultaneous therapeutic administration in the treatment of a psychotic disorder. The invention further provides the use of compounds of formula (I) in the manufacture of a medicament for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides the use of at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a psychotic disorder. The invention further pro- vides at least one antipsychotic agent for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a psychotic disorder.
In further aspects, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent, a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent, the use of a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent in the manufacture of a medicament for the treatment of a psychotic disorder, and a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent for use in the treatment of a psychotic disorder.
Antipsychotic agents include both typical and atypical antipsychotic drugs. Examples of antipsychotic drugs that are useful in the present invention include, but are not limited to: butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene; thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines; imidazolidinones; benziso- thiazolyl-piperazines; triazine such as lamotrigine; dibenzoxazepines, such as loxapine; dihydroindolones, such as molindone; aripiprazole; and derivatives thereof that have antipsychotic activity.
Examples of tradenames and suppliers of selected antipsychotic drugs are as follows: clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis); olanzapine (available under the tradename ZYPREX®, from Lilly); ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); haloperidol (available under the tradename HALDOL®, from Ortho-McNeil); chlorpromazine (available under the tradename
THORAZINE®, from SmithKline Beecham (GSK)); fluphenazine (available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena); thiothixene (available under the tradename NAVANE®, from Pfizer); trifluoperazine (10-[3-(4-methyl-1-piperazinyl)propyl]-2- (trifluoro- methyl)phenothiazine dihydrochloride, available under the tradename STELAZINE®, from Smith Klein Beckman); perphenazine (available under the tradename TRILAFON®; from Schering); thioridazine (available under the tradename MELLARIL®; from Novartis, Rox- ane, HiTech, Teva, and Alpharma) ; molindone (available under the tradename MOBAN®, from Endo); and loxapine (available under the tradename LOXITANE(D; from Watson). Furthermore, benperidol (Glianimon®), perazine (Taxilan®) or melperone (Eunerpan®) may be used. Other antipsychotic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRI N®), chlor- prothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®), pro- chlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename Pl- POTRIL®), ziprasidone, and hoperidone.
In a further aspect, the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease. In a further aspect, the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease.
In a further aspect, the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by adjunctive therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease to a patient receiving therapeutic administration of compounds of formula (I). In a further aspect, the invention provides the use of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of compounds of formula (I). The invention further provides at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of compounds of formula (I).
In a further aspect, the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by simultaneous therapeutic administration of com- pounds of formula (I) in combination with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides the use of a combination of compounds of formula (I) and at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides a combination of compounds of formula (I) and at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for simultaneous therapeutic administration in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides the use of compounds of formula (I) in the manufac- ture of a medicament for simultaneous therapeutic administration with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides the use of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a neurodegenerative disorder such as Alzheimer Disease.
Examples of agents suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease that are useful in the present invention include, but are not limited to: cholinesterase inhibitors, agents targeting nicotinic or muscarinic acetylcholine receptors, NMDA receptors, amyloid formation, mitochondrial dysfunctions, disease associated cal- pain activity, neuroinflamation, tumor necrosis factor receptors, NF-kappaB, peroxisome proliferator activator receptor gamma, Apolipoprotein E variant 4 (ApoE4), disease- associated increase of the HPA axis, epileptic discharges, vascular dysfunction, vascular risk factors, and oxidative stress.
Suitable cholinesterase inhibitors which may be used in combination with the compounds of the inventions include for example tacrine, donepezil, galantamine and rivastigmine.
Suitable NMDA receptors targeting agents which may be used in combination with the compounds of the inventions include for example memantine.
Suitable agents affecting increased HPA axis activity which may be used in combination with the compounds of the inventions include for example CRF1 antagonists or V1 b antagonists.
In a further aspect therefore, the invention provides a method of treatment of pain by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain. In a further aspect, the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain. The invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain.
In a further aspect, the invention provides a method of treatment of pain by adjunctive therapeutic administration of at least one agent suitable for the treatment of pain to a patient receiving therapeutic administration of compounds of formula (I). In a further aspect, the invention provides the use of at least one agent suitable for the treatment of pain in the manufacture of a medicament for adjunctive therapeutic administration for the treat- ment of pain in a patient receiving therapeutic administration of compounds of formula (I). The invention further provides at least one agent suitable for the treatment of pain for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of compounds of formula (I).
In a further aspect, the invention provides a method of treatment of pain by simultaneous therapeutic administration of compounds of formula (I) in combination with at least one agent suitable for the treatment of pain. The invention further provides the use of a combination of compounds of formula (I) and at least one agent suitable for the treatment of pain in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of pain. The invention further provides a combination of compounds of formula (I) and at least one agent suitable for the treatment of pain for simultaneous therapeutic administration in the treatment of pain. The invention further provides the use of compounds of formula (I) in the manufacture of a medicament for simultaneous therapeu- tic administration with at least one agent suitable for the treatment of pain in the treatment of pain. The invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one agent suitable for the treatment of pain in the treatment of pain. The invention further provides the use of at least one agent suitable for the treatment of pain in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of pain. The invention further provides at least one agent suitable for the treatment of pain for simultaneous therapeutic administration with compounds of formula (I) in the treatment of pain.
Examples of agents suitable for the treatment of pain that are useful in the present inven- tion include, but are not limited to: NSAIDs (Nonsteroidal Antiinflammatory Drugs), anticonvulsant drugs such as carbamazepine and gabapentin, sodium channel blockers, antidepressant drugs, cannabinoids and local anaesthetics.
Suitable agents used in combination with the compounds of the inventions include for ex- ample celecoxib, etoricoxib, lumiracoxib, paracetamol, tramadol, methadone, venlafaxine, imipramine, duloxetine, bupropion, gabapentin, pregabalin, lamotrigine, fentanyl, pare- coxib, nefopam, remifentanil, pethidine, diclofenac, rofecoxib, nalbuphine, sufentanil, pethidine, diamorphine and butorphanol.
It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1 B antagonists, 5HT1 D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents, as well as cognitive enhancers.
Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.
Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
Suitable anticonvulsant agents which may be used in combination of the compounds of the invention include for example divalproex, carbamazepine and diazepam.
The following examples serve to explain the invention without limiting it.
The compounds were characterized by mass spectrometry, generally recorded via HPLC- MS in a fast gradient on C18-material (electrospray-ionisation (ESI) mode).
Preparation Examples
All final compounds have cis configuration at the tetrahydronaphthalen core if not otherwise noted.
Example 1 : [7-(2-tert-Butoxycarbonylamino-ethoxy)-1 -(3,4-dichloro-benzyl)-1 ,2,3,4- tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester
1.1 1-(3,4-Dichlorobenzyl)-7-methoxy-3,4-dihydronaphthalen-2(1 H)-one
Figure imgf000093_0001
15 g (85 mmol) of 7-methoxy-3,4-dihydronaphthalen-2(1 H)-one were dissolved in 200 ml of dry MeOH under nitrogen. Then 6.66 g (94 mmol) of pyrrolidine were added dropwise and slowly and the colour changes. The mixture is stirred for one h. The solvent was re- duced under vacuo and the residue was dissolved in MeCN. At 5°C 22.5 g (94 mmol) 4- (bromomethyl)-1 ,2-dichlorobenzene dissolved in MeCN were added and the mixture was stirred over night at RT. The solvent was reduced under vacuo and the residue was mixed with MeOH/CH2CI2/H2O 1 :1 :1 (50 ml, 50 ml, 50 ml) and 10 ml of glacial acid were added. The mixture was stirred over night. Work-up: The reaction mixture was put on ice water and extracted 3x with CH2CI2. The combined organic layers were washed Ix with NaHCO3 solution and 1x with saturated NaCI solution. The organic phase was dried on MgSO4 and the solvent was evaporated. The residue (31.5 g) was purified by flash-chromatography on silica gel with heptane/EtOAc 2:1. 24.1 g (71.7 mmol, 84%) of the product were obtained. ESI-MS [M+H+] = 335.1 Calculated for Ci8H16CI2O2 = 334.05.
1.2 1 -(3,4-Dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-amine hydrochloride
Figure imgf000093_0002
To 1-(3,4-dichlorobenzyl)-7-methoxy-3,4-dihydronaphthalen-2(1 H)-one 5.2 g (15.5 mmol) in MeOH reactant ammonium acetate (12.0 g, 155 mmol) and sodium cyanoborohydride (1.46 g, 23.3 mmol) were added under nitrogen. The mixture was stirred for 4d at RT. The solvent was reduced under vacuo and extracted with EtOAc after addition of water. The organic layer was washed with NaCI, dried on MgSO4 and the solvent was removed. The residue was dissolved in iPrOH and HCI in iPrOH (6N) was added. After crystallization over night the HCI-salt was separated from the mother liquor and transferred to the free base with NaOH (1 N). An oil was obtained that after treatment with HCI gave the cis product (1.95 g, 5.80 mmol, 37.4%) after crystallization. The mother liquor contained a cis/ trans mixture of the product. ESI-MS [M+H+] = 336.2 Calculated for Ci8H19CI2NO = 336.26. 1.3 Ethyl 1 -(3,4-dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate To 1-(3,4-dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-amine hydrochloride (1.95 g, 5.80 mmol) in pyridine 10 ml) the ethylchloroformate (1.00 g, 9.28 mmol) was added slowly under nitrogen. The mixture was stirred over night at RT. The solvent was reduced under vacuo and extracted with CH2CI2 after addition of HCI (1 N). The organic layer was washed with HCI (1 N), NaHCO3 solution, and NaCI solution, then dried on MgSO4 and the solvent was removed. The product was obtained as an orange oil that precipitates after a few hours (2.10 g, 5.14 mmol, 89%).
Figure imgf000094_0001
ESI-MS [M+H+] = 408.2 Calculated for C2iH23CIN2O3 =407.11.
1.4 Ethyl 1-(3,4-dichlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate
Figure imgf000094_0002
Ethyl 1-(3,4-dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (2.1 g, 5.14 mmol) was dissolved in CH2CI2 (50 ml) and BBr3 (3.87 g, 15.4 mmol) was added at -100C. The reaction mixture was slowly warmed to RT and stirred for 2h. The reaction mixture was added to ice water and extracted with CH2CI2. The organic layer was washed with NaHCO3 solution and NaCI solution, then dried on MgSO4 and the solvent was re- moved. The product was obtained as a brown oil (2.05 g, 5.14 mmol, 100%). ESI-MS [M+H+] = 394.1 Calculated for C20H21CI2NO3 = 393.09.
1.5 7-(2-tert-Butoxycarbonylamino-ethoxy)-1 -(3,4-dichloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000095_0001
NaH (55% in paraffin, 34.5 mmol) was suspended in DMA (80 ml) and ethyl 1-(3,4- dichlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (6.80 g, 17.3 mmol) dissolved in DMA (40 ml) was added. The mixture was stirred for another h. Then the bromide was added in portions and the mixture was stirred for 3d at RT. The reaction mixture was added to half concentrated NaCI and extracted with EtOAc. The organic layer was washed wit H2O, NaCI solution, then dried on MgSO4 and the solvent was removed. Some DMA was removed on an oil pump. The residue was purified by flash chromatography using silica gel and CH2CI2/ MeOH 98:2. The product was obtained as an yellow oil (9.27 g, 17.3 mmol, 100%) that becomes solid after a few hours. ESI-MS [M+H+] = 481.1 Calculated for C27H34CI2N2O5 = 536.18
Example 2:
Ethyl 1-(3,4-dichlorobenzyl)-7-(2-(1-methyl-1 H-imidazole-4-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate
2.1 Ethyl 7-(2-aminoethoxy)-1-(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2- ylcarbamate hydrochloride
Figure imgf000095_0002
[7-(2-tert-Butoxycarbonylamino-ethoxy)-1-(3,4-dichloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester (9.27 g, 17.3 mmol) example 1 was dissolved in CH2CI2 (200 ml) and HCI in iPrOH (6N) was added. The reaction was stirred at RT over night after which a solid precipitates. To the reaction mixture diethyl ether was added and the precipitating HCI salt was separated by filtration to give the final product as a solid
(5.85 g, 12.3 mmol, 72%).
ESI-MS [M+H+] = 437.1 Calculated for C22H26CI2N2O3 = 436.13
2.2 Ethyl 1-(3,4-dichlorobenzyl)-7-(2-(1-methyl-1 H-imidazole-4-sulfonamido)ethoxy)- 1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate
Figure imgf000096_0001
Ethyl 7-(2-aminoethoxy)-1 -(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2- ylcarbamate hydrochloride (100 mg, 0.229 mmol) and DMAP (27.9 mg, 0.229 mmol) were dissolved in CH2CI2 (15 ml) and 1-methyl-1 H-imidazole-4-sulfonyl chloride (41.3 mg, 0.229 mmol) dissolved in CH2CI2 (15 ml) was added. The reaction mixture was stirred over night at RT. After addition of H2O the phases were separated and the aqueous phase was extracted with CH2CI2. The organic layer was washed with HCI (1 N), NaHCO3 solution and NaCI solution, then dried on MgSO4 and the solvent was removed. To the residue EtOAc/ diethylether (1 :1 ) was added, stirred, and the precipitate was separated by filtration to obtain a brown solid of product (100 mg). ESI-MS [M+H+] = 581.5 Calculated for C26H30CI2N4O5S = 580.13
Example 3: N-(2-(7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000096_0002
Ethyl 1-(3,4-dichlorobenzyl)-7-(2-(1-methyl-1 H-imidazole-4-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (1.00 g, 1.72 mmol) example 2 was refluxed in 25 g of EtOH/ 20% KOH for 2h. To the reaction mixture half concentrated NaCI solution was added and the mixture was extracted with ethyl acetate. The organic layers were com- bined and washed with NaCI solution, then dried on MgSO4 and the solvent was removed. A significant amount was found to be bound on MgSO4 and so additional separation/ extraction with H2O/ CH2CI2 and drying on Na2SO4 resulted in a yellow oil (830 mg). This residue was dissolved in little MeOH, HCI (1 N) was added, and the final product (650 mg, 1.19 mmol, 69%) was separated by filtration. ESI-MS [M+H+] = 509.1 Calculated for C23H26CI2N4O3S = 508.1 1
Example 4:
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000097_0001
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrodrochloride was prepared analogously to example 3 using 1-methyl-1 H-pyrazole-4-sulfonyl chloride in place of 1-methyl-1 H- imidazole-4-sulfonyl chloride.
ESI-MS [M+H+] = 509.1 Calculated for C23H26CI2N4O3S = 508.11
Example 5:
Pyridine-3-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000097_0002
Pyridine-3-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl}-amide hydrochloride was prepared analogously to example 3 using pyridyl- 3-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 506.1 Calculated for C24H25CI2N3O3S = 505
Example 6:
Figure imgf000098_0001
N-(2-(7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)propane- 1 -sulfonamide (example 8) (66.0 mg, 0.140 mmol), paraformaldehyde (7.63 mg, 0.254 mmol), and formic acid (21.6 mg, 0.469 mmol) were dissolved in ethanol (5 ml) and re- fluxed for 4h. The solvent was reduced and to the residue NaOH (1 N) was added. After extraction with CH2CI2 the organic layers were washed with water and saturated NaCI solution, dried with Na2SO4, filtered, and the solvent was removed. The residue was purified by column chromatography (CH2CI2/ MeOH 97:7 -> 95:5). The final product (15.0 mg, 0.028 mmol, 20%) was obtained as a brown, solid HCI salt from isopropanol treated with HCI in isopropanol (6N). ESI-MS [M+H+] = 499.1 Calculated for C24H32CI2N2O3S = 498
Example 7: 1 -(3,4-Dichloro-benzyl)-7-[2-(propane-1 -sulfonylamino)-ethoxy]-1 ,2,3, 4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000098_0002
{1 -(3,4-Dichloro-benzyl)-7-[2-(propane-1 -sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester was prepared analogously to example example 3 using propane-1-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 543.2 Calculated for C25H32CI2N2O5S = 542
Example 8:
Propane-1 -sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000099_0001
Propane-1 -sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared analogously to example 3 using propane-1-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 471.1 Calculated for C22H28CI2N2O3S = 470
Example 9:
{1 -(3,4-Dichloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000099_0002
{1 -(3,4-Dichloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester was prepared analogously to example example 3 using 1 -methyl-1 H-pyrazole-4-sulfonyl chloride in place of 1 -methyl-1 H- imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 581.2 Calculated for C26H30CI2N4O5S = 580
Example 10:
{1-(3,4-Dichloro-benzyl)-7-[2-(pyridine-3-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000100_0001
{1-(3,4-Dichloro-benzyl)-7-[2-(pyridine-3-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester was prepared analogously to example 3 using pyridine-3-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 578.2 Calculated for C27H29CI2N3O5S = 577
Example 1 1 :
N-(2-(7-Amino-8-(3!4-dichlorobenzyl)-5,6!7,8-tetrahydronaphthalen-2-yloxy)ethyl)-N- methylpropane-1 -sulfonamide hydrochloride
1 1.1 N-(1-(3,4-Dichlorobenzyl)-7-(2-(propylsulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-yl)-2,2,2-trifluoroacetamide
Figure imgf000100_0002
N-(2-(7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)propane- 1 -sulfonamide (example 3, 150 mg, 0.318 mmol) and triethylamine (32.2 mg, 0.318 mmol) were dissolved in THF (10 ml) and trifluoro acetic anhydride (66.8 mg, 0.318 mmol) was added. The mixture was stirred at RT for 48 h. Ethyl acetate was added and the mixture was extracted with water and then washed with a NaHCO3 solution and a saturated NaCI solution. After drying with MgSO4 and removal of the solvent the residue was purified by chromatography on silica gel using CH2Cb/ MeOH 98:2 to give the final product as a colourless oil that becomes solid after a while (80.0 mg, 0.141 mmol, 44%).
1 1.2 N-(2-(7-Amino-8-(3!4-dichlorobenzyl)-5,6!7,8-tetrahydronaphthalen-2-yloxy)ethyl)- N-methylpropane-1 -sulfonamide hydrochloride
Figure imgf000101_0001
NaH (3.38 mg, 0.078 mmol, 55% in oil) was suspended in DMA (5 ml) and N-(1-(3,4- dichlorobenzyl)-7-(2-(propylsulfonamido)ethoxy)-1 ,2,3,4-tetrahydronaphthalen-2-yl)-2,2,2- trifluoroacetamide (40 mg, 0.07 mmol) dissolved in DMA (4 ml) was added dropwise. After stirring for 1 h iodomethane (10.5 mg, 0.074 mmol) dissolved in DMA (1 ml) was added. After stirring for another 14 h the reaction mixture was added to a halfconcentrated solution of NaCI. Extraction with ethyl acetate, washing of the organic layers with water and saturated NaCI solution followed by drying with Na2SO4 gave a residue that was washed with diisopropyl ether. Cleavage of the amide bond was achieved by stirring the residue with concentrated NaOH in water and subsequent extraction with ethyl acetate. The organic layer was dried with MgSO4 and evaporated. The residue was purified by preparative HPLC (RP-18, acetonitrile/ water, 0.01 % TFA). After transferring the product into the HCI salt a yellow solid (11.0 mg, 0.021 mmol, 30%) was obtained. ESI-MS [M+H+] = 485.2 Calculated for C23H30CI2N2O3S = 484
Example 12:
[1-(3,4-Dichloro-benzyl)-7-(2-methanesulfonylamino-ethoxy)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000102_0001
[1-(3,4-Dichloro-benzyl)-7-(2-methanesulfonylamino-ethoxy)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester was prepared analogously to example 3 using methyl sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 515.1 Calculated for C23H28CI2N2O5S = 514
Example 13:
[7-(2-Benzenesulfonylamino-ethoxy)-1-(3,4-dichloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000102_0002
[7-(2-Benzenesulfonylamino-ethoxy)-1-(3,4-dichloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester was prepared analogously to example 3 using phenyl sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 577.2 Calculated for C28H30CI2N2O5S = 576
Example 14:
{1-(3,4-Dichloro-benzyl)-7-[2-(thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000103_0001
{^(S^-Dichloro-benzyl^y-p-^hiophene^-sulfonylamino^ethoxyl-i ^^^-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester was prepared analogously to example 3 using phenyl sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 583.1 Calculated for C26H28CI2N2O5S2 = 582
Example 15:
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5,6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}- methanesulfonamide hydrochloride
Figure imgf000103_0002
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5,6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}- methanesulfonamide was prepared analogously to example 3 using methyl sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 443.1 Calculated for C20H24CI2N2O3S = 442
Example 16:
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5,6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}- benzenesulfonamide hydrochloride
Figure imgf000104_0001
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}- benzenesulfonamide was prepared analogously to example 3 using phenyl sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 505.1 Calculated for C25H26CI2N2O3S = 504
Example 17:
Thiophene-2-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000104_0002
Thiophene-2-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide was prepared analogously to example 3 using thiophene sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 51 1.1 Calculated for C23H24CI2N2O3S2 = 510
Example 18:
N-{1 -(3,4-Dichloro-benzyl)-7-[2-(1 -methyl-1 H-imidazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-2,2,2-trifluoro-acetamide
Figure imgf000105_0001
N-{1 -(3,4-Dichloro-benzyl)-7-[2-(1 -methyl-1 H-imidazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-2,2,2-trifluoro-acetamide was prepared analogously to example 1 1 using the product of example 3 in place of example 8. ESI-MS [M+H+] = 605.1 Calculated for C25H25CI2F3N4O4S = 604
Example 19:
Pyrrolidine-3-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000105_0002
Pyrrolidine-3-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared analogously to example 3 using benzyl 3-(chlorosulfonyl)pyrrolidine-1-carboxylate (synthesis described in WO2008075070) in place of 1 -methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 498.2 Calculated for C23H29CI2N3O3S = 497
Example 20:
1 -Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-formylamino-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000106_0001
Ethyl 1-(3,4-dichlorobenzyl)-7-(2-(1-methyl-1 H-imidazole-4-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (example3, 60.0 mg, 0.103 mmol) was dissolved in THF (5 ml) and LiAIH4 (7.83 mg, 0.206 mmol) was added at RT. The residue was added to 2N NaOH and extracted with dichloromethane. The organic layer was washed with saturated NaHCC>3 solution and then with saturated NaCI solution, dried and evaporated. The product was precipitated as an HCI salt from 6N HCI in isopropanol and isopro- pylether to obtain the product as a white salt (36 mg, 61 %). ESI-MS [M+H+] = 537.1 Calculated for C24H26CI2N4O4S = 536
Example 21 :
1-(3,4-Dichloro-benzyl)-7-[2-(4-methyl-thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000106_0002
1-(3,4-Dichloro-benzyl)-7-[2-(4-methyl-thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester was prepared analogously to example 3 using 4-methylthiophene-2-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4- sulfonyl chloride. ESI-MS [M+H+] = 597.1 Calculated for C27H30CI2N2O5S2 = 596
Example 22: {1 -(3,4-Dichloro-benzyl)-7-[2-(3-fluoro-propane-1 -sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000107_0001
{1 -(3,4-Dichloro-benzyl)-7-[2-(3-fluoro-propane-1 -sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester was prepared analogously to example 3 using 3-fluoropropane-1-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4- sulfonyl chloride. ESI-MS [M+H+] = 561.2 Calculated for C25H3ICI2FN2O5S = 560
Example 23:
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-ethylamino-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000107_0002
Ethyl 1-(3,4-dichlorobenzyl)-7-(2-(1-methyl-1 H-imidazole-4-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (example 3, 60.0 mg, 0.103 mmol) was dissolved in dichloromethane (5 ml) and acetaldehyde (5.45 mg, 0.124 mmol μl) and molsieve 3λ were added and the mixture was stirred for 3h. Acetic acid (7.07 mg, 0.1 18 mmol) was added and the mixture was stirred for another 3h. MeOH (5 ml) and sodium cyanoborohydride (14.8 mg, 0.236 mmol) were added and it was stirred for another 14 h. Water was added and it was extracted with dichloromethane. The organic layer was washed with saturated NaHCO3 solution, washed and evaporated. The residue was purified by column chromatography using SiO2 and CH2CI2/ MeOH 95:5 -> 90:10. The product was precipitated as an HCI salt from 6N HCI in isopropanol and isopropylether to obtain the product as a white salt (17 mg, 25%).
ESI-MS [M+H+] = 537.2 Calculated for C25H30CI2N4O3S = 536
Example 24:
4-Methyl-thiophene-2-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000108_0001
4-Methyl-thiophene-2-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared analogously to example 3 using 4-methylthiophene-2-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 525.1 Calculated for C24H26CI2N2O3S2 = 524
Example 25:
N'-(2-{[7-amino-8-(3!4-dichlorobenzyl)-5!6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-N!N- dimethylsulfuric diamide hydrochloride
Figure imgf000108_0002
N'-(2-{[7-Amino-8-(3!4-dichlorobenzyl)-5!6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-N!N- dimethylsulfuric diamide hydrochloride was prepared analogously to example 3 using di- methylsulfamoyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 472.1 Calculated for C2i H27CI2N3O3S = 471 Example 26:
{1 -(3,4-Dichloro-benzyl)-7-[2-(3,3,3-trifluoro-propane-1 -sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000109_0001
{1 -(3,4-Dichloro-benzyl)-7-[2-(3,3,3-trifluoro-propane-1 -sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester was prepared analogously to example 3 using dimethylsulfamoyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chlo- ride.
ESI-MS [M+H+] = 597.1 Calculated for C25H29CI2F3N2O5S = 596
Example 27:
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(4-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000109_0002
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(4-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared analogously to example 3 using 1-methyl-1 H-imidazole-4-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4- sulfonyl chloride and 4-(bromomethyl)-1-dichlorobenzene instead of 4-(bromomethyl)-1 ,2- dichlorobenzene.
ESI-MS [M+H+] = 475.1 Calculated for C23H27CIN4O3S = 474
Example 28: 1 -Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(4-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000110_0001
1 -Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(4-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared analogously to example 3 using 1 -methyl-1 H-pyrazole-4-sulfonyl chloride in place of 1 -methyl-1 H-imidazole-4- sulfonyl chloride and 4-(bromomethyl)-1-dichlorobenzene instead of 4-(bromomethyl)-1 ,2- dichlorobenzene.
ESI-MS [M+H+] = 475.1 Calculated for C23H27CIN4O3S = 474
Example 29: 7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile trifluoroacetate
29.1 8-(3,4-Dichlorobenzyl)-7-[(ethoxycarbonyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate
Figure imgf000110_0002
Ethyl 1-(3,4-dichlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (700 mg, 1.775 mmol, cf. example 3d) and 1 ,1 ,1-trifluoro-N-phenyl-N- (trifluoromethylsulfonyl)methanesulfonamide (761 mg, 2.13 mmol) were dissolved in di- chloromethane (30 ml_). The reaction mixture was cooled to 00C and a solution of triethyl- amine (0.495 ml_, 3.55 mmol) in dichloromethane (5 ml.) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirring was continued over night. The solvent was evaporated in vacuo and the crude product was purified by flash chromatography (dichloromethane, silica gel). Yield: 934 mg (100 %). ESI-MS [M+H+] = 526 Calculated for C2i H20CI2F3NO5S = 525. 29.2 Ethyl [7-cyano-1-(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate
Figure imgf000111_0001
8-(3,4-Dichlorobenzyl)-7-[(ethoxycarbonyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl trifluo- romethanesulfonate (250 mg, 0.475 mmol), zinc cyanide (139 mg, 1.187 mmol) and tetra- kistriphenyl palladium (82 mg, 0.071 mmol) in dimethylformamide (5 ml.) were heated in the microwave at 1200C (100 W) under stirring for 35 min. The solvent was evaporated in vacuo and the crude product was partitioned between ethyl acetate (40 ml.) and water (30 ml_). The aqueous layer was extracted with ethyl acetate one more time (20 ml.) and the combined organic extracts were dried (Na2SC>4) and concentrated in vacuo. The crude product (460 mg) was purified by flash chromatography (dichloromethane to dichloro- methane:methanol = 100 : 1 , silica gel). Yield: 109 mg (0.270 mmo, 57%, colorless solid). ESI-MS [M+H+] = 403 Calculated for C2IH20CI2N2O2 = 402.
29.3 7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile trifluo- roacetate
Figure imgf000111_0002
Ethyl [7-cyano-1-(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (50 mg, 0.124 mmol) was dissolved in 10% potassium hydroxide in ethanol (1.5 ml.) and the reaction mixture was stirred at 800C for 2.5 h. The solvent was evaporated in vacuo. To the crude product brine (5 ml.) and 2N hydrochloric acid were added until pH 7 was reached. The aqueous layer was extracted with dichloromethane three times. The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. The crude product (60 mg) was purified by preparative HPLC (xTerra prep MS C18 column, 19x150 mm, 5 μm; gradient: water, acetonitrile with 0.1% trifluoroacetic acid, flow: 20 mL/min). Yield: 6 mg (0.013 mmol, 11 %).
ESI-MS [M+H+] = 331 Calculated for Ci8H16CI2N2 =330.
Example 30:
7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile hydrochloride
30.1 7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-ol
Figure imgf000112_0001
1-(4-chlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-amine (13.18 g, 43.7 mmol, prepared analogously to 1-(3,4-dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen- 2-amine cf. example 3) was dissolved in dichloromethane (200 ml_). The solution was cooled to -100C and a 1 M solution of borontribromide in dichloromethane (131 ml_, 131 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature and stirring was continued for 2h. The reaction mixture was poured on ice water and sodium hydroxide was added until pH 8 was reached. The aqueous layer was extracted with dichloromethane. The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. The crude product was used for the next step without further purification. Yield: 8.89 g (30.9 mmol, 71 %, colorless solid). ESI-MS [M +H+] = 288 Calculated for Ci7H18CINO =287.
30.2 Tert-butyl [1 -(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate
Figure imgf000112_0002
7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-ol (2.0 g, 6.95 mmol) was dissolved in dry tetrahydrofurane and di-tertiar butyl carbonate (1.517 g, 6.95 mmol) and triethylamine (2.91 ml_, 20.85 mmol) were added. The reaction mixture was stirred at room temperature for 3 h. The solvent was evaporated in vacuo. Water was added and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried (Na2SC>4) and concentrated in vacuo. The crude product was recrystallized from n-hexane. Yield: 2.2 g (5.67 mmol, 82%). ESI-MS [M-isobutene +H+] = 332 Calculated for C22H26CINO3 =387.
30.3 7-[(Tert-butoxycarbonyl)amino]-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate
Figure imgf000113_0001
Tert-butyl [1 -(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (850 mg, 2.191 mmol) and 1 ,1 ,1-trifluoro-N-phenyl-N-
(trifluoromethylsulfonyl)methanesulfonamide (939 mg, 2.63 mmol) were dissolved in dichloromethane (45 ml_). The pale yellow solution was cooled to 00C and a solution of triethylamine (0.61 1 ml_, 4.38 mmol) in dichloromethane (5 ml.) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirring was continued over night. The solvent was evaporated in vacuo and the crude product was purified by flash chromatography (dichloromethane, silica gel). Yield: 1.03 g (1.981 mmol, 90%, colorless solid). ESI-MS [M-isobutene+CH3CN+H+] = 505 Calculated for C23H25CIF3NO5S =519.
30.4 Tert-butyl [1-(4-chlorobenzyl)-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate
Figure imgf000113_0002
DPPF (8.1 mg, 0.015 mmol) and Pd2dba3 (3.35 mg, 0.00365 mmol) were suspended in dimethylformamide ( 0.4 ml.) and after stirring at room temperature under an inert atmosphere of nitrogen for 20 min 7-[(tert-butoxycarbonyl)amino]-8-(4-chlorobenzyl)-5,6,7,8- tetrahydronaphthalen-2-yl trifluoromethanesulfonate (38 mg, 0.073 mmol) and zinc cyanide (12.87 mg, 0.110 mmol) were added. The reaction mixture was stirred at 900C for 1 h. The solvent was evaporated in vacuo. Water (10 ml.) was added to the crude product and the aqueous layer was extracted with ethyl acetate (two times with 10 ml_). The combined organic extracts were dried (Na2SC>4) and concentrated in vacuo. The crude product was purified by flash chromatography (dichloromethane, silica gel). Yield: 16 mg (0.040 mmol, 55%). ESI-MS [M-isobutene+CH3CN+H+] = 382 Calculated for C23H25CIN2O2 =396.
30.5 7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile hydrochloride
Figure imgf000114_0001
Tert-butyl [1-(4-chlorobenzyl)-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (15 mg, 0.038 mmol) was dissolved in dichloromethane (1.5 ml.) and 5 M hydrochloric acid in isopropanol (0.3 ml.) was added. The reaction mixture was stirred for 3 h at room temperature. The solvent and the excess hydrochloric acid were evaporated in vacuo. Yield: 1 1 mg (0.033 mmol, 87 %, colorless solid). ESI-MS [M+H+] = 297 Calculated for Ci8H17CIN2 =296.
Example 31 : N-[(7-amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl]-3- fluoropropane-1 -sulfonamide trifluoroacetate
31.1 Tert-butyl [7-(aminomethyl)-1-benzyl-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate
Figure imgf000114_0002
Tert-butyl [1-(4-chlorobenzyl)-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (52 mg, 0.131 mmol, cf. example 3Od) were dissolved in methanol (5 ml_). Raney nickel (about 30 mg) was added and the reaction mixture was stirred at room temperature for 4 h under an atmosphere of hydrogen. The catalyst was removed by filtration. The solvent was evaporated in vacuo. The crude product was used without further purification for the next step. Yield: 32 mg (0.087 mmol, 67%). ESI-MS [M-isobutene+H+] = 311 Calculated for C23H30N2O2 = 366.
31.2 Tert-butyl [1-benzyl-7-({[(3-fluoropropyl)sulfonyl]amino}methyl)-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate
Figure imgf000115_0001
Tert-butyl [7-(aminomethyl)-1-benzyl-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (32 mg, 0.87 mmol) was dissolved in dichloromethane (15 ml.) and 4-dimethylaminopyridine (12 mg, 0.096 mmol) and 3-fluoropropane-1-sulfonyl chloride (14 mg, 0.087 mmol) were added. The reaction mixture was stirred at room temperature over night. The dichloromethane solution of the crude product was washed successively with 1 N aqueous hydrochloric acid and aqueous NaHCO3 solution, dried (Na2SO4) and concentrated in vacuo. The crude product was purified by flash chromatography (dichloromethane, methanol, silica gel). Yield: 9.3 mg (0.019 mmol, 22 %). ESI-MS [M-isobutene+H+] = 435 Calculated for C26H35FN2O4S = 490.
31.3 N-{[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-3-fluoropropane-1- sulfonamide trifluoroacetate
Figure imgf000115_0002
Tert-butyl [1 -benzyl-7-({[(3-fluoropropyl)sulfonyl]amino}methyl)-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate (9.3 mg, 0.019 mmol) was dissolved in dichloromethane (10 ml.) and trifluoroacetic acid (excess) was added. The reaction mixture was stirred at room temperature for 4 h. The solvent was evaporated in vacuo and the crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 4 mg (0.0079 mmol, 42%). ESI-MS [M+H+] = 391 Calculated for C2IH27FN2O2S =390.
Example 32:
Ethyl [7-cyano-1 -(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate
Figure imgf000116_0001
Cf. Example 29b.
ESI-MS [M+H+] = 403 Calculated for C2iH20CI2N2O2 = 402.
Example 33: 1-(3-chlorobenzyl)-7-[2-(1 ,1-dioxidoisothiazolidin-2-yl)ethoxy]-1 ,2,3,4- tetrahydronaphthalen-2-amine hydrochloride
Figure imgf000116_0002
ESI-MS [M+H+] = 435 Calculated for C22H27CIN2O3S = 434.
Example 34: tert-Butyl [7-cyano-1 -(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate
34.1 7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-ol
Figure imgf000117_0001
1-(3,4-Dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-amine (10 g, 26.8 mmol, cf. example 3.2 were dissolved in dichloromethane (240 ml_). The suspension was cooled to -100C and a 1 M solution of bortribromide in dichloromethane (80 ml_, 80 mmol). The solution was allowed to warm to room temperature and stirring was continued for 3 h. The reaction mixture was poured on ice (1 L). The aqueous layer was made alkaline (pH 10) with 2N sodium hydroxide solution. The layers were separated. The aqueous layer was extracted with dichloromethane and the combined organic layers were washed with saturated NaHCO3 solution and water. The organic layers were dried (Na2SO4) and concentrated in vacuo. The crude product was used without further purification for the next step. Yield: 10.8 g ESI-MS [M+H+] = 322 Calculated for Ci7H17CI2NO= 321.
34.2 tert-Butyl [1 -(3,4-dichlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate
Figure imgf000117_0002
7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-ol (10.8 g) and triethyl- amine (14.01 ml_, 101 mmol) were dissolved in dry tetrahydrofuran (200 ml_). Di-tert-butyl carbonate (7.31 g, 33.5 mmol) was added in small portions at room temperature. The reaction mixture was stirred over night. The solvent was evaporated in vacuo. The residue was dissolved in ethyl acetate (300 ml.) and washed with water (2x 200 ml_). The ethyl acetate solution of the crude product was dried (Na2SO4). The solvent was evaporated in vacuo and the crude product was used for the next step without further purification. Yield: 12.2 g. ESI-MS [M-isobutene+CH3CN+H+] = 407 Calculated for C22H25CI2NO3= 421.
34.3 7-[(tert-Butoxycarbonyl)amino]-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen- 2-yl trifluoromethanesulfonate
Figure imgf000118_0001
tert-Butyl [1 -(3,4-dichlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (4.06 g, 9.66 mmol) and 1 ,1 ,1-trifluoro-N-phenyl-N-
(trifluoromethylsulfonyl)methanesulfonamide (4.14 g, 1 1.59 mmol) were dissolved in dichloromethane (190 ml_). The light brown solution was cooled to 00C and triethylamine (2.69 ml_, 19.32 mmol) in dichloromethane (10 mL) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirring was continued over night. The solvent was evaporated in vacuo and the crude product was purified by flash chromatography (dichloromethane, silica gel). Yield: 3.2 g (5.77 mmol, 60%).
34.4 tert-Butyl [7-cyano-1-(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate
Figure imgf000118_0002
Diphenylphosphinoferrocene (100 mg, 0.18 mmol) and dipalladium trisdibenzylideneacetone (41 mg, 0.045 mmol) were suspended under an atmosphere of argon in dry dimethylformamide (5 mL). After stirring at room temperature for 40 min 7- [(tert-butoxycarbonyl)amino]-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate (0.5 g, 0.902 mmol) was added and the reaction mixture was heated to 900C. Over 30 min zinc cyanide (159 mg, 1.353 mmol) was added in small portions. After complete addition stirring was continued at 900C for 2 h. The reaction mix- ture was cooled to room temperature diluted with dichloromethane (50 ml_), washed with saturated NaHCO3 (3x 10 ml_). The organic layer was dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash chromatography (dichloromethane, silica gel). Yield: 97 mg (0.225 mmol, 25%). ESI-MS [M+Na+] = 453 Calculated for C23H24CI2N2O2 = 430.
Example 35:
7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-ol trifluoroacetate (salt)
Figure imgf000119_0001
Cf. example 34a
ESI-MS [M+H+] = 322 Calculated for Ci7H17CI2NO = 321.
Example 36:
1-(4-chlorobenzyl)-7-(difluoromethoxy)-1 ,2,3,4-tetrahydronaphthalen-2-amine hydrochloride
36.1 tert-Butyl [1-(4-chlorobenzyl)-7-(difluoromethoxy)-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate
Figure imgf000119_0002
Tert-butyl [1 -(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (180 mg, 0.464 mmol, prepared analogously to tert-butyl [1-(3,4-dichlorobenzyl)-7- hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate, cf. Example 34.2 and potassium hydroxide (1.4 g, 25 mmol) were suspended in acetonitrile (4 ml_). After stirring the two phase system for 45 min at room temperature the reaction mixture was cooled to -15°C and a solution of 2-chloro-2,2-difluoro-1-phenylethanone (442 mg, 2.32 mmol) in acetonitrile (1 ml.) was added dropwise over 30 min. The reaction mixture was warmed to room temperature and then heated at 800C for 2 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined extracts were dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash chromatography (dichloromethane, silica gel). Yield: 30 mg (0.069 mmol, 15 %). ESI-MS [M-isobutene+CH3CN+H+] = 423 Calculated for C23H26CIF2NO3= 437.
36.2 1-(4-Chlorobenzyl)-7-(difluoromethoxy)-1 ,2,3,4-tetrahydronaphthalen-2-amine hydrochloride
Figure imgf000120_0001
tert-Butyl [1 -(4-chlorobenzyl)-7-(difluoromethoxy)-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate (30 mg, 0.069 mmol) was dissolved in dichloromethane (2 ml_). 5N isopro- panolic hydrochloric acid (0.3 ml.) were added and the reaction mixture was stirred at room temperature for 3 h. The solvents were evaporated in vacuo. Yield: 26 mg (0.069 mmol, 100%, colorless solid). ESI-MS [M+H+] = 338 Calculated for Ci8H18CIF2NO = 337.
Example 37:
Benzyl [1 -(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate
Figure imgf000120_0002
tert-Butyl [1-(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (2 g, 6.95 mmol, prepared analogously to tert-butyl [1-(3,4-dichlorobenzyl)-7-hydroxy-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate, cf. example 34.2 were suspended in dimethylfor- mamide (40 ml_). Triethylamine (0.969 ml_, 6.95 mmol) and benzyl carbonochloridate (1.186 g, 6.95 mmol) were added. The reaction mixture was stirred at room temperature over night. The solvent was evaporated in vacuo. To the crude product ethyl acetate and water were added. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 393 mg (0.931 mmol, 13.4%, colorless foam). ESI-MS [M+H+] = 422 Calculated for C25H24CINO3 = 421.
Example 38: tert-Butyl [7-(aminomethyl)-1 -(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate
Figure imgf000121_0001
tert-Butyl [7-cyano-1 -(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate (30 mg, 0.07 mmol, cf. example 34d) were dissolved in methanol (3 ml_). Raney nickel (10 mg) was added and the reaction mixture stirred at room temperature under an atmosphere of hydrogen for 4 h. The catalyst was removed by filtration and the methanol was evaporated in vacuo. Yield: 18 mg (0.041 mmol, 59%). ESI-MS [M+H+] = 435 Calculated for C23H28CI2N2O2 = 434.
Example 39: tert-Butyl [1 -(3,4-dichlorobenzyl)-7-{[(propylsulfonyl)amino]methyl}-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate
Figure imgf000121_0002
tert-Butyl [7-(aminomethyl)-1 -(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate (120 mg, 0.276 mmol, cf. Example 38) was dissolved in dichloromethane (5 ml_). 4-Dimethylaminopyridine (35 mg, 0.289 mmol) was added. After stirring at room temperature for 5 min propane-1-sulfonyl chloride (39 mg, 0.031 mmol) was added and stirring was continued over night. The reaction mixture was diluted with dichloromethane and washed successively with 0.5 N hydrochloric acid (2x 2 ml.) and saturated NaHCO3
(1x 2 ml_). The organic phase was dried (MgSO4) and concentrated in vacuo. The crude product was used for the next step without further purification. Yield: 125 mg (0.231 mmol,
84%).
ESI-MS [M+Na+] = 563 Calculated for C26H34CI2N2O4S = 540.
Example 40:
N-{[7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride
Figure imgf000122_0001
Tert-butyl [1 -(3,4-dichlorobenzyl)-7-{[(propylsulfonyl)amino]methyl}-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate (120 mg, 0.222 mmol, cf. example 39) was dissolved in 5 N isopropanolic hydrochloric acid (2 ml_). The reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated and the product was dried in vacuo. Yield: 101 mg (0.21 1 mmol, 95%). ESI-MS [M+H+] = 441 Calculated for C2i H26CI2N2O2S = 440.
Example 41 :
N-{[7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-3- fluoropropane-1 -sulfonamide hydrochloride
Figure imgf000122_0002
The compound was prepared analogously to example 40 using 3-fluoropropane-1-sulfonyl chloride in place of n-propane-1-sulfonyl chloride. ESI-MS [M+H+] = 459 Calculated for C2IH25CI2FN2O2S = 458.
Example 42:
N-{[ 7-Amino-8-benzyl-5, 6, 7, 8-tetrahydronaphthalen-2-yl]methyl}propane-1 -sulfonamide trifluoroacetate
Figure imgf000123_0001
N-{[7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride (40 mg, 0.084 mmol, cf. example 40) were dissolved in methanol (4 ml.) and hydrogenated at the H-cube (1 h, 40 0C, 30 bar, 20% Pd/C). The solvent was evaporated and the crude product was purified by preparative HPLC (xTerra prep MS C18 column, 19x150 mm, 5 μm; gradient: water, acetonitrile with 0.1 % trifluoroacetic acid, flow: 20 mL/min). Yield: 4.9 mg (0.0102 mmol, 12%). ESI-MS [M+H+] = 373 Calculated for C2i H28N2O2S = 372.
Example 43:
N-{[ cis-7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}cyclobutanesulfonamide hydrochloride
Figure imgf000123_0002
The compound was prepared analogously to example 40 using cyclobutylsulfonyl chloride in place of n-propane-1-sulfonyl chloride.
ESI-MS [M+H+] = 385 Calculated for C22H28N2O2S = 384.
Example 44:
N-{[cis-7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000124_0001
The compound was prepared analogously to example 40 using cyclopropylmethanesul- fonyl chloride in place of n-propane-1-sulfonyl chloride. ESI-MS [M+H+] = 385 Calculated for C22H28N2O2S = 384.
Example 45:
N-ftcis^-amino-δ-benzyl-S^J^-tetrahydronaphthalen^-yllmethylJ-N-methylpropane-i- sulfonamide hydrochloride
Figure imgf000124_0002
Tert-butyl-1 -benzyl-7-(propylsulfonamidomethyl)-1 ,2,3,4-tetrahydronaphthalen-2- ylcarbamate (35 mg, 0.074 mmol, prepared analog to example 40) was dissolved in ace- tonitrile (1 ml_). Cesium carbonate (29 mg, 0.09 mmol) ) and methyliodide (12 μl_, 0.19 mmol) were added successively and the reaction mixture was heated in the microwave to 1000C for 3 h. The solvents were evaporated in vacuo. The residue was treated with di- chloromethane and washed with water. The organic layer was dried (MgSO4) and concentrated. The crude product was dissolved in isopropanol and treated with 5 M hydrochloric acid in isopropanol. The solvent was evaporated in vacuo to yield the final product as colorless solid. Yield: 18 mg (0.043 mmol, 58%). ESI-MS [M+H+] = 387 Calculated for C22H30N2O2S = 386.
Example 46:
{1 -(3-Chloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
46.1 7-(2-tert-Butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000125_0001
7-(2-tert-Butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)-1 ,2,3,4-tetrahydro-naphthalen- 2-yl]-carbamic acid ethyl ester was prepared in analogy to example 1 using 1- bromomethyl-3-chloro-benzene in place of 4-(bromomethyl)-1 ,2-dichlorobenzene. ESI-MS [M+H+] = 503 Calculated for C27H35CIN2O5 = 502
46.2 {1 -(3-Chloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000125_0002
{1 -(3-Chloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester was prepared starting from 7-(2-tert-
Butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester from previous step in analogy to example 2 using 1 -methyl-1 H- pyrazole-4-sulfonyl chloride in place of 1 -methyl-1 H-imidazole-4-sulfonyl chloride.
ESI-MS [M+H+] = 547 Calculated for C26H3iCIN4O5 = 546
Example 47:
1 -Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000126_0001
1 -Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 3 starting from {1 -(3-Chloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]- 1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 46) ESI-MS [M+H+] = 475 Calculated for C23H27CIN4O3S = 474
Example 48:
1 -Methyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000126_0002
1 -Methyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared in three steps from 7-(2-tert- Butoxycarbonylamino-ethoxy)-1 -(3-chloro-benzyl)-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester in analogy to example 47 using 1 -Methyl-1 H-imidazole-4- sulfonyl chloride. ESI-MS [M+H+] = 475 Calculated for C23H27CIN4O3S = 474
Example 49:
{1-(3-Chloro-benzyl)-7-[2-(2,4-dimethyl-thiazole-5-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000127_0001
Prepared in two steps from 7-(2-tert-Butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 2,4-dimethyl-thiazole-5-sulfonyl chloride. ESI-MS [M+H+] = 578 Calculated for C27H32CIN3O5S2 = 577
Example 50:
{1-(3-Chloro-benzyl)-7-[2-(thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000127_0002
Prepared in two steps from 7-(2-tert-Butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using thiophene-2-sulfonyl chloride. ESI-MS [M+H+] = 549 Calculated for C26H29CIN2O5S2 = 548
Example 51 :
{1-(3-Chloro-benzyl)-7-[2-(5-chloro-thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000127_0003
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 5-Chloro-thiophene-2-sulfonyl chloride. ESI-MS [M+H+] = 583 Calculated for C26H28CI2N2O5S2 = 582
Example 52:
{1-(3-Chloro-benzyl)-7-[2-(2-methyl-3H-imidazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000128_0001
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 2-Methyl-3H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 547 Calculated for C26H3ICIN4O5S = 546
Example 53:
{1-(3-Chloro-benzyl)-7-[2-(5-methyl-thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000128_0002
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 5-Methyl-thiophene-2-sulfonyl chloride. ESI-MS [M+H+] = 563 Calculated for C27H3iCIN2O5S2 = 562
Example 54: {1 -(3-Chloro-benzyl)-7-[2-(4-methyl-thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000129_0001
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 4-Methyl-thiophene-2-sulfonyl chloride. ESI-MS [M+H+] = 563 Calculated for C27H3ICIN2O5S2 = 562
Example 55:
Propane-1 -sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-amide hydrochloride
Figure imgf000129_0002
Prepared in three steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)-
1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 48 using propane-1 -sulfonyl chloride.
ESI-MS [M+H+] = 437 Calculated for C22H29CIN2O3S = 436
Example 56:
Thiophene-2-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl}-amide
Figure imgf000129_0003
Prepared in one step from {1-(3-chloro-benzyl)-7-[2-(thiophene-2-sulfonylamino)-ethoxy]- 1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester in analogy to example 48.
ESI-MS [M+H+] = 477 Calculated for C23H25CIN2O3S2 = 476
Example 57: 2,4-Dimethyl-thiazole-5-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000130_0001
Prepared in one step from {1-(3-Chloro-benzyl)-7-[2-(2,4-dimethyl-thiazole-5- sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (e- xample 49) in analogy to example 48.
ESI-MS [M+H+] = 506 Calculated for C24H28CIN3O3S2 = 505
Example 58:
2-Methyl-3H-imidazole-4-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000130_0002
Prepared in one step from {1-(3-Chloro-benzyl)-7-[2-(2-methyl-3H-imidazole-4- sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (e- xample 52) in analogy to example 48. ESI-MS [M+H+] = 475 Calculated for C23H27CIN4O3S = 474
Example 59: δ-Chloro-thiophene^-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000131_0001
Prepared in one step from {1-(3-chloro-benzyl)-7-[2-(5-chloro-thiophene-2-sulfonylamino)- ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 51 ) in analogy to example 48. ESI-MS [M+H+] = 51 1 Calculated for C23H24CI2N2O3S2 = 510
Example 60:
{1-(3-Chloro-benzyl)-7-[2-(2,5-dimethyl-thiophene-3-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000131_0002
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 2,5-Dimethyl-thiophene-3-sulfonyl chloride. ESI-MS [M+H+] = 577 Calculated for C28H33CIN2O5S2 = 576
Example 61 :
{1 -(3-Chloro-benzyl)-7-[2-(1 -ethyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000131_0003
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 1-Ethyl-1 H-pyrazole-4-sulfonyl chloride. ESI-MS [M+H+] = 561 Calculated for C27H33CIN4O5S = 560
Example 62:
{1 -(2,4-Dichloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000132_0001
Prepared as described for example 46 using 1-bromomethyl-2,4-dichloro-benzene in place of 4-(bromomethyl)-3-chlorobenzene. ESI-MS [M+H+] = 581 Calculated for C26H30CI2N4O5S = 580
Example 63: {1 -(2,4-Dichloro-benzyl)-7-[2-(thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000132_0002
Prepared as described for example 62 using thiophene-2-sulfonyl chloride in place of 1- methyl-1 H-pyrazole-4-sulfonyl chloride. ESI-MS [M+H+] = 583 Calculated for C26H28CI2N4O5S2 = 582
Example 64:
{1-(2,4-Dichloro-benzyl)-7-[2-(5-methyl-thiophene-2-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000133_0001
Prepared as described for example 62 using 5-methyl-thiophene-2-sulfonyl chloride in place of 1-Methyl-1 H-pyrazole-4-sulfonyl chloride. ESI-MS [M+H+] = 597 Calculated for C27H30CI2N2O5S2 = 596
Example 65:
[1-(3-Chloro-benzyl)-7-(2-ethanesulfonylamino-ethoxy)-1 ,2,3,4-tetrahydro-naphthalen-2- yl]-carbamic acid ethyl ester
Figure imgf000133_0002
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using ethane-sulfonyl chloride. ESI-MS [M+H+] = 495 Calculated for C24H3ICIN2O5S = 494
Example 66:
1 -Ethyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000133_0003
Prepared in one step from {1 -(3-chloro-benzyl)-7-[2-(1 -ethyl-1 H-pyrazole-4- sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (e- xample 61 ) in analogy to example 48. ESI-MS [M+H+] = 489 Calculated for C24H29CIN4O3S = 488 Example 67:
4-Methyl-thiophene-2-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000134_0001
Prepared in one step from {1-(3-chloro-benzyl)-7-[2-(2-methyl-3H-imidazole-4- sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (e- xample 53) in analogy to example 48. ESI-MS [M+H+] = 491 Calculated for C24H27CIN2O3S2 = 490
Example 68:
5-Methyl-thiophene-2-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000134_0002
Prepared in one step from {1-(3-chloro-benzyl)-7-[2-(5-methyl-thiophene-2-sulfonylamino)- ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 53) in analogy to example 48. ESI-MS [M+H+] = 491 Calculated for C24H27CIN2O3S2 = 490
Example 69:
2,5-Dimethyl-thiophene-3-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000135_0001
Prepared in one step from {1-(3-Chloro-benzyl)-7-[2-(2,5-dimethyl-thiophene-3- sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 60) in analogy to example 48. ESI-MS [M+H+] = 505 Calculated for C25H29CIN2O3S2 = 504
Example 70:
Ethanesulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-amide hydrochloride
Figure imgf000135_0002
Prepared in one step from [1-(3-chloro-benzyl)-7-(2-ethanesulfonylamino-ethoxy)-1 ,2,3,4- tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester (example 65) in analogy to example
48.
ESI-MS [M+H+] = 423 Calculated for C2i H27CIN2O3S = 422
Example 71 :
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(2,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000135_0003
Prepared in one step from {1-(2,4-dichloro-benzyl)-7-[2-(1-methyl-1 H-pyrazole-4- sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 62) in analogy to example 48. ESI-MS [M+H+] = 509 Calculated for C23H26CI2N4O3S = 508
Example 72:
Thiophene-2-sulfonic acid {2-[7-amino-8-(2,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000136_0001
Prepared in one step from {1-(2,4-dichloro-benzyl)-7-[2-(thiophene-2-sulfonylamino)- ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 63) in analogy to example 48.
ESI-MS [M+H+] = 51 1 Calculated for C23H24CI2N2O3S2 = 510
Example 73:
5-Methyl-thiophene-2-sulfonic acid {2-[7-amino-8-(2,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000136_0002
Prepared in one step from {1-(2,4-dichloro-benzyl)-7-[2-(5-methyl-thiophene-2- sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 64) in analogy to example 48. ESI-MS [M+H+] = 525 Calculated for C24H26CI2N2O3S2 = 524
Example 74:
{1 -(2,4-Dichloro-benzyl)-7-[2-(propane-1 -sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000137_0001
Prepared as described for example 62 using propane-1-sulfonyl chloride in place of 1- methyl-1 H-pyrazole-4-sulfonyl chloride. ESI-MS [M+H+] = 543 Calculated for C25H32CI2N2O5S = 542
Example 75:
Propane-1 -sulfonic acid {2-[7-amino-8-(2,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000137_0002
Prepared in one step from {1-(2,4-dichloro-benzyl)-7-[2-(propane-1-sulfonylamino)- ethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester (example 74) in analogy to example 48. ESI-MS [M+H+] = 471 Calculated for C22H28CI2N2O3S = 470
Example 76:
(1 -(4-Chloro-benzyl)-7-{2-[methyl-(propane-1 -sulfonyl)-amino]-ethoxy}-1 ,2,3,4-tetrahydro- naphthalen-2-yl)-carbamic acid ethyl ester
76.1 2-(N-methylpropylsulfonamido)ethyl propane-1 -sulfonate
Figure imgf000137_0003
To a cooled solution (0-50C) of 2-(methylamino)ethanol (8.56 ml, 107 mmol) in 100 ml
DCM was added dropwise a solution of propane-1-sulfonyl chloride (13.1 ml, 1 17 mmol) in 50 ml DCM over an 1 h period. The resulting mixture was stirred at room temperature over night. Water and 10% citric acid were added and then was extracted with DCM, dried over MgSO4, filtrated and evaporated to obtain a yellow/orange oil. (13,6 g) Chromatography afforded 2.75 g of product. 76.2 (1 -(4-Chloro-benzyl)-7-{2-[methyl-(propane-1 -sulfonyl)-amino]-ethoxy}-1 ,2,3,4- tetrahydro-naphthalen-2-yl)-carbamic acid ethyl ester
Figure imgf000138_0001
A solution of ethyl 1-(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2- ylcarbamate (0,128 g, 0,355 mmol) in DMF under N2 was treated with sodium hydride (0,014 g, 0,568 mmol) and the reaction was stirred for 30 minutes at room temperature. A solution of 2-(N-methylpropylsulfonamido)ethyl propane-1 -sulfonate (0,102 g, 0,355 mmol) (see step 1 ) in DMF was added and the reaction mixture wasstirred at ambient tempera- ture over night. The mixture was portioned between ethyl acetate and water. The organic layer was washed with water, dried (MgSO4), filtrated and evaporated to afford brown/white crystals. After addition of a few drops of ethyl acetate/cyclohexane (1 : 4) a white precipitate formed. Yield 43 mg ESI-MS [M+H+] = 523 Calculated for C26H35CIN2O5S = 522
Example 77:
Propane-1 -sulfonic acid {2-[7-amino-8-(4-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-methyl-amide hydrochloride
Figure imgf000138_0002
Prepared in one step from (1-(4-chloro-benzyl)-7-{2-[methyl-(propane-1-sulfonyl)-amino]- ethoxy}-1 ,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid ethyl ester (example 76) in analogy to example 48. ESI-MS [M+H+] = 451 Calculated for C23H3ICIN2O3S = 450
Example 78:
(1 -(3-Chloro-benzyl)-7-{2-[methyl-(propane-1 -sulfonyl)-amino]-ethoxy}-1 ,2,3,4-tetrahydro- naphthalen-2-yl)-carbamic acid ethyl ester
Figure imgf000139_0001
Prepared from [1-(3-chloro-benzyl)-7-hydroxy-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester as described example 77. ESI-MS [M+H+] = 523 Calculated for C26H35CIN2O5S = 522
Example 79:
Propane-1 -sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro naphthalen-2- yloxy]-ethyl}-methyl-amide hydrochloride
Figure imgf000139_0002
Prepared in one step from (1-(3-chloro-benzyl)-7-{2-[methyl-(propane-1-sulfonyl)-amino]- ethoxy}-1 ,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid ethyl ester (example 78) in analogy to example 48. ESI-MS [M+H+] = 451 Calculated for C23H3ICIN2O3S = 450
Example 80:
{1 -(3-Chloro-benzyl)-7-[2-(1 -methyl-1 H-imidazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000139_0003
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 1 -Methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 547 Calculated for C26H3ICIN4O5S = 546
Example 81 :
{1 -(3-Chloro-benzyl)-7-[2-(1 -difluoromethyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000140_0001
Prepared in two steps from 7-(2-tert-butoxycarbonylamino-ethoxy)-1-(3-chloro-benzyl)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 46 using 1 -difluoromethyl-1 H-pyrazole-4-sulfonyl chloride.
ESI-MS [M+H+] = 583 Calculated for C26H29CIF2N4O5S = 582
Example 82:
1 -(3-Chloro-benzyl)-7-[(R)-1 -(propane-1 -sulfonyl)-pyrrolidin-2-ylmethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-ylamine hydrochloride
82.1 (Propane-1 -sulfonic acid (R)-1 -(propane-1 -sulfonyl)-pyrrolidin-2-ylmethyl ester
Figure imgf000140_0002
Prepared as described for 2-(N-methylpropylsulfonamido)ethyl propane-1 -sulfonate (example 76, step 1 using (R)-1-pyrrolidin-2-yl-methanol instead of 2-(methylamino)ethanol.
82.2 1 -(3-Chloro-benzyl)-7-[(R)-1 -(propane-1 -sulfonyl)-pyrrolidin-2-ylmethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-ylamine hydrochloride
Figure imgf000141_0001
Prepared in two steps from (propane-1 -sulfonic acid (R)-1 -(propane-1 -sulfonyl)-pyrrolidin- 2-ylmethyl ester (see previous step) and ethyl 1-(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate as described for example 77. ESI-MS [M+H+] = 477 Calculated for C25H33CIN2O3S = 476
Example 83:
1 -(3-Chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-yloxy]-1 ,2,3,4-tetrahydro- naphthalen-2-ylamine hydrochloride
83.1 1 -(Propane-1 -sulfonyl)-azetidin-3-ol
Figure imgf000141_0002
To a cooled solution (0-50C) of azetidin-3-ol hydrochloride (1 g, 9,13 mmol) in 10 ml di- chloromethane containing diisopropyl ethyl amine (2,391 ml, 13,69 mmol) was added dropwise a solution of propane-1 -sulfonyl chloride (1 ,126 ml, 10,04 mmol) dissolved in 5 ml dichloromethane over an 1 h period. The mixture was allowed to warm up to room temperature and was stirred over night. Citric acid (10%) was added, extracted with dichloromethane, dried over MgSO4, filtered and the solvent was evaporated to obtain 597 mg of a yellow oil, which was purified by chromatography (yield 470 mg)
83.2 Methanesulfonic acid 1 -(propane-1 -sulfonyl)-azetidin-3-yl ester
Figure imgf000141_0003
To a solution of 1 -(propane-1 -sulfonyl)-azetidin-3-ol (236 mg, 1 ,317 mmol) in pyridine was added drop wise methane sulfonyl chloride (205 μl, 2,63 mmol) at 00C. The mixture was allowed to warm up to room temperature and was stirred for 3h. Dichloromethane was added. The mixture was subsequently washed with water, saturated NaHCO3 and brine, dried (MgSO4), and filtrated. The solvent was evaporated to obtain 293 mg of crude product which was used without further purification. 83.3 1 -(3-Chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-yloxy]-1 ,2,3,4-tetrahydro- naphthalen-2-ylamine hydrochloride
Figure imgf000142_0001
Prepared in two steps from methanesulfonic acid 1 -(propane-1 -sulfonyl)-azetidin-3-yl ester (see previous step) and ethyl 1-(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate as described for example 77. ESI-MS [M+H+] = 449 Calculated for C23H29CIN2O3S = 448
Example 84:
1-(3-Chloro-benzyl)-7-(3-ethanesulfonyl-propoxy)-1 ,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride
Figure imgf000142_0002
Prepared in two steps from 1-chloro-3-ethanesulfonyl-propane (see: Synthetic Communi- cations, 19(9-10), 1583-91 ; 1989) and ethyl 1-(4-chlorobenzyl)-7-hydroxy-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate in analogy to example 77. ESI-MS [M+H+] = 422 Calculated for C22H28CINO3S = 421
Example 85: Cyclohexanesulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000142_0003
Cyclohexanesulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 3 using cyclohexyl-sulfonyl chloride in place of 1-methyl-1 H-imidazole-4-sulfonyl chloride. ESI-MS [M+H+] = 511 Calculated for C25H32CI2N2O3S = 510
Example 86:
2-Trimethylsilanyl-ethanesulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000143_0001
2-Trimethylsilanyl-ethanesulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amid hydrochloride was prepared in analogy to ex- ample 3.
ESI-MS [M+H+] = 529 Calculated for C24H34CI2N2O3SSi = 528
Example 87:
N-{2-[7-Amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C-(5- methyl-isoxazol-3-yl)-methanesulfonamide hydrochloride
Figure imgf000143_0002
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C-(5- methyl-isoxazol-3-yl)-methanesulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 524 Calculated for C24H27CI2N3O4S = 523
Example 88:
Cyclobutanesulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1 -yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000144_0001
88.1 1-(1-(3,4-Dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-yl)pyrrolidine
Figure imgf000144_0002
1-(3,4-Dichlorobenzyl)-7-methoxy-3,4-dihydronaphthalen-2(1 H)-one (5.5 g, 16.4 mmol, example 1 ), pyrrolidine (1.40 g, 19.7 mmol), and p-toluenesulfonic acid monohydrate (31.0 mg, 0.164 mmol) were dissolved in toluene (100 ml) and refluxed for 2h using a Dean- Stark condenser. The solvent was removed and after addition of MeOH (50 ml) and sodium cyanohydride (1.57 g, 24.6 mmol) the mixture was stirred for 4d at room temperature under nitrogen. Water was added, the organic phase separated and the aqueous phase extracted with ethyl acetate. The combined organic layers were washed with saturated NaCI solution, dried over MgSO4, and concentrated to afford a residue that was purified by flash chromatography (silica gel, MeOH/ CH2CI23:97 → 5:95). The beige solid product (1.6 g, 25%) was obtained from precipitation in ethyl acetate/diisopropylether (1 :1 ). 88.2 8-(3!4-Dichlorobenzyl)-7-(pyrrolidin-1-yl)-5!6!7,8-tetrahydronaphthalen-2-ol
Figure imgf000145_0001
1 -(1 -(3,4-Dichlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-yl)pyrrolidine (1.6 g, 4.10 mmol) was dissolved in CH2CI2 (100 ml) and BBr3 (1 molar in CH2CI2, 12.3 ml, 12.3 mmol) was added at -100C. It was stirred for 2h after which time the temperature rose to room temperature. Ice water was added, the organic phase separated and the aqueous phase extracted with CH2CI2. The combined organic layers were washed with saturated NaHCO3 and NaCI solution, dried over Na2SO4, and concentrated to afford a residue. The beige solid product (1.2 g, 78%) was obtained from precipitation in ethyl acetate.
88.3 tert-Butyl 2-(8-(3,4-dichlorobenzyl)-7-(pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen- 2-yloxy)ethylcarbamate
Figure imgf000145_0002
NaH in paraffin (0.278 g, 6.38 mmol, 55% in paraffin) was washed wit n-hexane and suspended in DMA (30 ml). 8-(3,4-Dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8- tetrahydronaphthalen-2-ol (1.2 g, 3.19 mmol) in DMA (20 ml) was added. After stirring for 1 h at room temperature tert-butyl 2-bromoethylcarbamate (2.14 g, 6.38 mmol) was added in portions and the mixture was stirred for 48h. Water was added and the aqueous phase was extracted with ethyl acetate. The combined organic layers were washed with saturated NaCI solution, dried over Na2SO4, and concentrated to afford a residue that was purified by flash chromatography (silica gel, MeOH/ CH2CI23:97). The product (1.6 g, 97%) was obtained as a yellow oil. 88.4 2-(8-(3,4-Dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yloxy)ethanamine hydrochloride
Figure imgf000146_0001
tert-Butyl 2-(8-(3!4-dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6!7,8-tetrahydronaphthalen-2- yloxy)ethylcarbamate (1.6 g, 3.08 mmol) was dissolved in CH2CI2 (70 ml) and HCI in iPrOH was added. It was stirred for 14h at room temperature after during which time the temperature rose to room temperature. The solvent was removed to obtain white salt (1.2 g, 85%).
88.5 Cyclobutanesulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1-yl-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000146_0002
2-(8-(3,4-Dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yloxy)ethanamine (120 mg, 0.286 mmol), para-(Λ/,Λ/-dimethylamino) pyridine (1.40 g, 19.7 mmol), and cyclobutanesulfonyl chloride (46.5 mg, 0.30 mmol) were dissolved in CH2CI2 (20 ml) and stirred for 14h at room temperature. 0.5N HCI was added, the organic phase separated and the aqueous phase extracted with CH2CI2. The combined organic layers were washed with water, NaHCO3 solution, and saturated NaCI solution, dried over Na2SO4, and concentrated to afford a residue that was purified by flash chromatography (silica gel, MeOH/ CH2CI23:97 → 5:95). The white solid product (164 mg, 32%) was transferred to an HCI salt and precipitated from diisopropyl ether. ESI-MS [M+H+] = 537 Calculated for C27H34CI2N2O3S = 536
Example 89: 1 -Methyl-1 H-pyrazole-4-sulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1-yl-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-methyl-amide hydrochloride
Figure imgf000147_0001
N-(2-(8-(3,4-Dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yloxy)ethyl)-1 -methyl-1 H-pyrazole-4-sulfonamide hydrochloride (41 mg, 0.068 mmol, Example 91 , iodomethane (11.6 mg, 0.082 mmol), caesium carbonate (49.0 mg, 0.150 mmol) were dissolved in acetonitrile (3 ml) and stirred for 1 h at 1000C in the microwave. After addition of another iodomethane (1 1.6 mg, 0.082 mmol) and caesium carbonate (49.0 mg, 0.150 mmol) it was stirred for another 1 h at 1000C in the microwave. Water and CH2CI2 were added, the organic phase separated and the aqueous phase extracted with CH2CI2. The combined organic layers were washed with saturated NaCI solution, dried over Na2SO4, and concentrated to afford a residue that was purified by flash chromatography (silica gel, MeOH/ CH2CI2 3:97 → 5:95). The white solid product (42 mg, 38%) was transferred to an HCI salt and precipitated from diisopropyl ether. ESI-MS [M+H+] = 577 Calculated for C28H34CI2N4O3S = 576
Example 90:
Butane-1 -sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-
2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000147_0002
Butane-1 -sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 485 Calculated for C23H30CI2N2O3S = 484 Example 91 :
Propane-2-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000148_0001
Propane-2-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 471 Calculated for C22H28CI2N2O3S = 470
Example 92:
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1-yl-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000148_0002
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1-yl-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 88. ESI-MS [M+H+] = 563 Calculated for C27H32CI2N4O3S = 562
Example 93:
2-Ethoxy-ethanesulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000149_0001
2-Ethoxy-ethanesulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 501 Calculated for C23H30CI2N2O4S = 500
Example 94:
Cyclobutanesulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1 -yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-methyl-amide hydrochloride
Figure imgf000149_0002
Cyclobutanesulfonic acid {2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1 -yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-methyl-amide hydrochloride was prepared from N-(2-(8-(3,4- dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yloxy)ethyl)cyclobutanesulfonamide hydrochloride (example 88) in analogy to example 89. ESI-MS [M+H+] = 551 Calculated for C28H36CI2N2O3S = 550
Example 95:
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5,6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000150_0001
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-methanesulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 483 Calculated for C23H28CI2N2O3S = 482
Example 96:
Propane-1 -sulfonic acid {2-[7-amino-8-(4-methoxy-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000150_0002
Propane-1 -sulfonic acid {2-[7-amino-8-(4-methoxy-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 433 Calculated for C23H32N2O4S = 432
Example 97:
N-[2-(7-Amino-8-benzyl-5!6,7,8-tetrahydro-naphthalen-2-yloxy)-ethyl]- methanesulfonamide hydrochloride
Figure imgf000151_0001
N-(2-(7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yloxy)ethyl)methanesulfonamide hydrochloride (50.0 mg, 0.104 mmol), Pd-C 10% (1.10 mg), and hydrazine monohydrate (522 mg, 10.4 mmol) were suspended in ethanol (5 ml) and stirred for 4h under reflux. Water and CH2Cb were added, the mixture filtered, and the filtrate was extracted with CH2CI2. The combined organic layers were washed with water, saturated NaCI solution, dried over Na2SO4, and concentrated to afford a residue that was purified by precipitation from diisopropylether. The residue was transferred to an HCI salt and finally gave the product as a white solid (31 mg, 72%). ESI-MS [M+H+] = 375 Calculated for C20H26N2O3S = 374
Example 98:
1-Methyl-1 H-imidazole-4-sulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide hydrochloride
Figure imgf000151_0002
1-Methyl-1 H-imidazole-4-sulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide hydrochloride was prepared in analogy to example 3 and 89. ESI-MS [M+H+] = 455 Calculated for C24H30N4O3S = 454
Example 99:
N-[2-(7-Amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-ethyl]- benzenesulfonamide hydrochloride
Figure imgf000152_0001
N-[2-(7-Amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-ethyl]- benzenesulfonamide hydrochloride was prepared from N-{2-[7-Amino-8-(3,4-dichloro- benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-benzenesulfonamide hydrochloride (example 16) in analogy to example 3 and 97.
ESI-MS [M+H+] = 437 Calculated for C25H28N2O3S = 436
Example 100:
3,3,3-Trifluoro-propane-1 -sulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-amide hydrochloride
Figure imgf000152_0002
3,3,3-Trifluoro-propane-1 -sulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-amide hydrochloride was prepared in analogy to example 3 and 97. ESI-MS [M+H+] = 457 Calculated for C22H27F3N2O3S = 456
Example 101 :
1-Methyl-1 H-imidazole-4-sulfonic acid [2-(8-benzyl-7-pyrrolidin-1-yl-5,6,7,8- tetrahydronaphthalen-2-yloxy)-ethyl]-methyl-amide hydrochloride
Figure imgf000152_0003
N-(2-{[7-Amino-8-benzyl-5!6,7!8-tetrahydronaphthalen-2-yl]oxy}ethyl)-N,1-dimethyl-1 H- imidazole-4-sulfonamide hydrochloride (98), 1 ,4-dibromobutane (49.9 mg, 0.231 mmol), and triethylamine (31.2 mg, 0.308 mmol) were dissolved in acetonitrile (3 ml) and stirred for 2h at 1300C in the microwave. Water and ethyl acetate were added and the organic phase was separated. After extraction of the aqueous phase with ethylacetate the combined organic layers were washed with saturated NaCI solution, dried over Na2SC>4, and concentrated to afford a residue a residue that was purified by flash chromatography (sil- ica gel, MeOH/ CH2CI25:95). The residue was transferred to an HCI salt and finally gave the product as a white solid (8.5 mg, 10%) after precipitation from diisopropylether. ESI-MS [M+H+] = 509 Calculated for C28H36N4O3S = 508
Example 102: Cyclopropanesulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)- ethyl]-amide hydrochloride
Figure imgf000153_0001
Cyclopropanesulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)- ethyl]-amide hydrochloride was prepared in analogy to example 3 and 97. ESI-MS [M+H+] = 401 Calculated for C22H28N2O3S = 400
Example 103:
N-[2-(7-Amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-ethyl]-propionamide hy- drochloride
Figure imgf000153_0002
Ethyl 7-(2-aminoethoxy)-1 -(3,4-dichlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2- ylcarbamate hydrochloride (example 2.1 , 100 mg, 0.229 mmol) and N,N-dimethyl amino pyridine (30.7 mg, 0.252 mmol) were dissolved in CH2CI2 (20 ml) and propionyl chloride (30.7 mg, 0,252 mmol) was added at RT. After stirring at RT for 14h 0.5 N HCI was added and the mixture was extracted with CH2CI2. The combined organic layers were washed with saturated NaHCC>3 and NaCI solution, dried over Na2SC>4, and concentrated to afford a residue. White solid ethyl 1-(3,4-dichlorobenzyl)-7-(2-propionamidoethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (98 mg, 87%) was obtained from precipitation in ethyl acetate. Further transformation in analogy to example 2 and 97 finally gave N-[2-(7- Amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-ethyl]-propionamide hydrochloride. ESI-MS [M+H+] = 353 Calculated for C22H28N2O2 = 352
Example 104:
1-Methyl-1 H-[1 ,2,4]triazole-3-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000154_0001
1-Methyl-1 H-[1 ,2,4]triazole-3-sulfonic acid {2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide was prepared in analogy to example 3. ESI-MS [M+H+] = 510 Calculated for C22H25CI2N5O3S = 509
Example 105:
1-Methyl-1 H-imidazole-4-sulfonic acid [2-(7-azetidin-1-yl-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide
Figure imgf000154_0002
1-Methyl-1 H-imidazole-4-sulfonic acid [2-(7-azetidin-1-yl-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide was prepared in analogy to example 101. ESI-MS [M+H+] = 495 Calculated for C27H34N4O3S = 494
Example 106: N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclobutyl-methanesulfonamide hydrochloride
Figure imgf000155_0001
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclobutyl-methanesulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 497 Calculated for C24H30CI2N2O3S = 496
Example 107:
Propane-1 -sulfonic acid {2-[7-amino-8-(3-fluoro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-amide hydrochloride
Figure imgf000155_0002
Propane-1 -sulfonic acid {2-[7-amino-8-(3-fluoro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-amide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 421 Calculated for C22H29FN2O3S = 420
Example 108:
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5,6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-N-methyl-methanesulfonamide hydrochloride
Figure imgf000156_0001
N-{2-[7-Amino-8-(3!4-dichloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-N-methyl-methanesulfonamide hydrochloride was prepared in analogy to example 1 1. ESI-MS [M+H+] = 497 Calculated for C24H30CI2N2O3S = 496
Example 109:
1-Methyl-1 H-pyrazole-4-sulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-
2-yloxy)-ethyl]-methyl-amide
Figure imgf000156_0002
1-Methyl-1 H-pyrazole-4-sulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-
2-yloxy)-ethyl]-methyl-amide was prepared in analogy to example 3 and 89. ESI-MS [M+H+] = 455 Calculated for C24H30N4O3S = 454
Example 110:
N-(2-(7-Amino-8-(3!4-dichlorobenzyl)-5,6!7,8-tetrahydronaphthalen-2-yloxy)ethyl)-N-ethyl- 1 -methyl-1 H-pyrazole-4-sulfonamide
Figure imgf000156_0003
N-(2-(7-Amino-8-(3!4-dichlorobenzyl)-5!6!7,8-tetrahydronaphthalen-2-yloxy)ethyl)-N-ethyl- 1 -methyl-1 H-pyrazole-4-sulfonamide was prepared in analogy to example 1 1. ESI-MS [M+H+] = 537 Calculated for C25H30CI2N4O3S = 536
Example 11 1 :
1 -Methyl-1 H-pyrazole-4-sulfonic acid [2-(8-benzyl-7-pyrrolidin-1-yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide hydrochloride
Figure imgf000157_0001
1 -Methyl-1 H-pyrazole-4-sulfonic acid [2-(8-benzyl-7-pyrrolidin-1-yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide hydrochloride was prepared in analogy to example 50. ESI-MS [M+H+] = 509 Calculated for C28H36N4O3S = 508
Example 112: 1 -Methyl-1 H-pyrazole-4-sulfonic acid [2-(7-azetidin-1 -yl-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide hydrochloride
Figure imgf000157_0002
1 -Methyl-1 H-pyrazole-4-sulfonic acid [2-(7-azetidin-1-yl-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-methyl-amide hydrochloride was prepared in analogy to example 50. ESI-MS [M+H+] = 495 Calculated for C27H34N4O3S = 494
Example 113: N-(2-(7-Amino-8-benzyl-5!6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-N-ethyl-1 -methyl-1 H- pyrazole-4-sulfonamide hydrochloride
Figure imgf000158_0001
N-(2-(7-Amino-8-benzyl-5!6!7,8-tetrahydronaphthalen-2-yloxy)ethyl)-N-ethyl-1-methyl-1 H- pyrazole-4-sulfonamide hydrochloride was prepared in analogy to example 3 and 89. ESI-MS [M+H+] = 469 Calculated for C25H32N4O3S = 468
Example 114:
N-(2-(7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)pentane- 1 -sulfonamide hydrochloride
Figure imgf000158_0002
N-(2-(7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)pentane- 1 -sulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 499 Calculated for C24H32CI2N2O3S = 498
Example 1 15: N-(2-(8-(3,4-Dichlorobenzyl)-7-(pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen-2- yloxy)ethyl)-1-methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000158_0003
N-(2-(8-(3!4-Dichlorobenzyl)-7-(pyrrolidin-1-yl)-5!6!7,8-tetrahydronaphthalen-2- yloxy)ethyl)-1-methyl-1 H-imidazole-4-sulfonamide hydrochloride was synthesized in analogy to example 88.
ESI-MS [M+H+] = 536 Calculated for C27H32CI2N4O3S = 535
Example 116:
N-(2-(8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1-methyl- 1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000159_0001
N-(2-(8-Benzyl-7-(pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl- 1 H-imidazole-4-sulfonamide hydrochloride was prepared from N-(2-(8-(3,4- dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1-methyl- 1 H-imidazole-4-sulfonamide (example 115) in analogy to 97. ESI-MS [M+H+] = 495 Calculated for C27H34N4O3S = 494
Example 117, 1 18 (Enantiomere 1 and 2 of 1 16)
Figure imgf000159_0002
The racemate of N-(2-(8-benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yloxy)ethyl)-1-methyl-1 H-imidazole-4-sulfonamide hydrochloride (ex. 1 16) was separated by chiral chromatography on Chiracel AD (n-heptane/ ethanol 35:65, 0.1 % TEA, 9 ml/min) to deliver (after transfer to the salt form) (-)-N-(2-(8-benzyl-7-(pyrrolidin-1-yl)-5,6,7,8- tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl-1 H-imidazole-4-sulfonamide hydrochloride ([α] = -76.0° in MeOH, c=1.040 g/100 ml [ex. 1 17]) and (+)-N-(2-(8-benzyl-7-(pyrrolidin-1- yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl-1 H-imidazole-4-sulfonamide hy- drochloride ([α] = -77.7° in MeOH, c=0.382 g/100 ml ex. 118]).
ESI-MS [M+H+] = 495 Calculated for C27H34N4O3S = 494 Example 119:
N-(2-(8-Benzyl-7-(pyrrolidin-1-yl)-5!6!7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl- 1 H-pyrazole-4-sulfonamide hydrochloride
Figure imgf000160_0001
N-(2-(8-Benzyl-7-(pyrrolidin-1-yl)-5!6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl- 1 H-pyrazole-4-sulfonamide hydrochloride was prepared from N-(2-(8-(3,4-dichlorobenzyl)- 7-(pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl-1 H-pyrazole-4- sulfonamide (example 114) in analogy to 97. ESI-MS [M+H+] = 495 Calculated for C27H34N4O3S = 494
Example 120:
N-(2-{[7-Amino-8-(3-chloro-4-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)propane-1 -sulfonamide hydrochloride
Figure imgf000160_0002
N-(2-{[7-Amino-8-(3-chloro-4-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)propane-1 -sulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 455 Calculated for C22H28CIFN2O3S = 454
Example 121 :
N-(2-{[7-Amino-8-benzyl-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000161_0001
N-(2-{[7-Amino-8-benzyl-5,6J,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 415 Calculated for C23H30N2O3S = 414
Example 122:
N-(2-{[7-Amino-8-(3!4-dichlorobenzyl)-5,6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-2- cyclopropylacetamide hydrochloride
Figure imgf000161_0002
N-(2-{[7-Amino-8-(3!4-dichlorobenzyl)-5,6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-2- cyclopropylacetamide hydrochloride was synthesized in analogy to example 103. ESI-MS [M+H+] = 447 Calculated for C24H28CI2N2O2 = 446
Example 123
N-(2-{[7-Amino-8-(3!4-dichlorobenzyl)-5,6!7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)benzamide hydrochloride
Figure imgf000162_0001
N-(2-{[7-Amino-8-(3!4-dichlorobenzyl)-5!6!7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)benzamide hydrochloride was synthesized in analogy to example 103. ESI-MS [M+H+] = 469 Calculated for C26H26CI2N2O2 = 468
Example 124:
N-(2-{[8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-N-ethyl-1- methyl-1 H-pyrazole-4-sulfonamide hydrochloride
Figure imgf000162_0002
N-(2-{[8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-N-ethyl-1- methyl-1 H-pyrazole-4-sulfonamide hydrochloride was synthesized from N-(2-(7-amino-8- benzyl-5, 6, 7, 8-tetrahydronaphthalen-2-yloxy)ethyl)-N-ethyl-1 -methyl-1 H-pyrazole-4- sulfonamide hydrochloride (example 1 13) in analogy to example 97. ESI-MS [M+H+] = 523 Calculated for C29H38N4O3S = 522
Example 125:
N-(2-{[7-Amino-8-(3!4-dichlorobenzyl)-5,6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-2- cyclopropylethanesulfonamide hydrochloride
Figure imgf000163_0001
N-(2-{[7-Amino-8-(3!4-dichlorobenzyl)-5!6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-2- cyclopropylethanesulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 497 Calculated for C24H30CI2N2O3S = 496
Example 126:
C-Cyclopropyl-N-{2-[8-(3!4-dichloro-benzyl)-7-pyrrolidin-1-yl-5,6!7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-N-methyl-methanesulfonamide hydrochloride
Figure imgf000163_0002
C-Cyclopropyl-N-{2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1 -yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-N-methyl-methanesulfonamide hydrochloride was synthesized in analogy to examples 89, 97, 101.
ESI-MS [M+H+] = 551 Calculated for C28H36CI2N2O3S = 550
Example 127:
N-(2-{[8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropyl-N-methylmethanesulfonamide hydrochloride
Figure imgf000164_0001
N-(2-{[8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropyl-N-methylmethanesulfonamide hydrochloride was synthesized from 1- cyclopropyl-N-(2-{[8-(3,4-dichlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen- 2-yl]oxy}ethyl)-N-methylmethanesulfonamide hydrochloride in analogy to example 97. ESI-MS [M+H+] = 483 Calculated for C28H38N2O3S = 482
Example 128:
N-(2-{[7-Amino-8-(4-chlorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000164_0002
N-(2-{[7-Amino-8-(4-chlorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 449 Calculated for C23H29CIN2O3S = 448
Example 129:
N-(2-{[7-Amino-8-(4-chlorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropyl-N-methylmethanesulfonamide hydrochloride
Figure imgf000165_0001
N-(2-{[7-Amino-8-(4-chlorobenzyl)-5!6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropyl-N-methylmethanesulfonamide hydrochloride was prepared in analogy to example 3, N-methylation was performed according to 89. ESI-MS [M+H+] = 463 Calculated for C24H3ICIN2O3S = 462
Example 130:
N-[2-(7-Amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-ethyl]-C-cyclopropyl-N- methyl-methanesulfonamide hydrochloride
Figure imgf000165_0002
N-[2-(7-Amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-ethyl]-C-cyclopropyl-N- methyl-methanesulfonamide hydrochloride was prepared from N-(2-{[7-amino-8-(3,4- dichlorobenzyO-δ.θJ.δ-tetrahydronaphthalen^-yOoxyJethyO-i-cyclopropyl-N- methylmethanesulfonamide hydrochloride (example 108) in analogy to example 97. ESI-MS [M+H+] = 429 Calculated for C24H32N2O3S = 428
Example 131 :
N-(2-{[7-Amino-8-(3!4-difluorobenzyl)-5,6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000166_0001
N-(2-{[7-Amino-8-(3!4-difluorobenzyl)-5!6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride was prepared in analogy to example 3. ESI-MS [M+H+] = 451 Calculated for C23H28F2N2O3S = 450
Example 132
C-Cyclopropyl-N-{2-[8-(3!4-dichloro-benzyl)-7-pyrrolidin-1-yl-5,6!7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-methanesulfonamide hydrochloride
Figure imgf000166_0002
C-Cyclopropyl-N-{2-[8-(3,4-dichloro-benzyl)-7-pyrrolidin-1 -yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-methanesulfonamide hydrochloride was prepared in analogy to example 88.
ESI-MS [M+H+] = 537 Calculated for C27H34CI2N2O3S = 536
Example 133:
N-(2-{[8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000166_0003
N-(2-{[8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride was prepared from C-cyclopropyl-N-{2-[8- (3,4-dichloro-benzyl)-7-pyrrolidin-1-yl-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}- methanesulfonamide hydrochloride (example 132) in analogy to example 97. ESI-MS [M+H+] = 469 Calculated for C27H36N2O3S = 468
Example 134
1-Cyclopropyl-N-[2-({8-(3!4-dichlorobenzyl)-7-[3-fluoropyrrolidin-1-yl]-5,6!7,8- tetrahydronaphthalen-2-yl}oxy)ethyl]methanesulfonamide
Figure imgf000167_0001
7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-ol (691 mg, 2.146 mmol, example 34), 2 eq of 1 ,4-dibromo-2-fluorobutane, and 3 eq of triethylamine were dissolved in acetonitrile (10 ml) and heated in the microwave for 2h. Addition of water with ethylace- tate, washing of the organic phase with saturated NaHCO3, NaCI, drying over Na2SO4 and flash chromatography (silica gel, CH2CI2/ MeOH 95:5) gave 8-(3,4-dichlorobenzyl)-7-(3- fluoropyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-ol (330 mg, 39%). The ethylene sulfonamide side chain was added in analogy to examples 1 , 7, 8 to give 1-cyclopropyl-N-[2- ({8-(3,4-dichlorobenzyl)-7-[3-fluoropyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2- yl}oxy)ethyl]methanesulfonamide. ESI-MS [M+H+] = 555 Calculated for C27H33CI2FN2O3S = 554
Example 135:
N-(2-{[7-(Azetidin-1-yl)-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-cyclopropylmethanesulfonamide
Figure imgf000167_0002
N-(2-{[7-(Azetidin-1-yl)-8-(3!4-dichlorobenzyl)-5!6!7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-cyclopropylmethanesulfonamide was prepared in analogy to example 320. ESI-MS [M+H+] = 523 Calculated for C26H32CI2N2O3S = 522
Example 136
N-[2-({8-Benzyl-7-[3-fluoropyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl}oxy)ethyl]-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000168_0001
N-[2-({8-Benzyl-7-[3-fluoropyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl}oxy)ethyl]-1- cyclopropylmethanesulfonamide hydrochloride was synthesized from 1-cyclopropyl-N-[2- ({8-(3,4-dichlorobenzyl)-7-[3-fluoropyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2- yl}oxy)ethyl]methanesulfonamide (example 134) in analogy to97. ESI-MS [M+H+] = 487 Calculated for C27H35FN2O3S = 486
Example 137:
N-(2-{[8-Benzyl-7-(methylamino)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000168_0002
The synthesis was performed starting from ethyl 1-benzyl-7-(2- (cyclopropylmethylsulfonamido)ethoxy)-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (synthesized in analogy to example 3), which was dissolved in THF (50 ml), after which LiAIH4 was added at room temperature and the mixture was stirred for 8h under reflux. Addition of 2N aqueous NaOH, extraction with CH2CI2, washing of the organic layers with saturated NaHCO3 solution and saturated NaCI solution and evaporation of the solvent gave a resi- due that was treated with iPrOH/HCI after which the product precipitated. After filtration a white salt (287 mg, 58%) were obtained. ESI-MS [M+H+] = 429 Calculated for C24H32N2O3S = 428 Example 138:
1-Cyclopropyl-N-(2-{[8-(3-fluorobenzyl)-7-(pyrrolidin-1-yl)-5!6!7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)methanesulfonamide hydrochloride
Figure imgf000169_0001
1-Cyclopropyl-N-(2-{[8-(3-fluorobenzyl)-7-(pyrrolidin-1-yl)-5!6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)methanesulfonamide hydrochloride was synthesized in analogy to examples
264/88.
ESI-MS [M+H+] = 487 C27H35FN2O3S = 486
Example 139:
N-(2-{[7-(Azetidin-1-yl)-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000169_0002
N-(2-{[7-(Azetidin-1 -yl)-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1 - cyclopropylmethanesulfonamide hydrochloride was synthesized in analogy to example 320. ESI-MS [M+H+] = 473 C26H33FN2O3S = 472
Example 140:
N-(2-{[8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000170_0001
N-(2-{[8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride was synthesized in analogy to examples 264/88 ESI-MS [M+H+] = 513 C27H33FN4O3S = 512
Example 141 :
N-(2-{[7-(Azetidin-1-yl)-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000170_0002
N-(2-{[7-(Azetidin-1-yl)-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride was synthesized in analogy to example
320.
ESI-MS [M+H+] = 499 C26H31FN4O3S = 498
Example 142:
N-(2-{[7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000170_0003
N-(2-{[7-(Azetidin-1-yl)-8-benzyl-5!6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride was synthesized in analogy to example 320.
ESI-MS [M+H+] = 455 C26H34N2O3S = 454
Examples 143, 144 (Enantiomeres 1 and 2 of example 142)
Chiral
Figure imgf000171_0001
The racemate of N-(2-{[7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-cyclopropylmethanesulfonamide hydrochloride (example 142) was sepa- rated by chiral chromatography on Chiracel AD (n-heptane/ ethanol 35:65, 0.1 % TEA, 9 ml/min) to deliver (after transfer to salt form) (-)-N-(2-(7-(azetidin-1-yl)-8-benzyl-5,6,7,8- tetrahydronaphthalen-2-yloxy)ethyl)-1-cyclopropylmethanesulfonamide ([α] = -103.0° in MeOH, c=0.461 g/100 ml [example 143]) and (+)-N-(2-(7-(azetidin-1-yl)-8-benzyl-5,6,7,8- tetrahydronaphthalen-2-yloxy)ethyl)-1-cyclopropylmethanesulfonamide succinate ([α] = +57.0° in MeOH, c=0.508 g/100 ml [example 144]) ESI-MS [M+H+] = 455 C26H34N2O3S = 454
Example 145:
N-(2-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1 -methyl-1 H- imidazole-4-sulfonamide
Figure imgf000171_0002
N-(2-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1 -methyl-1 H- imidazole-4-sulfonamide was synthesized in analogy to example 320. ESI-MS [M+H+] = 481 C26H32N4O3S = 480
Example 146: Chiral
Figure imgf000172_0001
The racemate of N-(2-{[7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-methyl-1 H-imidazole-4-sulfonamide (145) can be separated by chiral chromatography to deliver (after transfer to the salt form) (-)-N-(2-((7S,8R)-7-(azetidin-1- yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl-1 H-imidazole-4- sulfonamide fumarate ([α] = -81.4° in MeOH, c=0.409 g/100 ml). ESI-MS [M+H+] = 481 Calculated for C27H34N4O3S = 480
Example 147: N-(2-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)cyclobutanesulfonamide
Figure imgf000172_0002
N-(2-{[7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)cyclobutanesulfonamide was synthesized in analogy to example 320. ESI-MS [M+H+] = 455 C26H34N2O3S = 454
Example 148:
Propane-1 -sulfonic acid [2-(7-azetidin-1 -yl-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2- yloxy)-ethyl]-amide
Figure imgf000172_0003
Propane-1 -sulfonic acid [2-(7-azetidin-1 -yl-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2- yloxy)-ethyl]-amide was synthesized in analogy to example 320. ESI-MS [M+H+] = 443 C25H34N2O3S = 442 Example 149:
N-(2-{[8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-pyrrole-3-sulfonamide hydrochloride
Figure imgf000173_0001
N-(2-{[8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-pyrrole-3-sulfonamide hydrochloride was synthesized in analogy to examples 264/88.
ESI-MS [M+H+] = 512 C28H34FN3O3S = 51 1
Example 150:
N-(2-{[7-Amino-8-(3-chloro-5-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000173_0002
N-(2-{[7-Amino-8-(3-chloro-5-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- cyclopropylmethanesulfonamide hydrochloride was synthesized in analogy to example 3. ESI-MS [M+H+] = 467 C23H28CIFN2O3S = 466
Example 151 :
N-(2-{[7-Amino-8-(3-chloro-5-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000174_0001
N-(2-{[7-Amino-8-(3-chloro-5-fluorobenzyl)-5!6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride was synthesized in analogy to example 3. ESI-MS [M+H+] = 493 C23H26CIFN4O3S = 492
Example 152:
N-[2-({8-Benzyl-7-[3-fluoropyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl}oxy)ethyl]-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000174_0002
N-[2-({8-Benzyl-7-[3-fluoropyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-2-yl}oxy)ethyl]-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride was synthesized in analogy to 264/88. ESI-MS [M+H+] = 513 C27H33FN4O3S = 512
Example 153:
N-(2-{[8-(3-Cyanobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)- 1 -methyl-1 H-imidazole-4-sulfonamide
Figure imgf000174_0003
N-(2-{[8-(3-Cyanobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)- 1 -methyl-1 H-imidazole-4-sulfonamide was synthesized in analogy to 264/88. ESI-MS [M+H+] = 520 C28H33N5O3S = 519
Example 154:
N-(2-{[8-(3-Cyanobenzyl)-7-(propan-2-ylamino)-5,6J,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000175_0001
N-(2-{[8-(3-Cyanobenzyl)-7-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-methyl-1 H-imidazole-4-sulfonamide hydrochloride was synthesized in analogy to example 88. ESI-MS [M+H+] = 508 C27H33N5O3S = 507
Example 155
N-(2-{[8-(3-Cyanobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)- 1 -cyclopropylmethanesulfonamide hydrochloride
Figure imgf000175_0002
N-(2-{[8-(3-Cyanobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-
1 -cyclopropylmethanesulfonamide hydrochloride was synthesized in analogy to examples
264/88.
ESI-MS [M+H+] = 494 C28H35N3O3S = 493
Example 156:
N-(2-{[8-(3-Cyanobenzyl)-7-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 -cyclopropylmethanesulfonamide hydrochloride
Figure imgf000176_0001
N-(2-{[8-(3-Cyanobenzyl)-7-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-cyclopropylmethanesulfonamide hydrochloride was synthesized in analogy to example 88. ESI-MS [M+H+] = 482 C27H35N3O3S = 481
Example 157:
N-(2-{[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)propane-1- sulfonamide hydrochloride
Figure imgf000176_0002
N-(2-{[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)propane-1- sulfonamide hydrochloride was synthesized from Propane-1 -sulfonic acid {2-[7-amino-8- (3,4-dichloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride (example 8) in analogy to example 97. ESI-MS [M+H+] = 403 C22H30N2O3S = 402
Example 158
N-(2-{[8-(3-Chloro-5-fluorobenzyl)-7-(methylamino)-5!6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 -cyclopropylmethanesulfonamide hydrochloride
Figure imgf000176_0003
The synthesis was performed starting from ethyl 1-(3-chloro-5-fluorobenzyl)-7-(2- (cyclopropylmethylsulfonamido)ethoxy)-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (synthesized in analogy to example 3), which was dissolved in THF (50 ml), after which LiAIH4 was added at room temperature and the mixture was stirred for 8h under reflux. Addition of 2N aqueous NaOH, extraction with CH2CI2, washing of the organic layers with saturated NaHCO3 solution and saturated NaCI solution and evaporation of the solvent gave a residue that was treated with iPrOH/HCI after which the product precipitated. After filtration a white salt (134 mg, 39%) was obtained. ESI-MS [M+H+] = 481 Calculated for C24H30CIFN2O3S = 480
Example 159:
N-(2-{[7-(Azetidin-1-yl)-8-(3-chloro-5-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-cyclopropylmethanesulfonamide (2E)-but-2-enedioate
Figure imgf000177_0001
N-(2-{[7-(Azetidin-1-yl)-8-(3-chloro-5-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-cyclopropylmethanesulfonamide (2E)-but-2-enedioate was synthesized in analogy to example 320. ESI-MS [M+H+] = 507 C26H32CIFN2O3S = 506
Example 160:
N-(2-{[7-(Azetidin-1-yl)-8-(3-chloro-5-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 -methyl-1 H-imidazole-4-sulfonamide (2E)-but-2-enedioate
Figure imgf000177_0002
N-(2-{[7-(Azetidin-1-yl)-8-(3-chloro-5-fluorobenzyl)-5!6!7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-methyl-1 H-imidazole-4-sulfonamide (2E)-but-2-enedioate was synthesized in analogy to example 320. ESI-MS [M+H+] = 533 C26H30CIFN4O3S = 532
Example 161 :
1-Cyclopropyl-N-(2-{[8-(4-fluorobenzyl)-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)methanesulfonamide
Figure imgf000178_0001
The synthesis was performed starting from ethyl 7-(2-(cyclopropylmethylsulfonamido)- ethoxy)-1-(4-fluorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (synthesized in analogy to example 3), which was dissolved in THF (50 ml), after which LiAIH4 was added at room temperature and the mixture was stirred for 8h under reflux. Addition of 2N aqueous NaOH, extraction with CH2CI2, washing of the organic layers with saturated NaHCO3 solution and saturated NaCI solution and evaporation of the solvent gave a residue that was treated with iPrOH/HCI after which the product precipitated. After filtration a white salt (89 mg, 76%) was obtained. ESI-MS [M+H+] = 447 C24H31FN2O3S = 446
Example 162:
(-)-N-(2-(8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1-methyl- 1 H-imidazole-4-sulfonamide hydrochloride
Chiral
Figure imgf000178_0002
The synthesis was performed starting from (-)-ethyl 1-benzyl-7-(2-(cyclopropylmethyl- sulfonamido)ethoxy)-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (137), which was dissolved in THF (50 ml), after which LiAIH4 was added at room temperature and the mixture was stirred for 8h under reflux. Addition of 2N aqueous NaOH, extraction with CH2Cb, washing of the organic layers with saturated NaHCC>3 solution and saturated NaCI solution and evaporation of the solvent gave a residue that was treated with iPrOH/HCI after which the product precipitated. After filtration a white salt (102 mg, 79%) was obtained. The ra- cemate was separated by chiral chromatography on Chiracel AD (n-heptane/ ethanol/ tert- butanol 800:150:50) to deliver (after transfer to the salt form) (-)-N-(2-(8-benzyl-7- (pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1 -methyl-1 H-imidazole-4- sulfonamide hydrochloride ([α] = -80.5° in MeOH, c=0.191 g/100 ml) ESI-MS [M+H+] = 429 C24H32N2O3S = 428
Example 163:
1-Methyl-N-(2-{[8-(3-methylbenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 H-imidazole-4-sulfonamide
Figure imgf000179_0001
1 -Methyl-N-(2-{[8-(3-methylbenzyl)-7-(pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 H-imidazole-4-sulfonamide was synthesized in analogy to 264/88. ESI-MS [M+H+] = 509 C28H36N4O3S = 508
Example 164: N-(2-{[8-(3-Methoxybenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 -methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000179_0002
N-(2-{[8-(3-Methoxybenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 -methyl-1 H-imidazole-4-sulfonamide hydrochloride was synthesized in analogy to examples 264/88.
ESI-MS [M+H+] = 525 C28H36N4O4S = 524 Example 165:
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(3-trifluoromethyl-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000180_0001
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(3-trifluoromethyl-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride was synthesized in analogy to example 3. ESI-MS [M+H+] = 509 C24H27F3N4O3S = 508
The following examples were prepared in analogy to example 40:
Example 166:
N-{[7-Amino-8-(3-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride
Figure imgf000180_0002
ESI-MS [M+H+] = 407 Calculated for C2-, H27CIN2O2S = 406
Example 167: N-[(7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl]methanesulfonamide hydrochloride
Figure imgf000180_0003
ESI-MS [M+H+] = 345 Calculated for Ci9H24N2O2S = 344
Example 168:
N-[(7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl]benzenesulfonamide hydrochloride
Figure imgf000181_0001
ESI-MS [M+H+] = 407 Calculated for C24H26N2O2S = 406
Example 169: Enantiomer 2 of N-{[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane- 1 -sulfonamide hydrochloride
Figure imgf000181_0002
The compound was obtained by chiral chromatography (Chiralpak AD-H 30 mm ID x 250 mm, n-hexane/EtOH/MeOH/diethylamine = 20/40/40/0.1 ) from the racemic compound (example 42) as the first eluting peak. Optical rotation = -50° (589 nm, 25°C, c = 0.1 in methanol). ESI-MS [M+H+] = 373 Calculated for C2i H28N2O2S = 372
Example 170: Enantiomer 1 of N-{[7-amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane- 1 -sulfonamide hydrochloride
Figure imgf000181_0003
The compound was obtained by chiral chromatography (Chiralpak AD-H 30 mm ID x 250 mm, n-hexane/EtOH/MeOH/diethylamine = 20/40/40/0.1 ) from the racemic compound (example 42) as the second eluting peak. Optical rotation = +49° (589 nm, 25°C, c = 0.1 in methanol).
ESI-MS [M+H+] = 373 Calculated for C2IH28N2O2S = 372
Example 171 :
N-{[7-Amino-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride
Figure imgf000182_0001
ESI-MS [M+H+] = 391 Calculated for C2iH27FN2O2S = 390
Example 172:
N-[(7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl]-1-methyl-1 H-pyrazole-4- sulfonamide hydrochloride
Figure imgf000182_0002
ESI-MS [M+H+] = 411 Calculated for C22H26N4O2S = 410
Example 173: N-[(7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl]-1 -methyl- 1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000182_0003
ESI-MS [M+H+] = 411 Calculated for C22H26N4O2S = 410
Example 174: N-{[7-Amino-8-(4-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}cyclobutanesulfonamide hydrochloride
Figure imgf000183_0001
ESI-MS [M+H+] = 403 Calculated for C22H27FN2O2S = 402
Example 175:
N-{[7-Amino-8-(4-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride
Figure imgf000183_0002
ESI-MS [M+H+] = 391 Calculated for C2-, H27FN2O2S = 390
Example 176:
N-{[7-Amino-8-(4-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1-methyl-1 H- imidazole-4-sulfonamide hydrochloride
Figure imgf000183_0003
ESI-MS [M+H+] = 429 Calculated for C22H25FN4O2S = 428
Example 177:
N-{[7-Amino-8-(3-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]methyl}-1-methyl-1 H- imidazole-4-sulfonamide hydrochloride
Figure imgf000184_0001
ESI-MS [M+H+] = 429 Calculated for C22H25FN4O2S = 428
Example 178:
N-{[7-Amino-8-(3-fluorobenzyl)-5!6J!8-tetrahydronaphthalen-2-yl]methyl}-1-methyl-1 H- pyrazole-4-sulfonamide hydrochloride
Figure imgf000184_0002
ESI-MS [M+H+] = 429 Calculated for C22H25FN4O2S = 428
Example 179:
N-{[7-Amino-8-benzyl-5,6J,8-tetrahydronaphthalen-2-yl]methyl}-3- methylbenzenesulfonamide hydrochloride
Figure imgf000184_0003
ESI-MS [M+H+] = 421 Calculated for C25H28N2O2S = 420
Example 180:
N-{[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1-methyl-1 H-pyrrole-3- sulfonamide hydrochloride
Figure imgf000185_0001
ESI-MS [M+H+] = 410 Calculated for C23H27N3O2S = 409
Example 181 : N-{[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}pyridine-3-sulfonamide dihydrochloride
Figure imgf000185_0002
ESI-MS [M+H+] = 408 Calculated for C23H25N3O2S = 407
Example 182:
N^^-Amino-δ-benzyl-S.ΘJ.δ-tetrahydronaphthalen^-yOmethylϊ-i-methyl-S- (trifluoromethyl)-i H-pyrazole-4-sulfonamide hydrochloride
Figure imgf000185_0003
ESI-MS [M+H+] = 479 Calculated for C23H25F3N4O2S = 478
Example 183:
N-{[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1-methyl-1 H-pyrazole-3- sulfonamide hydrochloride
Figure imgf000185_0004
ESI-MS [M+H+] = 411 Calculated for C22H26N4O2S = 410 Example 184:
N-{[7-Amino-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}cyclobutanesulfonamide hydrochloride
Figure imgf000186_0001
ESI-MS [M+H+] = 403 Calculated for C22H27FN2O2S = 402
Example 185:
N-{[7-Amino-8-(3,4-difluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000186_0002
ESI-MS [M+H+] = 421 Calculated for C22H26F2N2O2S = 420
Example 186:
Λ/-{[7-Amino-8-(3,4-difluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}cyclobutanesulfonamide hydrochloride
Figure imgf000186_0003
ESI-MS [M+H+] = 421 Calculated for C22H26F2N2O2S = 420
Example 187: N-{[8-Benzyl-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride
Figure imgf000187_0001
tert-Butyl [1-benzyl-7-{[(propylsulfonyl)amino]methyl}-1 ,2,3,4-tetrahydronaphthalen-2- yl]carbamate prepared in analogy to example 39 (1240 mg, 2.62 mmol) was dissolved in tetrahydrofuran (50 ml_). A solution of lithium aluminium hydride (1 M in tetrahydrofuran, 7.87 ml_, 7.87 mmol) was added dropwise at room temperature. The reaction mixture was then heated to 600C for 1 h. Aqueous work-up, purification of the extracted product by flash chromatography (silica gel, dichloromethane, methanol) and treatment with 1.25 M hydrochloric acid in ethanol followed by concentration in vacuo gave the desired product. Yield: 590 mg (1.4 mmol, 53%). ESI-MS [M+H+] = 425 Calculated for C22H30N2O2S = 424
In analogy to example 187 the following examples were prepared:
Example 188:
N-{[8-Benzyl-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}cyclobutanesulfonamide hydrochloride
Figure imgf000187_0002
ESI-MS [M+H+] = 400 Calculated for C23H30N2O2S = 399
Example 189:
N-{[8-Benzyl-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-3- methylbenzenesulfonamide hydrochloride
Figure imgf000188_0001
ESI-MS [M+H+] = 435 Calculated for C26H30N2O2S = 434
Example 190: N-{[8-Benzyl-7-(methylamino)-5!6!7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- pyrrole-3-sulfonamide hydrochloride
Figure imgf000188_0002
ESI-MS [M+H+] = 424 Calculated for C24H29N3O2S = 423
Example 191 :
N-{[8-Benzyl-7-(methylamino)-5!6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- pyrazole-3-sulfonamide hydrochloride
ESI-MS [M+H+] = 425 Calculated for C23H28N4O2S = 424
Example 192:
Enantiomer 1 of N-{[8-benzyl-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}propane-1 -sulfonamide hydrochloride iral
Figure imgf000189_0001
A chiral building block, i.e. an enantiomer of fe/f-butyl (1 -benzyl-7-cyano-1 , 2,3,4- tetrahydronaphthalen-2-yl)carbamate
Figure imgf000189_0002
was used for the synthesis.
te/f-Butyl (1-benzyl-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2-yl)carbamate can be prepared in analogy to the dichloroderivative described in example 34. The cis-isomer can be separated into the enantiomers by chiral chromatography (Daicel, Chiralpak IC, 250x4,6 mm ID, 5μ, n-heptane/ethanol = 1/9 with 0.1 % triethylamine). The enantiomer eluting second was used in the syntheses described above. ESI-MS [M+H+] = 387 Calculated for C22H30N2O2S = 386
Example 193:
Enantiomer 1 of N-{[8-benzyl-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}cyclobutanesulfonamide hydrochloride
Figure imgf000189_0003
The enantiomer of te/f-butyl (1-benzyl-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2- yl)carbamate described in example 192 was as chiral building block for the synthesis. ESI-MS [M+H+] = 399 Calculated for C23H30N2O2S = 398
Example 194: N-{[trans-8-Benzyl-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride
Figure imgf000190_0001
Prepared from the trans derivative obtained as a by-product in the recrystallization of
Figure imgf000190_0002
(cf. example 1 ). ESI-MS [M+H+] = 387 Calculated for C22H30N2O2S = 386
Example 195: N-{[8-Benzyl-7-(methylamino)-5!6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- imidazole-4-sulfonamide hydrochloride
Figure imgf000190_0003
ESI-MS [M+H+] = 425 Calculated for C23H28N4O2S = 424
Example 196:
N-(1-Benzyl-7-{[(propylsulfonyl)amino]methyl}-1 ,2,3,4-tetrahydronaphthalen-2- yl)acetamide
Figure imgf000190_0004
N-{[7-Amino-8-benzyl-5, 6, 7, 8-tetrahydronaphthalen-2-yl]methyl}propane-1 -sulfonamide (cf. example 42) was acetylated in dichloromethane with acetyl chloride in the presence of ethyldiisopropylamine at room temperature. ESI-MS [M+H+] = 415 Calculated for C23H30N2O3S = 414
Example 197:
N-[(1 -(4-Fluorobenzyl)-7-({[(1 -methyl-1 H-imidazol-4-yl)sulfonyl]amino}methyl)-1 ,2,3,4- tetrahydronaphthalen-2-yl]acetamide
Figure imgf000191_0001
This compound was prepared in analogy to example 196.
ESI-MS [M+H+] = 471 Calculated for C24H27FN4O3S = 470
Example 198:
N-{[8-Benzyl-7-(ethylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide hydrochloride
Figure imgf000191_0002
N-(1-Benzyl-7-{[(propylsulfonyl)amino]methyl}-1 ,2,3,4-tetrahydronaphthalen-2- yl)acetamide (example 196, 153 mg, 0.37 mmol) was dissolved in tetrahydrofuran (5 ml_). 1 M Boran dimethylsulfide complex solution in tetrahydrofuran (852 μl_, 8.52 mmol) was added and the reaction mixture stirred at room temperature over night. Water was added and the mixture extracted with dichloromethane (three times). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Excess 6 M hydrochloric acid in isopropanol was added. The solvent was evaporated and the product dried in vacuo. Yield: 70 mg (0.16 mmol, 36%).
ESI-MS [M+H+] = 401 Calculated for C23H32N2O2S = 400
The following examples were prepared in analogy to example 198: Example 199:
1 -Methyl-1 H-imidazole-4-sulfonic acid [7-ethylamino-8-(4-fluoro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-ylmethyl]-amide hydrochloride
Figure imgf000192_0001
ESI-MS [M+H+] = 457 Calculated for C24H29FN4O2S = 456
Example 200:
1-Methyl-1 H-pyrazole-4-sulfonic acid [7-ethylamino-8-(3-fluoro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-ylmethyl]-amide hydrochloride
Figure imgf000192_0002
ESI-MS [M+H+] = 457 Calculated for C24H29FN4O2S = 456
Example 201 : N-{3-[7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1 - sulfonamide hydrochloride
201.1 tert-Butyl [1-(4-chlorobenzyl)-7-{3-[(propylsulfonyl)amino]propyl}-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate
Figure imgf000192_0003
To a solution of 9-BBN (0.5 M in tetrahydrofuran, 8.85 ml_, 4.42 mmol) was added drop- wise a solution N-allylpropane-1 -sulfonamide (1152 mg, 7.06 mmol) in tetrahydrofuran (1 ml.) a 00C. After stirring at 00C to 5°C for 3.5 hours dioxane (25 ml.) was added followed by 7-(tert-butoxycarbonylamino)-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate (1000 mg, 1.923 mmol, prepared analogously to example 34.3), palladium acetate (43.2 mg, 0.192 mmol), triphenylphosphine (101 mg, 0.385 mmol) and cesium carbonate (1253 mg, 3.85 mmol). The yellow reaction mixture was heated under reflux for 3 hours. The reaction mixture was diluted with ethyl acetate (60 ml.) and washed with water (2x 40 ml_). The organic layer was dried and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloro methane, methanol). Yield: 854 mg (1.596 mmol, 83%).
201.2N-{3-[7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane- 1 -sulfonamide hydrochloride
Figure imgf000193_0001
tert-Butyl [1 -(4-chlorobenzyl)-7-{3-[(propylsulfonyl)amino]propyl}-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate (150 mg, 0.281 mmol) was dissolved in dichloro- methane (3 ml.) and a solution of hydrochloric acid (0.5 ml_, 5 M in isopropanol) was added. After stirring at room temperature for 2 hours the solvent was removed in vacuo. Water was added (15 ml.) and the pH was adjusted to 9 with aqueous saturated sodium bicarbonate and the mixture was extracted with dichloromethane (3x 15 ml_). The combined organic extracts were dried and concentrated in vacuo. The crude product was puri- fied by flash chromatography (silica gel, dichloromethane, methanol). The product was dissolved in dichloromethane (2 ml.) and a solution of hydrochloric acid in ethanol (1.25 M) was added. The solvent was removed in vacuo. Yield: 31.4 mg (0.187 mmol, 36%). ESI-MS [M+H+] = 435 Calculated for C23H3ICIN2O2S = 434
The following examples were prepared in analogy to example 201 :
Example 202:
N-{3-[7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000194_0001
ESI-MS [M+H+] = 447 Calculated for C24H3ICIN2O2S = 446
Example 203: N-{3-[7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1- sulfonamide hydrochloride
Figure imgf000194_0002
ESI-MS [M+H+] = 469 Calculated for C23H30CI2N2O2S = 468
Example 204:
N-{3-[7-Amino-8-(3!4-difluoro-benzyl)-5,6!7,8-tetrahydro-naphthalen-2-yl]-propyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000194_0003
ESI-MS [M+H+] = 449 Calculated for C24H30F2N2O2S = 448
Example 205:
N-{3-[7-Amino-8-benzyl-5, 6, 7, 8-tetrahydronaphthalen-2-yl]propyl}propane-1 -sulfonamide hydrochloride
Figure imgf000195_0001
ESI-MS [M+H+] = 401 Calculated for C23H32N2O2S = 400
Example 206: N-{3-[7-Amino-8-(3,4-difluoro-benzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1- sulfonamide hydrochloride
Figure imgf000195_0002
ESI-MS [M+H+] = 437 Calculated for C23H30F2N2O2S = 436
Example 207:
N-{3-[7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide trifluoroacetate
Figure imgf000195_0003
ESI-MS [M+H+] = 413 Calculated for C24H32N2O2S = 412
Example 208:
N-{3-[7-Amino-8-(4-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide hydrochloride
HCI
Figure imgf000195_0004
ESI-MS [M+H+] = 431 Calculated for C24H3IFN2O2S = 430
Example 209:
N-{3-[7-Amino-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1- sulfonamide hydrochloride
Figure imgf000196_0001
ESI-MS [M+H+] = 419 Calculated for C23H3iFN2O2S = 418
Example 210: N-{3-[7-Amino-8-(3-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]propyl}-1 ■ cyclopropylmethanesulfonamide hydrochloride
Figure imgf000196_0002
ESI-MS [M+H+] = 431 Calculated for C24H31FN2O2S = 430
Example 211 :
N-{3-[7-Amino-8-(2-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1- sulfonamide hydrochloride
Figure imgf000196_0003
ESI-MS [M+H+] = 435 Calculated for C23H31CIN2O2S = 434
Example 212: N-{3-[7-Amino-8-(2-chloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yl]-propyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000197_0001
ESI-MS [M+H+] = 447 Calculated for C24H3ICIN2O2S = 446
Example 213:
N-{3-[7-Amino-8-(4-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1- sulfonamide hydrochloride
Figure imgf000197_0002
ESI-MS [M+H+] = 419 Calculated for C23H3I FN2O2S = 418
Example 214:
N-[1-(3-Fluorobenzyl)-7-{3-[(propylsulfonyl)amino]propyl}-1 ,2,3,4-tetrahydronaphthalen-2- yl]acetamide
Figure imgf000197_0003
N-(3-(7-Amino-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)propyl)propane-1- sulfonamide (cf. example 209: 45 mg, 0.108 mmol) and triethylamine (15μl_, 0.108 mmol) were dissolved in dichloromethane (2 ml_). Acetylchloride (7.64 μl_, 0.108 mmol) were added. The reaction mixture was stirred for 12 hours at room temperature. The reaction mixture was diluted with dichloromethane and successively washed with hydrochloric acid, water and saturated sodium chloride solution. The organic layer was dried and concentrated in vacuo. The crude product was purified by flash-chromatography (silica gel, dichloromethane, methanol). Yield: 37 mg (0.08 mmol, 75%). ESI-MS [M+H+] = 461 Calculated for C25H33FN2O3S = 460
In analogy to example 214 the following examples were prepared:
Example 215:
N-[1-(4-Fluorobenzyl)-7-{3-[(propylsulfonyl)amino]propyl}-1 ,2,3,4-tetrahydronaphthalen-2- yl]acetamide
Figure imgf000198_0001
ESI-MS [M+H+] = 461 Calculated for C25H33FN2O3S = 460
Example 216:
N-[1-Benzyl-7-(3-{[(cyclopropylmethyl)sulfonyl]amino}propyl)-1 ,2,3,4- tetrahydronaphthalen-2-yl]acetamide
Figure imgf000198_0002
ESI-MS [M+H+] = 455 Calculated for C26H34N2O3S = 454
Example 217:
N-[1-Benzyl-7-{3-[(propylsulfonyl)amino]propyl}-1 ,2,3,4-tetrahydronaphthalen-2- yl]acetamide
Figure imgf000198_0003
ESI-MS [M+H+] = 443 Calculated for C25H34N2O3S = 442
Example 218: N-[7-(3-{[(Cyclopropylmethyl)sulfonyl]amino}propyl)-1-(3-fluorobenzyl)-1 ,2,3,4- tetrahydronaphthalen-2-yl]acetamide
Figure imgf000199_0001
ESI-MS [M+H+] = 473 Calculated for C26H33FN2O3S = 472
Example 219:
Propane-1 -sulfonic acid {3-[7-ethylamino-8-(3-fluoro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yl]-propyl}-amide hydrochloride
Figure imgf000199_0002
N-(1 -(3-Fluorobenzyl)-7-(3-(propylsulfonamido)propyl)-1 ,2,3,4-tetrahydronaphthalen-2- yl)acetamide (cf. example 214, 19.5 mg, 0.042 mmol) was dissolved in tetrahydrofuran (1 ml.) and borane dimethylsulfide (106 μl_, 0.212 mmol) was added. The reaction mixture was stirred for 5 hours at 500C. After cooling to room temperature aqueous hydrochloric acid was added. The mixture was made alkaline by the addition of sodium bicarbonate and extracted several times with dichloromethane. The combined organic extracts were dried (MgSO4), concentrated in vacuo and the crude product purified by flash- chromatography (silica gel, dichloromethane, methanol). An excess of 1 M hydrochloric acid in ether was added to the purified product and the ether distilled off. Yield: 7 mg (0.016 mmol, 37%). ESI-MS [M+H+] = 447 Calculated for C25H35FN2O2S = 446
The following examples were prepared in analogy to example 219:
Example 220: N-{3-[7-(Ethylamino)-8-(4-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane- 1 -sulfonamide hydrochloride
Figure imgf000200_0001
ESI-MS [M+H+] = 447 Calculated for C25H35FN2O2S = 446
Example 221 : C-Cyclopropyl-N-{3-[7-ethylamino-8-(3-fluoro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yl]- propyl}-methanesulfonamide hydrochloride
Figure imgf000200_0002
ESI-MS [M+H+] = 459 Calculated for C26 H35 FN2O2S = 458
Example 222:
Propane-1 -sulfonic acid {3-[8-(2-chloro-benzyl)-7-ethylamino-5,6,7,8-tetrahydro- naphthalen-2-yl]-propyl}-amide hydrochloride
Figure imgf000200_0003
ESI-MS [M+H+] = 463 Calculated for C25H35CIN2O2S = 462
Example 223:
N-{3-[8-Benzyl-7-(ethylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1- sulfonamide hydrochloride
Figure imgf000200_0004
ESI-MS [M+H+] = 429 Calculated for C25H36N2O2S = 428 Example 224:
N-{3-[8-Benzyl-7-(ethylamino)-5,6J,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000201_0001
ESI-MS [M+H+] = 441 Calculated for C26H36N2O2S = 440
Example 225:
N-{3-[8-(3!4-Difluorobenzyl)-7-(ethylamino)-5,6!7,8-tetrahydronaphthalen-2- yl]propyl}propane-1 -sulfonamide trifluoroacetate
Figure imgf000201_0002
ESI-MS [M+H+] = 465 Calculated for C25H34F2N2O2S = 464
Example 226: 1 -Cyclopropyl-N-{3-[8-(3!4-difluorobenzyl)-7-(ethylamino)-5,6!7,8-tetrahydronaphthalen-2- yl]propyl}methanesulfonamide trifluoroacetate
Figure imgf000201_0003
ESI-MS [M+H+] = 477 Calculated for C26H34F2N2O2S = 476
Example 227:
N-{3-[7-Amino-8-(3-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]propyl}-N- methylpropane-1 -sulfonamide hydrochloride
Figure imgf000202_0001
tert-Butyl (1 -(3-fluorobenzyl)-7-(3-(propylsulfonamido)propyl)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (cf. 209 and 201 a, 65 mg, 0.125 mmol) was dissolved in acetonitrile (800 μl_) and methyl iodide (24 μl_, 0.376 mmol) and cesium carbon- ate (0.102 g, 0.313 mmol) was added. The reaction mixture was heated for 24 hours in a sealed vessel to 800C. The reaction mixture was diluted with ethyl acetate. The ethyl acetate solution was successively washed with water and saturated sodium chloride solution. The organic phase was dried (MgSO4) and concentrated in vacuo. The crude product was purified by preparative thin-layer chromatography (silica gel, dichloromethane, methanol). The obtained tert-butyl 1-(3-fluorobenzyl)-7-(3-(N-methylpropylsulfonamido)propyl)-
1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (65 mg, 0.122 mmol) was dissolved in 4 M hydrochloric acid in isopropanol and stirred at room temperature for 4 hours. The solvent was removed in vacuo. Diethyl ether was added and the precipitate removed by filtration and dried. Yield: 22 mg (0.047 mmol, 38%). ESI-MS [M+H+] = 433 Calculated for C24H33FN2O2S = 432
The following examples were prepared in analogy to example 227:
Example 228: N-{3-[7-Amino-8-(2-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yl]-propyl}-C- cyclopropyl-N-methyl-methanesulfonamide hydrochloride
Figure imgf000202_0002
ESI-MS [M+H+] = 461 Calculated for C25H33CIN2O2S = 460
Example 229:
Propane-1 -sulfonic acid {3-[7-amino-8-(2-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yl]-propyl}-methyl-amide hydrochloride
Figure imgf000203_0001
ESI-MS [M+H+] = 449 Calculated for C24H33CIN2O2S = 448
Example 230:
N-{3-[7-Amino-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1-cyclopropyl- N-methylmethanesulfonamide hydrochloride
Figure imgf000203_0002
ESI-MS [M+H+] = 445 Calculated for C25H33FN2O2S = 444
Example 231 :
N-{3-[7-Amino-8-(4-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1-cyclopropyl- N-methylmethanesulfonamide hydrochloride
Figure imgf000203_0003
ESI-MS [M+H+] = 445 Calculated for C25H33FN2O2S = 444
Example 232:
N-{3-[7-Amino-8-(4-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]propyl}-N- methylpropane-1 -sulfonamide hydrochloride
Figure imgf000203_0004
ESI-MS [M+H+] = 433 Calculated for C24H33FN2O2S = 432 Example 233:
N-{3-[7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1-cyclopropyl- N-methylmethanesulfonamide hydrochloride
Figure imgf000204_0001
ESI-MS [M+H+] = 461 Calculated for C25H33CIN2O2S = 460
Example 234:
N-{3-[7-Amino-8-(4-chlorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]propyl}-N- methylpropane-1 -sulfonamide hydrochloride
Figure imgf000204_0002
ESI-MS [M+H+] = 449 Calculated for C24H33CIN2O2S = 448
Example 235 was prepared in analogy to example 47: N-(2-{[7-Amino-8-(3-fluorobenzyl)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1 ■ cyclopropylmethanesulfonamide hydrochloride
Figure imgf000204_0003
ESI-MS [M+H+] = 433 Calculated for C23H29FN2O3S = 432
The following examples were prepared in analogy to example 46:
Example 236: Ethyl [1 -(3,5-difluorobenzyl)-7-(2-{[(1 -methyl-1 H-pyrrol-3-yl)sulfonyl]amino}ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate
Figure imgf000205_0001
ESI-MS [M+H+] = 548 Calculated for C27H3IF2N3O5S = 547
Example 237:
Ethyl [7-(2-{[(cyclopropylmethyl)sulfonyl]amino}ethoxy)-1 -(3,5-difluorobenzyl)-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate
Figure imgf000205_0002
ESI-MS [M+H+] = 523 Calculated for C26H32F2N2O5S = 522
Example 238 was prepared in analogy to example 47:
Enantiomer 1 of N-(2-{[7-amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000205_0003
Could be separated by chiral chromatography of the final compound or an intermediate.
ESI-MS [M+H+] = 441 Calculated for C23H28N4O3S = 440
The following examples were prepared in analogy to example 137:
Example 239:
Enantiomer 2 of C-cyclopropyl-N-{2-[8-(3-fluoro-benzyl)-7-methylamino-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-methanesulfonamide hydrochloride
Figure imgf000206_0001
C-Cyclopropyl-N-{2-[8-(3-fluoro-benzyl)-7-methylamino-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-methanesulfonamide (Daicel, Chiralpak IC, 250x4,6 mm ID, 5μ, methyl t-butyl ether/dichloromethane/methanol/triethylamine = 900/50/50/1 ). The second eluting enanti- omer was used for synthesis of the final compound.
ESI-MS [M+H+] = 447 Calculated for C24H3IFN2O3S = 446
Example 240:
Enantiomer 1 of 1-cyclopropyl-N-(2-{[8-(3-fluorobenzyl)-7-(methylamino)-5, 6,7,8- tetrahydronaphthalen-2-yl]oxy}ethyl)methanesulfonamide hydrochloride
Figure imgf000206_0002
Ethyl 7-(2-(cyclopropylmethylsulfonamido)ethoxy)-1 -(3-fluorobenzyl)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate was separated by chiral chromatography (Daicel, Chiralpak IC, 250x4,6 mm ID, methyl t-butyl ether/dichloromethane/methanol/triethylamine = 900/50/50/1 ). The first eluting enantiomer was used for synthesis of the final compound. ESI-MS [M+H+] = 447 Calculated for C24H31FN2O3S = 446
Example 241 :
Enantiomer 1 of N-(2-{[8-(3,5-difluorobenzyl)-7-(methylamino)-5,6,7,8- tetrahydronaphthalen-2-yl]oxy}ethyl)-1-methyl-1 H-pyrrole-3-sulfonamide hydrochloride
Ethyl 1 -(3,5-difluorobenzyl)-7-(2-(1 -methyl-1 H-pyrrole-3-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate was separated by chiral chromatography (Daicel, Chiralpak AD,250x20 mm ID, 10μ, n-heptane/ethanol/triethylamine = 35/65/1 ). The second eluting enantiomer was used for synthesis of the final compound. Can be separated by chiral chromatography of the final compound or an intermediate. ESI-MS [M+H+] = 490 Calculated for C25H29F2N3O3S = 489
Example 242:
Enantiomer 2 of N-(2-{[8-(3,5-difluorobenzyl)-7-(methylamino)-5,6,7,8- tetrahydronaphthalen-2-yl]oxy}ethyl)-1 -methyl-1 H-pyrrole-3-sulfonamide hydrochloride
Figure imgf000207_0001
Ethyl 1 -(3,5-difluorobenzyl)-7-(2-(1 -methyl-1 H-pyrrole-3-sulfonamido)ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate was separated by chiral chromatography (Daicel,
Chiralpak AD,250x20 mm ID, 10μ, n-heptane/ethanol/triethylamine = 35/65/1 ). The first eluting enantiomer was used for synthesis of the final compound.
ESI-MS [M+H+] = 490 Calculated for C25H29F2N3O3S = 489
Example 243:
1-Cyclopropyl-N-(2-{[8-(3,5-difluorobenzyl)-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-
2-yl]oxy}ethyl)methanesulfonamide hydrochloride
Figure imgf000207_0002
ESI-MS [M+H+] = 465 Calculated for C24H30F2N2O3S = 464
Example 244:
Enantiomer 2 of 1-cyclopropyl-N-(2-{[8-(3,5-difluorobenzyl)-7-(methylamino)-5, 6,7,8- tetrahydronaphthalen-2-yl]oxy}ethyl)methanesulfonamide hydrochloride Chiral
Figure imgf000208_0001
Ethyl 7-(2-(cyclopropylmethylsulfonamido)ethoxy)-1 -(3,5-difluorobenzyl)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate was separated by chiral chromatography (Daicel, Chiralpak AD,250x20 mm ID, 10μ, n-heptane/ethanol/t-butanol = 800/150/50). The first eluting enantiomer was used for synthesis of the final compound. ESI-MS [M+H+] = 465 Calculated for C24H30F2N2O3S = 464
Example 245:
Enantiomer 1 of 1-cyclopropyl-N-(2-{[8-(3,5-difluorobenzyl)-7-(methylamino)-5, 6,7,8- tetrahydronaphthalen-2-yl]oxy}ethyl)methanesulfonamide hydrochloride
Figure imgf000208_0002
Ethyl 7-(2-(cyclopropylmethylsulfonamido)ethoxy)-1 -(3,5-difluorobenzyl)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate was separated by chiral chromatography (Daicel, Chiralpak AD,250x20 mm ID, 10μ, n-heptane/ethanol/t-butanol = 800/150/50). The sec- ond eluting enantiomer was used for synthesis of the final compound. ESI-MS [M+H+] = 465 Calculated for C24H30F2N2O3S = 464
Example 246:
N-(2-{[8-(3,5-Difluorobenzyl)-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1-methyl-1 H-pyrrole-3-sulfonamide hydrochloride
Figure imgf000208_0003
ESI-MS [M+H+] = 490 Calculated for C25H29F2N3O3S = 489 Example 247:
1-Cyclopropyl-N-(2-{[8-(3-fluorobenzyl)-7-(methylamino)-5!6!7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)methanesulfonamide hydrochloride
Figure imgf000209_0001
ESI-MS [M+H+] = 447 Calculated for C24H3IFN2O3S = 446
Example 248:
N-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- imidazole-4-sulfonamide
248.1 7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalene-2-carbonitrile
Figure imgf000209_0002
Tert-butyl 1-benzyl-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (1.1 g, 3.03 mmol) was dissolved in dichloromethane (20 ml.) and 5 M hydrochloric acid in isopropanol (2 ml.) was added. The reaction mixture was stirred at room temperature for 12 h followed by 4 h at 35°C. The solvent was evaporated in vacuo. Water (30 ml.) was added and the pH was adjusted to pH 9 using aqueous saturated sodium bicarbonate solution. The aqueous layer was extracted with dichloromethane. The combined extracts were dried (MgSO4) and the solvent was evaporated in vacuo. Yield: 790 mg (3.03 mmol, 100%).
248.2 7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalene-2-carbonitrile
Figure imgf000209_0003
7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalene-2-carbonitrile (790 mg, 3.03 mmol), 1 ,3- dibromopropane (0.4 ml_, 3.93 mmol) and triethylamine (0.914 ml_, 6.56 mmol) were dissolved in acetonitrile (8 ml.) and the reaction mixture heated to 1200C in the microwave for 2 h. The solvent was evaporated in vacuo. Water (30 ml.) and ethyl acetate (40 ml.) were added. The layers were separated and the aqueous layer extracted with ethyl acetate. The combined organic extracts were dried (MgSO4) and the solvent evaporated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloro- methane, methanol). Yield: 346 mg (1.14 mmol, 37.6 %).
248.3 1 -[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methanamine
Figure imgf000210_0001
7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalene-2-carbonitrile (340 mg, 1.12 mmol) was dissolved in dry methanol (20 ml.) under a nitrogen atmosphere. Raney nickel (900 mg, 3.36 mmol) was added under nitrogen and the reaction mixture stirred at room temperature for 48 h under an atmosphere of hydrogen. Methanol (20 ml.) and dichloro- methane (30 ml.) were added. After stirring at room temperature for 20 minutes the catalyst was removed by filtration and the solvent evaporated in vacuo. Yield: 338 mg (1.10 mmol, 98%).
248.4 N-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 - methyl-1 H-imidazole-4-sulfonamide
Figure imgf000210_0002
(7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)methanamine (250 mg, 0.816 mmol) and N,N-dimethyl-4-aminopyridine (199 mg, 1.632 mmol) were dissolved in dichloromethane (18 ml_). 1-Methyl-1 H-imidazole-4-sulfonyl chloride (147 mg, 0.816 mmol) dissolved in dichloromethane (2 ml.) was added dropwise. The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with dichloromethane (20 ml.) and washed successively with saturated ammonium chloride (3x 15 ml.) and water (2x 10 ml_). The organic phase was dried (MgSO4) and the solvent was evapo- rated in vacuo. The crude product was purified by flash chromatography (silica gel, di- chloromethane, methanol). Yield: 64 mg (0.142 mmol, 17%). ESI-MS [M+H+] = 451 Calculated for C25H30N4O2S = 450
The following examples were prepared in analogy to 248:
Example 249:
N-{[7-(Azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide
Figure imgf000211_0001
ESI-MS [M+H+] = 413 Calculated for C24H32N2O2S = 412
Example 250: N-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- pyrazole-4-sulfonamide
Figure imgf000211_0002
ESI-MS [M+H+] = 451 Calculated for C25H30N4O2S = 450
Example 251 :
N-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- pyrrole-3-sulfonamide trifluoroacetate
Figure imgf000212_0001
ESI-MS [M+H+] = 450 Calculated for C26H3IN3O2S = 449
Example 252: Enantiomer 1 of N-{[7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}- 1 -methyl-1 H-imidazole-4-sulfonamide
Chiral
Figure imgf000212_0002
The enantiomer of te/f-butyl (1-benzyl-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2- yl)carbamate described in example 192 was used as chiral building block for the synthe- sis.
ESI-MS [M+H+] = 451 Calculated for C25H30N4O2S = 450
Example 253:
Enantiomer 1 of N-{[7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}pyridine-2-sulfonamide
Chiral
Figure imgf000212_0003
The enantiomer of te/f-butyl (1-benzyl-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2- yl)carbamate described in example 192 was used as chiral building block for the synthesis. ESI-MS [M+H+] = 448 Calculated for C26H29N3O2S = 447
Example 254:
Enantiomer 1 of N-{[7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-
1 -methyl-1 H-pyrazole-4-sulfonamide Chiral
Figure imgf000213_0001
The enantiomer of te/f-butyl (1-benzyl-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2- yl)carbamate described in example 192 was as chiral building block for the synthesis. ESI-MS [M+H+] = 451 Calculated for C25H30N4O2S = 450
Example 255:
Enantiomer 1 of N-{[7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}thiophene-2-sulfonamide
Chiral
Figure imgf000213_0002
The enantiomer of te/f-butyl (1 -benzyl-7-cyano-1 ,2,3,4-tetrahydronaphthalen-2- yl)carbamate described in example 192 was used as chiral building block for the synthesis. ESI-MS [M+H+] = 453 Calculated for C25H28N2O2S2 = 452
Example 256:
N-{[7-(Azetidin-1-yl)-8-(3-fluorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1- methyl-1 H-imidazole-4-sulfonamide hydrochloride
Figure imgf000213_0003
468
Example 257:
N-{[8-Benzyl-7-(morpholin-4-yl)-5!6,7,8-tetrahydronaphthalen-2-yl]methyl}-1-methyl-1 H- imidazole-4-sulfonamide
Figure imgf000214_0001
This compound was prepared in analogy to example 248 using 1-bromo-2-(2- bromoethoxy)ethane in place of 1 ,3-dibromopropane. ESI-MS [M+H+] = 481 Calculated for C26H32N4O3S = 480
The following examples were prepared in analogy to 257:
Example 258: N-{[8-Benzyl-7-(morpholin-4-yl)-5!6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- pyrazole-4-sulfonamide
Figure imgf000214_0002
ESI-MS [M+H+] = 481 Calculated for C26H32N4O3S = 480
Example 259:
N-{[8-Benzyl-7-(morpholin-4-yl)-5!6,7,8-tetrahydronaphthalen-2-yl]methyl}-1- cyclopropylmethanesulfonamide
Figure imgf000214_0003
ESl-MS [M+H+] = 455 Calculated for C26H34N2O3S = 454
Example 260:
N-{[8-Benzyl-7-(morpholin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}propane-1- sulfonamide
Figure imgf000215_0001
ESl-MS [M+H+] = 443 Calculated for C25H34N2O3S = 442
Example 261 :
N-{[8-Benzyl-7-(morpholin-4-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]methyl}cyclobutanesulfonamide
Figure imgf000215_0002
ESI-MS [M+H+] = 455 Calculated for C26H34N2O3S = 454
Example 262:
N-{[8-Benzyl-7-(pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1 -methyl-1 H- imidazole-4-sulfonamide
Figure imgf000215_0003
This compound was prepared in analogy to example 248 using 1 ,4-dibromobutane in place of 1 ,3-dibromopropane.
ESI-MS [M+H+] = 465 Calculated for C26H32N4O2S = 464
Example 263:
N-{[8-Benzyl-7-(2-oxopyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-1-methyl- 1 H-imidazole-4-sulfonamide
Figure imgf000215_0004
N-((7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)methyl)-1-methyl-1 H-imidazole-4- sulfonamide (271 mg, 0.66 mmol, cf. 173) was dissolved in dichloromethane (10 ml_). Pyridine (0.191 mL, 2.357 mmol) was added. 4-Chlorobutanoyl chloride (0.116 mL, 1.038 mmol) was added dropwise. After 2 h N,N-dimethyl-4-aminopyridine (46 mg, 0.378 mmol) was added and stirring was continued over night. 1 N sodium hydroxide solution was added and the mixture extracted with dichloromethane. The combined organic extracts were dried (MgSO4) and concentrated in vacuo. The crude product was suspended in dry tetrahydrofuran and a suspension of sodium hydride (60% in oil, 179 mg, washed twice with pentane prior to addition) in tetrahydrofuran (3 mL) was added. The reaction mixture was heated to 45°C for 1 h. Water was added and the mixture was extracted with dichloromethane (3x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 98 mg (0.205 mmol, 46%). ESI-MS [M+H+] = 479 Calculated for C26H30N4O3S = 478
Example 264:
N-{3-[8-(3-Chlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]propyl}propane-1 -sulfonamide hydrochloride
264.1 1-[1-(3-Chlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]pyrrolidine
Figure imgf000216_0001
1-(3-Chlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-amine (6 g, 19.88 mmol) was dissolved in acetonitrile (150 mL). 1 ,4-Dibromobutane (2.61 mL, 21.87 mmol) and triethylamine (6.1 mL, 43.7 mmol) were added and the reaction mixture heated under reflux for 3 h. The reaction mixture was poured on ice and extracted with dichloromethane. The combined organic extracts were successively washed with water and brine, dried (MgSO4) and the solvent was evaporated in vacuo. The crude product (6.6 g) was used for the next step without further purification.
264.2 8-(3-Chlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-ol
Figure imgf000217_0001
1-(1-(3-Chlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-yl)pyrrolidine (6.6 g, 18.54 mmol) was dissolved in dichloromethane (100 ml_). A 1 M solution of bortribromide in dichloromethane (55.6 ml_, 55.6 mmol) was added dropwise under cooling maintaining the reaction mixture at room temperature. The reaction mixture was stirred at room temperature for 2 h. The reaction was poured on ice, made alkaline with sodium hydroxide. The aqueous phase was extracted with ethyl acetate and the combined organic extracts were washed successively with sodium bicarbonate and brine. The combined extracts were dried (MgSO4) and the solvent was evaporated in vacuo. The crude product (5.5 g) was used for the next step without further purification.
264.3 8-(3-Chlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate
Figure imgf000217_0002
8-(3-Chlorobenzyl)-7-(pyrrolidin-1 -yl)-5,6,7,8-tetrahydronaphthalen-2-ol (5.5 g, 16.09 mmol) was dissolved in dichloromethane (150 ml_). 1 ,1 ,1-trifluoro-N-phenyl-N- (trifluoromethylsulfonyl)methanesulfonamide (6.9 g, 19.31 mmol) was added at 00C followed by the addition of a solution of triethylamine (4.48 ml_, 32.2 mmol) in dichloromethane (50 ml_). The reaction mixture was allowed to warm to room temperature and stirring was continued over night. The reaction was poured on ice and extracted with dichloromethane. The combined extracts were washed successively with ammonium chloride solution, water and brine. The extracts were dried (Na2SO4) and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 6.33 g (13.36 mmol, 83%). 264.4 N-{3-[8-(3-Chlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]propyl}propane-1 -sulfonamide hydrochloride
Figure imgf000218_0001
N-allylpropane-1 -sulfonamide (0.238 g, 1.456 mmol) is added to a solution of 9- borabicyclo[3.3.1]nonane (0.185 g, 1.519 mmol) in tetrahydrofuran (4 ml_). The reaction mixture was stirred for 2 h at room temperature. (7R,8S)-8-(3-chlorobenzyl)-7-(pyrrolidin- 1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate (0.3 g, 0.633 mmol) dissolved in tetrahydrofuran (2 ml_), sodium hydroxide (0.063 g, 1.582 mmol in 0.06 ml. water) and palladium tetrakistriphenylphosphine (0.073 g, 0.063 mmol) were added. The reaction mixture was heated under reflux over night. The reaction mixture was diluted with ethyl acetate and washed with 1 M sodium hydroxide solution. The aqueous phase was extracted two more times with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO4) and the solvent was evaporated in vacuo. The crude product was purified by preparative thin-layer-chromatography (silica gel, dichloromethane, methanol). The product was dissolved in dichloromethane. Excess 5N hydrochloric acid in ethanol was added. The solvent was evaporated and the product dried in vacuo. Yield: 53 mg (0.108 mmol, 17%). ESI-MS [M+H+] = 489 Calculated for C27H37CIN2O2S = 488
The following examples were prepared in analogy to 264:
Example 265:
Propane-1 -sulfonic acid [3-(8-benzyl-7-pyrrolidin-1-yl-5,6,7,8-tetrahydro-naphthalen-2-yl)- propyl]-amide hydrochloride
Figure imgf000218_0002
ESI-MS [M+H+] = 455 Calculated for C27H38N2O2S = 454
Example 266: N-{3-[8-Benzyl-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide hydrochloride
Figure imgf000219_0001
ESI-MS [M+H+] = 467 Calculated for C28H38N2O2S = 466
Example 267:
N-(2-{[8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5!6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1- methyl-1 H-pyrrole-3-sulfonamide
267.1 8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5!6,7,8-tetrahydronaphthalen-2-ol
Figure imgf000219_0002
8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-ol was prepared in analogy to 8-(3-chlorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-ol (cf. 264).
267.2 2-{[8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethanamine
Figure imgf000219_0003
2-{[8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethanamine was prepared in analogy to example 1 and 2 from 8-(3-fluorobenzyl)-7- (pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-ol.
267.3 N-(2-{[8-(3-fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 -methyl-1 H-pyrrole-3-sulfonamide
Figure imgf000220_0001
2-(8-(3-Fluorobenzyl)-7-(pyrrolidin-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethanamine (50 mg, 0.136 mmol) was dissolved in dichloromethane (2 ml_). N,N-Dimethyl-4- aminopyridine (49.7 mg, 0.407 mmol) and 1-methyl-1 H-pyrrole-3-sulfonyl chloride (24.4 mg, 0.136 mmol) were added successively. The reaction mixture was stirred at room temperature over night. The reaction was diluted with dichloromethane and washed with water. The organic phase was dried (MgSO4) and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 31 mg (0.061 mmol, 45%). ESI-MS [M+H+] = 512 Calculated for C28H34FN3O3S = 51 1
The following examples were prepared in analogy to 267:
Example 268: N-(2-{[7-(Azetidin-1 -yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)-1 -methyl-1 H- pyrrole-3-sulfonamide
Figure imgf000220_0002
ESI-MS [M+H+] = 480 Calculated for C27H33N3O3S = 479
Example 269:
1 -Methyl-1 H-pyrrole-3-sulfonic acid {2-[7-azetidin-1-yl-8-(3-fluoro-benzyl)-5,6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000220_0003
ESI-MS [M+H+] = 498 Calculated for C27H32FN3O3S = 497 Example 270:
Enantiomer 1 of N-{1 -benzyl-7-[2-(1 -methyl-1 H-imidazole-4-sulfonylamino)-ethoxy]-
1 ,2,3,4-tetrahydro-naphthalen-2-yl}-propionamide
Figure imgf000221_0001
N-{1 -Benzyl-7-[2-(1 -methyl-1 H-imidazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-propionamide was prepared in analogy to example 2 using propionyl chloride in place of ethyl chloroformate.
Could be separated by chiral chromatography of the final compound or an intermediate. ESI-MS [M+H+] = 497 Calculated for C26H32N4O4S = 496
Example 271 :
N-(2-{[8-(3!5-Difluorobenzyl)-7-(formylamino)-5,6!7,8-tetrahydronaphthalen-2-yl]oxy}ethyl)- 1 -methyl-1 H-pyrrole-3-sulfonamide
271.1 Ethyl [1-(3,5-difluorobenzyl)-7-(2-{[(1 -methyl-1 H-pyrrol-3- yl)sulfonyl]amino}ethoxy)-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate
Figure imgf000221_0002
Ethyl[1 -(3,5-difluorobenzyl)-7-(2-{[(1 -methyl-1 H-pyrrol-3-yl)sulfonyl]amino}ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate was prepared in analogy to example 2.
271.2 N-(2-{[8-(3,5-Difluorobenzyl)-7-(formylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]oxy}ethyl)-1 -methyl-1 H-pyrrole-3-sulfonamide
Figure imgf000222_0001
Ethyl[1 -(3,5-difluorobenzyl)-7-(2-{[(1 -methyl-1 H-pyrrol-3-yl)sulfonyl]amino}ethoxy)-1 ,2,3,4- tetrahydronaphthalen-2-yl]carbamate (200 mg, 0.365 mmol) was dissolved in tetrahydro- furan (16 ml_). A 1 M solution of lithium aluminium hydride in tetrahydrofuran (0.73 ml_, 0.73 mmol) was added dropwise at room temperature. The reaction mixture was heated to 500C for 2 h. Under cooling 2N sodium hydroxide solution (3 ml.) was added dropwise. Water (30 ml.) and ethyl acetate (30 ml.) were added. The aqueous phase was extracted twice with ethyl acetate. The combined extracts were dried (MgSO4) and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 61 mg (0.116 mmol, 32%). ESI-MS [M+H+] = 504 Calculated for C25H27F2N3O4S = 503
Example 272:
N-{3-[8-(3,4-Dichlorobenzyl)-7-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]propyl}propane-1 -sulfonamide
272.1 1-(3,4-Dichlorobenzyl)-7-methoxy-N-(propan-2-yl)-1 ,2,3,4- tetrahydronaphthalen-2-amine
Figure imgf000222_0002
1 -(3,4-Dichlorobenzyl)-7-methoxy-N-(propan-2-yl)-1 ,2,3,4-tetrahydronaphthalen-2-amine was isolated as a minor by-product in the recrystallization of 1-(3,4-dichlorobenzyl)-7- methoxy-1 ,2,3,4-tetrahydronaphthalen-2-amine hydrochloride from isopropanol.
272.2 N-{3-[8-(3,4-Dichlorobenzyl)-7-(propan-2-ylamino)-5, 6,7,8- tetrahydronaphthalen-2-yl]propyl}propane-1 -sulfonamide
Figure imgf000223_0001
N-{3-[8-(3,4-Dichlorobenzyl)-7-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]propyl}propane-1 -sulfonamide was prepared in analogy to example 264 using 1-(3,4- dichlorobenzyl)-7-methoxy-N-(propan-2-yl)-1 ,2,3,4-tetrahydronaphthalen-2-amine in place of 1 -[1 -(3-chlorobenzyl)-7-methoxy-1 ,2,3,4-tetrahydronaphthalen-2-yl]pyrrolidine. ESI-MS [M+H+] = 51 1 Calculated for C25H32CI2N2O3S = 510
Example 273:
N-{3-[8-Benzyl-7-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}propane-1- sulfonamide hydrochloride
Figure imgf000223_0002
N-{3-[8-(3,4-Dichlorobenzyl)-7-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]propyl}propane-1 -sulfonamide (70 mg, 0.137 mmol) was dissolved in methanol (1.5 ml.) and palladium hydroxide (30 mg, 0.214 mmol) was added. The reaction mixture was heated under reflux in an atmosphere of hydrogen for 6h. The catalyst was removed by filtration and the crude product was purified by flash chromatography (silica gel, dichloro- methane, methanol). The obtained amine was dissolved in dichloromethane (2 ml.) and 5 N hydrochloric acid in isopropanol (0.3 ml.) was added. The solvent was evaporated and the product dried in vacuo. Yield: 30 mg (0.63 mmol, 46%). ESI-MS [M+H+] = 443 Calculated for C26H38N2O2S = 442
Example 274:
N-{3-[8-(4-Chlorobenzyl)-7-(diethylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide hydrochloride
274.1 N-{3-[7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide
Figure imgf000224_0001
N-{3-[7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]propyl}-1- cyclopropylmethanesulfonamide (cf. 202).
274.2 N-{3-[8-(4-Chlorobenzyl)-7-(diethylamino)-5,6,7,8-tetrahydronaphthalen-2- yl]propyl}-1 -cyclopropylmethanesulfonamide hydrochloride
Figure imgf000224_0002
N-(3-(7-Amino-8-(4-chlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)propyl)-1- cyclopropylmethanesulfonamide (49 mg, 0.1 1 mmol) was dissolved in dichloromethane (2 ml_). Acetic acid (7 μl_, 0.1 1 mmol) was added followed by acetaldehyde (18 μl_, 0.322 mmol) in dichloromethane (2 ml.) and sodium triacetoxyborohydride (34 mg, 0.16 mmol).
The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane (20 ml.) and washed with water (2x 10 ml_). The organic layer was dried (MgSO4) and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). The amine was dissolved in dichloromethane (3 ml.) and excess hydrochloric acid in ethanol was added. The solvents were evaporated and the product dried in vacuo. Yield: 22 mg (0.041 mmol, 38%).
ESI-MS [M+H+] = 503 Calculated for C28H39CIN2O2S = 502
Example 275:
N-{[8-Benzyl-7-(methylamino)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl}-N- methylpropane-1 -sulfonamide trifluoroacetate
Figure imgf000224_0003
This compound could be prepared in analogy to example 227 using tert-butyl [(1 S,2R)-1- benzyl-7-{[(propylsulfonyl)amino]methyl}-1 ,2,3,4-tetrahydronaphthalen-2-yl]carbamate in place of tert-butyl 1-(3-fluorobenzyl)-7-(3-(propylsulfonamido)propyl)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (alkylation of sulfonamide). The tert-butyl carbamate could then be reduced with lithium aluminium hydride as in example 187. ESI-MS [M+H+] = 401 Calculated for C23H32N2O2S = 400
Example 276:
N-[1 -Benzyl-7-{3-[(propylsulfonyl)amino]prop-1 -yn-1 -yl}-1 ,2,3,4-tetrahydronaphthalen-2- yl]acetamide
Figure imgf000225_0001
7-Acetamido-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate (100 mg, 0.234 mmol; prepared in analogy to 8-(3,4-dichlorobenzyl)-7-[(ethoxycarbonyl)amino]- 5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate, example 29), N-(prop-2- ynyl)propane-1 -sulfonamide (75 mg, 0.468 mmol), palladium tetrakistriphenylphosphine (54 mg, 0.047 mmol), copper(l) iodide (35.6 mg, 0.187 mmol) and triethylamine (65 μl_, 0.468 mmol) in dioxane (3 ml.) were heated under reflux for 16 h. Water (15 ml.) was added and the mixture extracted with dichloromethane (3x 20 ml_). The combined organic extracts were dried (MgSO4) and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 56 mg (0.132 mmol, 57%). ESI-MS [M+H+] = 439 Calculated for C25H30N2O3S = 438
Example 277: N-(2-(8-Benzyl-7-(oxetan-3-ylamino)-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1- cyclopropylmethanesulfonamide
Figure imgf000225_0002
N-(2-(7-Amino-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl)-1- cyclopropylmethanesulfonamide (50 mg, 0.121 mmol) was dissolved in methanol. Oxetan- 3-one (87 mg, 1.21 mmol), zinc chloride (66 mg, 0.482 mmol) and sodium cyanoboro- hydride (23 mg, 0.362 mmol) were added at 00C. The reaction mixture was then heated to 400C for 5 h. Aqueous ammonium chloride solution was added and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, dichloromethane, methanol). Yield: 3 mg (6.4 μmol, 5%). ESI-MS [M+H+] = 471 Calculated for C26H34N2O4S = 470
Example 278: Propane-1 -sulfonic acid (δ-benzyl^-cyclopropylamino-δ^J^-tetrahydro-naphthalen^- ylmethyl)-amide hydrochloride
Figure imgf000226_0001
N-((7-Amino-8-benzyl-5, 6, 7, 8-tetrahydronaphthalen-2-yl)methyl)propane-1 -sulfonamide (51 mg, 0.137 mmol), (i-ethoxycyclopropoxy)trimethylsilane (26 mg, 0.151 mmol), acetic acid (0.078 ml_, 1.37 mmol), sodium cyanoborohydride (26 mg, 0.411 mmol) and molecular sieve (50 mg) in methanol (1.5 ml.) were heated in the microwave at 100°C for 25 min. The solvent was evaporated and the crude product purified by flash chromatography (silica gel, dichloromethane, methanol) and converted into the hydro chloride. Yield: 18 mg (0.04 mmol, 29%). ESI-MS [M+H+] = 413 Calculated for C24H32N2O2S = 412
Example 279:
(1 -(4-Chloro-benzyl)-7-{2-[methyl-(propane-1 -sulfonyl)-amino]-ethoxy}-1 ,2,3,4-tetrahydro- naphthalen-2-yl)-carbamic acid ethyl ester
279.1 Propane-1 -sulfonic acid cyclopropyl amide
Figure imgf000226_0002
To a solution of cyclopropylamine (1.2 ml, 17.5 mmol) in 100 ml CH2CI2 and DMAP (2.4 g, 17.5 mmol) was added dropwise a solution of propane-1 -sulfonyl chloride (2.3 ml, 19.2 mmol) in 50 ml CH2CI2. The resulting mixture was stirred at room temperature over night and diluted with 50 ml of CH2CI2. The mixture was extracted subsequently with water, 1 M HCI, and brine, tried over Na2SC>4, filtered and the solvent evaporated to obtain 2.8 g of product (oil) which was used in the next step without further purification.
279.2 Acetic acid 2-[cyclopropyl-(propane-1-sulfonyl)-amino]-ethyl ester
Figure imgf000227_0001
A mixture of propane-1 -sulfonic acid cyclopropyl amide (1.3 g, 8 mmol), K2CO3 (2.4 g, 14.4 mmol) and acetic acid 2-bromo-ethyl ester (9.5 g, 16 mmol) mmol) in 10 ml acetone was heated for 6h to 1200C in the microwave (Biotage). After cooling the mixture was filtered and the solvent evaporated to obtain 1.7 g of product as an oil which was used without further purification in the next step.
279.3 Propane-1 -sulfonic acid cyclopropyl-(2-hydroxy-ethyl)-amide
Figure imgf000227_0002
A mixture of acetic acid 2-[cyclopropyl-(propane-1-sulfonyl)-amino]-ethyl ester (1.7 g, 6.8 mmol) and KOH (0.57 g, 10.2 mmol) in 30 ml Methanol was stirred over night at room temperature. The solvent was evaporated the residue dissolved in ethyl acetate und subsequently extracted with water and 1 M KOH, dried over Na2SO4 and the solvent evaporated to obtain 0.46 g of product which was used purified by chromatography (253.5 mg of colorless oil)
279.4 Propane-1 -sulfonic acid 2-[cyclopropyl-(propane-1-sulfonyl)-amino]-ethyl ester
Figure imgf000227_0003
To a solution of propane-1 -sulfonic acid cyclopropyl-(2-hydroxy-ethyl)-amide (150 mg, 0.8 mmol) in CH2CI2 and DMAP (97 mg, 0.8 mmol) was added dropwise a solution of propane-1 -sulfonyl chloride (97 mg, 0.8 mmol) in CH2CI2. The resulting mixture was stirred at room temperature over night, diluted with 50 ml of CH2CI2, extracted subsequently with water, 1 M HCI, and brine, tried over Na2SC>4, filtered and the solvent evaporated to obtain 197.5 mg of product which was used in the next step without further purification.
279.5 1 -(3-Chloro-benzyl)-7-{2-[cyclopropyl-(propane-1 -sulfonyl)-amino]-ethoxy}-
1 ,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid ethyl ester
Figure imgf000228_0001
Prepared in one step from ethyl 1-(3-chlorobenzyl)-7-hydroxy-1 , 2,3,4- tetrahydronaphthalen-2-ylcarbamate (prepared in analogy to example 1d) and propane-1 - sulfonic acid 2-[cyclopropyl-(propane-1-sulfonyl)-amino]-ethyl ester in analogy to example 76. ESI-MS [M+H+] = 549 Calculated for C28H37CIN2O5S = 548
Example 280: 1 -Benzyl-7-{2-[cyclopropyl-(propane-1 -sulfonyl)-amino]-ethoxy}-1 ,2,3,4-tetrahydro- naphthalen-2-yl)-carbamic acid ethyl ester
Figure imgf000228_0002
Prepared in one step from ethyl 1-benzyl-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2- ylcarbamate (prepared in analogy to example 1d) and propane-1 -sulfonic acid 2- [cyclopropyl-(propane-1-sulfonyl)-amino]-ethyl ester in analogy to example 76. ESI-MS [M+H+] = 515 Calculated for C28H38N2O5S = 514
Example 281 : Propane-1 -sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-cyclopropyl-amide hydrochloride
Figure imgf000229_0001
Prepared in one step from 1-(3-Chloro-benzyl)-7-{2-[cyclopropyl-(propane-1-sulfonyl)- amino]-ethoxy}-1 ,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid ethyl ester (example 279) example in analogy to example 3. ESI-MS [M+H+] = 477 Calculated for C25H33CIN2O3S = 476
Example 282:
Propane-1 -sulfonic acid [2-(7-amino-8-benzyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)- ethyl]-cyclopropyl-amide hydrochloride
Figure imgf000229_0002
Prepared in one step from 1-Benzyl-7-{2-[cyclopropyl-(propane-1-sulfonyl)-amino]- ethoxy}-1 ,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid ethyl ester (example 280) in analogy to example 3.
ESI-MS [M+H+] = 443 Calculated for C25H34N2O3S = 442
Example 283:
1 -(3-Chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-yl]-1 ,2,3,4-tetrahydro-naphthalen-
2-ylamine hydrochloride
283.1 3-[8-(3-Chloro-benzyl)-7-ethoxycarbonylamino-5,6,7,8-tetrahydro-naphthalen-
2-yl]-azetidine-1-carboxylic acid tert-butyl ester
Figure imgf000229_0003
A suspension of zinc powder (152 mg, 2.3 mmol) in 1 ml of DMA in a dry flask was heated under N2 to 65-700C. A mixture of TMS-CI (28 mg, 0.26 mmol) and 1 ,2-dibromoethane (49 mg, 0.26 mmol) was added dropwise, stirred for 30 min, followed by slow (15 min) addition of 3-iodo-azetidine-i-carboxylic acid tert-butyl ester (510 mg, 1.8 mmol) in 1 ml DMA. The reaction was cooled slowly (3h) to room temperature, added to a mixture of 8- (3,4-chlorobenzyl)-7-[(ethoxycarbonyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl trifluoro- methanesulfonate (633 mg, 1.3 mmol, prepared in analogy to example 29), CuI (74 mg, 0,39 mmol) and PdCI2(dppf) (63 mg, 0.08 mmol) in 4 ml DMA preheated to 700C and stirred for 7h at 700C Water and MTB (1 :1 20 ml) were added and the resulting mixture filtered. The organic layer was separated, dried (Na2SO4) and the solvent evaporated. Purification by chromatography afforded 560 mg of product (white foam).
283.2 1 -(3-Chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-yl]-1 ,2,3,4-tetrahydro- naphthalen-2-ylamine hydrochloride
Figure imgf000230_0001
Prepared in three steps from 3-[8-(3-chloro-benzyl)-7-ethoxycarbonylamino-5, 6,7,8- tetrahydro-naphthalen-2-yl]-azetidine-1-carboxylic acid tert-butyl ester in analogy to example 46/47.
Cleavage of Boc-group was done in formic acid. ESI-MS [M+H+] = 433 Calculated for C23H29CIN2O2S = 432
Example 284:
1 -Benzyl-7-[1 -(propane-1 -sulfonyl)-azetidin-3-yl]-1 ,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride
Figure imgf000230_0002
Prepared in analogy to example 283. ESI-MS [M+H+] = 399 Calculated for C23H30N2O2S = 398
Example 285:
{1 -(3-Chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-ylmethoxy]-1 ,2,3,4- tetrahydronaphthalen-2-yl}-carbamic acid ethyl ester 285.1 1-(Propane-1-sulfonyl)-azetidine-3-carboxylic acid methyl ester
Figure imgf000231_0001
Prepared by standard procedure from azetidine-3-carboxylic acid methyl ester and pro- pane-1-sulfonyl chloride (e.g. example 279).
285.2 [1 -(Propane-1 -sulfonyl)-azetidin-3-yl]-methanol
Figure imgf000231_0002
Prepared by reduction of 1 -(propane-1 -sulfonyl)-azetidine-3-carboxylic acid methyl with LiAIH4 in THF at room temperature to 500C (e.g. example 300).
285.3 Methanesulfonic acid 1 -(propane-1 -sulfonyl)-azetidin-3-ylmethyl ester
O
Il
Prepare Λd by standard procedure from [1 -(propane-1 -sulfonyl)-azetidin-3-yl]-methanol and methan-1-sulfonyl chloride (e.g. example 40)
285.4 {1 -(3-Chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-ylmethoxy]-1 ,2,3,4- tetrahydronaphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000231_0003
Prepared from 1-(3-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate and methanesulfonic acid 1 -(propane-1 -sulfonyl)-azetidin-3-ylmethyl ester in analogy to example 315.
ESI-MS [M+H+] = 536 Calculated for C27H35CIN2O5S = 535 Example 286:
1 -(3-Chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-ylmethoxy]-1 ,2,3,4-tetrahydro- naphthalen-2-ylamine hydrochloride
Figure imgf000232_0001
Prepared from {1 -(3-chloro-benzyl)-7-[1 -(propane-1 -sulfonyl)-azetidin-3-ylmethoxy]- 1 ,2,3,4-tetrahydronaphthalen-2-yl}-carbamic acid ethyl ester in analogy to example 3. ESI-MS [M+H+] = 463 Calculated for C24H3ICIN2O3S = 462
Example 287:
[1-(3-Chloro-benzyl)-7-(2-cyclopropylmethanesulfonylamino-ethoxy)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000232_0002
Prepared in analogy to example 3.
ESI-MS [M+H+] = 521 Calculated for C26H33CIN2O5S = 520
Example 288: N-{2-[7-Amino-8-(3-chloro-benzyl)-5!6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000232_0003
Prepared from [1 -(3-chloro-benzyl)-7-(2-cyclopropylmethanesulfonylamino-ethoxy)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 3. ESI-MS [M+H+] = 449 Calculated for C23H29CIN2O3S = 448
Example 289:
[1 -(3-Chloro-benzyl)-7-(1 -cyclopropylmethanesulfonyl-azetidin-3-ylmethoxy)-1 ,2,3,4- tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000233_0001
Prepared from 1-(3-chlorobenzyl)-7-hydroxy-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate and methanesulfonic acid Methanesulfonic acid i-cyclopropylmethanesulfonyl-azetidin-3- yl methylester (prepared in analogy to example 285) in analogy to example 315. ESI-MS [M+H+] = 547 Calculated for C28H35CIN2O5S= 546
Example 290: {1 -(3-Chloro-benzyl)-7-[2-(cyclopropylmethanesulfonyl-methyl-amino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000233_0002
Prepared from [1 -(3-chloro-benzyl)-7-(2-cyclopropylmethanesulfonylamino-ethoxy)- 1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 45. ESI-MS [M+H+] = 535 Calculated for C27H35CIN2O5S= 534
Example 291 :
N-{2-[7-Amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl- N-methyl-methanesulfonamide
Figure imgf000234_0001
{i-β-Chloro-benzyl^-p^cyclopropylmethanesulfonyl-methyl-amino^ethoxyH ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester in analogy to example 3. ESI-MS [M+H+] = 463 Calculated for C24H3ICIN2O3S = 462
Example 292:
1 -Benzyl-7-[1 -(propane-1 -sulfonyl)-azetidin-3-ylmethoxy]-1 ,2,3,4-tetrahydro-naphthalen-2- ylamine hydrochloride
Figure imgf000234_0002
Prepared in analogy to example 46.
ESI-MS [M+H+] = 429 Calculated for C24H31CIN2O3S = 428
Example 293:
Propane-1 -sulfonic acid {2-[7-amino-8-(2-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-amide hydrochloride
Figure imgf000234_0003
Prepared in analogy to example 3.
ESI-MS [M+H+] = 437 Calculated for C22H29CIN2O3S= 436
Example 294:
Cyclopropanesulfonic acid {2-[7-amino-8-(2-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen- 2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000235_0001
Prepared in analogy to example 3.
ESI-MS [M+H+] = 435 Calculated for C22H27CIN2O3S= 434
Example 295:
N-{2-[7-Amino-8-(2-chloro-benzyl)-5!6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000235_0002
Prepared in analogy to example 3.
ESI-MS [M+H+] = 449 Calculated for C23H29CIN2O3S= 448
Example 296:
N-{3-[7-Amino-8-(3-chloro-benzyl)-5!6,7,8-tetrahydro-naphthalen-2-yl]-propyl}-C- cyclopropyl-methanesulfonamide hydrochloride
296.1 [7-(3-tert-Butoxycarbonylamino-propyl)-1-(3-chloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000235_0003
A solution of tert-butyl allylcarbamate (297 mg, 1 ,9 mmol) in dry THF under nitrogen was added dropwise at 00C to 9-BBN dissolved in THF (0,5 M, 2.3 ml, 1.2 mmol) and stirred for 4 h. This mixture was subsequently treated with 8-(3,4-chlorobenzyl)-7- [(ethoxycarbonyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate (250 mg, 0.5 mmol), palladium(ll)acetate (1 1.5 mg, 0.05 mmol), triphenylphosphine (27 mg, 0.1 mmol) and cesium carbonate (333 mg, 1 mmol) after which the mixture was heated to reflux for 2h.
The solvent was evaporated the residue dissolved in ethylacetate, extracted with water, dried (Na2SC>4). Evaporation of solvent gave 0.51 g of a brown oil which was treated with diisopropyl ether to afford 91 mg of a brownish powder.
296.2 N-{3-[7-Amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yl]-propyl}-
C-cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000236_0001
Prepared from [7-(3-tert-butoxycarbonylamino-propyl)-1-(3-chloro-benzyl)-1 ,2,3,4- tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester in analogy to example 3. ESI-MS [M+H+] = 447 Calculated for C24H3ICIN2O2S= 446
Example 297:
Propane-1 -sulfonic acid {3-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yl]-propyl}-amide hydrochloride
Figure imgf000236_0002
Prepared in analogy to example 296.
ESI-MS [M+H+] = 435 Calculated for C23H3iCIN2O2S= 434
Example 298: {1 -(2-Chloro-benzyl)-7-[2-(1 -methyl-1 H-imidazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000237_0001
Prepared in analogy to example 3.
ESI-MS [M+H+] = 547 Calculated for C26H3ICIN4O5S= 546
Example 299:
{1 -(2-Chloro-benzyl)-7-[2-(1 -methyl-1 H-pyrazole-4-sulfonylamino)-ethoxy]-1 ,2,3,4- tetrahydro-naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000237_0002
Prepared in analogy to example 3.
ESI-MS [M+H+] = 547 Calculated for C26H3ICIN4O5S= 546
Example 300:
N-{2-[8-(3-Chloro-benzyl)-7-methylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000237_0003
A solution of LiAIH4 in THF (1 M, 1.5 ml, 1.5 mmol) was added dropwise to [1-(3-chloro- benzyl)-7-(2-cyclopropylmethanesulfonylamino-ethoxy)-1 ,2,3,4-tetrahydro-naphthalen-2- yl]-carbamic acid ethyl ester (523 mg, 1 mmol, example 287) dissolved in 100 ml of dry THF. The mixture was heated to reflux for 1 h, treated with 2N NaOH, and extracted with CH2CI2. The organic layer was extracted with sat. NaHCO3 and brine, dried (Na2SO4) filtered and the solvent evaporated. Purification by chromatography afforded 324 mg of product as colorless oil which was transformed to the hydrochloride in a mixture of HCI in isopropanol. (325 mg, white powder)
ESI-MS [M+H+] = 463 Calculated for C24H3ICIN2O3S= 462
Example 301 :
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-amino-8-(2-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000238_0001
Prepared in analogy to example 3.
ESI-MS [M+H+] = 475 Calculated for C23H27CIN4O3S= 474
Example 302:
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[8-(2-chloro-benzyl)-7-methylamino-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000238_0002
Prepared in analogy to example 3/300. ESI-MS [M+H+] = 489 Calculated for C24H29CIN4O3S= 488
Example 303:
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(2-chloro-benzyl)-7-methylamino-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000238_0003
Prepared in analogy to example 3/300. ESI-MS [M+H+] = 489 Calculated for C24H29CIN4O3S= 488
Example 304:
Propane-1 -sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yl]-ethyl}-amide hydrochloride
304.1 [7-(2-Benzyloxycarbonylamino-ethyl)-1-(3-chloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000239_0001
A mixture of potassium (2-(benzyloxycarbonylamino)ethyl)trifluoroborate (1 ,130 g, 3,96 mmol), cesium carbonate (2,58 g, 7,93 mmol), 8-(3-chlorobenzyl)-7- (ethoxycarbonylamino)-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate (1 ,3 g, 2,64 mmol), Pd(OAc)2 (0,030 g, 0,132 mmol) and 2-dicyclohexyphosphino-2',6'-di-i- propoxy-1 ,1 '-biphenyl (0,130 g, 0,264 mmol) under N2 in toluene/water 3:1 (15 ml) was heated to refluxed for 13h. The reaction was filtered, the solvent evaporated and the residue purified by chromatography to afford 1.04 g of product as colorless oil.
304.2 [7-(2-Amino-ethyl)-1 -(3-chloro-benzyl)-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester
Figure imgf000239_0002
To [7-(2-benzyloxycarbonylamino-ethyl)-1 -(3-chloro-benzyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester (500 mg, 0,960 mmol) was added at room temperature 8 ml of 33%HBr in acetic acid. After 2h the mixture was diluted with CH2CI2, washed twice with NaHCO3, dried and filtered. The solvent was evaporated to obtain the product as a yellow oil (392 mg), which was used without further purification. 304.3 Propane-1 -sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yl]-ethyl}-amide hydrochloride
Figure imgf000240_0001
Prepared from [7-(2-amino-ethyl)-1-(3-chloro-benzyl)-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester in analogy to example 3. ESI-MS [M+H+] = 421 Calculated for C22H29CIN2O2S= 420
Example 305: 1 -Methyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(2-chloro-benzyl)-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000240_0002
Prepared in analogy to example 3.
ESI-MS [M+H+] = 475 Calculated for C23H27CIN4O3S= 474
Example 306:
N-[1-(3-Chloro-benzyl)-7-(2-cyclopropylmethanesulfonylamino-ethoxy)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-acetamide
Figure imgf000240_0003
Prepared in analogy to example 214. ESI-MS [M+H+] = 491 Calculated for C25H3ICIN2O4S= 490
Example 307:
N-{2-[8-(3-Chloro-benzyl)-7-ethylamino-5!6!7,8-tetrahydro-naphthalen-2 -yloxyJ-ethylJ-C-cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000241_0001
Prepared in analogy to example 300.
ESI-MS [M+H+] = 477 Calculated for C25H33CIN2O3S= 476
Example 308:
Propane-1 -sulfonic acid {3-[8-(3-chloro-benzyl)-7-methylamino-5,6,7,8-tetrahydro- naphthalen-2-yl]-propyl}-amide hydrochloride
Figure imgf000241_0002
Prepared in analogy to examples 297/300.
ESI-MS [M+H+] = 449 Calculated for C24H33CIN2O2S= 448
Example 309:
Propane-1 -sulfonic acid {2-[8-(3-chloro-benzyl)-7-methylamino-5,6,7,8-tetrahydro- naphthalen-2-yl]-ethyl}-amide
Figure imgf000242_0001
Prepared in analogy to examples 304/300.
ESI-MS [M+H+] = 435 Calculated for C23H3ICIN2O2S= 434
Example 310:
N-{2-[7-Amino-8-(3-chloro-benzyl)-5!6,7,8-tetrahydro-naphthalen-2-yl]-ethyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000242_0002
Prepared in analogy to example 304.
ESI-MS [M+H+] = 433 Calculated for C23H29CIN2O2S = 432
Example 311 : Propane-1 -sulfonic acid {2-[8-(2-fluoro-benzyl)-7-methylamino-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000242_0003
Prepared in analogy to examples 3/300. ESI-MS [M+H+] = 435 Calculated for C23H31FN2O3 = 434
Example 312:
C-Cyclopropyl-N-{2-[8-(2-fluoro-benzyl)-7-methylamino-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-methanesulfonamide hydrochloride
Figure imgf000243_0001
Prepared in analogy to examples 3/300. ESI-MS [M+H+] = 447 Calculated for C24H3IFN2O3S = 446
Example 313:
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(3-chloro-benzyl)-7-methylamino-5, 6,7,8- tetrahydro-naphthalen-2-yl]-ethyl}-amide
Figure imgf000243_0002
Prepared in analogy to examples 304/300. ESI-MS [M+H+] = 473 Calculated for C24H29CIN4O2S = 472
Example 314:
Propane-1 -sulfonic acid [2-(8-cyclohexylmethyl-7-methylamino-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-amide trifluoroacetate
Figure imgf000243_0003
Prepared in analogy to examples 3/300.
ESI-MS [M+H+] = 423 Calculated for C23H38N2O3S = 422
Example 315: 1 -Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(2-chloro-benzyl)-7-pyrrolidin-1 -yl-5,6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride 315.1 1-Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(2-chloro-benzyl)-7-(2-oxo- pyrrolidin-1-yl)-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-amide
Figure imgf000244_0001
Prepared in analogy to example 263.
315.2 1-Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(2-chloro-benzyl)-7-pyrrolidin-1-yl-
5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000244_0002
Prepared from compound of previous step by reduction with LiAIH4 in analogy to 300. ESI-MS [M+H+] = 529 Calculated for C27H33CIN4O3S = 528
Example 316:
1 ,2-Dimethyl-1 H-imidazole-4-sulfonic acid {2-[7-amino-8-(3-chloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000244_0003
Prepared in analogy to example 3.
ESI-MS [M+H+] = 489 Calculated for C24H29CIN4O3S = 488
Example 317:
N-{2-[8-(3-Chloro-benzyl)-7-pyrrolidin-1-yl-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-methanesulfonamide hydrochloride
Figure imgf000245_0001
Prepared in analogy to examples 264/88.
ESI-MS [M+H+] = 503 Calculated for C27H35CIN2O3S = 502
Example 318:
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[8-(3-chloro-benzyl)-7-pyrrolidin-1-yl-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000245_0002
Prepared in analogy to examples 264/88.
ESI-MS [M+H+] = 529 Calculated for C27H33CIN4O3S = 528
Example 319: 1 -Methyl-1 H-imidazole-4-sulfonic acid {2-[8-(3-chloro-benzyl)-7-pyrrolidin-1 -yl-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000245_0003
Prepared in analogy to examples 264/88.
ESI-MS [M+H+] = 529 Calculated for C27H33CIN4O3S = 528 Example 320:
N-{2-[7-Azetidin-1-yl-8-(3-chloro-benzyl)-5!6!7,8-tetrahydro-naphthalen-2-yloxy]-ethyl}-C- cyclopropyl-methanesulfonamide
320.1 1-[1-(3-Chloro-benzyl)-7-methoxy-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- azetidine
Figure imgf000246_0001
Prepared in analogy to example 264 using 1 ,3-dibromopropane instead of 1 ,4- dibromobutane.
320.2 N-{2-[7-Azetidin-1-yl-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2- yloxy]-ethyl}-C-cyclopropyl-methanesulfonamide
Figure imgf000246_0002
Prepared from compound of previous step in analogy to example 88. ESI-MS [M+H+] = 489 Calculated for C26H33CIN2O3S = 488
Example 321 :
1-Methyl-1 H-imidazole-4-sulfonic acid {2-[7-azetidin-1-yl-8-(3-chloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000246_0003
Prepared in analogy to example 320.
ESI-MS [M+H+] = 515 Calculated for C26H31CIN4O3S = 514 Example 322:
1-Methyl-1 H-pyrazole-4-sulfonic acid {2-[7-azetidin-1-yl-8-(3-chloro-benzyl)-5, 6,7,8- tetrahydro-naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000247_0001
Prepared in analogy to example 320.
ESI-MS [M+H+] = 515 Calculated for C26H3ICIN4O3S = 514
Example 323:
Propane-1 -sulfonic acid {2-[8-(3-chloro-benzyl)-7-pyrrolidin-1 -yl-5,6,7,8-tetrahydro- naphthalen-2-yloxy]-ethyl}-amide hydrochloride
Figure imgf000247_0002
Prepared in analogy to examples 264/88.
ESI-MS [M+H+] = 491 Calculated for C26H35CIN2O3S = 490
Example 324:
1-Methyl-1 H-pyrazole-4-sulfonic acid [2-(7-azetidin-1-yl-8-benzyl-5,6,7,8-tetrahydro- naphthalen-2-yloxy)-ethyl]-amide hydrochloride
Figure imgf000247_0003
Prepared in analogy to example 320.
ESI-MS [M+H+] = 481 Calculated for C26H32N4O3S = 480 Example 325:
1 -Benzyl-7-[2-(propane-1 -sulfonyl)-ethyl]-1 ,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride
325.1 [1-(3-Chloro-benzyl)-7-vinyl-1 ,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester
Figure imgf000248_0001
Synthesis performed in analogy to: Organic Letters; 2002, Vol4; p.107-109.
A solution of potassium trifluoro(vinyl)borate (1 ,000 g, 7,46 mmol), PdCI2(dppf)-CH2Cl2 adduct (0,102 g, 0,124 mmol), 8-(3-chlorobenzyl)-7-(ethoxycarbonylamino)-5,6,7,8- tetrahydronaphthalen-2-yl trifluoromethanesulfonate (3,06 g, 6,22 mmol) and triethylamine (0,867 ml, 6,22 mmol) in 100 ml n-BuOH was stirred under N2 at 85-900C for 4h and then cooled to room temperature.
Water was added, followed by extraction with ether. The ethereal solution was washed with brine, dried, filtered and evaporated to obtain a brown oil. Chromatography afforded
1.55 g of product as a pale yellow solid.
325.2 [1 -(3-Chloro-benzyl)-7-(2-hydroxy-ethyl)-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester
Figure imgf000248_0002
BH3 ■ DMS (1 M in THF, 0.838 ml, 0.838 mmol) was added a solution of ethyl 1-(3- chlorobenzyl)-7-vinyl-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (1 ,55 g, 4,19 mmol) in 20 ml dry THF. The reaction was stirred at 600C for 1 h and cooled to room temperature. Some water was added to destroy the excess of borane complex and the resulting mixture refluxed for 1 h with 30% H2O2 (8,56 ml, 84 mmol) and 2N NaOH (9,74 ml, 19,49 mmol). The reaction mixture was extracted with CH2CI2, washed with water and brine, dried, filtered and the solvent evaporated to obtain a pale brown solid (1 ,7 g) , which was purified by chromatography to afford 854 mg of product as a white solid.
325.3 [7-(2-Bromo-ethyl)-1 -(3-chloro-benzyl)-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester
Figure imgf000249_0001
To a solution of [1-(3-chloro-benzyl)-7-(2-hydroxy-ethyl)-1 ,2,3,4-tetrahydro-naphthalen-2- yl]-carbamic acid ethyl ester (554 mg, 1 ,428 mmol) in 15 ml dry CH2CI2 cooled to 00C was added triphenylphosphine (562 mg, 2,142 mmol) and carbon tetrabromide (0,208 ml, 2,142 mmol). The mixture was stirred for 1 h, after which solvents were evaporated. The residue was purified by chromatography to obtain 277 mg of product as a white solid.
325.4 [1 -(3-Chloro-benzyl)-7-(2-propylsulfanyl-ethyl)-1 ,2,3,4-tetrahydro-naphthalen-
2-yl]-carbamic acid ethyl ester
Figure imgf000249_0002
To a suspension of NaH (4,73 mg, 0,177 mmol) in 3 ml dry DMF under N2 was added 1- propanthiol (0,012 ml, 0,133 mmol, dissolved in 1 ml dry DMF). The reaction was stirred at room temperature for 2h, followed by addition of triethylamine (0,019 ml, 0,133 mmol) and ethyl 7-(2-bromoethyl)-1-(3-chlorobenzyl)-1 ,2,3,4-tetrahydronaphthalen-2-ylcarbamate (40 mg, 0,089 mmol, dissolved in 2 ml dry DMF). The mixture was stirred at room temperature over night, the solvent evaporated, the residue re-dissolved in ethyl acetate, washed with water, citric acid, NaHCC>3 and brine and filtered. The solvent was evaporated to obtain 31 mg of an off white solid which was used without further purification.
325.5 {1 -(3-Chloro-benzyl)-7-[2-(propane-1 -sulfonyl)-ethyl]-1 ,2,3,4-tetrahydro- naphthalen-2-yl}-carbamic acid ethyl ester
Figure imgf000250_0001
To a cooled mixture (00C) of ethyl 1 -(3-chlorobenzyl)-7-(2-(propylthio)ethyl)-1 ,2,3,4- tetrahydronaphthalen-2-ylcarbamate (31 ,4 mg, 0,070 mmol) in 2 ml ethyl acetate was added m-CPBA (33,4 mg, 0,155 mmol). The reaction was stirred for 2h allowing warming up to room temperature. The mixture was diluted with ethyl acetate, washed with Na- HCO3, water and brine, dried, filtered and the solvent evaporated to obtain a white solid, which was purified by chromatography (27 mg).
325.6 [1 -Benzyl-7-(2-propylsulfanyl-ethyl)-1 ,2,3,4-tetrahydro-naphthalen-2-yl]- carbamic acid ethyl ester
Figure imgf000250_0002
Ethyl 1 -(3-chlorobenzyl)-7-(2-(propylsulfonyl)ethyl)-1 ,2,3,4-tetrahydronaphthalen-2- ylcarbamate (27,1 mg, 0,057 mmol) and ammonium formiate (71 ,5 mg, 1 ,134 mmol) were dissolved in 5 ml MeOH. Pd/C (0,845 mg, 7,94 μmol) was added and stirred at 800C for 4h. The mixture was filtered, the solvent evaporated, the residue re-dissolved in ethyl acetate, which was subsequently washed with water, NaHCO3 and brine, dried, filtered. Solvent was evaporated to obtain white solid which was purified by chromatography affording 12.7 mg of product as a white solid. 325.7 1 -Benzyl-7-[2-(propane-1 -sulfonyl)-ethyl]-1 ^S^-tetrahydro-naphthalen^- ylamine hydrochloride
Figure imgf000251_0001
Prepared in analogy to example 3 [1-Benzyl-7-(2-propylsulfanyl-ethyl)-1 ,2,3,4-tetrahydro- naphthalen-2-yl]-carbamic acid ethyl ester. ESI-MS [M+H+] = 372 Calculated for C22H29NO2S = 371
Example 326: 1 -(3-Chloro-benzyl)-7-[2-(propane-1 -sulfonyl)-ethyl]-1 ,2,3,4-tetrahydro-naphthalen-2- ylamine hydrochloride
Figure imgf000251_0002
Prepared in analogy to example 325 leaving out the de-chlorination step. ESI-MS [M+H+] = 406 Calculated for C22H28CINO2S = 405
Biological testing
1. [3H]-Glycine uptake into recombinant CHO cells expressing human GIyTI :
Human GIyTI c expressing recombinant hGlyT1 c_5_CHO cells were plated at 20,000 cells per well in 96 well Cytostar-T scintillation microplates (Amersham Biosciences) and cultured to sub-confluency for 24h. For glycine uptake assays the culture medium was aspirated and the cells were washed once with 100 μl HBSS (Gibco BRL, #14025-050) with 5 mM L-Alanine (Merck #1007). 80 μl HBSS buffer were added, followed by 10 μl inhibitor or vehicle (10% DMSO) and 10 μl [3H]-glycine (TRK71 , Amersham Biosciences) to a final concentration of 200 nM for initiation of glycine uptake. The plates were placed in a WaI- lac Microbeta (PerkinElmer) and continuously counted by solid phase scintillation spectrometry during up to 3 hours. Nonspecific uptake was determined in the presence of 10 μM Org24598. IC50 calculations were made by four-parametric logistic nonlinear regression analysis (GraphPad Prism) using determinations within the range of linear increase of [3H]-glycine incorporation between 60 and 120 min.
2. Radioligand binding assays using recombinant CHO cell membranes expressing human GIyTI :
Radioligand binding to human GIyTI c transporter-expressing membranes was carried out as described in Mezler et al., Molecular Pharmacology 74:1705-1715, 2008.
The following results were obtained with the compounds disclosed in the examples:
Table 1 :
Figure imgf000252_0001
Figure imgf000253_0001
Figure imgf000254_0001
Figure imgf000255_0001
Figure imgf000256_0001
Figure imgf000257_0001
Figure imgf000258_0001
Figure imgf000259_0001
Figure imgf000260_0001
Figure imgf000261_0001

Claims

We claim:
1. Aminotetraline derivatives of the formula (I)
Figure imgf000262_0001
wherein
A is a 5- or 6-membered ring;
R is R1-W-A1-Q-Y-A2-X1-;
R1 is hydrogen, CrC6-alkyl, C3-Ci2-cycloalkyl-Ci-C4-alkyl, halogenated CrC6-alkyl, tri- (Ci-C4-alkyl)-silyl-Ci-C4-alkyl, hydroxy-CrC4-alkyl, Ci-C6-alkoxy-Ci-C4-alkyl, amino- Ci-C4-alkyl, Ci-C6-alkylamino-Ci-C4-alkyl, di-Ci-C6-alkylamino-Ci-C4-alkyl, Ci-C6- alkylcarbonylamino-Ci-C4-alkyl, Ci-C6-alkyloxycarbonylamino-Ci-C4-alkyl, CrC6- alkylaminocarbonylamino-Ci-C4-alkyl, di-Ci-Ce-alkylaminocarbonylamino-Ci-d- alkyl, Ci-Ceralkylsulfonylamino-Ci-d-alkyl, (optionally substituted C6-Ci2-aryl-Ci- C6-alkyl)amino-Ci-C4-alkyl, optionally substituted C6-Ci2-aryl-Ci-C4-alkyl, optionally substituted C3-Ci2-heterocyclyl-Ci-C4-alkyl, C3-Ci2-cycloalkyl, CrC6-alkylcarbonyl,
Ci-C6-alkoxycarbonyl, halogenated Ci-C6-alkoxycarbonyl, CerC^-aryloxycarbonyl, aminocarbonyl, Ci-Ceralkylaminocarbonyl, (halogenated Ci-C4- alkyl)aminocarbonyl, Ce-C^-arylaminocarbonyl, C2-C6-alkenyl, C2-C6-alkynyl, optionally substituted C6-Ci2-aryl, hydroxy, Ci-C6-alkoxy, halogenated Ci-C6-alkoxy, Ci-C6-hydroxyalkoxy, Ci-C6-alkoxy-CrC4-alkoxy, amino-Ci-C4-alkoxy, d-C6- alkylamino-Ci-C4-alkoxy, di-Ci-C6-alkylamino-d-C4-alkoxy, d-C6- alkylcarbonylamino-Ci-C4-alkoxy, C6-Ci2-arylcarbonylamino-d-C4-alkoxy, d-C6- alkoxycarbonylamino-Ci-C4-alkoxy, C6-Ci2-aryl-d-C4-alkoxy, d-C6- alkylsulfonylamino-Ci-C4-alkoxy, (halogenated Ci-C6-alkyl)sulfonylamino-CrC4- alkoxy, C6-Ci2-arylsulfonylamino-Ci-C4-alkoxy, (C6-Ci2-aryl-Ci-C6- alkyl)sulfonylamino-Ci-C4-alkoxy, C3-Ci2-heterocyclylsulfonylamino-Ci-C4-alkoxy, C3-Ci2-heterocyclyl-CrC4-alkoxy, C6-Ci2-aryloxy, C3-Ci2-heterocyclyloxy, CrC6- alkylthio, halogenated CrC6-alkylthio, Ci-C6-alkylamino, (halogenated CrC6- alkyl)amino, di-Ci-C6-alkylamino, di-(halogenated Ci-C6-alkyl)amino, CrC6- alkylcarbonylamino, (halogenated d-Ce-alky^carbonylamino, C6-Ci2- arylcarbonylamino, Ci-C6-alkylsulfonylamino, (halogenated CrC6- alkyl)sulfonylamino, C6-Ci2-arylsulfonylamino or optionally substituted C3-Ci2- heterocyclyl;
W is -NR8- or a bond;
A1 is optionally substituted Ci-C4-alkylene or a bond;
Q is -S(O)2- or -C(O)-;
Y is -NR9- or a bond;
A2 is optionally substituted Ci-C4-alkylene, Ci-C4-alkylene-CO-, -CO-Ci-C4-alkylene, Ci-C4-alkylene-O-CrC4-alkylene, Ci-C4-alkylene-NR10-CrC4-alkylene, optionally substituted C2-C4-alkenylen, optionally substituted C2-C4-alkynylene, optionally substituted C6-Ci2-arylene, optionally substituted C6-Ci2-heteroarylene or a bond;
X1 is -O-, -NR11-, -S-, optionally substituted Ci-C4-alkylene, optionally substituted C2- C4-alkenylen, optionally substituted C2-C4-alkynylene;
R2 is hydrogen, halogen, Ci-C6-alkyl, halogenated Ci-C4-alkyl, hydroxy-Ci-C4-alkyl, - CN, C2-C6-alkenyl, C2-C6-alkynyl, optionally substituted C6-Ci2-aryl, hydroxy, CrC6- alkoxy, halogenated Ci-C6-alkoxy, Ci-Ce-alkoxycarbonyl, C2-C6-alkenyloxy, C6-Ci2- aryl-Ci-C4-alkoxy, d-Ce-alkylcarbonyloxy, Ci-C6-alkylthio, Ci-C6-alkylsulfinyl, d-
C6-alkylsulfonyl, aminosulfonyl, amino, Ci-C6-alkylamino, C2-C6-alkenylamino, nitro or optionally substituted C3-Ci2-heterocyclyl, or two radicals R2 together with the ring atoms of A to which they are bound form a 5- or 6 membered ring; R3 is hydrogen, halogen, d-C6-alkyl or d-C6-alkoxy, or two radicals R3 together with the carbon atom to which they are attached form a carbonyl group;
R4a is hydrogen, d-C6-alkyl, C3-Ci2-cycloalkyl-Ci-C4-alkyl, halogenated Ci-C4-alkyl, hydroxy-Ci-C4-alkyl, Ci-Ce-alkoxy-Ci-d-alkyl, amino-CrC4-alkyl, CH2CN, -CHO,
Ci-C4-alkylcarbonyl, (halogenated Ci-C4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, d-C4- alkoxycarbonyl, C6-d2-aryloxycarbonyl, Ci-Ce-alkylaminocarbonyl, C2-C6-alkenyl, - C(=NH)NH2, -C(=NH)NHCN, Ci-Ce-alkylsulfonyl, C6-Ci2-arylsulfonyl, amino, -NO or C3-Ci2-heterocyclyl;
R4b is hydrogen, d-C6-alkyl, halogenated Ci-C4-alkyl, hydroxy-Ci-C4-alkyl, d-C6- alkoxy-Ci-C4-alkyl, amino-CrC4-alkyl, CH2CN, -CHO, d-C4-alkylcarbonyl, (halogenated Ci-C4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, Ci-C4-alkoxycarbonyl, C6-Ci2- aryloxycarbonyl, Ci-Ce-alkylaminocarbonyl, C2-C6-alkenyl, -C(=NH)NH2, - C(=NH)NHCN, Ci-Ce-alkylsulfonyl, C6-Ci2-arylsulfonyl, amino, -NO or C3-Ci2- heterocyclyl; or
R4a, R4b together are optionally substituted d-C6-alkylene, wherein one -CH2- of d-C4- alkylene may be replaced by an oxygen atom or -NR16;
X2 is -O-, -NR6-, -S-, >CR12aR12b or a bond;
X3 is -O-, -NR7-, -S-, >CR13aR13b or a bond;
R5 is optionally substituted C6-d2-aryl, optionally substituted C3-Ci2-cycloalkyl or optionally substituted C3-Ci2-heterocyclyl;
n is 0, 1 or 2;
R6 is hydrogen or d-C6-alkyl;
R7 is hydrogen or d-C6-alkyl; R8 is hydrogen or d-C6-alkyl;
R9 is hydrogen, CrC6-alkyl, C3-Ci2-cycloalkyl, amino-Ci-C6-alkyl, optionally substituted
C6-Ci2-aryl-Ci-C4-alkyl or C3-Ci2-heterocyclyl; or
R9, R1 together are Ci-C4-alkylene; or
R9 is Ci-C4-alkylene that is bound to a carbon atom in A2 and A2 is Ci-C4-alkylene or to a carbon atom in X1 and X1 is CrC4-alkylene;
R10 is hydrogen, d-C6-alkyl or CrC6-alkylsulfonyl;
R11 is hydrogen or d-C6-alkyl, or
R9, R11 together are Ci-C4-alkylene,
R12a is hydrogen, optionally substituted Ci-C6-alkyl, d-C6-alkylamino-d-d-alkyl, di-d- C6-alkylamino-Ci-d-alkyl, C3-Ci2-heterocyclyl-Ci-C6-alkyl, optionally substituted
C6-Ci2-aryl or hydroxy;
R12b is hydrogen or d-C6-alkyl, or
R12a, R12b together are carbonyl or optionally substituted d-C4-alkylene, wherein one -CH2- of d-d-alkylene may be replaced by an oxygen atom or -NR14-;
R13a is hydrogen, optionally substituted d-C6-alkyl, d-C6-alkylamino-d-C4-alkyl, di-d- C6-alkylamino-Ci-d-alkyl, C3-Ci2-heterocyclyl-Ci-C6-alkyl, optionally substituted
C6-Ci2-aryl or hydroxy;
R13b is hydrogen or d-C6-alkyl, or p13a p13b together are carbonyl or optionally substituted CrC4-alkylene, wherein one -CH2- of Ci-C4-alkylene may be replaced by an oxygen atom or -NR15-;
R14 is hydrogen or d-C6-alkyl;
R15 is hydrogen or d-C6-alkyl; and
R is hydrogen or CrC6-alkyl,
or a physiologically tolerated salt thereof.
2. Compound as claimed in claim 1 , wherein A is a benzene ring or a ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:
Figure imgf000267_0001
Figure imgf000267_0002
3. Compound as claimed in claim 1 or 2, wherein -Y-A2-X1- comprises at least 2, 3 or 4 atoms in the main chain.
4. Compound as claimed in any one of claims 1 to 3, wherein R1 is CrC6-alkyl, C3-Ci2- cycloalkyl-CrC4-alkyl, halogenated CrC6-alkyl, Ci-C6-alkoxy-Ci-C4-alkyl, amino-Ci-C4- alkyl, Ci-C6-alkylamino-Ci-C4-alkyl, di-Ci-C6-alkylamino-Ci-C4-alkyl, CrC6- alkyloxycarbonylamino-Ci-C4-alkyl, Ci-C6-alkylaminocarbonylamino-Ci-C4-alkyl, C6-Ci2- aryl-Ci-C4-alkyl, C3-Ci2-cycloalkyl, C2-C6-alkenyl, optionally substituted C6-Ci2-aryl, hy- droxy, Ci-C6-alkylamino, (halogenated Ci-C6-alkyl)amino, di-Ci-C6-alkylamino or optionally substituted C3-Ci2-heterocyclyl.
5. Compound as claimed in any one of claims 1 to 4, wherein W is -NR8- and Y is a bond, or W is a bond and Y is -NR9-.
6. Compound as claimed in any one of claims 1 to 5, wherein A1 is a bond.
7. Compound as claimed in any one of claims 1 to 5, wherein A1 is Ci-C4-alkylene and W is -NR8-.
8. Compound as claimed in any one of claims 1 to 7, wherein A2 is CrC4-alkylene.
9. Compound as claimed in any one of claims 1 to 7, wherein A2 is C6-Ci2-arylene selected from the group consisting of phen-1 ,4-ylene and phen-1 ,3-ylene, or C6-Ci2- heteroarylene selected from the group consisting of pyrid-2,5-ylene and pyrid-2,4-ylene.
10. Compound as claimed in any one of claims 1 to 9, wherein X1 is -O- or -NR11, or X1 is optionally substituted Ci-C4-alkylene and A2 is a bond, or X1 is optionally substituted C2- C4-alkynylene and A2 is a bond.
1 1. Compound as claimed in any one of claims 1 to 10, wherein R1-W-A1-Q-Y-A2-X1- is R1- S(O)2-N H-A2-X1-, R1-N H-S(O )2-A2-X1-, R1-C(O)-NH-A2-X1- or R1-N H-C(O )-A2-X1-.
12. Compound as claimed in any one of claims 1 to 1 1 , having one of the formulae
Figure imgf000269_0001
wherein R1, W, A1, Q, Y, A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n are as defined in any one of claims 1 to 1 1.
->2 -
13. Compound as claimed in any one of claims 1 to 12, wherein R is hydrogen, halogen or Ci-C6-alkoxy.
14. Compound as claimed in claim 12, having one of the formulae
Figure imgf000270_0001
wherein R1, W, A1, Q, Y, A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n are as defined in any of claims 1 to 13.
15. Compound as claimed in any one of claims 1 to 14, wherein R is hydrogen or Ci-Cβ- alkyl.
16. Compound as claimed in any one of claims 1 to 15, having the formula
Figure imgf000270_0002
wherein R3a, R3b, R3c, R3d, R3e, R3f independently have the meaning of R3, and A, R, R2,
R3, R4a, R4b, X2, X3, R5 are as defined in any one of claims 1 to 15.
17. Compound as claimed in claim 1 to 16, wherein R4a is hydrogen, Ci-Cβ-alkyl, C3-C12- cycloalkyl-Ci-C4-alkyl, halogenated CrC4-alkyl, amino-Ci-C4-alkyl, CH2CN, -CHO, Ci-C4- alkylcarbonyl, (halogenated CrC4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, d-C4- alkoxycarbonyl, C6-Ci2-aryloxycarbonyl, -C(=NH)NH2, -C(=NH)NHCN, Ci-C6- alkylsulfonyl, amino, -NO or C3-Ci2-heterocyclyl.
18. Compound as claimed in any one of claims 1 to 17, wherein R4b is hydrogen or Ci-C6- alkyl.
19. Compound as claimed in any one of claims 1 to 16, wherein R4a, R4b together are optionally substituted CrCβ-alkylene, wherein one -CH2- of CrC4-alkylene may be replaced by an oxygen atom.
20. Compound as claimed in any one of claims 1 to 19, wherein X2 is CR12aR12b.
21. Compound as claimed in any one of claims 1 to 20, wherein X3 is a bond.
22. Compound as claimed in any one of claims 1 to 21 , wherein R12a is hydrogen or Ci-C6- alkyl and R12b is hydrogen or CrC6-alkyl.
23. Compound as claimed in any one of claims 1 to 21 , wherein R12a, R12b together are optionally substituted Ci-C4-alkylene.
24. Compound as claimed in any one of claims 1 to 23, wherein R5 is optionally substituted aryl or optionally substituted C3-Ci2-cycloalkyl.
25. Compound as claimed in claim 24, having the formula
Figure imgf000272_0001
wherein A, R, R2, R3, R4a, R4b, X2, X3, n are as defined in any one of claims 1 to 23; and o15a o15b o15c o15d o15e o15f independently are hydrogen, halogen, optionally substituted Ci-C6-alkyl, halogenated Ci-C6-alkyl, CN, hydroxy, Ci-C6-alkoxy, amino, Ci-C6-alkylamino, di-Ci-C6-alkylamino or Cs-C^-heterocyclyl.
26. Compound as claimed in any one of claims 1 to 25, wherein R is hydrogen.
27. Compound as claimed in any one of claims 1 to 26, wherein R9 is hydrogen, d-C6-alkyl or C3-Ci2-cycloalkyl, or R9 and R1 together are CrC4-alkylene; or R9 is CrC4-alkylene that is bound to a carbon atom in A2 and A2 is Ci-C4-alkylene or to a carbon atom in X1 and X1 is Ci-C4-alkylene.
28. Compound as claimed in any one of claims 1 to 27, wherein R10 is hydrogen.
29. Compound as claimed in any one of claims 1 to 28, wherein R11 is hydrogen.
30. Compound as claimed in any one of claims 1 to 29, wherein n is 1.
31. Compound as claimed in claim 1 , wherein
A is a benzene ring;
R is R1-W-A1-Q-Y-A2-X1-; R1 is d-Ce-alkyl, C3-Ci2-cycloalkyl-Ci-C4-alkyl, halogenated CrC6-alkyl, tri-(CrC4- alkyl)-silyl-Ci-C4-alkyl, Ci-Ce-alkoxy-Ci-d-alkyl, C3-Ci2-cycloalkyl, C2-C6-alkenyl, optionally substituted C6-Ci2-aryl, or optionally substituted C3-Ci2-heterocyclyl;
W is a bond;
A1 is a bond;
Q is -S(O)2- or -C(O)-;
Y is -NR - or a bond;
A2 is Ci-C4-alkylene or a bond;
X1 is -O- or optionally substituted Ci-C4-alkylene or C2-C4-alkynylene;
R2 is hydrogen;
R3 is hydrogen;
R4a is hydrogen, CrC6-alkyl, C3-Ci2-cycloalkyl-CrC4-alkyl, halogenated Ci-C4-alkyl, - CHO, Ci-C4-alkylcarbonyl, (halogenated Ci-C4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, Ci-C4-alkoxycarbonyl, C6-Ci2-aryloxycarbonyl;
R4b is hydrogen or CrC6-alkyl; or
R4a, R4b together are optionally substituted Ci-C6-alkylene, wherein one -CH2- of d-C4- alkylene may be replaced by an oxygen atom;
X2 is CR12aR12b;
X is a bond; R5 is optionally substituted phenyl or optionally substituted C3-Ci2-cycloalkyl;
n is 1 ;
R9 is hydrogen, d-C6-alkyl or C3-Ci2-cycloalkyl; or
R9, R1 together are d-C4-alkylene; or
R9 is Ci-C4-alkylene that is bound to a carbon atom in A2 and A2 is Ci-C4-alkylene or to a carbon atom in X1 and X1 is Ci-C4-alkylene;
R12a is hydrogen; and
R12b is hydrogen.
32. Compound as claimed in claim 1 , wherein
A is a benzene ring;
R is R1-W-A1-Q-Y-A2-X1-;
R1 is d-Ce-alkyl, C3-Ci2-cycloalkyl-Ci-C4-alkyl, halogenated CrC6-alkyl, C3-Ci2- cycloalkyl, C2-C6-alkenyl, optionally substituted C6-Ci2-aryl, or optionally substituted C3-Ci2-heterocyclyl;
W is a bond;
A1 is a bond;
Q is -S(O)2- or -C(O)-;
Y is -NR9- or a bond; A2 is Ci-C4-alkylene or a bond;
X1 is -O- or optionally substituted Ci-C4-alkylene;
R2 is hydrogen;
R3 is hydrogen;
R4a is hydrogen, CrC6-alkyl, C3-Ci2-cycloalkyl-Ci-C4-alkyl, halogenated Ci-C4-alkyl, d- C4-alkylcarbonyl, (halogenated Ci-C4-alkyl)carbonyl, C6-Ci2-arylcarbonyl, d-C4- alkoxycarbonyl, C6-Ci2-aryloxycarbonyl;
R4b is hydrogen or CrC6-alkyl;
X2 is CR12aR12b;
X is a bond;
R5 is optionally substituted phenyl;
is 1 ;
R9 is hydrogen or alkyl; or
R9, R1 together are Ci-C4-alkylene; or
R9 is Ci-C4-alkylene that is bound to a carbon atom in A2 and A2 is Ci-C4-alkylene;
R12a is hydrogen; and
R12b is hydrogen.
33. The compound as claimed in any one of claims 1 to 32 for use in therapy.
34. Pharmaceutical composition which comprises a carrier and a compound of any one of claims 1 to 32.
35. A method for inhibiting the glycine transporter GIyTI in a mammal in need thereof which comprises the administration of an effective amount of a compound of any one of claims 1 to 32.
36. The use of a compound of any one of claims 1 to 32 in the manufacture of a medica- ment for inhibiting the glycine transporter GIyTI .
37. A method for treating a neurologic or psychiatric disorder or pain in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of any one of claims 1 to 32.
38. The use of a compound of any one of claims 1 to 32 in the manufacture of a medicament for treating a neurologic or psychiatric disorder or pain.
39. The compound of any one of claims 1 to 32 for use in a method of treating a neurologic or psychiatric disorder or pain.
40. The method, use or compound as claimed in any one of claims 33 to 39, wherein the disorder is associated with glycinergic or glutamatergic neurotransmission dysfunction.
41 The method, use or compound as claimed in any one of claims 33 to 40, wherein the neurologic disorder is a cognitive disorder such as dementia, cognitive impairment, or attention deficit disorder.
42. The method, use or compound as claimed in claim 40, wherein the attention deficit dis- order is an attention deficit disorder with hyperactivity.
43. The method, use or compound as claimed in any one of any one of claims 33 to 40, wherein the psychiatric disorder is an anxiety disorder, a mood disorder such as depression, a bipolar disorder, schizophrenia, or a psychotic disorder.
44. Aminotetraline derivatives of the formula (II)
Figure imgf000277_0001
wherein L is an amino-protecting group, Y is NR9, and A2, X1, R2, R3, R4a, R4b, X2, X3, R5, n, R9 are defined as in any one of claims 1 to 32.
PCT/EP2010/051903 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy WO2010092180A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SG2011052636A SG173079A1 (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2011549597A JP5816557B2 (en) 2009-02-16 2010-02-16 Aminotetralin derivatives, pharmaceutical compositions containing them, and their use in therapy
CN201080017287.9A CN102395558B (en) 2009-02-16 2010-02-16 Aminotetralin derivatives, the pharmaceutical composition containing described Aminotetralin derivatives and purposes in the treatment thereof
EP10706575.7A EP2396296B1 (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
ES10706575.7T ES2584002T3 (en) 2009-02-16 2010-02-16 Aminotetralin derivatives, pharmaceutical compositions containing them and their use in therapy
NZ594928A NZ594928A (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
UAA201111056A UA105036C2 (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
DK10706575.7T DK2396296T3 (en) 2009-02-16 2010-02-16 Aminotetralin derivatives PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY
BRPI1008045A BRPI1008045A2 (en) 2009-02-16 2010-02-16 aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2010212762A AU2010212762B2 (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2011008634A MX2011008634A (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy.
RU2011138027/04A RU2546649C2 (en) 2009-02-16 2010-02-16 Aminotetraline derivatives containing their pharmaceutical compositions and using them in therapy
CA2750793A CA2750793A1 (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
IL214175A IL214175A (en) 2009-02-16 2011-07-19 Aminotetraline derivatives, pharmaceutical compositions containing them and use thereof
ZA2011/05486A ZA201105486B (en) 2009-02-16 2011-07-25 Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15282509P 2009-02-16 2009-02-16
US61/152,825 2009-02-16

Publications (1)

Publication Number Publication Date
WO2010092180A1 true WO2010092180A1 (en) 2010-08-19

Family

ID=42129294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/051903 WO2010092180A1 (en) 2009-02-16 2010-02-16 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy

Country Status (29)

Country Link
US (3) US8563617B2 (en)
EP (1) EP2396296B1 (en)
JP (1) JP5816557B2 (en)
KR (1) KR20110116233A (en)
CN (1) CN102395558B (en)
AR (1) AR075442A1 (en)
AU (1) AU2010212762B2 (en)
BR (1) BRPI1008045A2 (en)
CA (1) CA2750793A1 (en)
CL (1) CL2011001924A1 (en)
CO (1) CO6430456A2 (en)
CR (1) CR20110424A (en)
DK (1) DK2396296T3 (en)
DO (1) DOP2011000264A (en)
EC (1) ECSP11011327A (en)
ES (1) ES2584002T3 (en)
IL (1) IL214175A (en)
MX (1) MX2011008634A (en)
NZ (2) NZ594928A (en)
PE (1) PE20120062A1 (en)
PL (1) PL2396296T3 (en)
PT (1) PT2396296T (en)
RU (1) RU2546649C2 (en)
SG (1) SG173079A1 (en)
TW (1) TWI530283B (en)
UA (1) UA105036C2 (en)
UY (1) UY32455A (en)
WO (1) WO2010092180A1 (en)
ZA (2) ZA201105486B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013120835A1 (en) 2012-02-13 2013-08-22 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014008350A1 (en) 2012-07-05 2014-01-09 Abbvie Inc. Process for preparing bicyclic amine derivatives
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055771A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9351954B2 (en) 2009-12-04 2016-05-31 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US10780074B2 (en) 2017-08-02 2020-09-22 Sunovion Pharmaceuticals Inc. Compounds and uses thereof
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US11077090B2 (en) 2016-07-29 2021-08-03 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010773A (en) * 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy.
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2951790C (en) 2014-06-10 2022-05-31 Ube Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
JP6572891B2 (en) * 2014-06-10 2019-09-11 宇部興産株式会社 N-substituted sulfonamide compound and process for producing the same
DE102015121017A1 (en) * 2015-12-03 2017-06-08 Karl Storz Gmbh & Co. Kg Observation device, in particular medical observation device, with an operating unit and use of an input module

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
WO2008075070A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Sulfonamide derivatives for therapeutic use as fatty acid synthase inhibitors
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20090093422A1 (en) 2006-10-23 2009-04-09 Roger Tung Oxazolidinone derivatives and methods of use
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US20090105307A1 (en) 2007-02-15 2009-04-23 Guido Galley 2-aminooxazolines as taar1 ligands
US20090105147A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090111840A1 (en) 2005-05-31 2009-04-30 Peter Herold Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US7534814B2 (en) 1999-07-30 2009-05-19 Nabriva Therapeutics Ag Mutilin derivatives and their use as antibacterials
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1284257A (en) * 1915-07-06 1918-11-12 Westinghouse Electric & Mfg Co Electric heating apparatus.
SE8004002L (en) 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik THERAPEUTICALLY APPLICABLE TETRALIN DERIVATIVES
ATE39483T1 (en) 1982-04-02 1989-01-15 Takeda Chemical Industries Ltd CONDENSED PYRROLINONE DERIVATIVES AND THEIR PREPARATION.
US4789678A (en) 1986-08-25 1988-12-06 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing α-alkyl-4-amino-3-quinolinemethanols and 1-(4-aralkylamino-3-quinolinyl)alkanones and related compounds
US4927838A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
CA1327795C (en) 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
WO1992006967A1 (en) 1990-10-12 1992-04-30 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
US5545755A (en) 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
JP2785879B2 (en) 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー Therapeutically useful 2-aminotetralin derivatives
US5071875A (en) 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
HUT57185A (en) * 1990-03-21 1991-11-28 Merrell Dow Pharma Process for producing 8-sulfamil-methylen-2-amino-tetraline derivatives and pharmaceutical compositions containing them
EP0581865A1 (en) * 1991-04-26 1994-02-09 The Upjohn Company Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins
JPH05213884A (en) 1991-06-14 1993-08-24 Upjohn Co:The Novel 4-aminoquinoline and prophylatic/ therapeutic agent for hypertensive/congestive heart failure using same as effective component
GB9127306D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
SI1014966T1 (en) 1996-05-31 2006-10-31 Allelix Neuroscience Inc Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6057357A (en) * 1997-04-30 2000-05-02 Warner-Lambert Company Peripherally selective kappa opioid agonists
AU7552198A (en) 1997-06-11 1998-12-30 Sankyo Company Limited Benzylamine derivatives
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
TW555757B (en) * 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
DE69922676T2 (en) 1998-10-07 2005-12-15 Ortho-Mcneil Pharmaceutical, Inc. N-ARALKYLAMINOTETRALINES AS NEUROPEPTIDE Y-Y5 RECEPTOR LIGANDS
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
CA2380032A1 (en) * 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
US6426364B1 (en) 1999-11-01 2002-07-30 Nps Allelix Corp. Diaryl-enynes
JP4850332B2 (en) 2000-10-18 2012-01-11 東京エレクトロン株式会社 Etching method of dual damascene structure
DE10115820A1 (en) * 2001-03-26 2002-10-17 Wieland Dental & Technik Gmbh Process for the production of all-ceramic dental molded parts
KR20040016844A (en) 2001-03-27 2004-02-25 액테리온 파마슈티칼 리미티드 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ⅱ receptors antagonists
AU2756602A (en) 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US6831193B2 (en) 2001-05-18 2004-12-14 Abbott Laboratories Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
PE20030297A1 (en) * 2001-08-09 2003-06-19 Fernandez Rafael Vidal CHEMICAL-MECHANICAL PROCESS TO REDUCE THE POLLUTION PRODUCED BY THE COMBUSTION OF FOSSIL FUELS, PETROLEUM AND ITS DERIVATIVES
ATE305917T1 (en) 2001-08-16 2005-10-15 Pfizer Prod Inc DIFLUOROMETHYLENE AROMATIC ETHERS AND THEIR USE AS GLYCINE TYPE 1 TRANSPORTER INHIBITORS
US6694193B2 (en) * 2001-09-14 2004-02-17 Koninklijke Philips Electronics N.V. Medical electrode and release liner configurations facilitating packaged electrode characterization
DE10149370A1 (en) 2001-10-06 2003-04-10 Merck Patent Gmbh New 1-(phenyl or pyridinyl)-1H-pyrazole derivatives, are glycine transporter inhibitors useful e.g. for treating schizophrenia, depression, dementia, neurodegenerative diseases or pain
BR0214309A (en) 2001-11-21 2004-10-13 Upjohn Co Substituted aryl-1,4-pyrazine derivatives
ES2280595T3 (en) 2001-12-20 2007-09-16 H. Lundbeck A/S DERIVATIVES OF ARYLOXYPHENYL AND ARYLSULPHANYLPHENYL.
GB0130696D0 (en) 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
DE10210779A1 (en) 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclic amides
DE10217006A1 (en) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituted indoles
FR2838739B1 (en) 2002-04-19 2004-05-28 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP1506166B1 (en) * 2002-05-17 2011-11-16 Janssen Pharmaceutica NV Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2004007468A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
FR2842804B1 (en) 2002-07-29 2004-09-03 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2842805A1 (en) 2002-07-29 2004-01-30 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND APPLICATION THERAPEUTICS
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
US6946227B2 (en) * 2002-11-20 2005-09-20 Xerox Corporation Imaging members
US7084154B2 (en) 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
ATE340782T1 (en) 2003-02-17 2006-10-15 Hoffmann La Roche PIPERIDINEBENZENESULFONAMIDE DERIVATIVES
US7399774B2 (en) 2003-03-07 2008-07-15 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
DE10315570A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh New 1-aryl-1,2,3-triazole derivatives useful for treating e.g. schizophrenia, depression, dementia, Parkinson's disease or Alzheimer's disease, are glycine transporter inhibitors
WO2004096761A1 (en) 2003-04-30 2004-11-11 H. Lundbeck A/S Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives
JP2004359633A (en) 2003-06-06 2004-12-24 Bayer Cropscience Ag Utilization of isoindolinone derivative as insecticide
GB0314476D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314479D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314478D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
ME00116B (en) 2003-08-11 2010-10-10 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
JP4563386B2 (en) 2003-09-09 2010-10-13 エフ．ホフマン−ラ ロシュ アーゲー 1- (2-Amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychosis
ES2322651T3 (en) 2003-09-09 2009-06-24 F. Hoffmann-La Roche Ag DERIVATIVES OF 1-BENZOIL-PIPERAZINA AS INHIBITORS OF GLYCINE ABSORPTION FOR THE TREATMENT OF PSYCHOSIS.
FR2861070B1 (en) 2003-10-17 2006-01-06 Sanofi Synthelabo DERIVATIVES OF N- [PHENYL (PYRROLIDIN-2-YL) METHYL] BENZAMIDE AND N - [(AZEPAN-2-YL) PHENYLMETHYL] BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861074B1 (en) 2003-10-17 2006-04-07 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861076B1 (en) 2003-10-17 2006-01-06 Sanofi Synthelabo N-HETEROCYCLYMETHYLBENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861073B1 (en) 2003-10-17 2006-01-06 Sanofi Synthelabo N- [HETEROARYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
FR2861071B1 (en) 2003-10-17 2006-01-06 Sanofi Synthelabo N- [PHENYL (ALKYLPIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
RU2006117368A (en) 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) TRIAZASPIROIPIPEREDINE DERIVATIVES INTENDED FOR USE AS GLYT-1 INHIBITORS IN TREATMENT OF NEUROLOGICAL AND PSYCHEONOLOGICAL DISORDERS
US20070105902A1 (en) 2003-11-12 2007-05-10 Lindsley Craig W 4-Phenyl piperdine sulfonyl glycine transporter inhibitors
GB0326840D0 (en) 2003-11-18 2003-12-24 Glaxo Group Ltd Compounds
WO2005058885A2 (en) 2003-12-18 2005-06-30 Glaxo Group Limited Piperidine derivatives and their use as glycine transporter inhibitors
GB0329362D0 (en) 2003-12-18 2004-01-21 Glaxo Group Ltd Compounds
WO2005058317A1 (en) 2003-12-18 2005-06-30 Glaxo Group Limited Glycine transporter-1 inhibirors
DE102004030099A1 (en) 2004-06-22 2006-01-12 Grünenthal GmbH Saturated and unsaturated 3-pyridylbenzocycloalkylmethylamines as serotonin and / or norepinephrine reuptake inhibitors and / or μ-opioid receptor modulators
CN101036158A (en) 2004-08-31 2007-09-12 松下电器产业株式会社 Content purchase processing terminal, method thereof and program
US20060074105A1 (en) 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
AU2005315914B2 (en) 2004-12-15 2011-03-03 F. Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
DE602006010665D1 (en) 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
EP1863804A1 (en) 2005-04-01 2007-12-12 Methylgene, Inc. Inhibitors of histone deacetylase
US20090221624A1 (en) 2005-05-06 2009-09-03 Olivo Paul D 4-aminoquinoline compounds for treating virus-related conditions
KR101589551B1 (en) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
TW200736255A (en) 2005-12-01 2007-10-01 Elan Pharm Inc 5-(Substituted)-pyrazolopiperidines
EP2032566A4 (en) 2006-06-12 2009-07-08 Merck Frosst Canada Ltd Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0619176D0 (en) 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
WO2008148755A2 (en) 2007-06-06 2008-12-11 Dsm Ip Assets B.V. Novel 5-substituted hydantoins
MX2009014235A (en) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy.
MX2010010773A (en) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy.
WO2010020548A1 (en) 2008-08-20 2010-02-25 F. Hoffmann-La Roche Ag Glyt1 receptor antagonists
US8822449B2 (en) 2008-09-02 2014-09-02 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
DE102008047162A1 (en) 2008-09-15 2010-03-25 Institut Für Solarenergieforschung Gmbh Rear contact solar cell with integrated bypass diode and manufacturing method thereof
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
WO2010138901A1 (en) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
TW201319049A (en) 2011-08-05 2013-05-16 Abbott Gmbh & Co Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US7538189B2 (en) 1997-10-08 2009-05-26 Isotechnika Inc. Methods of making deuterated cyclosporin analogs
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US7534814B2 (en) 1999-07-30 2009-05-19 Nabriva Therapeutics Ag Mutilin derivatives and their use as antibacterials
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20090111840A1 (en) 2005-05-31 2009-04-30 Peter Herold Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20090093422A1 (en) 2006-10-23 2009-04-09 Roger Tung Oxazolidinone derivatives and methods of use
WO2008075070A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Sulfonamide derivatives for therapeutic use as fatty acid synthase inhibitors
US20090105307A1 (en) 2007-02-15 2009-04-23 Guido Galley 2-aminooxazolines as taar1 ligands
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090105147A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
"Fortschritte der Arzneimittelforschung", vol. 10, 1966, BIRKHAUSER VERLAG, BASEL AND STUTTGART, pages: 224 FF
"Protective Groups in Organic Chemistry", 1973, PLENUM PRESS
BIOORG. MED. CHEM. LET, vol. 17, no. 22, 2007, pages 6160
BLAGOJEVIC N ET AL.: "Dosimetry & Treatment Planning for Neutron Capture Therapy", ADVANCED MEDICAL PUBLISHING, pages: 125 - 134
BLAKE ET AL., J. PHARM. SCI., vol. 64, no. 3, 1975, pages 367 - 391
BRICKNER, S J ET AL., J MED CHEM, vol. 39, no. 3, 1996, pages 673
BUTTE N F ET AL., BR. J. NUTR., vol. 65, 1991, pages 3
C.W. LINDSLEY, ET AL.: "Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfon yl)piperidin-4-yl]methyl benzamides.", CHEMMEDCHEM, vol. 1, no. 8, August 2006 (2006-08-01), WILEY-VCH VERLAG, WEINHEIM, DE, pages 807 - 811, XP002581674, ISSN: 1860-7179, DOI: 10.1002/cmdc.200600097 *
COWARD W A ET AL., LANCET, vol. 7, 1979, pages 13
CZAJKA D M; FINKEL A J, ANN. N.Y. ACAD. SCI., vol. 84, 1960, pages 770
CZAKJA D M ET AL., AM. J. PHYSIOL., vol. 201, 1961, pages 357
DIABETES METAB., vol. 23, 1997, pages 251
E. NÚÑEZ, ET AL.: "Differential effects of the tricyclic antidepressant amoxapine on glycine uptake mediated by the recombinant GLYT1 and GLYT2 glycine transporters", BRITISH JOURNAL OF PHARMACOLOGY, vol. 130, no. 1, January 2000 (2000-01-01), NATURE PUBLISHING GROUP, BASINGSTOKE, GB, pages 200 - 206, XP002581673, ISSN: 0007-1188, DOI: 10.1038/sj.bjp.0703049 *
FIEDLER, H.P.: "Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields", 1996, ECV-EDITIO-CANTOR-VERLAG, article "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete"
FOSTER ET AL.: "Advances in Drug Research", vol. 14, 1985, ACADEMIC PRESS, pages: 2 - 36
HARSING L.G. ET AL., CURRENT MEDICINAL CHEMISTRY, vol. 13, 2006, pages 1017 - 1044
HASHIMOTO K., RECENT PATENTS ON CNS DRUG DISCOVERY, vol. 1, 2006, pages 43 - 53
J. HET. CHEM., vol. 23, no. 2, 1997, pages 343
J. LOWE, ET AL.: "A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 6, 9 January 2007 (2007-01-09), ELSEVIER SCIENCE, OXFORD, GB, pages 1675 - 1678, XP005895388, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2006.12.109 *
JAVITT D.C., MOLECULAR PSYCHIATRY, vol. 9, 2004, pages 984 - 997
KATO ET AL., J. LABELLED COMP. RADIOPHARMACEUT., vol. 36, no. 10, 1995, pages 927 - 932
KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., vol. 77, 1999, pages 79 - 88
LINDSLEY C.W. ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 6, 2006, pages 1883 - 1896
LINDSLEY, C.W. ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 6, 2006, pages 771 - 785
LIZONDO, J ET AL., DRUGS FUT, vol. 21, no. 11, 1996, pages 1116
MACLENNAN A H ET AL., AM. J. OBSTET GYNECOL., vol. 139, 1981, pages 948
MALLESHAM, B ET AL., ORG LETT, vol. 5, no. 7, 2003, pages 963
MEZLER ET AL., MOLECULAR PHARMACOLOGY, vol. 74, 2008, pages 1705 - 1715
ORGANIC LETTERS, vol. 4, 2002, pages 107 - 109
PONS G; REY E, PEDIATRICS, vol. 104, 1999, pages 633
RODEWALD L E ET AL., J. PEDIATR., vol. 114, 1989, pages 885
SCHWARCZ H P, CONTROL. CLIN. TRIALS, vol. 5, no. 4, 1984, pages 573
SYNTHETIC COMMUNICATIONS, vol. 19, no. 9-10, 1989, pages 1583 - 91
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
THOMSON J F, ANN. NEW YORK ACAD. SCI, vol. 84, 1960, pages 736
ZHIJIAN ZHAO, ET AL.: "Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl )benzamides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, no. 23, 20 September 2006 (2006-09-20), ELSEVIER SCIENCE, OXFORD, GB, pages 5968 - 5972, XP005850583, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2006.08.131 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894033B2 (en) 2009-12-04 2021-01-19 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
US10085968B2 (en) 2009-12-04 2018-10-02 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
US9351954B2 (en) 2009-12-04 2016-05-31 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN103889968A (en) * 2011-08-05 2014-06-25 艾伯维德国有限责任两合公司 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2014521682A (en) * 2011-08-05 2014-08-28 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Aminochroman, aminothiochroman and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (en) * 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2015506969A (en) * 2012-02-13 2015-03-05 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013120835A1 (en) 2012-02-13 2013-08-22 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9227901B2 (en) 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
WO2014008350A1 (en) 2012-07-05 2014-01-09 Abbvie Inc. Process for preparing bicyclic amine derivatives
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055771A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US10927124B2 (en) 2016-07-29 2021-02-23 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US11077090B2 (en) 2016-07-29 2021-08-03 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US11958862B2 (en) 2016-07-29 2024-04-16 Sumitomo Pharma America, Inc. Compounds and compositions and uses thereof
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
US10780074B2 (en) 2017-08-02 2020-09-22 Sunovion Pharmaceuticals Inc. Compounds and uses thereof
US11491133B2 (en) 2017-08-02 2022-11-08 Sunovion Pharmaceuticals Inc. Heteroaryl-isochroman compounds and uses thereof
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US11440921B2 (en) 2018-02-16 2022-09-13 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US11987591B2 (en) 2018-02-16 2024-05-21 Sumitomo Pharma America, Inc. Salts, crystal forms, and production methods thereof
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
PL2396296T3 (en) 2017-08-31
AR075442A1 (en) 2011-03-30
RU2011138027A (en) 2013-03-27
IL214175A0 (en) 2011-08-31
CR20110424A (en) 2012-01-19
CN102395558A (en) 2012-03-28
UY32455A (en) 2010-09-30
AU2010212762B2 (en) 2012-08-09
CO6430456A2 (en) 2012-04-30
US8563617B2 (en) 2013-10-22
US20100273739A1 (en) 2010-10-28
NZ608314A (en) 2014-06-27
RU2546649C2 (en) 2015-04-10
ZA201206062B (en) 2014-04-30
TWI530283B (en) 2016-04-21
EP2396296B1 (en) 2016-05-25
UA105036C2 (en) 2014-04-10
NZ594928A (en) 2013-03-28
ZA201105486B (en) 2012-12-27
CL2011001924A1 (en) 2011-11-11
CN102395558B (en) 2015-09-02
US20140031331A1 (en) 2014-01-30
PE20120062A1 (en) 2012-03-10
DOP2011000264A (en) 2011-09-15
JP5816557B2 (en) 2015-11-18
ES2584002T3 (en) 2016-09-23
AU2010212762A1 (en) 2011-08-18
SG173079A1 (en) 2011-08-29
CA2750793A1 (en) 2010-08-19
DK2396296T3 (en) 2016-08-22
MX2011008634A (en) 2011-09-06
US9067871B2 (en) 2015-06-30
US20130184238A1 (en) 2013-07-18
PT2396296T (en) 2016-08-31
JP2012517983A (en) 2012-08-09
BRPI1008045A2 (en) 2016-03-15
KR20110116233A (en) 2011-10-25
EP2396296A1 (en) 2011-12-21
IL214175A (en) 2015-09-24
ECSP11011327A (en) 2011-10-31
TW201032797A (en) 2010-09-16
US9096619B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
US9067871B2 (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3057960B1 (en) Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2013001786A (en) Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy.
EP2814810A1 (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2396323A1 (en) Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
WO2012020131A2 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2707358A1 (en) Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012020130A1 (en) Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013072520A1 (en) N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3057958B1 (en) Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2013001785A (en) Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080017287.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10706575

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2750793

Country of ref document: CA

Ref document number: 2010212762

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2011-000424

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2011549597

Country of ref document: JP

Ref document number: 001496-2011

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12011501642

Country of ref document: PH

Ref document number: MX/A/2011/008634

Country of ref document: MX

Ref document number: 2010706575

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010212762

Country of ref document: AU

Date of ref document: 20100216

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 594928

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 11117486

Country of ref document: CO

Ref document number: 14139541

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 7029/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117021559

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011138027

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1008045

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2014001802

Country of ref document: CL

ENP Entry into the national phase

Ref document number: PI1008045

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110816